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Abstract 
The aim of this project was to identify urinary markers of hepatic and renal toxicity in 
the male Hanover-Wistar rat; acute and chronic injury models were developed by 
administration of CCl4. Nephrotoxicity was induced by administration of HCBD. 
In an acute dose study, CCl4-induced nephrotoxicity occurred above 2.0 mL/kg CCl4. 
To avoid kidney injury, 2.0 mL/kg CCl4 was chosen as the optimal dose. 
1
H NMR 
revealed many changes to the urinary metabolome following CCl4-induced liver injury 
including an increase in the resonances of taurine, creatine and formate and a decrease 
in hippurate and creatinine.  
Protein and gene expression markers were investigated in a HCBD-model of 
nephrotoxicity. Urinary α-GST, KIM-1 and albumin were the most sensitive biomarkers 
of proximal tubular injury. These markers could be used to detect unwanted kidney 
injury in future CCl4 hepatic studies.  
In a time course study, maximal liver injury from CCl4 was reached 24-48 hours post-
dosing. Urinary metabolites followed the same trend and levels increased during the 
first 18-24 hours post-dosing. After 24 hours, there was a tendency for metabolites to 
return to control levels.  
A chronic model of CCl4-induced liver fibrosis was developed by dosing animals 3 
times a week for 6 weeks to investigate the potential for reversibility and changes in 
urinary metabolites. After 6 weeks of CCl4-administration there was development of 
fibrous structures in the liver parenchyma followed by slight regeneration during the 
recovery period. Urinary metabolites that best reflected the development of fibrosis 
were creatinine, citrate and succinate. Taurine and hippurate may be useful for showing 
regenerative changes. 
In this project, we developed a good rat model of fibrosis which showed potential to 
reverse. 
1
H NMR analysis allowed characterisation of urinary metabolite changes in 
acute and chronic studies. Some of these metabolites have potential to be urinary 
markers for hepatic fibrosis. 
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Chapter 1  
1.1 The liver 
1.1.1 Anatomy of the liver 
The liver is one of the largest organs in the body and is located in the right upper 
quadrant of the abdominal cavity just beneath the diaphragm and held in place by 
several ligaments (Ramadori et al., 2008; Wu et al., 2013). 
The liver is the most metabolically active organ in the body and normally is a dark red 
colour due to the large quantity of blood it contains. 
The rat liver consists of four lobes of different size: left, middle, right and caudate; each 
representing approximately 30, 40, 21 and 7 % of the total liver mass respectively 
(Kogure et al., 1999) (Figure 1.1). The middle lobe is divided into right and left 
portions, by one of the ligaments; the right liver lobe is located on the right side of the 
vena cava and is divided into 2 portions, the right superior and the right inferior lobe. 
The caudate lobe is located on the left side of the vena cava, and is divided into the 
superior caudate lobe and inferior caudate lobe (Madrahimov et al., 2006). The 
paracaval tissue is composed of the bases of the right superior, right inferior and caudate 
lobes covering the intrahepatic vena cava and makes up between 2.5 to 3 % of the liver 
(Madrahimov et al., 2006). 
 
 
 
 
 
 
 
Figure 1.1 Weight distribution of rat liver lobes (Madrahimov et al., 2006). 
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The vascular system of the rat liver includes the hepatic arterial system and the hepatic 
portal venous system. The hepatic artery delivers arterial blood and is responsible for 25 
% of the blood supply to the liver. The hepatic portal vein is responsible for the 
remaining 75 % of the blood supply and delivers deoxygenated blood which is rich in 
nutrients from the spleen, stomach, small and large intestine, gallbladder and pancreas 
(Eipel et al., 2010). The portal venous system is composed of conducting systems that 
ensure blood is delivered to the farthest corner of the liver, and multiple branching and 
branches of different lengths to ensure the even blood supply to the liver parenchyma. 
The portal venous system also has distributing systems which are responsible for the 
exchanges between blood and the hepatocytes (Saxena et al., 1999). The portal vein 
enters the liver at the hilus before dividing into a capillary network, known as liver 
sinusoids which supply the different lobes of the liver (Kogure et al., 1999). Blood is 
drained from the liver via the hepatic vein, and joins the inferior vena cava (Kogure et 
al., 1999).  
1.1.2 Histology 
Hepatocytes, or parenchymal liver cells, make up approximately 80 % of the liver 
volume (Blouin et al., 1977). They are polyhedral in shape and have a diameter of 25 to 
30 µm in length and between 20 to 25 µm in width (Motta, 1984). Each hepatocyte 
contains a large nucleus occupying 5-10 % of the cell volume with the cytoplasm 
constituting approximately 50 % of the volume. The hepatocytes are joined together to 
form rows of cells, approximately 1 cell thick, that branch out from the central vein. The 
liver sinusoids line each side of a row of hepatocytes. Blood flowing in the sinusoids 
empties into the central vein (Figure 1.2).  
 
 
 
 
 
Figure 1.2 Organisation of the liver. A central vein is presented in the centre of the lobule with radially 
arranged plates of hepatocytes. Branches of the portal vein and hepatic artery are located in the periphery 
of the lobule (Haschek et al., 2010). 
 Sinusoids 
Bile duct 
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Three major concepts have been suggested to the structure of the functional units of the 
liver: the classical lobular organisation, the portal lobule of Mall and the liver acinus of 
Rappaport (Figure 1.3). 
In the classical lobular organisation, each of the 4 liver lobes is divided into many 
hexagonal lobules. A central vein is located at the centre of each lobule; and portal 
tracts, each containing a branch of the portal vein, hepatic arteriole and a bile duct are 
located at each corner of the lobule. Each lobule has 3 regions: centrilobular, which is 
closest to the central vein, midzonal and periportal (Bhunchet and Wake, 1998). Mall’s 
proposal describes the liver as a hexagonal unit with the portal tract as its axis. The 
functional unit of the liver according to Rappaport (1958) is divided into 3 zones and is 
known as the hepatic acinus. Zone 1 is closest to the portal tracts, whereas zone 3 is 
closest to the central vein.  
1
CV
2
3
A
C
B
Acinus
Classic
lobule
Portal 
lobule
HA PV
CV
 
Figure 1.3 Representation of the classical liver lobule, portal lobule and liver acinus. PV: portal vein, 
HA: hepatic arteriole; CV: central vein. Zone 1 of the liver acinus is the closest to the portal vein and 
zone 3 is closest to the central vein, with its axis composed of the portal tract. A, B and C represent the 
centrilobular, midzonal and periportal zones of the classical liver lobule with the central vein at its axis 
(adapted from McQueen, 2010). 
 
Each of the zones in the liver acinus has different blood pressure, oxygen and nutrient 
supply, metabolism and enzymatic activity. Blood flows unidirectionally from zone 1 to 
3. Therefore, zone 1 is exposed to the most oxygenated blood and has the highest level 
of nutrients whereas, zone 3 is closest to the central vein and therefore is the least 
oxygenated zone (Saxena et al., 1999). Centrilobular hepatocytes have a greater number 
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and bigger mitochondria which may potentially reflect the high metabolic activity of 
these cells (Blouin et al., 1977).  
The hepatic sinusoids are lined by endothelial cells which have fenestrated membranes 
and lack a basement membrane. Between the endothelium layer and the hepatocytes is a 
space known as the space of Disse. The space of Disse is normally between 0.2 and 0.5 
µm wide and contains components of the extracellular matrix. The presence of pores 
along the endothelial membrane facilitates the exchange of substances between the 
lumen of the sinusoids, the space of Disse and the hepatocytes. Kupffer cells and Ito 
cells are the 2 other major cells found in the sinusoidal space. Kupffer cells comprise 
approximately 15 % of all liver cells (Wisse, 1974; Naito et al., 2004). These cells are 
phagocytic and are the macrophages of the liver (Naito et al., 2004). It has also been 
shown that Kupffer cells are most frequently found in the periportal region (Sleyster and 
Knook, 1982). The Kupffer cells located in the periportal region are different from those 
found in the centrilobular area in terms of enzyme activity, receptors and subcellular 
structures. In the periportal region, Kupffer cells are larger, have greater phagocytic 
activity and generate less superoxide anions (Mochida et al., 1989). Ito cells, also 
known as fat-storing cells or stellate cells, account for 8 % of total cells in the liver 
(Hautekeete and Geerts, 1997; Unanue, 2007; Winau et al., 2007). In the presence of 
cellular damage Ito cells differentiate into myofibroblast-like cells with high 
proliferative capacity and produce extracellular matrix proteins such as collagens (I, III, 
IV, V and VI), and extracellular matrix degrading metalloproteinases and the 
corresponding inhibitors (Mallat et al., 1995; Hautekeete and Geerts, 1997). 
1.1.3 Functions  
The liver has many functions and is involved in: secretory; metabolic; detoxification; 
storage; excretory and synthesis processes.  
The liver is responsible for the production of bile. Bile is composed of bile salts, 
phospholipids and organic anions; bile salts are synthesised from cholesterol. Bile is 
synthesised in the hepatocytes and secreted into the bile canaliculi. From here the bile 
travels to the gall bladder where it is concentrated. Bile salts and bile are released from 
the gall bladder into the duodenum where they promote digestion and, in particular, the 
absorption of fat through the process of micellar emulsification (Alrefai and Gill, 2007). 
Bile salts have a hydrophobic layer and a hydrophilic layer. Therefore, micelles are 
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water soluble due to their hydrophilic shell, but can carry hydrophobic substances in 
their lipid core. These micelles can diffuse through the water to the enterocytes where 
its components are absorbed. 
The liver has a key role in the metabolism of carbohydrates by the processes of: 
glycogenesis, glycogenolysis and gluconeogenesis. In glycogenesis, glycogen is 
synthesised in the liver from glucose when glucose is present in high amounts. 
Glycogen is then stored in the liver. When the glucose levels in the blood are low the 
liver acts as a source of glucose by breaking down the glycogen reserves to release 
glucose, a process known as glucogenolysis. The process of gluconeogenesis describes 
the synthesis of glucose from non-carbohydrate sources including amino acids (Nordlie 
et al., 1999). 
The liver is also responsible for the synthesis and degradation of lipids. The liver 
synthesises very low-density lipoproteins (VLDL) from fatty acids. VLDLs are 
converted into intermediate-density lipoproteins (IDL) and low-density lipoproteins 
(LDL) (Adiels et al., 2008). VLDLs have a high concentration of triglycerides, whereas 
LDLs are the primary carrier of cholesterol in the blood. Degradation of lipids occurs 
via the action of lipoprotein lipase which is responsible for hydrolysing triglycerides, 
cholesterol and phospholipids into fatty acids (Zambon et al., 2003). β-oxidation is the 
process by which fatty acids are oxidised to generate energy and occurs in the 
mitochondria (Rao and Reddy, 2001). 
The majority of proteins are synthesised and degraded in the liver. The liver is also the 
main site for the production of most plasma proteins, including albumin, α- and β-
globulins; clotting factors such as fibrinogen, factors V, VII, IX and X; enzymes and 
cholesterol; and of non-essential amino acids (Turton and Hooson, 2005). 
The liver is the primary organ involved in the metabolism of xenobiotics via Phase I and 
II reactions. Phase I reactions involve hydrolysis, reduction and oxidation reactions and 
the major enzyme involved is the microoxygenase system cytochrome P-450. The 
product of Phase I reactions is often a highly reactive free radical species. Phase II 
reactions include glucuronidation, glutathione conjugation and acetylation (Turton and 
Hooson, 2005).  
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1.2 Liver injury 
The liver is very susceptible to injury following exposure to toxicants. One of the main 
reasons is that most xenobiotics enter the body via the gastrointestinal (GI) tract and are 
transported via the hepatic portal vein to the liver, thus exposing the liver to high 
concentrations of the chemical (Sturgill and Lambert, 1997). Additionally, the liver has 
a very high concentration of xenobiotic-metabolising enzymes such as cytochrome P-
450s which metabolise many toxicants to a more water-soluble form allowing them to 
be more readily excreted from the body (Davidson, 2000). However, some toxic 
compounds form highly reactive metabolites, such as free radicals, upon metabolism by 
cytochrome P-450. These reactive metabolites can induce injury to the local hepatic 
area. Consequently, hepatic injury is commonly localised to the centrilobular region, 
since this region has the highest concentration of cytochrome P-450 enzymes (Lindros, 
1997; Sweeney, 1981).  
1.2.1 Fatty liver 
Fatty liver disease covers both fatty liver without inflammation (hepatic steatosis) and 
fatty liver that is associated with inflammation (steatohepatitis). Hepatic steatosis is 
reversible but it may develop into steatohepatitis, cirrhosis and liver cancer if exposure 
to the stimuli continues (Reddy and Rao, 2006). Hepatic steatosis is characterised by the 
excessive accumulation of triglycerides in the hepatocytes, usually more than 5-10 % by 
weight (Kelishadi et al., 2013). The accumulation of triglycerides may result from 
increased fatty acid synthesis via de novo lipogenesis, decreased β-oxidation of fatty 
acids and decreased secretion of cholesterol esters and triglycerides from the liver as 
VLDL. VLDLs are usually secreted from the liver and taken up by peripheral tissues 
such as the heart, skeletal muscle and adipose tissue (Minehira et al., 2008). A 
decreased ability to produce and secrete VLDL may be the result of decreased 
production of apolipoproteins by the liver (Elias et al., 1999; Maugeais et al., 2000). 
Apolipoproteins are carrier proteins that combine with lipids to form lipoprotein 
particles (Cryer et al., 1986). The liver is the major site for apolipoprotein synthesis; 
therefore, conditions in which liver function is affected, including cirrhosis, may be 
accompanied by decreased levels of apolipoproteins (Lombardi and Ugazio, 1965; 
Ciccarese et al., 1998). In animals this can occur following the exposure of rats to 
compounds such as CCl4 (Boll et al., 2001). Accumulation of triglycerides may also 
  
38 
 
occur as a result of excessive dietary intake (Donnelly et al., 2005, Kallwitz et al., 
2008).  
Hepatic steatosis may be described as microvesicular when there is accumulation of 
small intracytoplasmic fat droplets, and macrovesicular if the fat droplets are large 
(Reddy and Rao, 2006).  
1.2.2 Cell death/necrosis 
Cell death can occur by one of two mechanisms: apoptosis or necrosis. During the 
process of apoptosis, the cells often shrink and become more dense, the chromatin 
condenses and the nucleus fragments (Elmore, 2007). Apoptotic cells usually lack 
inflammatory cell infiltrates. The reason for this is that apoptotic cells do not release 
their cellular contents and, therefore, there is insufficient release of chemoattractants 
from individual cells to produce a large scale inflammatory response (Majno and Joris, 
1995). 
Necrosis is characterised histologically by changes to the nucleus such as karyolysis 
(complete dissolution of the chromatin due to the increased activity of DNAase); 
pyknosis (irreversible condensation of chromatin in the nucleus of a cell) and 
karyorhexis (nuclear fragmentation) (Arredondo et al., 2005; Stoica and Faden, 2010). 
These changes are accompanied by cellular swelling, swollen mitochondria, distended 
endoplasmic reticulum and the formation of cytoplasmic vacuoles. Cytoplasmic 
eosinophilia occurs due to the dissociation of ribosomes from the endoplasmic 
reticulum, as well as a disruption of the membranes of cellular organelles and the 
denaturation of proteins (Majno and Joris, 1995; Itoh et al., 2002; Elmore, 2007; 
Kroemer et al., 2009). The loss of cellular membrane integrity, due to necrosis, leads to 
the release of cytoplasmic contents including enzymes. The release of cellular contents 
produces an inflammatory response and this can lead to more severe injury occurring as 
a result of the influx of inflammatory cells, secretion of cytokines and production 
oxygen species (Majno and Joris, 1995; Darzynkiewicz et al., 1997; Elmore, 2007).  
Hepatocyte necrosis can occur after exposure to a hepatotoxicant agent. This is due to 
the particularly high concentration of cytochrome P-450 that can be found in the 
centrilobular region (Lindros, 1997; Sweeney, 1981). Centrilobular necrosis commonly 
occurs in rats exposed to compounds that undergo cytochrome P-450 bioactivation such 
as CCl4 (Slater, 1978; Smyth et al., 2007; Smyth et al., 2008; Smyth et al., 2009a), 
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acetaminophen (Waters et al., 2001; James et al., 2003) and thioacetamide (Diaz-Gil et 
al., 1987; Caballero et al., 2001).  
Midzonal necrosis is the least common type of hepatocellular injury and generally 
involves 2 or 3 cells in the middle of the lobule (Mackie et al., 2009). Midzonal necrosis 
has been described following phytol administration to mice (Mackie et al., 2009).  
In periportal necrosis, the necrotic hepatocytes are confined to the areas close to the 
portal tracts. This region is exposed first to blood containing toxicants and arriving at 
the liver via the portal vein. This type of injury often happens with compounds that do 
not require bioactivation, for example allyl alcohol (Belinsky et al., 1984).  
In the liver, necrosis can be focal, involving the death of a small number of cells in the 
central, midzonal or periportal regions, or massive, involving the death of a large 
number of cells, spanning to different lobules. In the case of focal necrosis there is 
potential for regeneration and repair since dead cells may be replaced by adjacent 
hepatocytes.  
Massive necrosis may occur when the liver is exposed to high concentrations of a 
toxicant agent, or a toxic compound is delivered directly to the vascular system, in 
particular to the portal vein. However, the liver has a great regenerating capacity, and 
therefore, even the death of a large number of hepatocytes may not be critical 
(Michalopoulos, 2007; Michalopoulos, 2011). 
1.2.3 Fibrosis 
Hepatic fibrosis is characterised by an excessive accumulation of extracellular matrix 
(ECM) proteins, in particular collagens, and occurs as a result of chronic injury to the 
liver (Clouthier et al., 1997). Fibrosis is a wound healing process that begins with 
inflammation and cellular necrosis which may undergo regeneration and repair. 
However, repeated injury may lead to increased synthesis of ECM proteins 
accompanied by decreased degradation. This imbalance between ECM production and 
degradation leads to deposition of excess collagens and scarring of the tissue (Parsons et 
al., 2004). The main causes of liver fibrosis in humans include hepatitis C, alcohol 
abuse and non-alcoholic steatohepatitis (Bataller and Brenner, 2005). 
ECM proteins including α-smooth muscle actin (α-SMA), vimentin, desmin and glial 
fibrillary acid protein (GFAP) perform numerous functions in the liver (Lin et al., 
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1998). These proteins have architectural and mechanical roles; are involved in providing 
tensile strength and resilience; modulate diffusion and vascular flow and participate in 
the process of regulating cell movement (Wells, 2008).  
The production of ECM is under the control of hepatic stellate cells (HSCs), also known 
as lipocytes, perisinusoidal or Ito cells. These are vitamin-A storing cells located in the 
perisinusoidal space of Disse (Jiao et al., 2009). Following hepatic insult the HSCs 
become activated and change to a myofibroblast-like cell with a corresponding 
reduction in the amount of vitamin-A stored within the cell (Figure 1.4) (Fallowfield, 
2011). HSC activation occurs in two sequential steps: initiation and perpetuation. The 
first step refers to the early events which occur after exposure to the hepatotoxicant and 
include the induction of β-platelet-derived growth factor (PDGF) and transforming 
growth factor-β1 (TGF-β1) receptors. The induction of these receptors makes the cells 
more responsive to cytokines. The perpetuating phase (second phase) comprises the 
response of the activated stellate cell to a variety of signals such as cytokines and 
growth factors (Friedman, 2008). The myofibroblast-like cells then proliferate and 
produce components of the ECM, including α-SMA, GFAP, vimentin and desmin as 
well as fibrillar collagen (collagen type-I and type-III) (Carpino et al., 2005; Friedman, 
2008; Krizhanovsky et al., 2008).  
α-SMA is an isoform of actin and a specific marker for activated HSCs displaying a 
myofibroblastic phenotype (Skalli et al., 1986). GFAP is an intermediate filament that 
has been shown to be present in the HSC in a normal rat liver and reported to be 
increased in response to acute hepatic injury but decreased in chronic injury (Niki et al., 
1996). The initial upregulation seen in the early stages of hepatic damage suggested that 
GFAP could be related to the process of HSC activation (Carotti et al., 2008).  
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Figure 1.4 Activation of hepatic stellate cells and resolution (modified from Fallowfield, 2011). 
Following injury, hepatic stellate cells (HSCs) undergo activation, whereby they change from vitamin-A 
storage cells into myofibroblast (MFB). The major phenotypic changes include proliferation, contractility, 
fibrogenesis, matrix degradation, chemotaxis and cytokine release. 
 
Activated HSCs also produce matrix metalloproteinases (MMPs), which degrade the 
ECM proteins (Nagase et al., 2006). MMPs are part of a family of zinc dependent 
endoproteinases capable of degrading fibrillar collagen such as collagens I, II, III, V and 
XI (Curran and Murray, 2000). According to their preferred substrates, MMPs can be 
divided into collagenases (MMP-1), gelatinases (MMP-2 and MMP-9), stromelysins 
(MMP-3, MMP-10 and MMP-11), matrilysins (MMP-7 and MMP-26) and membrane-
type MMPs (MMP-14, MMP-15, MMP-16) (Nagase et al., 2006).  
MMPs are synthesised as proenzymes and the structure includes a catalytic domain and 
an autoinhibitory pro-domain. Activation of MMPs requires the removal of the pro-
domain by proteases such as plasmin (Visse and Nagase, 2003; Page-McCaw et al., 
2007). Plasmin is generated from plasminogen by plasminogen activators (Lee et al., 
1996).  
It has also been shown that HSCs are capable of synthesising plasminogen activator 
inhibitor-1 (PAI-1) which in turn inhibits plasmin synthesis (Leyland et al., 1996). This 
suggests that decreased synthesis of plasmin by activated HSCs may have a role in the 
progression of the fibrotic process by inhibiting the activation of MMPs and hence the 
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degradation of excessive ECM proteins (Leyland et al., 1996). TGF-β is secreted by 
Kupffer cells and HSCs and contributes to the pathogenesis of fibrosis by stimulating 
the expression of fibronectin, collagens, and matrix proteoglycans (components of the 
ECM), and also via the induction of MMP inhibitors and PAI-1 (Branton and Kopp, 
1999). It has been previously reported that TGF-β can be inhibited by α2-macroglobulin 
(A2M) by binding to activated TGF-β (Tiggelman et al., 1997). A2M is secreted by 
hepatocytes and is an acute phase protein and a proteinase inhibitor (Kawser et al., 
1998). Tiggelman et al., (1997) suggested an antifibrogenic effect for A2M due to their 
ability to bind and inactivate TGF-β, and therefore, inhibit the TGF-β-induced collagen 
synthesis. 
The activity of MMPs is regulated by tissue inhibitors of metalloproteinases (TIMPs) 
which bind to MMPs and block their proteolytic activity (Brew et al., 2000; Han, 2006). 
TIMPs expression is induced by TGF-β (Knittel et al., 2000). The decrease in the 
catalytic activity of MMPs is an important regulator in the progression of fibrosis. 
Increased TIMP-1 expression by HSCs has been reported in rats following repeated 
administration of CCl4 (Iredale et al., 1996; Herbst et al., 1997).  
Accumulation of ECM can disrupt the normal liver architecture and compromise liver 
function. An increase in fibrillar collagen in the space of Disse may result in the 
defenestration of the hepatic sinusoidal epithelium, a process known as sinusoidal 
capillarisation (Hahn et al., 1980; Siegmund et al., 2005). In the fibrotic liver this 
sinusoidal epithelium becomes rich in collagen and fibronectin and the loss of the pores 
blocks the bidirectional exchange of substances between the sinusoidal lumen and the 
adjacent hepatocytes (Hahn et al., 1980; Friedman, 1993). This leads to an increase in 
the intrahepatic vascular resistance and may result in the development of portal 
hypertension which is characterised by an increase in pressure in the portal vein 
(Rockey, 1997).  
Fibrosis was previously considered to be an irreversible condition. However, evidence 
now indicates that even advanced stages of fibrosis may be reversible and that increased 
collagenolytic activity is one of the major factors contributing to the recovery (Benyon 
and Iredale, 2000). Survival factors such as insulin-like growth factor-1 (IGF-1) and 
tumour necrosis factor-α (TNF-α) regulate the activity of HSCs. Loss of these survival 
factors makes activated HSCs more susceptible to apoptosis. Activated HSCs have been 
reported to be more susceptible to apoptotic signals (Li and Friedman, 1999). Thus, 
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during resolution of fibrosis there is an increase in the number of cells undergoing 
apoptosis. Consequently, the decrease in the number of HSC will result in decreased 
levels of TIMP and therefore, the activity of MMPs increases. Iredale and colleagues 
(1998) have shown that spontaneous liver recovery is accompanied by loss of α-SMA 
positive HSCs indicating a loss of activated HSCs. It has been proposed that this is due 
to apoptosis as opposed to a regression of phenotype from the activated to a quiescent 
HSC (Iredale et al., 1998).  
Currently, there remains great debate regarding the mechanism for the reversibility of 
fibrosis and the origin of the myofibroblast-like cells is not yet completely understood 
(Ramachandran and Iredale, 2012; Sohrabpour et al., 2012; Czaja, 2014; Machado and 
Diehl, 2014). The latest antifibrotic therapy strategies have focused on increasing the 
rate of HSC apoptosis, or in targeting myofibroblasts (Liu et al., 2013), whereas 
Rosenbloom et al., (2013) suggested the selective inhibition of the TGF-β pathway as a 
possible therapy.  
1.2.4 Cirrhosis 
Cirrhosis is defined as the “histological development of regenerative nodules 
surrounded by fibrous bands in response to chronic liver injury” (Schuppan and Afdhal, 
2008). Liver cirrhosis is the end result of fibrosis. In the Western world, cirrhosis is 
frequently associated with alcoholic liver disease and hepatitis C, whereas hepatitis B is 
an important cause in Africa (Schuppan and Afdhal, 2008). 
Cirrhosis is characterised by extensive fibrous scarring of the liver tissue leading to loss 
of hepatic architecture and distortion of the hepatic vasculature. This compromises the 
exchanges between hepatic sinusoids and hepatocytes (Vollmar et al., 1997; Kamath et 
al., 2000). Histological examination of cirrhotic livers is characterised by the presence 
of vascularised fibrotic septa that surround hepatocytes creating islands devoid of a 
central vein (Schuppan and Afdhal, 2008). Human patients with cirrhosis often suffer 
from arterial vasodilatation, increased cardiac output, hyponatremia (serum sodium 
level of less than 135 mEq/L in humans) and hepatorenal syndrome (Lee, 2009). 
Hepatorenal syndrome describes the compromise of renal function occurring as a 
consequence of cirrhosis. In a cirrhotic liver, portal hypertension often arises and is 
characterised by an increase in pressure in the portal vein. This event is followed by the 
release of vasodilators, for example nitric oxide, which can escape from the splanchnic 
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circulation into the systemic circulation causing vasodilatation, this in turn will be 
counteracted by stimulation of the vasoconstrictor systems as well as retention of salt 
and water in an attempt to maintain the blood pressure. It is this constant 
vasoconstriction that can lead to renal failure (Ginès et al., 2003; Betrosian et al., 2007). 
Ascites is one of the most common complications of cirrhosis and is described as the 
accumulation of fluid in the peritoneal cavity. Ascites occurs as a consequence of portal 
hypertension. It results from a leakage of lymph fluid from the blood vessel of the GI 
tract into the peritoneal cavity. Eventually, sodium and water also move from the 
capillaries into the peritoneal space resulting in the development of ascites (Kashani et 
al., 2008).  
Splenomegaly is also frequently observed in patients with portal hypertension. This 
enlargement of the spleen is a consequence of the increase in the portal vascular 
resistance which compromises the blood flow through the splenic vein (Gusberg et al., 
1994).  
Anatomically, cirrhosis can be classified as either micronodular or macronodular. In 
micronodular cirrhosis the nodules are smaller than 3 mm and it is often observed in 
Wilson’s disease and primary biliary cirrhosis (PBC). PBC is characterised by the 
accumulation of lymphocytes and plasma cells close to the intrahepatic bile ducts 
leading to the inflammation of the bile ducts, loss of ducts and eventual impairment of 
the bile flow. This damages the liver cells leading to the scarring of the tissue and 
eventually cirrhosis (Selmi et al., 2011). The nodules in micronodular cirrhosis are of 
the same order of size as the original lobule and the lesions are regularly distributed 
throughout the liver. In macronodular cirrhosis, nodules are enlarged to 3 mm or larger 
in size and are encircled by collagen bands (Scheuer, 1970). Macronodular cirrhosis is 
often seen in patients with viral hepatitis and in animal models of drug-induced injury 
(Yu et al., 2010a). 
In rodents, cirrhosis can occur following repeated, low dose, CCl4 administration 
(Proctor and Chatamra, 1983; Ariosto et al., 1989; Lee et al., 2005; Jaramillo-Juarez et 
al., 2008).  
Traditionally, cirrhosis is classified as an irreversible condition, however, it has been 
suggested that cirrhosis may potentially reverse (Benyon and Iredale, 2000; Friedman, 
2003; Pinzani et al., 2011). It has been recently proposed that reversibility of cirrhosis in 
humans may occur but it is a very slow process that may take years and that not all 
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patients have this ability. However, at a certain point cirrhosis of the liver is considered 
to be irreversible (Sohrabpour et al., 2012). In humans, it has been shown that absence 
of alcohol for at least 6 months was associated with regression of cirrhosis in 8 % of the 
patients in a retrospective study (Serpaggi et al., 2006). Signs of cirrhosis regression 
have also been described in rat models of CCl4-induced cirrhosis (Di Vinicius et al., 
2005). 
1.2.5 Liver cancer 
Hepatocellular carcinoma (HCC) is the sixth most common cancer and one of the top 3 
causes of cancer-related deaths in the world (Parkin et al., 2005; Forner et al., 2012). 
The pathogenic process includes the development of regenerative nodules leading to 
invasive HCC (Schuppan and Afdhal, 2008). Risk factors for HCC include cirrhosis, 
viral hepatitis B and C and aflatoxin exposure. The mechanism by which viral hepatitis 
increases the risk of hepatocellular carcinoma is not completely understood but is 
thought to be dependent upon oxidative stress-induced DNA damage (Mendy and 
Walton, 2009). The formation of reactive oxygen species (ROS) may result from both 
endogenous and exogenous stimuli. Xenobiotics such as 2-butoxyethanol and CCl4 
undergo cytochrome P-450 metabolism to form free radicals (Sasaki, 2006). 
Additionally, it has been shown that Kupffer cells and macrophages have the ability to 
generate ROS in the hepatocytes (Friedman, 2003). It is thought that nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase in the Kupffer cells catalyses the 
reduction of O2 to O2
.-
 (Cubero and Nieto, 2012). Oxidative stress results from the 
imbalance between the generation of ROS and the antioxidant mechanisms (Suzuki et 
al., 2013). It is thought that these reactive oxygen species have an effect on the normal 
proliferation of hepatocytes leading to tumour development (El-Serag and Rudolph, 
2007). 
1.3 Detection of hepatic injury 
This project is concerned with the identification of biomarkers of hepatotoxicity. A 
biomarker was described by Atkinson et al., (2001) as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention”.  
Currently, biomarkers are used to determine the severity of a disease and its prognosis. 
However, biomarkers are also used in preclinical and clinical studies to evaluate new 
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candidate drugs with regards to safety and effectiveness and have great use in 
toxicology studies (Lewin and Weiner, 2004).  
An ideal biomarker should indicate the early stages of a disease or injury, be organ 
specific and have a strong correlation with well defined histomorphologic changes. A 
biomarker is more ideal if it can be detected by tests which are simple to perform, 
reliable, inexpensive and high-throughput. Non-invasive collection of samples is also 
preferential to invasive methods such as blood collection (Ozer et al., 2008). 
1.3.1 Serum enzymes 
Traditionally, liver injury has been assessed by the measurement of serum enzymes 
such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and 
glutamate dehydrogenase (GLDH). These enzymes are called hepatic leakage enzymes 
since they are released from the hepatocytes when there is loss of cellular membrane 
integrity (Solter, 2005; Schmidt and Schmidt, 1988; Gores et al., 1990; Van Hoof et al., 
1997). This may occur as a result of cell necrosis or inflammation (Bridges et al., 1983). 
The standard unit used to quantify the amount of enzyme is called the international unit 
of enzyme activity (U), which measures the amount of enzyme needed to convert 1 
µmol of substrate into product in 1 minute. Enzyme concentration is expressed as U/L, 
that is, enzyme activity divided by volume. 
ALT is a cytosolic enzyme which is mainly located in the liver, but low levels of the 
enzyme are also found in skeletal muscle and heart tissues. The highest concentration of 
this enzyme has been reported to be found in the periportal hepatocytes with lower 
concentrations in the centrilobular region (Rappaport, 1958). AST is found in both the 
cytosol and mitochondria and is present in high concentrations in a number of tissues 
including the heart, brain, skeletal muscle and liver (Wroblewski, 1959). Therefore, 
injury to any of these tissues may result in significant serum AST elevations. Therefore, 
ALT is more specific to hepatic injury than AST (Ramaiah, 2007). 
Additionally, ALT has a longer half-life than AST (approximately 50 hours for ALT 
and 16 hours for AST) (Krishnamurthy et al., 2009).  
The ratio of AST to ALT is often used to provide information about the causes of liver 
disease. Serum AST is generally increased by greater amounts compared to ALT in 
chronic liver damage, whereas, acute liver injury results in increased levels of ALT 
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compared to AST (Williams and Hoofnagle, 1988). The AST/ALT ratio tends to be 
greater than 2 in patients with alcoholic liver disease and less than 1 in patients with 
chronic hepatitis (Williams and Hoofnagle, 1988). A study has shown that 
mitochondrial AST is not released into the blood circulation until most of the cytosolic 
enzyme has leaked out. This suggests that mitochondrial enzymes only leak from 
hepatocytes when a greater degree of injury has occurred than that which results in 
leakage of the cytosolic enzymes (Kamiike et al., 1989). 
GLDH is located both in the cytosol and mitochondrial matrix (O'Brien et al., 2002) 
with the highest concentration found in the liver. However, GLDH can also be found in 
the kidneys, lungs, brain and skeletal muscle (Mihara et al., 1982, Schmidt and Schmidt, 
1988, Lee et al., 1999). Within the liver, GLDH levels are greatest in the centrilobular 
region and therefore, injury to this area will produce a significant increase in plasma 
GLDH concentration (O'Brien et al., 2002). GLDH is thought to be a good biomarker 
for acute liver injury since its levels increase significantly after hepatocellular damage 
and it has high tissue specificity (O'Brien et al., 2002; Ramaiah, 2007). 
Alkaline phosphatase (ALP) is mainly located within the biliary canaliculi and epithelial 
cells comprising the bile ducts (Kaplan and Righetti, 1970). ALP can also be found in 
the bone and kidneys (Yusa et al., 2000). Increases in the plasma levels of this enzyme 
are considered a marker of hepatobiliary effects and cholestasis (Swain et al., 1993; 
Ramaiah, 2007).  
The current standard for assessing liver injury relies on the measurement of ALT and 
AST. The problem with these enzymes is that the levels do not change considerably 
from control values, until a great degree of injury has been induced. Also, neither of 
these enzymes are uniquely specific to the liver; therefore, increased blood levels do not 
necessarily mean hepatocyte injury. This has led to a major increase in the investigation 
for new biomarkers that perform better and can easily translate from preclinical to 
clinical studies (Schmidt and Schmidt, 1988; Gores et al., 1990; Van Hoof et al., 1997; 
Giffen et al., 2002). 
1.3.2 Markers of fibrosis 
Serum biomarkers for liver fibrosis can be differentiated into 2 categories: indirect and 
direct markers. Indirect markers may be released into the blood as a result of 
inflammation (ALT and AST) (Giffen et al., 2002) and also include molecules that are 
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synthesised or excreted by the liver, for example albumin, clotting factors and bilirubin. 
Additionally, markers of biochemical pathways that may be disrupted as a consequence 
of impairment to liver function, including for example the development of insulin 
resistance, can be considered indirect markers (Adams, 2011; Castera, 2011). Direct 
markers of fibrosis include degradation products of extracellular matrix (for example 
MMPs, TIMPs, hyaluronic acid (HA)). 
1.3.2.1 Indirect markers  
Albumin is the most abundant plasma protein and is synthesised in the liver. 
Consequently, a reduction in plasma albumin levels often occurs when there is impaired 
liver function, such as fibrosis and cirrhosis (Carey and Carey, 2010). Decreases in the 
serum concentration of albumin have been previously reported in models of CCl4-
induced hepatic fibrosis/cirrhosis (Gou et al., 2013). 
Most of the clotting factors, including factors I, II, V, VII, IX and X, are synthesised in 
the liver by parenchymal cells, therefore, disruption of hepatocellular function will be 
reflected in coagulation abnormalities (Mammen, 1992). In cirrhosis, the liver function 
is compromised and consequently there is decreased production of clotting factors 
which results in increased prothrombin time (Kujovich, 2005; Amarapurkar and 
Amarapurkar, 2011). 
Increased bilirubin is also frequently observed in end stage cirrhosis (Grigorescu et al., 
2007; Carey and Carey, 2010). Bilirubin results from the breakdown of haemoglobin in 
the liver and may be classified as direct or indirect bilirubin. Direct or conjugated 
bilirubin is the form that has been removed from the blood by the liver and absorbed by 
the hepatocytes, whereas indirect or unconjugated bilirubin may increase in cases of 
anaemia or diseases where there is increased breakdown of red blood cells.  
Indirect markers of fibrosis also include glucose, which is often increased in the serum 
as a consequence of insulin resistance. Impaired insulin sensitivity and subsequent 
impaired glucose tolerance are often present in chronic liver disease including cirrhosis 
(Petrides et al., 1998; Hickman and Macdonald, 2007).  
Monocyte chemoattractant factor 1 (MCP1) is thought to be a marker of liver fibrosis 
and the expression of MCP1 has been widely studied in several pathological conditions 
including pulmonary fibrosis, kidney disease and atherosclerosis (Yu et al., 1993; 
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Grandaliano et al., 1996). However, the role of MCP1 in the liver has not been fully 
studied. Marra and colleagues (1993) demonstrated that MCP1 is one of the most 
important chemotactic factors secreted by HSCs. Data collected from both in vitro and 
in vivo studies suggests a role for HSC in the expression of MCP both in chronic and 
acute liver injury (Maher and McGuire, 1990; Czaja et al., 1994; Marra et al., 1998). In 
a experimental model of CCl4-induced liver damage in mice MCP1 levels were found to 
be increased in the serum (Karlmark et al., 2009). 
A2M is a plasma globulin secreted by hepatocytes and functions as an inhibitor of the 
coagulation and fibrinolytic systems (Kawser et al., 1998). A2M has been shown to 
bind and inactivate proteases from the metalloproteinase class including collagenases 
(Barrett and Starkey, 1973). Therefore, the increase in A2M expression is thought to 
play a role in mediating the decrease in MMP activity as fibrosis progresses (Truden 
and Boros, 1988; Kawser et al., 1998).  
α-1-acid glycoprotein (AGP) is one of the major acute phase proteins. It is mainly 
secreted by hepatocytes and has been shown to increase following hepatic injury 
(Fournier et al., 2000). Sugihara and co-workers proposed a mechanism for the increase 
in AGP plasma levels involving necrosis of the parenchymal cells and infiltration of 
inflammatory cells leading to the secretion of cytokines which would in turn trigger the 
production of acute-phase proteins like AGP (Sugihara et al., 1992). Goldberg et al., 
(1983) have also previously reported increases in plasma AGP levels in rat models of 
CCl4-induced hepatic necrosis. Similarly, upregulation of AGP expression has been 
documented in cirrhotic livers (Mirpuri et al., 2002). 
1.3.2.2 Direct markers  
As described in Section 1.3.2, liver fibrosis can be detected by measurement of direct 
markers for the fibrotic process. ECM degradation is mediated by MMPs which in turn 
are regulated by TIMPs (Brew et al., 2000). In hepatic fibrosis there is a significant 
accumulation of ECM that results from both increased synthesis and decreased 
degradation. This leads to a wound healing process characterised by progression of the 
scarring of the tissue instead of resolution (Benyon and Arthur, 2001). 
TIMPs are important regulators of MMPs, including interstitial collagenase and 
gelatinase A and B (Murphy et al., 1991; Iredale et al., 1996). TIMPs act by inhibiting 
the proteolytic activity of the MMPs (Brew et al., 2000).  
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Both MMPs and TIMPs are regulated by growth factors such as TGF-β resulting in 
downregulation of MMP expression and upregulation of TIMP expression (McAnulty et 
al., 1991; Hall et al., 2003).  
The major sources for TIMP-1 production in liver fibrosis are activated HSCs and 
Kupffer cells (Herbst et al., 1997; Wang et al., 2011). Therefore, serum levels of TIMP-
1 are thought to be good indicators of liver fibrosis (Roderfeld et al., 2006). TIMPs are 
known to increase in expression as fibrosis progresses which will result in greater 
inhibition of MMPs. Therefore, decreased levels of MMPs and increased TIMP levels 
in the serum are strongly associated with fibrotic progression and will be apparent with 
increased injury. Previous studies investigating interstitial collagenase activity during 
CCl4-induced liver fibrosis have shown a decrease in activity as the disease progresses 
(Montfort and Perez-Tamayo, 1978) and an increase in TIMP-1 expression by HSCs 
(Iredale et al., 1996; Herbst et al., 1997).  
Hyaluronic acid (HA) is classified as a direct marker of liver fibrosis. It is a component 
of the extracellular matrix and is synthesised by hyaluronic acid synthases located in 
HSCs (Rostami and Parsian, 2013). HA is a high molecular weight polymer (>1x10
6
 
Da) (Maharjan et al., 2011), and can be found in the extracellular, pericellular and 
intracellular spaces (Rostami and Parsian, 2013). The main function of HA is to regulate 
water flow in the extracellular matrix; water flow is important for maintaining the 
structural organisation of the tissue (George et al., 2004). The liver is responsible for 
both the synthesis and removal of HA by sinusoidal endothelial cells which have the 
ability to uptake and metabolise HA (Deaciuc et al., 1993). During liver injury, HA 
breaks down into smaller fragments (Maharjan et al., 2011). In fibrosis, dysfunctional 
sinusoidal endothelial cells are responsible for increased serum levels of HA as the 
ability to eliminate HA is compromised. Accumulation of HA in the sinusoidal 
endothelial cells plays a major role in the formation of the basement membrane 
responsible for the capillarisation of sinusoids (George et al., 2004). CD44 is the major 
receptor for HA in sinusoidal endothelial cells and regulates the degradation of HA. 
Decreased levels of this receptor have been reported in models of cirrhosis (George et 
al., 2004). Additionally, activation of HSCs and proliferation during fibrogenesis may 
also contribute to an increased expression of HA which can leak into the blood. 
Consequently, increased serum levels of HA can be used to measure the progression of 
liver fibrosis (Deaciuc et al., 1993; Saegusa et al., 2002; Rossi et al., 2007). 
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1.3.3 Serum marker panels 
Since no one serum marker is reliable enough to be used individually for the detection 
of fibrosis, several different serum markers have been selected for the creation of 
algorithms which can be used to evaluate fibrosis. These biomarker panels may include 
direct and indirect serum markers of fibrosis. The diagnostic value of these panels is 
assessed by calculating the area under the receiver operating characteristic curves 
(AUROC), which represents the probability that a particular test will be able to correctly 
classify 2 patients, one with a normal liver biopsy and one with a liver biopsy 
considered abnormal (Bedossa and Carrat, 2009). These scores have been able to 
substantially increase diagnostic accuracy. 
Currently, there are several different serum panels for differentiating control from 
fibrotic livers. These include the FibroTest, which measures A2M, haptoglobin, γ-
glutamyltransferase, apolipoprotein A1 and bilirubin; and the Fibrometer which 
comprises platelet count, prothrombin index, AST, A2M, HA, urea and age (Rossi et 
al., 2003; Friedrich-Rust et al., 2010). 
1.3.4 Imaging techniques 
Deposition of ECM is responsible for causing changes to the liver microstructure and 
architecture that can be detected using imaging techniques. Some of these techniques 
include ultrasonography (US) and transient ultrasound elastography. 
1.3.4.1 Ultrasonography  
Ultrasonography (US) is one of the imaging techniques used for non-invasive 
estimation of the degree of fibrosis. US uses high-frequency sound waves to create an 
image of the internal organs. Sound waves that are reflected to the transducer are 
converted into an image (Nishiura et al., 2005).  
Hepatic US is inexpensive and is considered to be a reliable tool in detecting 
hepatocellular carcinoma (Nishiura et al., 2005). US allows the characterisation of 
several parameters that are useful in assessing the degree of chronic liver injury, 
including the nodularity of the tissue, degree of homogeneity of the liver parenchyma, 
size of the lymph nodes around the hepatic artery, size of the spleen and presence of 
ascites (Outwater, 2010).  
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Echogenicity refers to the variety of characteristics that define the appearance of tissues. 
Normally, the hepatic parenchyma is homogeneous with medium level echogenecity 
and equal or slightly more echogenic than the kidneys. Its echogenic texture is 
interrupted by the portal and hepatic veins; whereas a fibrotic/cirrhotic liver is 
characterised by heterogeneous patchy or diffuse echogenecity and this is related to the 
development of fatty liver and scar tissue (Tchelepi et al., 2002).  
1.3.4.2 Transient ultrasound elastography (FibroScan) 
This imaging technique measures the stiffness of the liver parenchyma by using a 
combination of ultrasound and low frequency elastic waves. The fibrotic liver is harder 
than a normal liver due to the deposition of collagen fibres which alter the architecture 
of the liver and increase the rigidity of the parenchyma. The FibroScan is composed of a 
probe that generates an elastic shear wave that propagates within the liver. 
Measurements are made to determine the speed of the shear wave and this correlates 
directly with tissue stiffness, the harder the tissue the faster this waves propagates. 
Measurements can take less than 5 minutes to collect (Baranova et al., 2011). However, 
this technique is considered unreliable in humans if the patient is obese or has ascites. 
Additionally, it cannot detect the early stages of the disease. 
1.3.5 Liver biopsy 
Currently, liver biopsy is still regarded as the gold standard for the diagnosis and 
assessment of hepatic fibrosis (Bataller and Brenner, 2005; Rossi et al., 2007; Martinez 
et al., 2011). It is a highly invasive procedure where, by using a needle, a tissue sample 
is surgically removed for histological examination. Therefore, liver biopsy cannot be 
used as a routine clinical method for assessing liver disease, and due to the reduced 
sample size may provide erroneous results (Bedossa et al., 2003; Standish et al., 2006; 
Carey and Carey, 2010).  
Therefore, a combination of routine biochemical tests, and abdominal US examination 
remain the most frequently used methods for the diagnosis of hepatic injury (Schuppan 
and Afdhal, 2008). More recently, the problems inherent to liver biopsy have fuelled the 
need for alternative methods of assessing liver injury, particularly in regards to their 
ability to detect early stages of disease (Castera, 2011).  
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It is the need for more specific and more sensitive biomarkers, which can be measured 
by non-invasive means, preferably in urine samples, that was the main driving force 
behind this project. 
1.4  Carbon tetrachloride  
CCl4 is one of the most commonly used hepatotoxicants (de Zwart et al., 1998; Hiyoshi 
et al., 2009). CCl4 is metabolised in the liver by cytochrome P-450 to produce reactive 
free radicals which can initiate lipid peroxidation (Recknagel and Ghoshal, 1966; 
Recknagel, 1967; Brattin et al., 1985).  
CCl4 is metabolised in the liver smooth endoplasmic reticulum by cytochrome P-450, 
mainly the cytochrome P-450 2E1 isoform. The product of this metabolism is the 
trichloromethyl free radical (CCl3
•
) which can undergo both anaerobic and aerobic 
reactions (Brattin et al., 1985). The half-life of the trichloromethyl free radical is 
approximately 100 µs, therefore, toxic effects caused by the radical tend to be close to 
the site of production (Slater, 1966). The concentration of cytochrome P-450 is greatest 
in the centrilobular region making this area most susceptible to injury (Recknagel et al., 
1989). Early studies proposed that the mechanism responsible for the formation of the 
free radical was the homolytic cleavage of CCl4 (Brattin et al., 1985). However, this 
reaction is thermodynamically unfavourable and requires 68 kcal/mol for the homolytic 
cleavage of the C-Cl bond. Therefore, it is considered that the mechanism involved in 
CCl4 metabolism consists of a one-electron reduction of CCl4 by the NADPH-
cytochrome P450 system which transfers one electron from NADPH to CCl4. This 
process results in the formation of an anion radical that will produce CCl3
•
 and a 
chlorine ion (Cl
-
) (Figure 1.5) (Brattin et al., 1985). 
In the absence of oxygen, CCl3
•
 may diffuse into the phospholipid bilayer of the 
endoplasmic reticulum (Rao and Recknagel, 1969; Trudell et al., 1982) where it may 
abstract a hydrogen atom from a methylene group on polyunsaturated fatty acids to 
form chloroform (CHCl3) (Trudell et al., 1982). Under these conditions, the CCl3
•
 free 
radical can also bind to lipids, proteins and DNA (Figure 1.5).  
Under aerobic conditions, the CCl3
•
 can react with oxygen to form a 
trichloromethylperoxyl free radical (Cl3COO
•
) (Figure 1.5). This radical has been 
proven to be a stronger electrophilic agent and more reactive than CCl3
•
 and can abstract 
a hydrogen atom from polyunsaturated fatty acids in the membrane to generate further 
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free radicals (Recknagel et al., 1989; Weber et al., 2003). This leads to a claim of free 
radicals and the initiation of a cascade of events called lipid peroxidation (Recknagel, 
1967; Brattin et al., 1985). This chain reaction terminates with the production of lipid 
breakdown products, including lipid alcohols, aldehydes or malondialdehyde 
(Recknagel, 1967; Bagchi et al., 1993; Fanelli and Castro, 1993). Ultimately, the chain 
of events results in the destruction of membrane structure and loss of organelle 
integrity. The products of lipid peroxidation have much longer half-lives than the 
trichloromethyl free radical or the trichloromethylperoxyl free radical and therefore they 
can migrate and induce more widespread injury (Slater et al., 1985). It has been 
proposed that the trichloromethylperoxyl free radical is responsible for most of the 
CCl4-induced toxic effects since the CCl3
•
 radical is less reactive. In fact, the covalent 
binding of CCl3
•
 to proteins occurs in the absence of oxygen, but the destruction of 
other enzymes of the endoplasmic reticulum requires oxygen to be present.  
Instead of initiating lipid peroxidation the trichloromethylperoxyl free radical may react 
further to produce trichloromethanol, which in turn can lead to the generation of 
phosgene and a chlorine radical (Figure 1.5). Phosgene was once thought to play an 
important role in CCl4-induced hepatotoxicity. However, in vitro studies using cysteine, 
a known phosgene scavenger, have shown that eliminating phosgene does not reduce 
the toxic effects of CCl4 (Waller and Recknagel, 1982). In addition, phosgene undergoes 
a high rate of spontaneous hydrolysis which means large concentrations would be 
required to produce the toxic effect of CCl4. The amount of phosgene produced from 
CCl4 metabolism is much lower than the necessary concentration (Brattin et al., 1985). 
NADPH-cytochrome P-450
1. CCl4 + e
- CCl4
- CCl3
 + Cl-
2. CCl3
 + H+ CHCl3
3. CCl3
 + O2 CCl3OO
-
4. CCl3COO
- Cl3COOH
5. Cl3COOH                                                   Cl3COH                                                   
6. Cl3COH                                                   Cl2CO  
Figure 1.5 Biotransformation of carbon tetrachloride. 1. One-electro reduction catalysed by NADPH
-
cytochrome P-450 system and production of trichloromethyl free radical (CCl3
•
)
 
and chlorine ion (Cl
-
); 2. 
trichloromethyl free radical abstract a hydrogen to produce chloroform (CHCl3); 3. trichloromethyl free 
radical reacts with oxygen to generate trichloromethylperoxyl free radical (CCl3COO
•
); 4./5. 
trichloromethylperoxyl free radical further reacts to produce trichloromethanol (Cl3COH); 6. 
trichloromethanol reacts to produce phosgene (Cl2CO).
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Lipid peroxidation occurs rapidly following CCl4 administration (Recknagel, 1983). It is 
known that CCl4-induced lipid peroxidation can be detected within 5 minutes of dosing 
(Recknagel, 1967; Rao and Recknagel, 1968). One of the main processes affected by 
lipid peroxidation is the capacity of the endoplasmic reticulum to sequester Ca
2+ 
ion. 
This would result in the release of Ca
2+ 
from the endoplasmic reticulum into the cytosol 
with pathological consequences (Recknagel, 1983; Pencil et al., 1984). The level of 
cytosolic free Ca
2+
 is reported to participate in the regulation of several processes, such 
as intracellular traffic of VLDLs and secretion of triglycerides by the liver cells. 
Disruption of this process will result in the accumulation of triglycerides and 
consequently, in the development of a fatty liver (Recknagel, 1983). Moreover, it has 
been shown that decreased amounts of calcium sequestered in the endoplasmic 
reticulum have an inhibitory effect on protein synthesis (Mandl et al., 1982; Kimball 
and Jefferson, 1992). This leads to a decrease in the synthetic function of the liver.  
One of the mechanisms that appears to confer some protection against CCl4-induced 
toxicity is the administration of a small dose of CCl4 prior to the administration of a 
much larger dose 24 hours later (Ugazio et al., 1972). Ugazio et al., (1972) 
demonstrated maximal protection from the second larger dose at 24 hours after a 
smaller first dose. This mechanism has been referred to as “suicidal inactivation” 
(Manno et al., 1992). Hepatocytes were protected for 3 days before susceptibility to 
CCl4-induced toxicity returned (Ugazio et al., 1972). This self protection is related to a 
depression of cytochrome P-450 enzyme activity by the first dose of CCl4 prior to the 
administration of a larger dose level. 
1.5  The kidney 
The kidney is composed of two regions: the outer cortex and the inner medulla. The 
main functional unit of the kidney is the nephron; each nephron consists of a glomerulus 
surrounded by the Bowman’s space, a proximal tubule, and a distal tubule. The 
proximal tubule plays an important part in maintaining homeostasis via the reabsorption 
of water, sodium and chloride ions, and also by a number of absorptive and secretory 
mechanisms (Zhang, 1999).  
The kidneys are responsible for the regulation of body fluid osmolarity and volume, 
electrolyte and acid-base balance and for maintaining blood pressure. Additionally, they 
are also involved in excretory and secretory processes and are the main site of 
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elimination of metabolic products and toxins as well as the production and secretion of 
hormones such as erythropoietin (Lote, 2012). 
1.5.1 Urine formation 
Urine formation occurs in 3 sequential steps: glomerular filtration, tubular reabsorption 
and tubular secretion.  
The filtration step occurs in the glomerulus and involves the ultrafiltration of plasma in 
the glomerulus. Blood is supplied to the kidney by the renal artery, before entering and 
leaving the nephron via the afferent and efferent arteriole. As blood flows through the 
glomerulus it is filtered into the Bowman’s capsule. The glomerulus is a semi-
permeable membrane which has a fenestrated endothelium, a glomerular basement 
membrane and a podocyte layer. This semi-permeable membrane is freely permeable to 
water and small molecules but is impermeable to larger molecules and blood particles. 
The hydrostatic pressure within the glomerular capillaries forces the protein-free plasma 
out of the capillaries and into the Bowman’s capsule (Khurana, 2009).  
There are however, two forces that oppose the hydrostatic pressure: the plasma osmotic 
pressure which results from the difference in protein concentration across the 
glomerular membrane; and the Bowman’s capsule hydrostatic pressure which is the 
pressure exerted by the fluid in the initial part of the tubule. Therefore, the net filtration 
pressure is the result of the balance between the hydrostatic pressure within the 
glomerular capillaries, that favours filtration; the plasma osmotic pressure and the 
Bowman’s capsule hydrostatic pressure, that oppose filtration (Williams and Schafer, 
1987). 
Tubular reabsorption of substances such as potassium, sodium and bicarbonates, 
consists of the passage from the tubular lumen into the blood capillaries and involves 
active and passive transport mechanisms. Cells in the proximal convoluted tubules 
actively reabsorb nutrients, ions and proteins from the tubular fluid. In man, virtually all 
proteins are reabsorbed back into the blood. However, if the concentration of the 
proteins being filtered increases significantly, some of these proteins may appear in the 
urine. The reabsorption of sodium into the cytosol of the epithelial cells, and further into 
the interstitium and subsequently into the blood creates an osmotic gradient leading to 
water reabsorption from the tubules. The final result is a highly concentrated fluid. In 
the ascending limb of the loop of Henle, Na
+
 and Cl
- 
are actively pumped out of the 
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tubular fluid by Na
+
-K
+ 
ATPase pump. In the distal tubule and collecting duct, Na
+
, Cl
- 
and Ca
2+ 
are reabsorbed along with water whereas K
+
 and H
+
 are secreted (Ashalatha 
and Deepa, 2011).  
The final step in urine formation consists of the movement of substances out of the 
capillaries and into the distal and collecting tubules (Sands and Layton, 2009) 
Once urine has been formed in the kidneys it travels through the ureters to the urinary 
bladder. Peristaltic contractions of the ureteral wall force the movement of urine into the 
bladder (Sherwood, 2013). 
The human urinary protein content is very different from that of rat urine. Indeed, it 
appears that the humans only excrete approximately 1 % of the protein concentration 
found in urine samples from male rats (Olson et al., 1990). 
1.6 Kidney injury 
The kidneys are one of the main target organs for drug-induced toxicity for several 
reasons. Firstly, the kidneys have a high blood flow. Therefore, drugs which are present 
in the systemic circulation will be delivered to the kidneys in particularly high amounts. 
Secondly, most toxicants will be excreted via the urine and often these xenobiotics 
become concentrated in the nephron as a result of water reabsorption. Progressive 
concentration of xenobiotics in the nephron may cause them to precipitate thus inducing 
acute kidney injury (AKI) secondary to tubular obstruction. Renal transport and 
metabolism of toxicants also greatly contribute to increased susceptibility of the kidney 
to drug-induced injury (Werner et al., 1995; Pfaller and Gstraunthaler, 1998). 
1.6.1 Biomarkers of kidney injury 
Biomarkers of renal injury can be used to: identify the primary location of the injury; 
determine the duration of kidney failure; distinguish between different types of AKI and 
different aetiologies; define the course of disease and monitor the response to 
interventions (Devarajan, 2007). 
1.6.1.1 Serum markers 
Traditionally, clinical evaluation of renal function relied on the measurement of blood 
urea nitrogen (BUN) and serum creatinine as markers of a reduction in the glomerular 
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filtration rate (GFR). Both urea and creatinine are freely filtered in the glomerulus. 
Creatinine undergoes tubular secretion, whereas, urea is not secreted but instead is 
reabsorbed by the renal tubules (Schrier, 2008). A decrease in renal blood flow or 
compromised kidney function, as a result of kidney injury, can reduce the glomerular 
filtration rate, and consequently result in increased serum creatinine and urea. 
Serum creatinine levels can also reflect several non-renal factors including body weight, 
age, gender, race, muscle metabolism and protein intake (Doi et al., 2009). Additionally, 
creatinine is not a very sensitive biomarker for kidney function in AKI, since levels do 
not reflect injury until approximately 50 % of the renal function is lost (Burke et al., 
1984; Jacobs et al., 2004). 
AKI is characterised by a rapid decrease in renal function with a reduced ability to 
excrete toxins, concentrate the urine and maintain fluid balance.  
1.6.1.2 Urinary markers 
Urine is the preferred biofluid for biomarker detection and measurement since it can be 
obtained by non-invasive methods, causes minimal stress to the patient or animal, 
allows repeated sampling and can be obtained in large quantities.  
In man, the presence of a large protein concentration in the urine is often a sign of renal 
dysfunction since proteins are not normally filtered from the glomerulus into the 
Bowman’s space. Additionally, almost 100 % of the protein that is filtered is reabsorbed 
in the proximal tubules. Increased urinary protein may occur when there is an excess of 
protein in the filtrate which exceeds the tubular reabsorptive capacity; a compromise of 
the glomerular permeability, thus allowing increased filtration of plasma proteins; or 
when there is an overflow of low-molecular weight proteins in the blood that are freely 
filtered by the glomerulus (overflow proteinuria) (for example. haemoglobinuria 
occurring in states of intravascular haemolysis, or myoglobinuria which occurs when 
there is severe muscle injury). 
In the last decade many studies have contributed to the development of useful panels of 
kidney injury biomarkers, including α-glutathione S-transferase (α-GST), glutathione S-
transferase Yb1 (GST Yb1), lipocalin-2 and osteopontin (Wang et al., 2008). More 
recently, in response to data arising from the search for biomarkers of renal injury in 
toxicology studies, the Food and Drug Administration (FDA) and the European 
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Medicines Agency (EMA) have allowed the inclusion of 7 urinary biomarkers in 
investigational or regulatory rat studies. These include KIM-1, albumin, total protein, β-
2 microglobulin, cystatin-C, clusterin and trefoil factor-3. These biomarkers can be used 
to evaluate kidney damage during animal studies as part of the drug-review process. 
Their inclusion is not compulsory but if measured they should be reported to the FDA. 
The ultimate goal is to be able to translate these biomarkers to human tests for detecting 
drug-induced kidney injury in people as early as possible, thus allowing healthcare 
professionals to closely monitor patients and therapeutics. 
Glutathione-S-transferases (GSTs) are cytosolic enzymes which are present in the 
proximal and distal tubules. GSTs are involved in the detoxification process of many 
compounds including electrophilic substrates, by decreasing their reactivity with 
cellular macromolecules (Armstrong, 1997; Lock and Reed, 1998; van Lieshout et al., 
1998). α-GST is thought to make up as much as 2 % of the total protein present in the 
cytosol of tubular epithelial cells and following damage to the cellular membranes the 
enzyme is released into the tubular lumen (Bruning et al., 1999). GSTs can also be 
found in the liver, testes, lungs and brain (Eaton and Bammler, 1999). Urinary α-GST 
levels appear to correlate well with histopathological evidence of degeneration and 
reflect the role of the enzyme as a marker of increased cellular membrane permeability 
and cellular damage (Maguire et al., 2013). GST Yb1 can be mainly found in the 
epithelial cells of the distal renal tubules (Rozell et al., 1993; Otieno et al., 1997). Both 
α-GST and GST Yb1 are considered to be good biomarkers of kidney injury and are 
often used in toxicological studies. Increased urinary levels of these enzymes have been 
previously reported in models of HCBD-induced proximal tubular injury (Swain et al., 
2012; Maguire et al., 2013).  
Lipocalin-2 is a 25-kDa glycoprotein classified as an extracellular transport protein with 
a high affinity for hydrophobic proteins such as fatty acids and cholesterol (Kjeldsen et 
al., 1994; Borkham-Kamphorst et al., 2011). It is present in many tissues including 
liver, kidneys, lungs, adipocytes and macrophages (Liu and Nilsen-Hamilton, 1995). 
Lipocalin-2 is highly expressed and released by the liver in response to inflammation 
(Liu and Nilsen-Hamilton, 1995; Flo et al., 2004). A study by Borkham-Kamphorst et 
al., (2011) showed increased lipocalin-2 expression in CCl4 injured hepatocytes 
compared to control animals in both acute and chronic liver injury models and it was 
hypothesised that damaged hepatocytes were the main source of lipocalin-2 production 
(Borkham-Kamphorst et al., 2013). However, there is evidence that lipocalin-2 is 
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excreted into the urine in the event of renal toxicity (Paragas et al., 2011). Therefore, 
urinary lipocalin-2 levels are often measured as a marker for ischemic renal injury 
(Mishra et al., 2003, Mori et al., 2005) despite the lack of specificity (Liu and Nilsen-
Hamilton, 1995).  
Osteopontin is a glycoprotein with a molecular weight of approximately 44 kDa. It is 
expressed in different tissues such as the kidney, lung and liver (Xie et al., 2001b). 
Osteopontin is secreted by the kidneys into the urine by epithelial cells, including the 
loop of Henle and distal convoluted tubule (Kleinman et al., 1995). It is thought to act 
as an inhibitor of calcium oxalate formation, thus having a role in preventing mineral 
precipitation and renal stone formation, since these are comprised of calcium oxalate 
(Asplin et al., 1998; Xie et al., 2001b). Osteopontin is normally found in cells in the 
distal tubules (Verhulst et al., 2002) and osteopontin mRNA expression has been shown 
to be upregulated in rodent models of kidney injury (Verstrepen et al., 2001). However, 
the is also evidence suggesting the association between increased urinary levels of 
osteopontin and histopathological signs of regeneration of the proximal tubular cells 
(Persy et al., 1999; Xie et al., 2001a; Swain et al., 2012). Xie et al., (2001a) 
hypothesised that the mechanism for osteopontin-mediated regeneration could be 
attributed to its ability to bind to CD44, which would block the binding of HA to CD44. 
HA has been shown to inhibit tubular cell proliferation and to have an inhibitory effect 
on cell growth and cell differentiation. By binding to CD44, osteopontin would block 
the inhibition of HA (Xie et al., 2001a).  
KIM-1 is a transmembrane protein and expression has been shown to increase in the 
proximal tubule of the post-ischemic rat kidney (Han et al., 2002; Ichimura et al., 2008; 
Zhou et al., 2008; Swain et al., 2012). KIM-1 is expressed on the apical membrane of 
proximal tubular cells followed by cleavage of the ectodomain (90 kDa) which is then 
released in the urine (Pennemans et al., 2011). The ectodomain of this protein is shed 
from the outside of the cell and is considered to be a marker of both kidney 
degeneration and repair (Swain et al., 2011; Swain et al., 2012; Maguire et al., 2013). It 
is found in the proximal epithelial cells of the S3 segment and is thought to be involved 
in the phagocytosis of apoptotic cells in the renal tubular lumen (Ichimura et al., 2008; 
Ichimura et al., 2012). 
Clusterin is a protein expressed on the proximal tubular cells and has been shown to 
protect cells from stress, transport lipids and promote cell aggregation. Clusterin is also 
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present in the testes, liver, stomach and brain; in the kidneys it has been suggested to 
have anti-apoptotic functions (Rosenberg and Silkensen, 1995; Dieterle et al., 2010; 
Garcia-Martinez et al., 2012). Clusterin has a molecular weight of 76-80 kDa and under 
normal conditions the concentration found in the urine is very low. Consequently, the 
appearance of increased clusterin in the urine is accompanied by renal damage (Dieterle 
et al., 2010). Increased urinary levels of clusterin have been reported following ischemic 
and reperfusion injury to the kidney, as well as toxicant-induced renal injury (Witzgall 
et al., 1994).  
β-2 microglobulin is a polypeptide chain with a molecular weight of 12 kDa. Normally, 
only a very small fraction of the β-2 microglobulin that is filtered by the glomerulus is 
excreted in the urine (0.3 %) (Dieterle et al., 2010). The majority of β-2 microglobulin 
is reabsorbed and degraded in the proximal tubules (Miyata et al., 1998). However, 
when tubular function is compromised, for example in AKI, the reabsorption of β-2 
microglobulin is impaired and therefore increased levels are present in the urine (Vaidya 
et al., 2008). Consequently, urinary β-2 microglobulin is measured as a marker for 
proximal tubular dysfunction (Miyata et al., 1998). 
Cystatin-C is a low molecular weight protein (13 kDa) that is filtered from the blood in 
the glomerulus (Vaidya et al., 2008). Similar to β-2 microglobulin, cystatin-C is freely 
filtered in the glomerulus and almost completely reabsorbed before being metabolised 
in the proximal tubules (Herget-Rosenthal et al., 2007; Dieterle et al., 2010). 
Consequently, impairment in the reabsorption of cystatin-C in the proximal tubules will 
result in the appearance of increased urinary levels of cystatin-C (Conti et al., 2006; 
Herget-Rosenthal et al., 2007). 
Trefoil factor-3 is a protein secreted by mucus-producing cells and by epithelial cells of 
several tissues including the kidney (Yu et al., 2010b). In humans, trefoil factor-3 is 
predominantly found in the cells of the proximal and distal tubules and in the collecting 
duct (Rinnert et al., 2010). Trefoil factor-3 has been shown to be involved in the 
formation of mucous barriers and has antiapoptotic effects. Yu and co-workers (2010b) 
reported a decrease in urinary trefoil factor-3 levels following the administration of 
cisplatin (a known nephrotoxicant) to rats. It has been proposed that this decrease in 
urinary levels of trefoil factor-3 is mediated by a gene regulatory response to tubular 
toxicity, however, the mechanism for this observation has yet to be fully described (Yu 
et al., 2010b). 
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Albumin is filtered from the blood and is almost completely reabsorbed by the proximal 
tubule (Lazzara and Deen, 2007); therefore, injury to the proximal tubules may result in 
albuminuria. Albumin is considered to be a marker for both proximal tubular function 
and glomerular integrity (Swain et al., 2011). Recent studies, investigating the potential 
for albumin as a urinary marker of AKI, have shown that it outperforms both serum 
creatinine and urea in terms of sensitivity (Yu et al., 2010b; Bolisetty and Agarwal, 
2011). 
In this project we are investigating urinary biomarkers of CCl4-induced liver toxicity. 
Therefore, it is of the utmost importance to guarantee that there will be no 
nephrotoxicity. These urinary markers of nephrotoxicity will be analysed to determine 
sensitivity to low levels of kidney injury and consequently used to detect any potential 
nephrotoxicity in our CCl4 liver models. 
1.7 Hexachlorobutadiene  
Hexachlorobutadiene (HCBD) is a halogenated solvent formed as a by-product of 
trichloroethylene and perchloroethylene (Ishmael and Lock, 1986).  
HCBD is known to have a toxic effect on the kidneys (Lock and Ishmael, 1981; Ishmael 
and Lock, 1986; Birner et al., 1995; Birner et al., 1998). It causes damage selectively to 
the pars recta of the proximal tubule in the rat. This segment is especially sensitive due 
to the concentration of cysteine β-lyase, which is involved in the mechanism for HCBD-
induced toxicity, than can be found here (Berndt and Mehendale, 1979; Lock and 
Ishmael, 1979).  
In the liver, HCBD undergoes conjugation with glutathione to give S-
(pentachlorobutadienyl)-glutathione (Nash et al., 1984). The toxic conjugate S-
(pentachlorobutadienyl)-glutathione is then translocated to the kidneys to be converted 
to S-(pentachlorobutadienyl)-L-cysteine (Birner et al., 1995). Alternatively, S-
(pentachlorobutadienyl)-glutathione may be converted by intestinal γ-glutamyl 
transpeptidases and dipeptidases to S-(pentachlorobutadienyl)-L-cysteine, which is 
reabsorbed from the gut and translocated to the kidneys (Dekant et al., 1988; Birner et 
al., 1995; Birner et al., 1998). In the kidneys, S-(pentachlorobutadienyl)-L-cysteine is 
N-acetylated producing N-acetyl-S-(pentachlorobutadienyl)-L-cysteine which is either 
excreted via the urine (Dekant et al., 1986) or cleaved by cysteine conjugate β-lyase to 
give pyruvate, ammonia and a reactive thiol (Nash et al., 1984; Dekant et al., 1986; 
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Ishmael and Lock, 1986; Dekant et al., 1988). This reactive thiol group may covalently 
bind to macromolecules, such as lipids and proteins, initiating a sequence of events 
which leads to an increase in the levels of cytosolic free Ca
2+
 and, consequently, 
necrosis (Chen et al., 1992; Townsend et al., 2003). It has also been suggested that the 
reactive thiol can bind to mitochondrial DNA and nuclear DNA and this can lead to the 
mechanism of HCBD-induced carcinogenesis (Schrenk and Dekant, 1989). Renal 
mitochondrial DNA is thought to be a target as a result of the high concentration of β-
lyase present in the mitochondrial membrane (Schrenk and Dekant, 1989). 
The histopathological lesion characteristic of HCBD-induced nephrotoxicity has been 
extensively described in the literature (Lock and Ishmael, 1979; Lock and Ishmael, 
1981; Ishmael et al., 1982; Lock et al., 1985; Ishmael and Lock, 1986; Birner et al., 
1995; Birner et al., 1998; Swain et al., 2011; Swain et al., 2012; Maguire et al., 2013). 
The nephrotoxic changes consist of degeneration and necrosis of the S3 segment of the 
proximal tubule. However, the glomeruli, loops of Henle, distal tubules and collecting 
tubules are often unaffected. The earliest pathological HCBD-induced changes occur 8 
hours post-administration and include aggregation of the smooth endoplasmic 
reticulum; mitochondrial swelling; cytoplasmic vacuoles, resulting from lysosomal 
degranulation, and cellular necrosis. By 16 to 24 hours post-dosing, there is more 
extensive tubular necrosis, particularly to the S3 segment (Ishmael et al., 1982). The 
presence of luminal granular casts has also been described in the distal segments of the 
nephron following HCBD administration (Ishmael et al., 1982). Casts consist of 
particles and debris from cellular breakdown as a consequence of necrosis of the 
proximal tubule segments (Hard, 2008). 
The accumulation of α-2µ globulin, which is a protein synthesised in the liver of the 
male rats (Roy et al., 1966; Pahler et al., 1997; Hard, 2008; Swain et al., 2011) is the 
primary cause for the observation of presence of hyaline droplets (Hard, 2008). 
Approximately half of the α-2µ globulin synthesised in the liver is excreted in the urine 
and the rest is reabsorbed in the proximal tubules (Swenberg, 1993). The reabsorbed 
protein is retained in vesicles known as hyaline droplets. The vesicles fuse with 
lysosomes and the protein is degraded. Hyaline bodies appear as small eosinophilic 
bodies following H&E staining. Hyaline droplets can be present in different sizes and 
are most often seen in proximal convoluted tubules. Accumulation of hyaline droplets is 
the first step in α-2µ globulin nephropathy (Cristofori et al., 2013). The occurrence of 
hyaline bodies may also be associated with xenobiotic administration, including HCBD. 
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It has been reported that HCBD can bind to α-2µ globulin, thus inhibiting its 
degradation in the lysosomes. This leads to accumulation of α-2µ globulin in the cells 
and may cause degeneration and cell necrosis (Lehman-McKeeman et al., 1990). 
1.8 Metabolomics and metabonomics 
Global metabolic profiling refers to the study of low molecular weight molecules, up to 
approximately 1000 Da, including amino acids, sugars, bile acids as well as 
intermediaries of biochemical pathways including the tricarboxylic acid cycle (Clarke 
and Haselden, 2008). Metabolic profiling studies are concerned with the investigation of 
metabolite changes that reflect the dynamic multiparametric response of living 
organisms to genetic modification, physiological and pathophysiological stimuli 
(Holmes et al., 2001; Clarke and Haselden, 2008; Wu et al., 2011). 
When describing the study of metabolites, metabonomics and metabolomics are two 
terms which are often used interchangeably in the literature. The term metabolome 
refers to the measurement of a complete set of metabolites within a cell under a 
particular set of conditions (Oliver et al., 1998). The metabolome changes depending on 
the physiological or pathophysiological state of the cell, tissue or organism (Oliver et 
al., 1998). Several types of metabolomes exist including the endogenous metabolome, 
the microbial metabolome and the xenometabolome, which includes metabolites that are 
a result of the metabolism of drugs and dietary compounds (Holmes et al., 2007; 
Monteiro et al., 2013). 
The study of the metabolome has gained importance in toxicological studies where the 
main objective is to investigate changes in metabolites following the administration of 
drugs (Aardema and MacGregor, 2002; Cockerell et al., 2002). Drug-induced toxicity 
may alter metabolic pathways, leading to changes in metabolite levels which may be 
detected in biological samples. Many of these metabolites may pass into the circulation 
and are present in the urine. Therefore, serum and urinary metabolites have the potential 
to provide a “snapshot” of the recent events happening in a biological pathway (Clarke 
and Haselden, 2008). The metabolome is the final downstream product of gene 
transcription and is closest to the phenotype of the biological system studied compared 
to the transcriptome or the proteome; it reflects changes to the metabolic pathways that 
are occurring in the cells at a particular time. Therefore, in the present studies, a 
1
H 
nuclear magnetic resonance (NMR) metabolomics-based investigation of changes to 
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urinary metabolites with drug-induced toxicity was preferred over a 
proteomics/genomics approach. 
Metabolomics-based studies have been successfully applied to the investigation of 
models of nephrotoxicity (Robertson et al., 2000; Wei et al., 2008; Hanna et al., 2013) 
and hepatotoxicity (Beckwith-Hall et al., 1998; Holmes et al., 2000; Nicholls et al., 
2001). Studies have focused on the identification of metabolite biomarkers for liver 
injury in animal studies using 
1
H NMR spectrometry following the administration of 
hepatotoxicants, such as CCl4, hydrazine and thioacetamide (model hepatotoxicant 
agents) in both acute and chronic models (Beckwith-Hall et al., 1998; Robertson et al., 
2000; Nicholls et al., 2001; Wu et al., 2005). In the urine of rats treated with a single 
dose of CCl4 the metabolite taurine was identified as a marker of hepatotoxicity 
(Waterfield et al., 1991; Waterfield et al., 1993; Waterfield et al., 1998). Repeated 
administration of CCl4 resulted in increased urinary excretion of citrate as detected by 
gas chromatography coupled to mass spectrometry (Gou et al., 2013). An acute dose 
study with hydrazine revealed decreased urinary excretion of hippurate, citrate and 
succinate in the male Hanover-Wistar rat (Nicholls et al., 2001). A chronic study using 
thioacetamide as the hepatotoxicant agent reported increases in lactate, acetate and 
alanine in hepatic extracts from thioacetamide-treated rats (Constantinou et al., 2007).  
The general metabolomics/metabonomics approach includes several steps; the first 
being sample generation/collection and preparation. Data collection follows and this is 
done by either mass spectrometry or NMR methods. Data collected by these methods 
requires processing prior to statistical analysis. For data obtained by NMR, data 
processing consists of peak alignment, data normalisation, signal extraction, baseline 
correction and integration. Multivariate statistical analysis is carried out using the 
processed data by pattern recognition methods such as principal component analysis 
(PCA). Variables displaying treatment-related effects are highlighted and potential 
biomarkers identified. Metabolite biomarkers require biological interpretation to 
confirm the relevance of the finding and prior to clinical application all biomarkers need 
to be validated in multiple studies (Figure 1.6) (Monteiro et al., 2013). 
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Figure 1.6 NMR metabolomics based-metabolite investigation of metabolites workflow (Monteiro et 
al., 2013). 
 
The Consortium on Metabonomic Toxicology (COMET) was formed between 5 
pharmaceutical companies and Imperial College, London, with the main objective to 
create a 
1
H NMR-derived database of biofluids to be used in the assessment of drug 
candidates (Lindon et al., 2003; Lindon et al., 2005; Nicholson et al., 2007). The 
COMET project collected data from a large number of studies in which different 
toxicants were administered to rodents and 
1
H NMR analysis of urine and serum 
samples was carried out. The NMR data was used to create a database that could be 
used for future reference in toxicological studies (Lindon et al., 2003). The information 
can be used to create a profile of metabolite changes according to the toxic compound 
administered. The ultimate goal is to provide a correlation between the 
1
H NMR data, 
clinical chemistry and histopathological outcomes to predict metabolite biomarkers for 
toxicology (Nicholson et al., 2007). The COMET project was able to create a database 
comprising approximately 35,000 NMR spectra for the prediction of toxicity which has 
been transferred to the sponsoring companies (Lindon et al., 2005). 
1.8.1 Application of technologies to biomarker identification 
NMR has been widely used in metabolomic studies. Other techniques include MS, 
liquid-chromatography mass spectrometry (LC-MS), and less commonly Raman and 
infrared spectroscopy. However, due to the great volume of data that can be generated 
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by metabolomic/metabonomic studies, chemometric analysis is essential for data 
interpretation and for the development of statistical pattern recognition (PR) models that 
will allow identification of biomarkers.  
In the present studies 
1
H NMR was the technique chosen to carry out the identification 
of biomarkers. In comparison to MS, NMR can provide detailed structural information, 
can be used to quantitatively analyse mixtures containing known compounds and allows 
for a fast analysis time. However, this technique lacks sensitivity and unknown peaks in 
NMR spectra require identification by MS. MS on the other hand is characterised by a 
high degree of sensitivity and coupled with liquid chromatography (LC-MS) can be 
used to separate and identify complex samples. Quantitative analysis using MS analysis 
is also more difficult to perform and more expensive than using NMR (Banoub and 
Limbach, 2010). 
1.8.1.1 Nuclear magnetic resonance (NMR) spectrometry 
NMR-based metabolite profiling presents several advantages over other techniques 
since it is a non-destructive technique that requires minimal sample preparation 
(Holmes et al., 2000; Beckonert et al., 2007; Beger et al., 2010). It is a highly 
reproducible method with the potential to analyse liquids including urine and serum, as 
well as solid tissue samples (Wang et al., 2010a; Monteiro et al., 2013). However, the 
main disadvantage associated with this technology is the low sensitivity. NMR has a 
limit of detection of 10 µM (Pan and Raftery, 2007) which means that metabolites 
present in low concentrations may be missed. In spite of this, NMR has the capacity to 
detect hundreds of metabolites and each spectrum includes thousands of signals, many 
of which overlap. The intensity of each peak is proportional to the concentration of that 
metabolite in the sample (Bollard et al., 2005). 
The NMR technique is based on the magnetic properties of atomic nuclei. Electrons, 
protons and neutrons spin on an axis. In the absence of a magnetic field these nuclei are 
randomly oriented, but when exposed to an external magnetic field (H0) they can absorb 
energy that will cause a transition from a low to a high energy state (Brown et al., 
2012).  
The overall spin of the nuclei depends on the number of protons and neutrons. If the 
number of both of these particles is even the nuclei does not spin. When the sum of the 
protons and neutrons adds up to an odd number this nuclei will have a half-integer spin 
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(e.g. ½). If the number of protons and neutrons are both odd numbers than the nucleus 
has integer spin (1, 2…). The overall spin is called the nuclear spin quantum number (I) 
(Shmaefsky, 2006).  
A proton has an atomic number of 1 and therefore this nucleus has a spin. The number 
of energy levels is determined using the spin quantum number according to the rule: 
2I+1. Therefore, a nucleus with spin 1/2 will have 2 possible orientations. When no 
external field is present these 2 orientations are of equal energy; however, when a 
magnetic field is applied the energy levels split and each level is given a magnetic 
quantum number (m) (-1/2, +1/2). The energy difference between the 2 states is 
proportional to the strength of the external magnetic field applied (Hayes, 2007). 
When an external magnetic field is present the nuclei will align themselves either with 
the magnetic field or against the magnetic field. When the proton is aligned with the 
field it is at a lower energy state, known as the α-spin state. A proton aligned against the 
external magnetic field occurs at a higher energy state known as the β-spin state. The α-
spin state is lower in energy; therefore, there will be more α-spins than β-spins (Figure 
1.7) (Balci, 2005). 
Ho
α-spin state β-spin state
External
magnetic field
 
Figure 1.7 Schematic representation of the α and β-spin states (lower and higher energy levels, 
respectively). 
 
The application of a radiofrequency pulse results in the nuclei absorbing energy and 
inverts the spins from a lower energy orientation to a higher energy orientation (i.e. the 
less stable alignment), thus changing them from the aligned state to the opposed to the 
magnetic field state. When this happens the nucleus is said to be “in resonance” and the 
energy required for this change in states is called resonance frequency. Consequently, 
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when the radiofrequency is switched off the nucleus undergoes relaxation to its original 
lower energy orientation producing a NMR signal in the form of spectra composed of a 
pattern of resonance peaks which are unique to each molecule. The NMR spectrum is a 
plot of the intensity of NMR signals versus the magnetic field in reference to an internal 
reference, such as 3-(trimethylsilyl) propionate (TSP). The position of each peak within 
a molecule in the spectrum depends on the chemical environment of the nuclei. The area 
under each peak is proportional to the concentration of that molecule in the sample 
(Goldsmith et al., 2010).  
However, in a given molecule the electrons circulate and in doing so they generate a 
magnetic field that opposes the externally applied field. When this happens the 
magnetic field at the nucleus is weaker than the external field, thus, the nucleus is said 
to be shielded. The effective magnetic field at the shielded proton results from the 
difference between the external magnetic field applied by the NMR spectrometer and 
the local magnetic field due to the movement of electrons around the nuclei. The greater 
the electron density surrounding the nucleus the greater the local magnetic field. This 
will result in a weaker effective magnetic field at the proton and subsequently a stronger 
external field will be required to achieve resonance at a given frequency. The result of 
this is a shift of signals to the right in the NMR spectrum (upfield) (Vollhardt and 
Schore, 2003). 
Protons that are in the presence of electronegative groups in a molecule are said to be 
deshielded. Protons will have higher chemical shift values and the NMR signals will 
move to the left of the spectrum (downfield). The chemical shift can be defined as the 
difference in parts per million (ppm) between the resonance frequency of the proton 
being studied, and that of the internal standard. The electrons in TSP (internal standard) 
are very well shielded resulting in a high-field absorption defined as 0 ppm. Most NMR 
absorptions are therefore downfield of TSP, to the left of the TSP peak. The NMR 
instrument measures the difference in magnetic field between the frequency at which 
the protons in the sample absorb and that at which TSP absorbs (Vollhardt and Schore, 
2003). 
If all the protons in a molecule had the same magnetic environment, i.e., they had the 
same degree of shielding they would be chemically equivalent protons. Therefore, all 
the protons would appear at the same chemical shift in an NMR spectrum. This occurs 
in symmetrical compounds such as benzene. Consequently, the number of different 
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chemical shifts in a spectrum is an indication of the number of different types of protons 
present (Balci, 2005). The position of the absorptions (chemical shifts) in the NMR 
spectrum and therefore the amount of shielding and deshielding provides information 
regarding the structure of the molecule. 
The intensity of the signal (integration) is proportional to the number of protons that 
make that signal (Walker et al., 2011). 
NMR signals normally appear as a pattern of split triangles labelled as doublets (2 
peaks), triplets (3 peaks) and quartets (4 peaks) described as signal splitting. 
Information obtained from the splitting of the signals helps to describe the influence of 
nearby protons on a proton spin (Fox and Whitesell, 2004). The process by which the 
spinning of the nucleus of one proton influences another proton in an adjacent carbon is 
called spin-spin coupling. The distance between each peak is called coupling constant 
(J) and is expressed in Hertz (Hz). The proximity of “n” equivalent protons on a 
neighbouring carbon atom causes the signals to be split into “N+1” rule. 
In this project we will use NMR to examine the possibility of identifying urinary 
biomarkers of hepatic fibrosis. The 
1
H NMR spectrum of urine samples results from the 
superimposition of the spectra of all the metabolites in the sample that contain 
resonating atomic nucleus (Wang et al., 2010a). 
1.8.2 Chemometrics 
Chemometrics has been defined as the “application of mathematical and statistical 
methods to chemistry” (Wold, 1995; Beger et al., 2010). The use of chemometrics 
facilitates the interpretation of complex data sets generated by NMR and MS. 
Mathematical and statistical models are applied to the data to extract the most relevant 
trends. When used in combination with NMR, chemometrics has the ability to facilitate 
the identification and discrimination of the variables that change due to disease and 
physiological or pathological status.  
Prior to chemometric analysis, it is necessary to perform a pre-processing step known as 
“bucketing” or “binning”. After exclusion of the water peaks, NMR spectra are reduced 
to regions 0.04 ppm wide from δ 10.0 to 0.2 producing 250 integral regions per 
spectrum. The area under the peaks in each integral region is calculated giving an 
integrated value for that region. This operation results in the production of a bucket 
table (X matrix) where the rows represent individual samples and the columns 
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(comprising 250 variables or buckets/bins) represent integrated peak areas. This table 
can then be imported into a chemometrics software to carry out the analysis (Wiklund, 
2008). 
One of the areas of chemometrics that has grown more rapidly is pattern recognition 
(PR) analysis which includes unsupervised (e.g. principal component analysis (PCA)) 
and supervised models (orthogonal partial least square (OPLS)). 
PCA is a form of multivariate data analysis (MVA) which is used when several 
measurements are made on each individual. Measurements refer to variables 
(integration areas in NMR spectrum/buckets) and individuals refer to observations 
(analytical samples). The main objective is to compare the variables to understand the 
relationships between them and identify variables that are related, i.e., those which co-
vary together. Covariance describes the influence that one variable has on other 
variables. MVA is commonly used in metabolomics studies since very large data sets 
are generated and MVA can be applied to establish the relationship between the many 
variables (Everitt and Hothorn, 2011). 
PCA is the oldest projection method and it consists of a mathematical manipulation of 
the data to reduce a great number of variables to a much smaller number, known as 
principal components (PCs). PCA, therefore, allows separation of samples according to 
the similarities and differences between them. It provides an overview of the data and 
facilitates the visualisation of groups of observations, trends and outliers (Eriksson et 
al., 2006). PCA is concerned with extracting the systematic variation in a data matrix X. 
This matrix (X) is composed of rows (N), also called observations (e.g. samples), and 
columns (K) which are called variables (integral regions/peak intensities) (Figure 1.8). 
 
 
 
 
 
Figure 1.8 Data matrix X in a PCA model. Rows (observations) are shown as N and can be analytical 
samples. Columns (variables) are shown as K and may be of spectral origin (NMR integral regions) 
(Eriksson et al., 2006). 
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The first steps towards generating a PCA model include the pre-processing of the data. 
Pre-processing includes scaling and mean-centering of the data. The scaling of the data 
is important since variables can have different intensities between different samples. 
Thus, variables with large variances in intensity may influence the data set and are more 
likely to dominate the PCA model, therefore making it difficult to identify chemical 
shift regions with lower variances. Therefore, scaling is applied to the data prior to 
analysis to ensure the data is normally distributed.  
There are several ways to scale the data, including unit variance (UV) or Pareto scaling. 
In UV scaling the standard deviation is calculated for each variable and each variable is 
then divided by its standard deviation so that the variance of scaled variables is 1. UV 
scaling gives the same weight to all the variables. Pareto scaling is normally preferred in 
metabolomics studies since variables tend to show large variance in intensities between 
different samples. This is used when variables with large variances dominate the 
PCA/OPLS model and overwhelm medium features. This method of scaling has the 
potential to give more relevance to medium features without inflating the baseline noise. 
In Pareto scaling, each variable is divided by the square root of its standard deviation 
(Wiklund, 2008). 
Following Pareto scaling of the data mean-centering is performed. This consists of 
calculating the average value of each variable and then subtracting this value from all 
the individual data to improve the interpretability of the model. 
The second step in generating a PCA model is to create a K-dimensional space (Figure 
1.9). A K-dimensional space may include thousands of variables (e.g. the information 
collected from a bucket table). Each variable (integral region) represents one co-
ordinate axis and the integrated area for each observation is plotted on the co-ordinate 
axis. Each observation is known as a scores point and represents a sample spectrum 
(observation). This K-dimensional space has as many dimensions as the number of 
variables in the X matrix. Each observation of the X-matrix (analytical sample) is 
placed in the variable space (Wiklund, 2008).  
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Figure 1.9 Representation of the K-dimensional space. The observations (rows in the X matrix) are 
placed in the K-dimensional space where each variable (columns in the X matrix/buckets) represents one 
co-ordinate axis. The K-dimensional space has as many dimensions as there are variables (Wiklund, 
2008). 
 
When observations are placed in the K-dimensional space they form a cluster in the 
space and the data set is then represented as principal components (PCs). The first PC is 
a line in the K-dimensional space that goes through the average point and best describes 
the shape of the cluster and shows the maximum variation between the points. Each 
observation is projected onto this line in order to get a co-ordinate value along the PC-
line. This is known as a score. The second PC (PC2) also goes through the average 
point and is orthogonal to the first PC (PC1). PC2 describes the second largest variation 
in the data. When the PC2 is computed it is possible to define a plane with PC1. Each 
observation can then be projected onto this low-dimensional plane. The co-ordinate 
values of the observations on this plane are called scores and this is called a score plot 
(Figure 1.10) (Wiklund, 2008). 
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Figure 1.10 Representation of PC1 and PC2. PC1 is the line going through the average point that best 
describes the shape of the points in the K-dimensional space and represents the maximum variance in the 
data. PC2 also goes through the average point, is orthogonal to PC1 and explains the second largest 
source of variation in the data (Wiklund, 2008). 
 
Each consequent PC (PC3, PC4 etc) contributes towards explaining the total variance 
between the observations not described by the previous PC, with PC1 describing the 
greatest source of variability. All PCs generated from a PCA model can be interpreted 
together to gain as much information regarding the relationship between different 
observations. The ideal situation would be to have a very small number of PCs 
describing as much information as possible in the model so that the rest of the variance 
can be attributed to noise (Robertson, 2005). 
The information obtained in a PCA model can be presented in two types of PCA plots: a 
scores plot where each point in the plot represents one single NMR spectrum 
(observation), and a loadings in which points represents one variable (chemical shift 
region/integral region) (Figure 1.11) (Bollard et al., 2005, Beger et al., 2010). Samples 
that cluster together in the scores plot have similar spectra and, therefore, are considered 
to be biochemically similar.  
The scores plot allows the observation of patterns, clusters and outliers between 
samples/observations. The loadings plot provides the information about the spectral 
regions which are associated with the observed sample clustering in the scores plot. 
Thus, the loadings plot is used as the basis for metabolite interpretation and 
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identification. The loadings plot represents how the original variables (integral regions) 
contribute to the direction of PC1. For each PC of the PCA model a new set of loadings 
will be required to explain the direction of that individual PC in relation to the original 
variables. 
 
Scores plot Loadings plot 
Interpretation 
        Observations Variables 
NMR spectrum 
(observation) 
Integral region/bucket 
(variable) 
 
Figure 1.11 Schematic representation of the PCA process. Each NMR spectrum (observation) is 
reduced to 250 regions (variables) which are manipulated to produce the scores plot and the loadings plot. 
 
If a variable has a very small loading it should not be used for interpretation, because 
that variable is badly accounted for by the PC. If a variable has a positive loading, it 
means that all samples with positive scores on the scores plot have higher than average 
values for that variable. All samples with negative scores have lower than average 
values for that variable. The higher the positive score of a sample, the larger its values 
for variables with positive loading. If a variable has a negative loading it means that all 
samples with positive scores have lower than average values for that variable and all 
samples with negative scores have higher than average values for that variable. The 
more negative the score of a sample, the smaller its values for variables with positive 
loading. Variables that are negatively, or inversely correlated, are positioned on 
opposite sides of the scores plot origin in diagonally opposed quadrants. Consequently, 
it is the combined interpretation of both the scores and loading plots that will allow 
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acquisition of the most detailed information concerning the samples being analysed 
(Eriksson et al., 2006). 
The quality of a PCA model can be evaluated by the goodness of fit (R
2
X) and the 
goodness of prediction (Q
2
X). R
2
X refers to the fraction of the variation of the X 
variables that is explained by the model whereas Q
2
X is related to the fraction of the 
variation of the X variables that is predicted by the model. Therefore, high R
2
X and 
Q
2
X are desirable. Q
2
X is calculated by cross-validation and is used to find the optimal 
model, and identify the ideal number of components to describe the PCA model. By 
default, data are divided into 7 groups and a PCA model is created for the data 
excluding 1 of the groups. The model that is created is then used to predict the data that 
was excluded from the model. This process is repeated 7 times. The predictive data are 
then compared with the original data. When a new component enhances the predictive 
power compared to a previous model this new component is kept. This operation is 
performed by the software (Jackson, 1991). 
OPLS (orthogonal partial least squares) is a supervised prediction and regression 
method that finds the information in the X matrix data that is related to known 
information, called the Y variable. Regression is a measurement of how values vary 
together whereas prediction tells us how well the known information is predicted. OPLS 
models are an extension of partial least square (PLS) (Wiklund, 2008). 
In OPLS, Y variables contain information about the observations. They can be 
measured or known information such as continuous variables (e.g. time), or discrete 
variables (male/female, or control/treated). When the Y variable is a discrete variable, 
the OPLS model is known as OPLS-discriminant analysis (OPLS-DA). OPLS-DA 
models use the same algorithm as OPLS and are of particular interest in classification 
studies and biomarker identification to distinguish variables which are due to gender or 
treatment groups (Wiklund, 2008).  
Pre-processing of the data prior to generating an OPLS/OPLS-DA model is carried out 
and includes scaling and mean-centering, as described previously for PCA models. 
Similar to PCA, OPLS-DA is a projection method and interpretation of plots is easiest if 
only 2 classes are used. The main advantage of OPLS-DA models is the ability to 
facilitate interpretation of data by separating the predictive variation, or the correlated 
variation between X and Y (e.g. effect of toxin concentration), and the orthogonal 
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variation, which describes the uncorrelated variation between X and Y (e.g. age of 
animals). The use of OPLS-DA models is, therefore, very useful in toxicology studies 
investigating the effect of treating animals with a particular toxicant, but when the age 
or gender of the animals used is also a contributor to the X matrix. Consequently, 
OPLS-DA often reveals sample clustering that was not evident in PCA models of the 
same data. In this project, OPLS-DA was used to compare control and CCl4-treated 
samples at different dose levels or time points.  
In OPLS-DA scores plots, the information that is correlated between X and Y will be 
shown along the discriminating component t[1] (e.g. control and treated samples), and 
interpretation of this information in the loadings plot will be carried out by analysis of 
the loadings p1. The orthogonal information (e.g. as a result of gender or intra-group 
variation), will be visualised along the orthogonal vector t[0] in the scores plot, and p0 
in the loadings plot. This makes it easier to see clustering which is due only to treatment 
with the toxicant. 
In OPLS and OPLS-DA models the goodness of fit (R
2
) is divided into predictive and 
orthogonal. R
2
X (cum) refers to the predictive and orthogonal variation in the X matrix 
that is explained by the model. R
2
X shows how much variation in the X matrix (made 
up of rows/observations and columns/chemical shifts) is related to the Y variable (e.g. 
different treatment dose levels). R
2
Y (cum) represents the total sum of variation in Y 
that is explained by the model (i.e. how good is the separation between the Y variables). 
Q
2
 (cum) is the goodness of prediction that is calculated by cross validation and 
represents the variation that is not related to our Y variable. Therefore, the higher the 
R
2
Y and Q
2 
the better the model and the separation between samples (Wiklund, 2008). 
Interpretation of the loadings plot in OPLS-DA models is compromised if there are 
more than 2 classes. OPLS-DA models allow the visualisation of the data in an S-plot 
which is useful for potential biomarker identification. The S-plot represents an 
alternative way of visualising the information shown in a loadings plot. The S-plot 
models the data so that if the X matrix (observations and variables) has a variation in 
peak intensities, the plot will take the shape of an “S”. The p1 axis in this plot describes 
the magnitude of each variable in X, whereas the p(corr)1 axis describes the reliability of 
each variable in X. Potential biomarkers will have high magnitude and high reliability 
values and will therefore be located in the extremes of the S-plot. The S-plot gives a list 
of chemical shifts that are statistically significant. 
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After creating a list of the most relevant metabolites in sample separation the next step 
is metabolite identification. Chemical shift regions that are different in the S-plot or 
loadings plot are then examined in the 1D 
1
H NMR spectra to obtain the exact chemical 
shifts of peaks in this region. These are then compared to relevant spectra in published 
literature for identification. 
1
H NMR is a technique that has been extensively applied to biomarker studies. The fact 
that is non-destructive, requires minimal samples preparation and is highly reproducible 
have contributed greatly to its vast application in metabolomic studies in humans 
investigating inflammatory bowel disease (Dawiskiba et al., 2014), acetaminophen-
induced hepatotoxicity (Kim et al., 2013) and pulmonary disease (Wang et al., 2013). In 
this project, 
1
H NMR spectrometry will be used for the identification of urinary 
biomarkers in a rat model of CCl4-induced acute and chronic injury. 
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1.9 Aim of this project 
The aim of the current studies is to identify novel urinary biomarkers of CCl4-induced 
acute and chronic hepatic injury in the male Hanover-Wistar rat. Urine was chosen for 
biomarker identification since it can be easily collected in relatively large volumes and 
without any associated pain, distress and discomfort to the animal. The identification of 
non-invasive markers of liver damage that could be used in the preclinical toxicology 
assessment and clinical safety testing of drugs would provide relevant information to the 
process of drug development and could be extremely useful in monitoring target organ 
toxicity in clinical trials.  
In the present investigations acute and chronic animal models of liver toxicity will be 
developed using CCl4 as the hepatotoxicant. Initially, a single administration of CCl4 at 
a range of concentrations will be used to determine the optimal dose level for our acute 
hepatic injury model. CCl4 exerts its toxic effects mainly in the liver; however, injury 
has also been detected in other organs, including the kidneys. Therefore, our primary 
goal will be to identify the dose level of CCl4 that is below the threshold for 
nephrotoxicity. To reliably determine the presence of renal damage we will investigate 
the sensitivity of a panel of kidney injury biomarkers recently approved by the FDA to 
use in toxicology studies. These will be used in our hepatic injury model to confirm the 
absence of a CCl4-induced toxic effect in the kidneys. Confirmation of absence of renal 
damage will be made by means of histopathological examination of kidney samples 
collected at autopsy. 
With the preliminary information collected from the dose response study regarding the 
most sensitive urinary markers of renal damage we will then focus on the development 
of a model of CCl4-induced liver fibrosis in the male rat. 
Identification of biomarkers in the urine samples collected from animals with hepatic 
injury in this project will be carried out using a metabonomics approach. 
1
H NMR 
combined with PCA and OPLS/OPLS-DA will be used for the identification of 
potential biomarkers. These biomarkers will be further assessed for sensitivity. A time 
course study will help to determine how sensitive any urinary biomarker is to early 
signs of injury and subsequent recovery following acute hepatotoxicity. A good 
biomarker for hepatic fibrosis will be present at the early stages and should regress 
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during a recovery period if the fibrotic lesion recovers. We will investigate this in a rat 
hepatic fibrosis model measuring urinary biomarkers. 
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CHAPTER TWO 
Materials and Methods 
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Chapter 2  
2.1 List of materials 
Rats were supplied by Harlan Laboratories Inc., Bicester, Oxfordshire, UK. The 
metabolism cages were manufactured by Techniplast, Kettering, Northants, UK. The 
animal diet came from SDS Ltd., Wiltham, Essex, UK.  
Euthatal (pentobarbital sodium) came from Merial, Harlow, Essex, UK. Qiagen, 
Crawley, West Sussex, UK, supplied the RNALater tubes. Bouin’s fixative, 10.5 % 
(v/v) phosphate buffered formalin fixative and industrial methylated spirit (IMS) were 
supplied by Sigma-Aldrich Co. Ltd, Gillingham, Dorset, UK. 
Carbon tetrachloride was purchased from Fluka Chemicals, Gillingham, Dorset, UK. 
Hexachloro-1:3-butadiene was purchased from Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany. The corn oil used in animal experiments was purchased from 
Mazola Corn Oil, Mazola Edible Foods, Liverpool, UK.  
SST
TM
 microtainer tubes came from Becton Dickinson and Co., Plymouth, Devon, UK.  
Trimethylsilyl propionate (TSP) and D2O were purchased from Cambridge Isotopes 
Laboratories, Inc., Maryland, USA. 
Sodium phosphate monobasic (NaH2PO4) and dibasic (Na2HPO4) for the preparation of 
NMR buffers were purchased from Sigma-Aldrich Co. Ltd, Gillingham, Dorset, UK. 
2.2 Animals and animal husbandry 
Male Hanover-Wistar rats, weighing approximately 180 to 200 g (approximately 7 
weeks of age), were used throughout except for studies in Chapter 4 when both younger 
and older animals were used. Rats were caged in groups of 5 when not in individual 
metabolism cages. Animals were allowed to acclimatise for a minimum of 3 days prior 
to each experiment. When in communal cages rats had access to diet and water ad 
libitum (Rat and Mouse No. 1, SDS, Witham, Essex, UK) and were bedded on wood 
shavings. A temperature of 19-22ºC was maintained with relative humidity of 45-65% 
and a light:dark cycle of 12:12 hours (lights on at 7 am). Animals were weighed on the 
day of delivery, before administration of the toxicant and at appropriate times post-
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dosing. Animals were observed daily for signs of ill health throughout the study. All 
animal procedures were conducted according to local Ethical Committee guidelines and 
approval for Home Office Project and Personal Licenses and followed the UK Home 
Office (1989) “Code of Practice for the Housing and Care of Animals used in Scientific 
Procedures”. For urine collection animals were placed individually in metabolism cages 
with water but no diet. Urine was collected over ice. 
2.3 Carbon tetrachloride administration 
CCl4 was dissolved in corn oil and administered by gavage. Control animals (vehicle-
treated) were also dosed by gavage with an equivalent volume of corn oil. Dosage 
volumes were adjusted according to the body weight of individual animals so that the 
maximum volume they received did not exceed 1.5 mL per rat.  
2.4 Hexacloro-1:3-diene administration 
HCBD was dissolved in corn oil and administered by intraperitoneal (i.p.) injection. 
Control animals were dosed in the same way with an equivalent volume of corn oil. For 
all animals a constant dosing volume of approximately 0.3 mL was administered.  
2.5 Ultrasonographic examination 
Animals were scanned using a Vivid 7i system (GE Medical Systems, Norway) 
equipped with a 10-14 MHz linear transducer (M12L). The system uses specific built-in 
software for rodent imaging, thus allowing an optimised ultrasonography examination 
for small anatomical parts. Images obtained for each animal were stored on the system 
as a loop or still frame image for off-line analysis.  
Animals were anaesthetised with isoflurane (3-4% isoflurane in 100% oxygen) in an 
anaesthesia chamber before undergoing ultrasonographic examination. Body 
temperature was maintained by the use of a thermal blanket. Animals were shaved in 
the abdominal region and US coupling gel was applied. Appropriate levels of 
anaesthesia were used throughout to minimise discomfort and to facilitate good 
acquisition of images.  
Images of the right or left kidney were recorded for comparison of echographic texture 
to that of the liver. Imaging acquisition was obtained by moving the scanhead from the 
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xyphoid region to the right or left in order to maximise both the sagittal and transverse 
liver planes and the vascular anatomy and cranial poles of the kidney. 
2.6 Post mortem 
Animals were killed by i.p. injection of pentobarbital sodium and exsanguinated from 
the abdominal aorta. At all autopsies blood was taken into SST
TM
 microtainer tubes for 
the separation of serum. After 30 minutes at room temperature serum tubes were 
centrifuged at 5000 rpm for 5 minutes. Serum was store at -80 ºC for future analysis.  
Both clinical and internal observations of the animals were made and recorded during 
the autopsies. The liver and the kidneys were removed and weighed. A section 2-3 mm 
wide and 20-30 mm long was cut from the left lobe of the liver, sliced into 5/6 pieces, 
placed in RNALater tubes and stored at 4 ºC until later gene expression analysis at 
GlaxoSmithKline, Ware. A section was also cut from the right kidney, placed in 
RNALater tubes and stored at 4 ºC until analysis at GlaxoSmithKline. The remainder of 
the liver and kidney were placed in 10.5 % (v/v) phosphate buffered formalin fixative 
for later histopathological examination.  
For dose ranging experiments, other tissues including the spleen, right and left adrenals, 
thymus and heart were removed at autopsy. Organs were weighed and placed in 10.5 % 
(v/v) phosphate buffered formalin fixative. The pancreas, lungs (inflation fixed with 
formalin), thyroid and head were removed and placed in 10.5 % (v/v) phosphate 
buffered formalin fixative. 
In the sexual maturity study, the right and left testes were removed, weighed and placed 
in Bouin’s fixative. After 24 hours, the Bouin’s fixative was removed from the testes 
and replaced with IMS. The epididymides were also collected at autopsy, placed in 
Bouins’s solution for 24 hours followed by replacement of the Bouin’s with IMS.  
Organs weights were expressed as grams per kilogram body weight (relative weight).  
2.7 Serum and urine clinical chemistry 
All serum and urine biochemistry was carried out at GlaxoSmithKline. 
Urine and serum samples were assayed on the Siemens Advia 1650 Clinical Chemistry 
System (Siemens Healthcare, Frimley, Surrey, UK) using commercially available 
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reagent kits. Testosterone was measured using a commercially available kit from R&D 
Systems (R&D Systems Europe Ltd, Abindgon, UK). 
2.7.1 Serum clinical chemistry 
2.7.1.1 ALT assay 
The enzyme ALT transfers one amino group from L-alanine to 2-oxoglutarate forming 
pyruvate and glutamate (Bergmeyer et al., 1986a). Pyruvate then enters a second 
reaction with nicotinamide adenine dinucleotide (NADH), catalysed by lactate 
dehydrogenase (LDH), producing lactate and NAD
+
. Absorbance is measured at 340 nm 
and the decrease due to NADH consumption is directly proportional to the ALT activity 
in the sample. 
ALT
L-Alanine + 2-Oxoglutarate L-Glutamate + Pyruvate
Pyruvate + NADH + H+ D-Lactate + NAD+
LDH
 
2.7.1.2 AST assay 
In this reaction AST catalyses the reversible transamination of L-aspartate and 2-
oxoglutarate to oxalacetate and L-glutamate (Bergmeyer et al., 1986b). Oxalacetate then 
reacts with NADH and is then further reduced to malate in the presence of malate 
dehydrogenase (MDH). AST activity is determined by measuring the rate of oxidation 
of NADH at 340 nm. 
AST
L-Aspartate + 2-Oxoglutarate L-Glutamate + Oxalacetate
MDH
Oxalacetate + NADH + H+ D-Malate + NAD+
 
2.7.1.3 ALP assay 
The enzyme ALP hydrolyses p-nitrophenylphosphate to form p-nitrophenol which is a 
yellow chromogen. The increase in absorbance at 415 nm due to the production of p-
nitrophenol is proportional to the ALP activity (Rec Gscc (DGKC) (1972)). 
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ALP
p-Nitrophenylphosphate + H2O Phosphate + p-Nitrophenol  
2.7.1.4 GLDH assay 
Measurement of GLDH occurs according to the reaction below and was measured using 
the kinetic DGKC method (Rec Gscc (DGKC) (1972)). Ammonia and 2-oxoglutarate 
are converted to glutamate in a reaction catalysed by GLDH. Simultaneously, one mole 
of NADH is oxidised. The absorbance is read at 340 nm and the decrease in absorbance 
per minute is proportional to the GLDH activity. 
GLDH
2-Oxoglutarate + NADH + NH4
+ Glutamate + NAD+ + H2O  
2.7.1.5 Glucose assay 
In this reaction glucose receives a phosphate group from adenosine triphosphate (ATP) 
in a reaction catalysed by hexokinase (Wright et al., 1971). The resulting product, 
glucose-6-phosphate, is then oxidised in the presence of NAD
+
. This reaction is 
catalysed by the enzyme glucose-6-phosphate dehydrogenase (G6PDH). At the same 
time NAD
+ 
is reduced to NADH. The increase in absorbance at 340 nm due to the 
NADH formation is directly proportional to the glucose concentration. 
Hexokinase
Glucose + ATP Glucose-6-phosphate + ADP
G6PDH
Glucose-6-phosphate + NAD+ 6-Phosphogluconate + NADH
 
2.7.1.6 Urea assay 
The enzyme urease catalyses the hydrolysis of urea to carbamate and ammonia (Talke 
and Schubert, 1965). Carbamate then spontaneously decomposes to yield ammonia and 
carbonic acid. The ammonia then reacts with 2-oxoglutarate and NADH in a reaction 
catalysed by GLDH with the production of NAD
+
. The decrease in absorbance at 340 
nm due to the decrease in NADH is proportional to the urea levels. 
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Urease
Urea + 2 H2O 2 NH4
+ +  2 HCO3
-
GLDH
2-Oxoglutarate + NADH + NH4
+ Glutamate + NAD+ + H2O  
2.7.1.7 Creatinine assay 
This is a multi-step reaction; the first step consists of the conversion of creatinine to 
creatine by the enzyme creatinine amidohydrolase (Moss et al., 1975). Creatine is then 
converted to urea and sarcosine. Further reactions result in the production of a coloured 
chromogen and the change in absorbance is read at 545 nm. 
Creatinine 
amidohydrolase
Creatinine + H2O Creatine
Creatine
amidinohydrolase
Creatine + H2O Sarcosine + Urea
Sarcosine oxidase
Sarcosine + H2O + O2 Glycine + Formaldehyde + H2O2
Peroxidase
2 H2O2 + 4-Aminoantipyridine + ESPMT Quinoneimine dye + 4 H2O  
 (ESPMT: N-ethyl-N-sulfopropryl-m-toluidine) 
2.7.1.8 Total protein assay 
Total protein measurement based on the Biuret assay (Lubran, 1978). This assay is 
based on the fact that peptides bonds have the ability to form a purple complex with 
copper salts in alkaline solution. Absorbance is read at 540 nm. 
2.7.1.9 Albumin assay 
Serum albumin was measured using the bromocresol green (BCG) method (Doumas et 
al., 1971). BCG forms a coloured complex with albumin and the intensity of the colour, 
measured at 620 nm is directly proportional do the albumin concentration in the sample. 
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2.7.1.10 Acetoacetate and β-Hydroxybutyrate assay 
The acetoacetate assay is based on the automated method of Galan et al., (2001). The 2 
assays are based on endpoint reactions catalysed by β-hydroxybutyrate dehydrogenase. 
The generation or consumption of NADH is measured by changes in absorbance at 340 
nm. 
β -Hydroxybutyrate + NAD- Acetoacetate + NADH- + H+
β-Hydroxybutyrate
dehydrogenase
 
2.7.2 Urinary clinical chemistry 
Urinary glucose and creatinine measurements were performed using the methods 
described in Sections 2.7.1.5 and 2.7.1.7, respectively. 
2.7.2.1 Total protein 
Urinary protein concentration was measured based on the pyrogallol red procedure, 
which is based on the change in absorbance that occurs when pyrogallol red-molybdate 
complex binds to basic amino acids of proteins (Watanabe et al., 1986). Absorbance is 
read at 600 nm and the increase is proportional to protein concentration. 
Protein + Pyrogallol Red-Molybdenum Complex Protein Pyrogallol-Red Molybdenum Complex
 
2.7.2.2 N-acetyl-β-D-glucosaminidase assay 
The detection of N-acetyl-β-D-glucosaminidase (NAG) is based on the method by Noto 
et al., (1983). This is a colourimetric assay using sodium m-cresolsulfonphthaleinyl N-
acetyl-β-D-glucosaminidase (MCP-NAG). NAG hydrolyses MCP-NAG to MCP and 
NAG. MCP shows maximum absorption at 580 nm. 
2.7.2.3 Testosterone assay 
Testosterone was measured in urine samples using a competitive enzyme immunoassay. 
A monoclonal antibody specific for testosterone binds to the goat anti-mouse antibody 
coated onto the microplate. The plate is washed to remove excess monoclonal antibody 
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and the testosterone present in the sample competes with a fixed amount of horseradish 
peroxidase-labelled testosterone for sites on the monoclonal antibody. This step is 
followed by another wash to remove excess conjugate and unbound sample after which 
a substrate solution is added to the wells to determine the bound enzyme activity. 
Absorbance is read at 450 nm and the intensity of the colour is inversely proportional to 
the concentration of testosterone in the sample. 
2.7.2.4 Microalbumin detection assay 
Microalbumin was measured on the Advia 1650 by Polyethylene glycol (PEG)-
enhanced immunoturbidimetric assay (Harmoinen et al., 1987). 
2.7.3 Meso Scale Discovery Immunoassays  
Where stated urine and serum samples were assayed for kidney biomarkers using two 
multiplexed test kits - the Rat Kidney Injury Panel 1 (albumin, KIM-1, lipocalin-2, 
osteopontin) and the Argutus Acute Kidney Injury Panel (α-GST, GST Yb1, RPA1), 
and one single-plex test kit - the Clusterin Test Kit. Levels of TIMP-1, MCP1, A2M and 
AGP were also measured in the samples using two different multiplexed kits. Responses 
were evaluated on the Sector
®
 Imager 6000 (Meso Scale Discovery; MSD, 
Gaithersburg, MD, USA). 
All assays were two-antibody type assays, except for albumin which was a single 
antibody in a competitive assay. In the two-antibody type assays the sample is premixed 
with a solution containing the corresponding detection antibodies conjugated with 
SULFO-TAG
TM
 labels. The mixture is then incubated with a plate pre-coated with the 
capture antibodies. If the analytes are present in the sample they will be captured by the 
immobilised antibodies and will attract the detection antibodies completing the 
sandwich. Inside the instrument a voltage is applied to the plate electrodes causing the 
labels bound to the electrode surface to emit light and the intensity is measured by the 
instrument to give a quantitative measure of the analytes in the sample. 
In the competitive assay used to measure albumin, free albumin in the samples 
(unconjugated) competes with the SULFO-TAG
TM
 labelled albumin for binding sites on 
the immobilised antibodies. The signal strength is therefore inversely proportional to the 
levels of free albumin in the sample.  
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2.8 Histopathological examination 
Histopathology examination was carried out at GlaxoSmithKline. 
Organs were removed at autopsy and taken into 10.5 % (v/v) phosphate buffered 
formalin fixative or Bouin’s fixative (testes and epididymides). Tissues were fixed 
overnight before being dehydrated using increasing concentrations of IMS. In the last 
dehydrating step 100 % IMS was used to ensure that no water was present prior to the 
next step which is a clearing step. The dehydrating agent was removed with a substance 
that is miscible with the embedding medium (paraffin) and the dehydrating agent 
(alcohol). The most commonly used clearing agent is xylene. Samples were then 
infiltrated with the embedding agent (molten paraffin) at 60 ºC for 2 to 4 days and the 
tissue wax allowed to cool in an ice tray for microtomy. Sections of approximately 3 
µm thickness were cut and floated onto a water bath containing warm distilled water 
and picked up onto a glass slide. Prior to staining slides were dried in an incubator. 
Slides were then stained with haematoxylin and eosin (H&E) or chromotrope-aniline-
blue (CAD). 
2.9 Gene expression measurement 
Gene expression measurement was carried out at GlaxoSmithKline. 
2.9.1 RNA isolation and conversion to complementary DNA 
Liver or kidney tissue previously stored in RNAlater (4 °C) was homogenised using a 
Tissue Lyser homogeniser (Retsch GmbH, Haan, Germany) and RNA/DNA extracted 
using the RNeasy Mini Kit (Qiagen). Samples were then treated for the removal of 
genomic DNA using DNase I enzyme (Ambion, Huntingdon, UK). Quantitation was 
performed using the RiboGreen RNA Quantitation Kit (Invitrogen, Paisley, UK) and 
RNA was converted to cDNA template using the High Capacity cDNA Reverse 
Transcription Kit protocol (Applied Biosystems, Warrington, UK). 
2.9.2 Real-time polymerase chain reaction analysis of gene expression 
Quantitative real-time polymerase chain reaction (PCR) was performed using the 7900 
HT Sequence Detection System (Applied Biosystems) and TaqMan
R
 Universal PCR 
Master Mix (Roche, New Jersey, USA) using between 2 and 5 ng cDNA per assay. 
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Specific TaqManR Gene Expression Assay number Rn00597703 m1 (Applied 
Biosystems) was used to quantify KIM-1 mRNA. Other mRNA levels were assayed 
using custom low density arrays (Applied Biosystems). Cycle threshold (Ct) values 
were converted to copy number using the equation: copy number=10 exp[(39 − Ct)/3.4]. 
2.10 1D 1H Nuclear Magnetic Resonance (NMR) spectroscopy  
Urine samples for 
1
H NMR spectroscopy were prepared by the addition of 200 μL 
buffer solution (0.2 M Na2HPO4/0.2 M NaH2PO4, pH 7.4) to 400 μL of urine. The 
mixture was allowed to stand at room temperature for 10 minutes followed by 
centrifugation at 13,000 rpm for 10 minutes. 500 μL aliquots were placed in 5 mm 
NMR tubes to which 50 μL of a standard solution of TSP in D2O was added (final 
concentration = 1 mM). The D2O and TSP provide both a chemical shift reference (δ 
0.0) and a deuterium lock signal for the NMR spectrometer. 
One-dimensional 
1
H NMR spectra of urine were measured at 500.00 MHz on a Bruker 
DRX-500 spectrometer using a standard pre-saturation pulse sequence for water 
suppression with irradiation at the water frequency during the relaxation delay of 3 s 
and the pulse sequence mixing time of 100 ms. Following 4 dummy scans, spectra were 
acquired using 64 scans into 64K points using a spectral width of 10,080 Hz, an 
acquisition time of 4.68 s, and a total pulse recycle time of 7.68 s. The free induction 
decays (FIDs) were multiplied by an exponential weighting function corresponding to a 
line broadening of 0.3 Hz prior to FT. 
All 
1
H NMR spectra were phase and baseline corrected using TopSpin (Bruker 
Analytik, Rheinstetten, Germany) and data reduced using AMIX (Bruker Analytik, 
Rheinstetten, Germany) to regions 0.04 ppm wide from δ 10.0 to 0.2 producing 250 
chemical shifts (variables), an operation known as binning or bucketing. The bucket size 
was chosen to allow for small changes in chemical shift due to variations in pH within 
the samples. The region between δ 6.1-4.5 in the urine spectra was set to zero integral 
value for the purposes of pattern recognition analysis to remove the variability in 
presaturation of the water resonance and cross-relaxation effects on the urea signal.  
The second step in data processing is a row operation known as normalisation. For each 
region of the spectra (bucket) (minus the water region), the area under the curve was 
calculated and expressed as an integral value. All regions of the spectra were normalised 
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to the sum of the integrals to reduce any significant differences in concentration 
between individual urine samples as described by Craig et al., (2006). The data were 
then imported into Microsoft Excel and converted into a bucket table. Each bucket table 
was then imported into SIMCA 13 (Simca v. 13, MKS Umetrics AB, Sweden). The pre-
processed data was compiled to create a bucket table where the rows represent 
individual samples and the columns (comprising 250 variables/buckets) represent 
integrated and normalised peak areas. 
Finally, a step is carried out to reduce the noise in the data. This is a column operation 
that acts on each spectral intensity across all samples, a process known as scaling. 
Mean-centering scaling was carried out in which the column mean is subtracted from 
each value in the column, so that each column has a mean of zero. This was followed by 
Pareto scaling where each variable is divided by the square root of its standard 
deviation. 
2.11 Pattern recognition analysis of 1H NMR spectral data of urine and serum 
PCA, OPLS and OPLS-DA were performed using SIMCA 13 (Simca v. 13, MKS 
Umetrics AB, Sweden).  
PCA is an unsupervised method which is used to identify similarities and differences 
between samples from controls and treated animals. It reduces the dimensionality of a 
data set by creating a new set of variables, known as Principal Components (PCs). PCs 
are uncorrelated, with the first component (PC1) explaining the largest variance in the 
data and the subsequent PCs describing progressively smaller proportions of the total 
variance (Wu et al., 2005; Rousseau et al., 2008). PCA was performed to determine the 
presence of patterns and outliers among samples which appeared distinct from other 
samples. Outliers are shown outside the Hotelling’s T2 elipse which defines the 95 % 
confidence interval. In the present studies, outlier samples that fell outside the 
Hotelling’s T2 plot were individually analysed and excluded from further analysis when 
necessary.  
The PCA scores plots were used to identify the presence of inherent clustering patterns 
between groups of samples and the corresponding loadings plot to identify the regions 
in the spectra that most contributed to the separation of groups of samples on the scores 
plot (Constantinou et al., 2007).  
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OPLS is a regression model used to describe the relationship between a descriptor 
matrix X, and a response matrix Y containing quantitative values. When OPLS is 
applied to qualitative data, such as discriminant analysis it is known as OPLS-DA. A 
variable importance plot (VIP) was also used to identify putative markers of CCl4-
induced toxicity. This type of plot describes which X variables characterise the X matrix 
well and which variables correlate with Y. The VIP values summarise the overall 
contribution of each X-variable to the OPLS model. Variables with small VIP scores, 
usually less than 0.5, are less important and can therefore be excluded from the model.  
Variables identified from the VIP plot as contributing to sample separation were then 
matched to chemical shifts in the 
1
H NMR spectra. Identification was carried out by 
visual comparison of peaks in the 
1
H NMR collected from this project with peaks in 
spectra from previously published literature (Nicholls et al., 2001). 
The quality of the PCA, OPLS and OPLS-DA models was calculated by determining 
the predictive ability of the models (Q
2
) and the correlation coefficient (R
2
) which is a 
measurement of how well the model fits the data. The predictive ability (Q
2
) was 
evaluated by performing a cross-validation (CV). Q
2 
values greater than 0.5 are 
generally considered good. The greater the value for R
2 
the better the fit. 
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2.12 Statistical analysis  
Urine data were corrected for volume and are reported as ‘per collection period’ (c.p.). 
Urine, and serum clinical chemistry data were log transformed before analysis. Data are 
presented as means (SD) for groups of animals. 
Group means and SD were compared by one-way analysis of variance (ANOVA) 
followed by a post-hoc Dunnet’s test, or by the means of a Student’s t-test using the 
software package SPSS (IBM SPSS statistics 19, Portsmouth, Hampshire, PO6 3AU). 
Signiﬁcance was set at *P<0.05, **P<0.01 and ***P<0.001.  
For 
1
H NMR statistical analysis of integral regions, a Student’s t-test was performed. 
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CHAPTER THREE 
Dose response study for the identification of a dose level to induce hepatotoxicity 
but not injury to other organs following CCl4 administration 
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Chapter 3  
3.1 Introduction 
In the present studies carbon tetrachloride (CCl4) was chosen as the hepatotoxicant 
agent since it is one of the most commonly used compounds for the investigation of 
liver toxicity (Brattin et al., 1985). CCl4 is metabolised in the liver by cytochrome P-450 
2E1 to produce reactive free radicals. Since the concentration of CYP450 is greatest in 
the centrilobular region of the liver this area is most susceptible to injury (Lindros, 
1997; Sweeney, 1981). However, CCl4 is highly lipophilic and therefore can be readily 
distributed throughout the body resulting in injury to other organs such as the kidneys, 
the lungs and the brain (Lundh, 1964; Striker et al., 1968; Chen et al., 1977; Boyd et al., 
1980; Tjalve and Lofberg, 1983; Paakko et al., 1996).  
The primary aim of this project was to identify biomarkers of hepatic toxicity; therefore, 
the first objective was to create a model of hepatotoxicity in the male Hanover-Wistar 
rat. Firstly, it was necessary to establish the optimal dose level of CCl4 capable of 
causing maximal hepatotoxicity without inducing injury to other tissues. Therefore, a 
dose response experiment was conducted to investigate the effect of a single CCl4 
administration in potential target organs. There is limited data available on CCl4-
induced injury to other organs. Consequently, in this experiment a wide range of animal 
tissues were histologically evaluated including the kidneys, pancreas, spleen, adrenals, 
thymus, thyroid, heart with lungs inflated, head and testes. Histological examination 
would confirm the presence or absence of CCl4-induced injury in the organs.  
Previous studies have showed the potential for CCl4-induced kidney damage in the rat 
in both single (Ozturk et al., 2003; Makni et al., 2012) and repeat dose studies (Deb and 
Chakravarty, 1962; Ogeturk et al., 2005). It has been previously demonstrated that the 
renal cytochrome P-450 concentration is lower than the concentration in the liver 
(Renaud et al., 2011). Therefore, the kidney has a reduced capacity for CCl4 metabolism 
compared to the liver and consequently, nephrotoxicity requires the administration of 
higher dose levels of CCl4. CCl4-induced nephrotoxicity may affect the kidney structure 
resulting in the compromise of glomerular filtration or reabsorption processes. This 
could lead to an increase in the urinary protein and metabolite concentration as a result 
of altered kidney function. We are interested in identifying urinary biomarkers of 
hepatic toxicity; therefore, injury to the kidney could affect our sample collection and 
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biomarker identification. In this situation, it would be difficult to determine if 
biomarkers identified in our study were present as a result of hepatic toxicity, 
nephrotoxicity or both. Consequently, in this study, great importance was attached to 
finding a dose level that induced hepatotoxicity but not nephrotoxicity. 
Serum samples obtained from animals in the study were analysed for serum enzymes. 
Levels of hepatic leakage enzymes such as ALT, AST and GLDH, are described as 
markers of hepatic injury and could thus help to confirm injury (Schmidt and Schmidt, 
1988; Gores et al., 1990; Van Hoof et al., 1997; Giffen et al., 2002) 
However, since the main focus of the present investigation was the identification of 
biomarkers of hepatotoxicity, which can be collected non-invasively, urine was chosen 
as the preferred biofluid for analysis. One of the main advantages of using urine as the 
sample for biomarker identification is the fact that it can be easily collected in relatively 
large volumes and without any associated pain, distress and discomfort to the animal or 
patient, if in a clinical setting (Hewitt et al., 2004; Wu et al., 2010; Boekelheide and 
Schuppe-Koistinen, 2012). Urine proteomic and metabolomic methods have been 
extensively used in the identification of urinary biomarkers for a wide range of disease 
types including heart disease (Schwedhelm et al., 2004; de Zeeuw et al., 2006; Larsson, 
2013), lung disease (Bode et al., 2000; Cannas et al., 2010; Niu et al., 2012), cancer 
(Yamaguchi et al., 2005; Sanchez-Carbayo et al., 2000; Slupsky et al., 2010) and kidney 
disease (Jorres et al., 1994; Kamijo et al., 2004; Dieterle et al., 2010). Previous 
metabolomic studies have identified taurine as a biomarker for liver toxicity (Waterfield 
et al., 1991; Waterfield et al., 1993). 
Therefore, the objective of the present study was to develop a good model of acute 
hepatotoxicity without inducing toxicity to other organs. Upon development of the 
model, urine samples were analysed for the identification of biomarkers of liver injury.  
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3.2 Animal experimental design 
Sixty male Hanover-Wistar rats (mean body weight 199.7 ± 28.6 g) were divided into 
10 groups of 6 animals each and dosed by gavage with CCl4 at 0 (controls), 0.4, 0.8, 
1.2, 1.6, 2.0, 2.4, 2.8, 3.2 and 3.6 mL/kg. Control animals were dosed with equivalent 
volumes of corn oil by gavage. After dosing, animals were returned to their communal 
cages for 6 hours during which water and diet were available ad libitum. At 6 hours 
post-dosing, animals were placed individually in metabolism cages for the collection of 
18 hour urine samples (6-24 hours post-dosing). During this period, animals had no 
access to diet. Urine samples were collected over ice and stored at -80 ºC for future 
analysis. All animals were weighed before dosing, before being placed in metabolism 
cages and at 24 hours post-dosing, just prior to autopsy. 
At autopsy (24 hours after dosing) blood was taken for the preparation of serum which 
was stored at -80 ºC until analysis. The liver, kidneys, spleen, pancreas, adrenals, 
thymus, thyroid, testes, heart with lungs inflated and head were removed and placed in 
fixative as described in Section 2.8. 
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3.3 Results 
3.3.1 Observations during the study 
Throughout the study, animals were observed for signs of ill-health and clinical 
observations were recorded during the post-mortem procedure. The behaviour of the 
animals was observed to guarantee their welfare and as a first indicator of pain and 
distress. During the period in the metabolism cages, animals treated with CCl4 at 3.2 
mL/kg and above appeared to be slightly subdued in comparison to the control animals. 
One animal treated with 3.6 mL/kg CCl4 had a hunched posture. At autopsy, i.e., 24 
hours post-dosing, livers from CCl4-treated animals appeared paler in colour when 
compared to the control livers and the change in colour was more pronounced as the 
CCl4 dose level increased.  
3.3.2 Body weights 
Table 3.1 shows the change in body weight (for both control and CCl4-treated animals) 
during the 18 hour period while rats were in the metabolism cages. The mean change in 
body weight for CCl4-treated animals was compared to the change in body weight for 
controls. Although all animals lost weight over the 18 hour period the decrease in body 
weight for animals in the 1.2 mL/kg dose level group was the greatest (-19.83 g). 
Animals dosed at 2.8 mL/kg lost the least weight, -9.03 g (
**
P<0.01). However, there 
appears to be no clear CCl4 dose-related effect on body weight of the animals. 
Table 3.1 Body weight change for male Hanover-Wistar rats treated with increasing doses of CCl4 
during an 18 hour period in metabolism cages. Animals were dosed with vehicle (control, 0 mL/kg) or 
CCl4 by gavage and placed individually in metabolism cages for the collection of 18 hour urine samples 
as described in Section 3.2. Animals had access to water but not diet while in the metabolism cages. 
Weight changes are shown as mean and SD of 6 animals per group. Changes in weight that are 
statistically different to the changes for control animals by one-way ANOVA test are shown: 
**
P<0.01. 
 
 
Dose level of CCl4 
(mL/kg) 
Mean (SD) change in body 
weight (g) 
0 -16.12 (2.09) 
0.4 -19.25 (1.95) 
0.8 -15.13 (2.89) 
1.2 -19.83 (2.16) 
1.6 -16.33 (1.84) 
2.0 -17.15 (2.32) 
2.4 -9.23
**
 (3.01) 
2.8 -9.03
**
 (3.77) 
3.2 -12.22 (4.52) 
3.6 -16.17 (2.58) 
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3.3.3 Liver weights 
Figure 3.1 A shows the mean relative liver weights at each CCl4 dose level. The liver 
weights for CCl4-treated animals were significantly increased over controls (
**
P<0.01) 
at 0.8 mL/kg and above, and there was a dose-related increase. At the highest dose level 
(3.6 mL/kg), relative liver weights were approximately 2-fold greater than control 
animals (
***
P<0.001). 
3.3.4 Kidney weights 
The mean relative kidney weights for rats treated with CCl4 were similar to control at 
the lower dose levels (0.4, 0.8, 1.2, 1.6 and 2.0 mL/kg CCl4) (Figure 3.1 B). However, 
at 2.4 mL/kg the relative kidney weights (4.23 g/kg BW) were significantly greater than 
controls (3.64 mg/kg BW) (
*
P<0.05), and at the highest dose level (3.6 mL/kg) there 
was a 1.23-fold increase over control weights (
**
P<0.01). However, there was no 
significant difference in kidney weights at 2.8 and 3.2 mL/kg CCl4 when compared to 
controls. 
3.3.5 Weights of other organs 
At post-mortem, the spleen, thymus, heart, adrenals and testes were removed and the 
relative weights calculated (Table 3.2). There were no CCl4-treatment related effects on 
the relative weights of the spleen, thymus and heart in this study. The mean relative 
adrenal weight was significantly decreased at 2.0 mL/kg compared to control animals 
(0.18 and 0.24 g/kg BW respectively; 
*
P<0.05) but similar to control at all other dose 
levels. The relative mean weight of the testes was decreased by 19 % in the 2.8 mL/kg 
group (
**
P<0.01) and by 16 % in the 3.6 mL/kg group (
*
P<0.05) when compared to 
control animals, however, in general, there was no CCl4 dose-related trend. 
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A 
B  
 
Figure 3.1 Relative liver (A) and kidney (B) weights from male Hanover-Wistar rats treated with 
increasing doses of CCl4. Animals were dosed with vehicle (control, 0 mL/kg) or CCl4 by gavage. At 24 
hours post-dosing animals were killed, livers and kidneys were removed and weighed as described in 
Section 3.2. The kidney weight was expressed as a mean of the left and right kidneys. Results are shown 
as mean organ weight per kg body weight (BW) with SD indicated by vertical bars of 6 animals per 
group. Relative organ weights that differ significantly from controls by one-way ANOVA test are shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001.  
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Table 3.2 Relative organ weights from male Hanover-Wistar rats treated with increasing doses of 
CCl4. Animals were dosed with vehicle (control, 0 mL/kg) or CCl4 by gavage. At 24 hours post-dosing 
animals were killed, organs were removed and weighed as described in Section 3.2. The testes and 
adrenals weight was expressed as a mean of the left and right organs. Results are shown as mean organ 
weight per kg body weight (BW) and SD of 6 animals per group. Relative organ weights that differ 
significantly from controls by one-way ANOVA test are shown: 
*
P<0.05; 
**
P<0.01. 
 
Dose level of 
CCl4 (mL/kg) 
Relative organ weight (g/kg BW) (SD) 
Spleen Thymus Heart Adrenals Testes 
0 2.54 (0.36) 2.82 (0.31) 3.41 (0.19) 0.24 (0.04) 7.08 (0.68) 
0.4 2.31 (0.30) 2.25 (0.21) 3.69 (0.45) 0.42 (0.04) 6.62 (0.25) 
0.8 2.67 (0.24) 2.53 (0.22) 3.75 (0.47) 0.23 (0.02) 7.27 (0.84) 
1.2 2.75 (0.42) 2.64 (0.65) 3.61 (0.43) 0.22 (0.03) 6.88 (0.46) 
1.6 2.47 (0.33) 2.60 (0.54) 3.32 (0.24) 0.25 (0.04) 6.81 (0.65) 
2.0 2.27 (0.24) 2.30 (0.59) 3.54 (0.36)  0.18
*
 (0.03) 6.33 (0.32) 
2.4 2.80 (0.79) 3.05 (0.42) 3.86 (0.50) 0.22 (0.05) 6.27 (0.49) 
2.8 2.64 (0.61) 3.11 (0.22) 3.67 (0.15) 0.23 (0.04) 5.74
**
(0.39) 
3.2 2.72 (0.65) 2.84 (0.83) 3.69 (0.19) 0.24 (0.02) 6.98 (0.89) 
3.6 2.55 (0.41) 2.78 (0.45) 3.43 (0.22) 0.23 (0.04) 5.98
*
(0.37) 
3.3.6 Serum clinical chemistry 
Clinical biochemical parameters including ALT, AST, GLDH, ALP, TIMP-1, MCP1, 
A2M, AGP, lipocalin-2, urea, creatinine, albumin, glucose and total protein were 
measured in the serum from control (vehicle-treated animals) and animals dosed with 
CCl4 at 0.4, 0.8, 1.2, 1.6, 2.0, 2.4, 2.8, 3.2 and 3.6 mL/kg (Figure 3.2, Table 3.3). 
Levels of ALT, AST and GLDH were measured to determine liver injury. There was an 
increase in ALT levels with increasing dose of CCl4 indicating a dose response 
relationship. At the lowest dose level serum ALT levels were 2.5-fold greater than 
control (89.67 and 35.83 U/L, respectively), however, this increase was not significantly 
different from control. At 0.8 mL/kg CCl4 and above, ALT levels were significantly 
increased in comparison to controls. At the highest dose level (3.6 mL/kg) the mean 
ALT value was 4640.17 U/L representing a 130-fold increase over controls. AST levels 
also showed a dose-related trend and were 1.4-fold greater than control values at the 
lowest dose level (0.4 mL/kg). However, the increased AST levels for animals dosed 
with CCl4 at 0.4, 0.8, 1.2 and 1.6 mL/kg were not statistically significant but were 
significant at 2.0 mL/kg CCl4 and above. At 2.0 mL/kg and 3.6 mL/kg CCl4 serum AST 
levels were 9.25-fold and 47-fold greater than control, respectively (
***
P<0.001) (Figure 
3.2). 
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Serum GLDH also increased with increasing dose level of CCl4 and levels were 
statistically greater than controls at all dose levels except at 0.4 mL/kg CCl4. At the 
highest dose level (3.6 mL/kg) there was a 136-fold increase in GLDH levels in treated 
animals compared to the values for control animals (
***
P<0.001) (Figure 3.2).  
ALP levels were significantly increased in all CCl4-treated groups and also 
demonstrated a general dose-related trend. The highest ALP measurement was 1142.17 
U/L for animals treated with 3.6 mL/kg CCl4 (
***
P<0.001); this represented a 3.2-fold 
increase (Table 3.3).  
Serum TIMP-1 levels were elevated over control in all CCl4-treated groups (Table 3.3). 
The increase was statistically significant at 1.2 mL/kg CCl4 (
**
P<0.01) and above with 
values of 24.67 μg/L in animals treated at 1.2 mL/kg CCl4, whereas control animals had 
an average TIMP-1 level of 7.00 μg/L. At 3.6 mL/kg CCl4 there was a 25-fold increase 
over control TIMP-1 levels (7.00 and 177.83 μg/L for control and CCl4-treated group, 
respectively).  
MCP1 levels in serum were similar to control for animals treated with CCl4 at 0.4 
mL/kg, however, mean values were increased 2-fold in the 0.8 mL/kg group and at 1.6 
mL/kg CCl4 and above the increase was statistically significant. A2M levels were 
similar to controls in all treated groups except at 2.4 mL/kg where there was a 2-fold 
significant increase over control (
*
P<0.05). Mean serum AGP was increased in all CCl4-
treated animals but only statistically greater than control at 2.0 mL/kg and above. 
Values of lipocalin-2 were similar to control in the lower dose level groups (0.4, 0.8, 1.2 
and 1.6 mL/kg). At dose levels above 1.6 mL/kg lipocalin-2 levels rose with increasing 
CCl4 dose, however, the values were only significant at 2.8 mL/kg and above (
**
P<0.01) 
(Table 3.3).  
To evaluate the possibility of kidney injury, which could affect the urinary proteome 
and metabolome, kidney function was assessed by measuring the serum levels of urea 
and creatinine (Table 3.3). Mean urea levels were higher than control in the serum from 
all CCl4-treated animals; at the lowest dose level (0.4 mL/kg) values were almost 2-fold 
greater than that of controls (6.62 compared to 13.12 mmol/L, respectively). Serum 
creatinine levels for CCl4-treated animals were not significantly different from control 
except for animals in the 3.6 mL/kg group (highest dose level). At this dose level 
creatinine was 3-fold increased over control (73.00 µmol/L for CCl4-treated and 25.17  
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µmol/L for controls, respectively; 
**
P<0.01). Serum albumin and glucose were similar 
to control in all CCl4-treated animals. At 2.4 mL/kg serum total protein levels were 
significantly lower in CCl4-treated animals compared to control. However, at all other 
CCl4 dose levels there was no significant difference in protein levels between control 
and CCl4-treated animals. 
 
 
Figure 3.2 Serum ALT, AST and GLDH levels for male Hanover-Wistar rats treated with 
increasing doses of CCl4. Animals were dosed with vehicle (control, 0 mL/kg) or CCl4 by gavage. At 24 
hours post-dosing, serum was collected as described in Section 3.2 and enzymes were assayed as 
described in Section 2.7. Values are the means with SD indicated by vertical bars of 6 animals per group. 
Values that differ significantly from controls by one-way ANOVA test are shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
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Table 3.3 Serum clinical chemistry parameters for male Hanover-Wistar rats treated with increasing doses of CCl4. Animals were dosed with vehicle (control, 0 mL/kg) or 
CCl4 by gavage. At 24 hours post-dosing, serum was collected as described in Section 3.2 and enzymes were assayed as described in Section 2.7. Values are the means and SD of 6 
animals per group. Values that differ significantly from controls by one-way ANOVA test are shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
 
Serum 
parameters 
CCl4 dose level (mL/kg) 
0 0.4 0.8 1.2 1.6 2.0 2.4 2.8 3.2 3.6 
ALP 
(U/L) 
356.00 
(45.17) 
521.83
*
 
(107.76) 
544.83
**
 
(94.71) 
642.17
***
 
(169.41) 
609.50
**
 
(96.42) 
759.67
***
 
(122.07) 
822.50
***
 
(218.99) 
1144.50
***
 
(270.71) 
884.17
***
 
(133.30) 
1142.17
***
 
(195.28) 
TIMP-1 
(μg/L) 
7.00 
(1.10) 
8.33 
(1.86) 
15.83 
(5.74) 
24.67
**
 
(9.63) 
23.50
**
 
(5.79) 
45.00
***
 
(38.16) 
39.83
***
 
(21.45) 
82.33
***
 
(50.43) 
70.33
***
 
(19.77) 
177.83
***
 
(189.76) 
MCP1 
(μg/L) 
8.33 
(0.82) 
7.67 
(1.75) 
14.67 
(5.92) 
23.83 
(15.65) 
28.83
**
 
(5.19) 
65.17
***
 
(69.16) 
54.67
***
 
(37.65) 
138.00
***
 
(105.46) 
117.50
***
 
(110.95) 
206.67
***
 
(123.67) 
A2M 
(mg/L) 
45.00 
(11.83) 
30.33 
(9.87) 
42.67 
(13.87) 
40.33 
(9.69) 
35.00 
(10.06) 
29.17 
(6.05) 
86.83
*
 
(43.60) 
55.50 
(17.52) 
59.50 
(24.52) 
44.17 
(10.83) 
AGP 
(mg/L) 
45.00 
(11.42) 
63.83 
(9.02) 
66.33 
(14.77) 
76.00 
(36.33) 
82.50 
(25.91) 
138.00
**
 
(86.84) 
130.33
*
 
(112.33) 
106.50
*
 
(39.35) 
155.17
**
 
(114.08) 
128.83
*
 
(89.30) 
Lipocalin-2 
(μg/L) 
75.17 
(13.12) 
77.17 
(14.13) 
81.50 
(25.24) 
93.00 
(25.51) 
90.33 
(5.72) 
437.50 
(704.85) 
612.17 
(857.02) 
854.67
**
  
(748.44) 
2054.50
**
  
(4185.14) 
1099.50
***
 
(748.17) 
Urea 
(mmol/L) 
6.62 
(0.67) 
13.12
***
 
(0.72) 
10.33
***
 
(1.72) 
10.57
***
 
(1.02) 
10.43
***
 
(1.29) 
10.82
***
 
(1.31) 
8.68
*
 
(1.03) 
9.07
***
 
(0.64) 
9.90
***
 
(1.32) 
13.03
***
 
(4.65) 
Creatinine 
(µmol/L) 
25.17 
(0.75) 
32.67 
(4.23) 
24.17 
(1.60) 
26.67 
(1.21) 
33.33 
(11.57) 
32.83 
(11.23) 
24.50 
(3.78) 
33.67 
(16.46) 
29.33 
(12.21) 
73.00
**
 
(55.02) 
Albumin 
(g/L) 
35.33 
(0.82) 
36.50 
(1.05) 
35.67 
(1.03) 
35.67 
(0.82) 
34.83 
(1.72) 
34.67 
(1.03) 
34.50 
(0.84) 
33.67 
(2.16) 
34.50 
(1.22) 
35.50 
(1.87) 
Glucose 
(mmol/L) 
5.60 
(1.17) 
6.15 
(0.40) 
5.74 
(0.53) 
5.50 
(0.62) 
5.97 
(0.57) 
5.81 
(0.65) 
5.28 
(0.36) 
4.29 
(1.35) 
5.41 
(0.48) 
4.34 
(2.22) 
Total protein 
(g/L) 
53.83 
(1.17) 
56.00 
(1.41) 
54.50 
(1.05) 
53.83 
(1.47) 
52.67 
(2.80) 
52.33 
(1.63) 
50.00
**
 
(2.68) 
49.00 
(4.29) 
50.33 
(2.66) 
53.67 
(2.50) 
 
ALP: alkaline phosphatase; TIMP-1: tissue inhibitor of matrix metalloproteinase; MCP 1: monocyte chemoattractant factor 1; A2M: alpha-2 macroglobulin; AGP: alpha-1 acid glycoprotein.  
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3.3.7 Urine clinical chemistry  
Urine clinical chemistry was carried out to further assess the possibility of kidney 
injury. 
Table 3.4 shows that creatinine levels were similar to control in all CCl4-treated groups 
apart from at 2.8 mL/kg and 3.2 mL/kg CCl4 when a statistically significant decrease 
was observed (
**
P<0.01 and 
*
P<0.05, respectively). 
Urinary total protein concentration was significantly lower than control in all CCl4-
treated rats apart from at the lowest dose (0.4 mL/kg) when levels were similar to 
control. However, there was no evidence of a dose-related trend. Urinary albumin levels 
were not affected by CCl4 administration in a dose-related manner; however, at the 
highest dose level (3.6 mL/kg) urinary albumin was significantly increased by 4.6-fold 
over control (
*
P<0.05). Urinary glucose levels were increased in all CCl4-treated 
animals with the greatest increase occurring in animals in the 2.0 mL/kg CCl4 group. 
Animals in this group had mean glucose levels of 6.17 µmol/c.p. in comparison to 3.00 
µmol/c.p. for the controls (
***
P<0.001). 
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Table 3.4 Urinary clinical chemistry parameters for male Hanover-Wistar rats treated with increasing doses of CCl4. Animals were dosed with vehicle (control, 0 mL/kg) or 
CCl4 by gavage and urine collected for 18 hours post-dosing as described in Section 3.2. Clinical parameters were assayed as described in Section 2.7. Values are the means and SD 
of 6 animals per group and are expressed as c.p. (collection period, 18 hours). Values that differ significantly from controls by one-way ANOVA test are shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
 
 
Urinary 
parameters 
CCl4 dose level ( mL/kg) 
0 0.4 0.8 1.2 1.6 2.0 2.4 2.8 3.2 3.6 
Creatinine 
(µmol/c.p.) 
34.17 
(9.04) 
43.83 
(4.17) 
31.50 
(2.26) 
35.00 
(2.45) 
34.83 
(2.56) 
40.50 
(8.02) 
26.67 
(10.03) 
22.17
**
 
(2.48) 
23.67
*
 
(4.13) 
27.67 
(4.23) 
Total protein 
(mg/c.p.) 
6.13 
(1.83) 
6.02 
(1.47) 
2.25
***
 
(0.27) 
1.95
***
 
(0.58) 
2.23
***
 
(0.60) 
2.42
**
 
(0.66) 
1.45
***
 
(0.62) 
1.32
***
 
(0.24) 
1.47
***
 
(0.68) 
3.90
*
 
(3.18) 
Albumin 
(ng/c.p.) 
149.98 
(70.37) 
216.37 
(56.12) 
146.42 
(89.83) 
125.99 
(43.14) 
130.83 
(10.78) 
225.64 
(107.93) 
199.49 
(67.43) 
154.26 
(75.37) 
204.26 
(152.58) 
688.33
*
 
(660.78) 
Glucose 
(µmol/c.p.) 
3.00 
(0.63) 
5.00
**
 
(0.89) 
4.17 
(0.98) 
4.50
*
 
(0.55) 
4.33 
(1.03) 
6.17
***
 
(1.72) 
5.17
**
 
(1.94) 
4.00 
(0.89) 
4.50
*
 
(0.84) 
5.67
***
 
(1.51) 
Volume 
(mL) 
10.48 
(4.90) 
11.77 
(5.74) 
19.90 
(7.07) 
28.73
**
 
(8.43) 
20.05 
(10.14) 
18.13 
(15.07) 
12.97 
(5.65) 
15.28 
(9.41) 
9.70 
(3.79) 
11.87 
(4.11) 
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3.3.8 Histopathology 
Animals were autopsied as described in Section 3.2. Tissue samples were collected and 
placed in fixative for histopathological examination.  
In this study, kidneys, liver and nasal cavity were examined in all animals, except for 
those in the 2.4 or 3.2 mL/kg CCl4-treated groups. These groups were eliminated as a 
result of the large number of tissue samples generated and the time taken to process the 
samples. In addition, adrenals, heart, lungs, pancreas, spleen, testes, thyroid and thymus 
were only examined from control animals and animals dosed at 2.0, 2.8 and 3.6 mL/kg 
CCl4 as the probability of finding CCl4-treatment-related injuries increases with 
increasing dose level.  
For each of the histopathological changes described below, Table 3.5 to Table 3.8 show 
the number of animals in each dose group exhibiting the pathological change. 
Hepatocellular changes associated with CCl4 treatment were apparent at all CCl4 dose 
levels (Table 3.5, Figure 3.3). Centrilobular hepatocellular vacuolation was either 
marked or very marked and a proportion of centrilobular hepatocytes showed 
ballooning of the cytoplasm in all treated animals (Figure 3.3). Hepatocyte necrosis was 
recorded in animals administered CCl4 at 0.8 mL/kg and above, the extent of which 
became more marked with increasing dose level. There was also a focal mixed 
inflammatory cell infiltrate present in all CCl4-treated animals.  
In the kidneys, pathological findings considered to be related to CCl4 treatment were 
observed in a small number of the animals at dose levels of 2.8 mL/kg and above. These 
changes included granular casts in collecting ducts, dilatation of distal and/or collecting 
tubules, and minimal proximal tubular necrosis (Table 3.6, Figure 3.4).  
Sections of the nasal cavity were prepared to include the ethmoid turbinates (Table 3.7). 
Turbinate bone refers to the thin and curved bone structures that project from the walls 
of the nasal cavity into the respiratory passage in vertebrates. The ethmoid turbinates 
extend from the ethmoid bone. Degeneration of the olfactory epithelium, characterised 
by necrosis and vacuolation, was present at all CCl4 dose levels. The severity and extent 
of nasal cavity injury varied between animals in a group and there was no clear dose 
response relationship, except for the findings of ulceration of the olfactory epithelium 
which only occurred in some animals administered CCl4 at 2.0 mL/kg and above. 
Additional histology sections of the nasal cavity were examined to evaluate the extent 
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of the lesion and in the 3.6 mL/kg CCl4 group 2 animals showed evidence of respiratory 
epithelial ulceration. 
Histological examination revealed that there was no evidence of CCl4-related toxicity in 
any of the other organs examined (spleen, pancreas, adrenals, thymus, thyroid, heart and 
lungs) apart from the testes where the presence of multinucleate spermatid giant cells 
was found in 1 animal in the 3.6 mL/kg CCl4 group (Table 3.8). Atrophy of the 
seminiferous tubules was seen in 1 control animal.  
In summary there were CCl4-treatment-related findings in the liver and nasal cavity at 
all CCl4 dose levels and in the kidneys at dose levels of 2.8 mL/kg CCl4 and above. 
 
Table 3.5 Histopathological findings in the liver of male Hanover-Wistar rats treated with 
increasing doses of CCl4. Animals were dosed with vehicle (control, 0 mL/kg) or CCl4 by gavage and 
autopsied at 24 hours post-dosing as described in Section 3.2. Six animals per group were examined. Each 
column represents the number of animals in that dose group showing the pathological changes described 
in the rows. 
 
 CCl4 dose level (mL/kg) 
 0 0.4 0.8 1.2 1.6 2.0 2.8 3.6 
No abnormality detected 
  6 0 0 0 0 0 0 0 
Centrilobular vacuolation 
Marked 0 6 6 5 0 0 1 0 
Very marked 0 0 0 1 6 6 5 6 
Centrilobular cytoplasmic  
ballooning 
Minimal 0 5 0 0 0 0 0 0 
Mild 0 1 2 1 0 1 1 5 
Moderate 0 0 2 4 4 1 4 1 
Marked 0 0 2 1 2 4 0 0 
Very marked 0 0 0 0 0 0 1 0 
Focal and mixed inflammatory  
cell infiltrate 
Mild 0 6 4 2 1 0 0 0 
Moderate 0 0 2 4 5 5 6 6 
Marked 0 0 0 0 0 1 0 0 
Centrilobular hepatocyte necrosis 
Minimal 0 0 2 2 0 0 0 0 
Mild 0 0 0 1 1 0 0 0 
Moderate 0 0 0 1 5 4 0 0 
Marked 0 0 0 0 0 2 6 2 
Very marked 0 0 0 0 0 0 0 4 
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Figure 3.3 Histology of liver sections from male Hanover-Wistar rats treated with different doses of 
CCl4. Original magnification of all images, x 100; H&E Animals were dosed with vehicle (control, 0 
mL/kg) or CCl4 at 0.4 and 3.6 mL/kg by gavage. At autopsy, liver samples were collected and processed 
for histopathological examination as described in Section 2.8. (A) control rat: central vein (c) and portal 
vein (p); (B) 0.4 mL/kg CCl4-treated rat: vacuolation of centrilobular hepatocytes (arrow) (central vein (c) 
and portal vein (p)); (C) 3.6 mL/kg CCl4-treated rat: necrosis of centrilobular hepatocytes and widespread 
vacuolation (central vein (c) and portal vein (p)). 
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Table 3.6 Histopathological findings in the kidneys of male Hanover-Wistar rats treated with 
increasing doses of CCl4. Animals were dosed with vehicle (control, 0 mL/kg) or CCl4 by gavage and 
autopsied at 24 hours post-dosing as described in Section 3.2. Six animals per group were examined. Each 
column represents the number of animals in that dose group showing the pathological changes described 
in the rows. 
 
 CCl4 dose level (mL/kg) 
 0 0.4 0.8 1.2 1.6 2.0 2.8 3.6 
No abnormality detected 
  0 4 5 5 5 0 0 0 
Proximal tubule vacuolation 
Minimal 4 0 0 0 0 4 2 0 
Mild 0 0 0 0 0 0 4 4 
Focal tubular basophilia 
Minimal 1 0 0 0 0 1 2 0 
Granular casts in papillary  
collecting ducts 
Mild 0 0 0 0 0 0 0 2 
Granular casts in collecting tubules 
Minimal 0 0 0 0 0 0 1 1 
Mild 0 0 0 0 0 0 0 1 
Distal and collecting tubule 
dilatation         
Mild 0 0 0 0 0 0 0 2 
Hyaline droplets in proximal tubule         
Minimal 5 2 1 1 1 5 0 2 
Proximal tubule necrosis         
Minimal 0 0 0 0 0 0 0 2 
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Figure 3.4 Histology of the kidney cortex from male Hanover-Wistar rats treated with different 
doses of CCl4. Original magnification of all images, x 100; H&E. Animals were dosed with vehicle 
(control, 0 mL/kg) or CCl4 at 3.6 mL/kg by gavage. At autopsy, kidney samples were collected and 
processed for histopathological examination as described in Section 2.8. (A) control rat: collecting tubule 
(c); (B) 3.6 mL/kg CCl4-treated rat: casts in a collecting tubule (c) (arrow); (C) 3.6 mL/kg CCl4-treated 
rat: casts in collecting duct (p) (arrows). 
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Table 3.7 Histopathological findings in the nasal cavity of male Hanover-Wistar rats treated with 
increasing doses of CCl4. Animals were dosed with vehicle (control, 0 mL/kg) or CCl4 by gavage and 
autopsied at 24 hours post-dosing as described in Section 3.2. Six animals per group were examined. Each 
column represents the number of animals in that dose group showing the pathological changes described 
in the rows. 
 CCl4 dose level (mL/kg) 
0 0.4 0.8 1.2 1.6 2.0 2.8 3.6 
No abnormality detected  
 6 0 0 0 0 0 0 1 
Olfactory epithelium vacuolation 
Minimal 0 0 0 0 1 0 0 0 
Mild 0 5 2 1 4 1 2 2 
Moderate 0 1 4 5 1 3 3 1 
Olfactory epithelium degeneration 
Minimal 0 0 1 0 4 1 0 1 
Mild 0 2 2 3 0 2 4 0 
Moderate  0 3 1 3 0 3 1 2 
Marked 0 0 0 0 0 0 0 2 
Olfactory epithelium ulceration 
 0   0 0 0 0 2 3 3 
Respiratory epithelium ulceration 
 0 0 0 0 0 0 0 2 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Histology of the nasal cavity from male Hanover-Wistar rats treated with different doses 
of CCl4. Original magnification of all images, x 20; H&E. Animals were dosed with vehicle (control, 0 
mL/kg) or CCl4 at 3.6 mL/kg by gavage. At autopsy, samples were collected and processed for 
histopathological examination as described in Section 2.8. (A) control rat; (B) 3.6 mL/kg CCl4-treated rat: 
degeneration of the olfactory epithelium and extensive necrosis (arrows). 
 
A B 
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Table 3.8 Histopathological findings in the testes of male Hanover-Wistar rats treated with 
increasing doses of CCl4. Animals were dosed with vehicle (control, 0 mL/kg) or CCl4 by gavage and 
autopsied at 24 hours post-dosing as described in Section 3.2. Six animals per group were examined. Each 
column represents the number of animals in that dose group showing the pathological changes described 
in the rows. 
 
 CCl4 dose level (mL/kg) 
  0 2.0 2.8 3.6 
No abnormality detected 
 5 6 6 5 
Focal unilateral atrophy of the seminiferous tubules 
Minimal 1 0 0 0 
Multinucleate spermatid giant cells 
Minimal   0 0 0 1 
3.3.9 1D 1H NMR spectrometry 
Urine samples were collected from rats between 6 and 24 hours post-dosing with a 
single dose of CCl4 at 0, 0.4, 0.8, 1.2, 1.6, 2.0, 2.4, 2.8, 3.2 and 3.6 mL/kg. Urine 
samples were prepared by the addition of D2O and analysed by 1D 
1
H NMR to assess 
changes in the urinary metabolite profile. 
Resonances in the urine 1D 
1
H NMR spectra were observed and identified as described 
in Section 2.11. 
Visual inspection of characteristic 1D 
1
H NMR spectra of urine samples revealed 
similarities between the metabolite profiles of CCl4-treated animals and control rats. 
However, some differences (e.g. change in peak intensity/concentration) in the profiles 
were evident particularly when urine from 3.6 mL/kg CCl4-treated animals (highest 
dose group) was compared to controls. Peaks displaying changes due to CCl4-induced 
injury included taurine (δ 3.14, δ 3.30), succinate (δ 2.30), creatine (δ 2.94, δ 3.78), 
creatinine (δ 3.02), 2-oxoglutarate (δ 2.34, δ 2.90), hippurate (δ 3.86, δ 7.54, δ 7.58, δ 
7.74), fumarate (δ 6.54) and citrate (δ 2.42, δ 2.62). 
Before analysis, spectra were pre-processed and multivariate data analysis was carried 
out using mean-centered data and Pareto-scaling as described in Section 2.11. PCA, an 
unsupervised pattern recognition method was used to analyse the spectra from the 6 
animals at each dose level. PCA is a pattern recognition technique that allows 
separation of samples into clusters according to the similarities between them. Results 
can be visualized into two types of plots, the scores plot where each point represents an 
individual sample, and allows the observation of patterns, clusters and outliers; and the 
D 
C 
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loadings plot, where each point represents a variable, i.e., a spectral signal. The loadings 
plot provides the basis for metabolite differences interpretation and identification. The 
PCA scores plot was obtained from the 1D 
1
H NMR analysis of the urine samples as 
described in Section 2.11. There was no evidence of distinct clustering patterns between 
control and CCl4-treated samples at the different dose levels and many of the data points 
displayed overlap (Figure 3.6). Outlier samples that fell outside the Hotelling’s T2 plot 
were individually analysed and excluded from further analysis when necessary as 
described in Section 2.11.  
The lack of distinct clustering patterns between the control and CCl4-treated samples 
may have been due to the type of data analysis (PCA) carried out. Therefore, to further 
investigate the possibility of metabolomic differences between vehicle-treated (control) 
and CCl4-treated samples, a supervised pattern recognition method (OPLS) was used. 
OPLS is a prediction and regression method that finds the information in the X data 
(which can be 1D 
1
H NMR spectral data) that is related to known information, the Y 
data (which can be class information, treatments, time or dose).  
Figure 3.7 A shows the OPLS scores plot of urine samples treated at 0, 0.4, 0.8, 1.2, 1.6, 
2.0, 2.4, 2.8, 3.2 and 3.6 mL/kg CCl4. There was an increased degree of sample 
separation compared to the PCA model (Figure 3.6), and it appeared there was a dose-
related trend. As the CCl4 dose level increased there was a shift towards the right hand 
side of the plot. Consequently, urine samples from control and CCl4 treated groups at 
0.4, 0.8, 1.2 and 1.6 mL/kg were mainly located on the left half of the plot, whereas 
urine samples from higher CCl4 dose levels (2.0 mL/kg CCl4 and above) clustered on 
the right half of the scores plot.  
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Figure 3.6 PCA scores plot from a PCA model derived from 1D 
1
H NMR spectral data of urine 
samples from male Hanover-Wistar rats treated with increasing doses of CCl4. Rats were treated 
with vehicle (control, 0 mL/kg) or CCl4 by gavage and urine collected for 18 hours as described in 
Section 3.2. Each spot in the scores plot represents one urine sample. R
2
X (cum) = 0.508, Q
2
 (cum) = 
0.251. 
 
 
Figure 3.7 OPLS scores plot from an OPLS model derived from 1D 
1
H NMR spectral data of urine 
samples from male Hanover-Wistar rats treated with increasing doses of CCl4. Rats were treated 
with vehicle (control, 0 mL/kg) or CCl4 by gavage and urine collected for 18 hours as described in 
Section 3.2. Each spot in the scores plot represents one urine sample. R
2
X (cum) = 0.615, Q
2
 (cum) = 
0.855. Arrows represent direction of movement.
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A second OPLS model was constructed after exclusion of urine samples from animals 
treated with CCl4 at dose levels above 2.0 mL/kg (Figure 3.8). At these higher dose 
levels, histopathological examination confirmed CCl4-induced kidney injury (see 
discussion in Section 3.4). Therefore, metabolite changes in the urine from animals 
dosed with CCl4 above 2.0 mL/kg may reflect nephrotoxicity as well as hepatotoxicity. 
Since the aim of these studies was to identify biomarkers of hepatotoxicity, the 
elimination of these samples from the analysis ensures that changes in metabolite levels 
are solely due to liver injury. 
Figure 3.8 shows the scores plot and the corresponding loadings plot for the OPLS 
model. The scores plot shows the presence of 6 different clusters corresponding to each 
of the treatment groups (controls, 0.4, 0.8 1.2, 1.6 and 2.0 mL/kg). A clear dose-
dependent separation along the first component (t[1]) is present; arrows in the scores 
plot represent the shift along PC1. By removing CCl4-treatment groups where urinary 
renal toxicity-specific metabolites may have been present we were able to eliminate 
confounding factors that were unrelated to the effect studied and therefore enhance the 
correlation between the X matrix and the Y variable of the OPLS model.  
The loadings plot (Figure 3.8 B) reveals the chemical shifts which contribute to sample 
separation in the scores plot. The position of each NMR variable on the loadings plot is 
related to the direction of its contribution to the separation of samples on the scores plot. 
Therefore, spectral regions corresponding to the chemical shifts located on the right 
hand side of the loadings plot were increased in urine samples from CCl4-treated rats at 
the higher dose levels.  
To further investigate the differences between control and treated samples an OPLS-DA 
model was used (Figure 3.9). When the Y variable in an OPLS model is a discrete 
variable (for example, male or female, control and treated or different dose levels, like 
in the present study), the model becomes an OPLS-DA model. OPLS-DA models are 
mostly useful in sample discrimination, that is, in the identification and classification of 
potential biomarker candidates and in the separation of multiple treatments (Rezzi et al., 
2007). In the OPLS-DA model, control samples were treated as class 1 and CCl4-treated 
urine samples were treated as class 2. Consequently, the data was modelled so that 
information contributing to sample separation was forced onto the first component 
(t[1]), whereas orthogonal information relating to intra group variability was modelled 
in the successive components.  
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Figure 3.8 OPLS scores plot (A) and loadings plot (B) from an OPLS model derived from 1D 
1
H 
NMR spectral data of urine samples from male Hanover-Wistar rats treated with increasing doses 
of CCl4. Rats were treated with vehicle (control, 0 mL/kg) or CCl4 by gavage and urine collected for 18 
hours as described in Section 3.2. Each spot in the scores plot represents one urine sample and each spot 
in the loadings plot represents a 1D 
1
H NMR variable labelled as chemical shift in ppm. R
2
X (cum) = 
0.790, Q
2 
(cum) = 0.864. Arrows represent direction of movement. 
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Interpretation of an OPLS-DA loadings plot is difficult to achieve with more than 2 
classes due to the presence of multiple sample clusters which all have the ability to 
influence the loadings plot simultaneously. Therefore, individual OPLS-DA models for 
control and treated samples at 0.4, 0.8, 1.2 and 1.6 mL/kg CCl4 were performed and are 
shown in Figure 3.9. These plots revealed a very good degree of separation between 
control and treated samples along the discriminating component t[1]. In all plots, 
control samples clustered on the left hand side of the scores plot and CCl4-treated 
samples clustered on the right hand side. 
In this study, the maximum CCl4 dose level which induced hepatotoxicity without 
causing kidney injury was 2.0 mL/kg as confirmed by histopathological examination 
which reported the absence of a CCl4-induced nephrotoxic effect at this dose level. 
Therefore, this dose level was chosen as the optimal CCl4 concentration for the further 
investigation of potential biomarkers of hepatotoxicity.  
The OPLS-DA scores plot, corresponding loadings plot, S-plot and VIP plot for control 
samples and samples treated at 2.0 mL/kg CCl4 are shown in Figure 3.10. The S-plot is 
used to visualise the OPLS-DA loadings plot and helps to extract potential biomarkers. 
An ideal biomarker should have a high magnitude and high reliability; therefore, 
variables which are responsible for most of the clustering separation will be located at 
the extremes of the S-plot. The upper right quadrant of the S-plot shows the chemical 
shifts that are increased in CCl4-treated samples, whereas chemical shifts located in the 
lower left quadrant of the S-plot are increased in control samples (Figure 3.10 C). 
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Figure 3.9 Scores plots from OPLS-DA models derived from 1D 
1
H NMR spectral data of urine 
samples from male Hanover-Wistar rats treated with increasing doses of CCl4. Rats were treated 
with vehicle (control, 0 mL/kg) or CCl4 by gavage and urine collected for 18 hours as described in 
Section 3.2. Each spot in the scores plot represents one urine sample. (A) control and 0.4 mL/kg CCl4-
treated animals; (B) control and 0.8 mL/kg CCl4-treated animals; (C) control and 1.2 mL/kg CCl4-treated 
animals and (D) control and 1.6 mL/kg CCl4-treated animals. Grey spots = control samples; coloured 
spots = CCl4-treated samples. 
 
A B 
C D 
0.8 mL/kg 
CCl4 
Control Control 0.4 mL/kg 
CCl4 
1.2 mL/kg 
CCl4 
1.6 mL/kg  
CCl4 
Control Control 
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Figure 3.10 Scores plot (A), loadings plot (B), S-plot (C) and VIP-plot (D) from an OPLS-DA model 
derived from 1D 
1
H NMR spectral data of urine samples from male Hanover-Wistar rats treated 
with vehicle (control) or CCl4 at 2.0 mL/kg. Rats were dosed by gavage and urine collected for 18 hours 
as described in Section 3.2. Each spot in the scores plot represents one urine sample and each spot in the 
loadings plot, S-plot and VIP-plot represents a 1D 
1
H NMR variable labelled as chemical shift in ppm. 
R
2
X (cum) = 0.680, Q
2
 = 0.695. 
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Variables of interest were chosen based on the variable importance in the projection plot 
(VIP) values (VIP≥1), having a high p[1] value and p(corr)[1] value (Figure 3.10 D). 
Each of these variables represents a chemical shift region (bin). Therefore, the NMR 
spectra were visually inspected at each of the regions identified. Peaks in these regions 
were evaluated for chemical shift value and multiplicity and this data was compared 
with data in previously published literature (Nicholls et al., 2001). Several other 
chemical shifts were also identified as major contributors to class separation but could 
not be assigned to metabolites. Subsequently, a list of some of the metabolites showing 
changes between control and 2.0 mL/kg CCl4-treated samples was constructed (Table 
3.9). A Student’s t-test was carried out to determine the statistical significance of the 
difference in the integral values for the chemical shift regions.  
The most relevant changes in the 1D 
1
H NMR urinary metabolomic profile of male 
Hanover-Wistar following the administration of 2.0 mL/kg CCl4 include an increase in 
the resonances of taurine, formate, creatine, 2-oxoglutarate, citrate, glucose and 
succinate, and a decrease in the resonances of hippurate, fumarate and creatinine. These 
changes in resonance relate to increases and decreases in the urinary concentration of 
these metabolites. 
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Table 3.9 OPLS-DA detected 1D 
1
H NMR chemical shifts responsible for the separation of 1D 
1
H 
NMR derived spectra in the urine of male Hanover-Wistar rats treated with vehicle (control) or 
CCl4 at 2.0 mL/kg. Rats were dosed by gavage and urine collected for 18 hours as described in Section 
3.2. Chemical shifts were statistically compared by means of a Students’ t-test. Values that differ 
significantly from controls are shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
 
 
Chemical shift 
(δ), multiplicity 
Endogenous 
metabolites 
Change in urinary metabolite 
concentration  
(increase (+); decrease (-)) 
8.34-8.38 (s) Formate +
*
 
7.74-7.78 (d) Hippurate -
***
 
7.58-7.62 (t) Hippurate -
**
 
7.54-7.58 (t) Hippurate -
**
 
7.46-7.50 Unidentified -
***
 
7.26-7.30 Unidentified -
*
 
7.10-7.14 Unidentified -
**
 
6.54-6.58 (s) Fumarate - 
4.42-4.46 Unidentified +
*
 
3.98-4.02 Unidentified - 
3.94-3.98 Unidentified +
*
 
3.86-3.90 (d) Hippurate - 
3.78-3.82 (s) Creatine +
*
 
3.74-3.78 (m) Glucose + 
3.70-3.74 Unidentified + 
3.62-3.66 (m) Glucose +
*
 
3.54-3.58 (m) Glucose + 
3.50-3.54 Unidentified + 
3.34-3.38 (m) Glucose +
*
 
3.30-3.34 (t) Taurine +
*
 
3.22-3.26 (s) TMAO - 
3.14-3.18 (t) Taurine + 
3.02-3.06 (s) Creatinine - 
2.94-2.98 (s) Creatine + 
2.90-2.94 (t) 2-oxoglutarate + 
2.62-2.66 (d) Citrate + 
2.58-3.62 Unidentified +
*
 
2.46-2.50 Unidentified +
*
 
2.42-2.46 (d) Citrate + 
2.34-2.38 (t) 2-oxoglutarate + 
2.30-2.34 (s) Succinate + 
2.22-2.26 Unidentified -
**
 
1.98-2.02 Unidentified -
**
 
1.54-1.58 Unidentified -
**
 
 
S, singlet; d, doublet; t, triplet; m, multiplet. TMAO=Trimethylamine N-oxide. 
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3.4 Discussion 
One of the primary objectives of this acute dose response study was to define a dose 
level of CCl4 that would induce injury to the liver of the male Hanover-Wistar rat, but 
not to the kidney. CCl4 was the toxic compound chosen for these studies since it is a 
widely used model compound for hepatotoxicity (Brattin et al., 1985). It is known to 
induce apoptosis and centrilobular necrosis acutely, followed by hepatic fibrosis when 
administered repetitively (Rees et al., 1961; Bruckner et al., 1986; Lindros et al., 1990).  
In the present study male Hanover-Wistar rats of approximately 7 weeks of age were 
administered CCl4 at dose levels from 0.4 to 3.6 mL/kg by gavage. At autopsy (24 hours 
post-dosing), organs were removed from all animals and weighed. In toxicology studies 
a change in relative organ weight has long been accepted as a potential initial indicator 
of organ toxicity (Peters and Boyd, 1966; Michael et al., 2007). In the present study, 
relative liver weights were significantly increased in all CCl4-treated animals at 0.8 
mL/kg and above and a dose-related trend was apparent (Figure 3.1 A). At the highest 
dose level relative liver weights were almost double control weights (60.65 g/kg BW 
and 30.55 g/kg BW for CCl4-treated and control animals respectively). These results 
strongly suggest that injury to the liver had occurred. A previous study by Smyth and 
co-workers (2008) also reported increases in relative liver weights compared to control 
rats following the administration of a single dose of CCl4 at a range of concentrations 
between 0.4 and 2.0 mL/kg. 
Serum ALT, AST and GLDH were measured in this study and found to be increased 
over controls at all dose levels (Figure 3.2). The first significant changes were apparent 
at 0.8 mL/kg CCl4. GLDH showed the greatest fold increase over control (9.56-fold), 
whereas the fold increase for ALT and AST was 4.44-fold and 1.81-fold at this dose 
level, respectively. It would appear that as the CCl4 dose level increased so did the 
levels of these hepatic enzymes in the serum. At the highest dose level (3.6 mL/kg) 
ALT, AST and GLDH were 130-fold, 48-fold and 136-fold increased over controls 
(
***
P<0.001) (Figure 3.2). ALT, AST and GLDH are often called hepatic leakage 
enzymes as they can leak out of the cytoplasm into the circulation when hepatocytes are 
damaged and membrane permeability is affected (Schmidt and Schmidt, 1988, Gores et 
al., 1990, Van Hoof et al., 1997).  
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A previous study evaluating the effect of administering 350 mg/kg CCl4 
intraperitoneally to male Sprague-Dawley rats on serum enzyme levels reported ALT 
and GLDH to have the greatest predictive value for hepatic necrosis (Carakostas et al., 
1986). The authors used a statistical method to determine if enzymes could be used to 
distinguish histopathologically different liver lesions. GLDH, which is a mitochondrial 
enzyme, was found to have the greatest predictive value for the presence of necrosis in 
any hepatic location. However, this also meant that GLDH was not very specific in 
differentiating the origin of liver damage (Carakostas et al., 1986). There was, however, 
no correlation between the degree of injury as detected by histopathological 
examination and the levels of the increased serum enzymes. Campo et al. (2001) 
measured serum ALT in male Sprague-Dawley rats 48 hours after a single i.p. injection 
of 1.0 mL/kg CCl4. Mean values were significantly increased over basal levels collected 
immediately after treatment. Ichi et al. (2007) also demonstrated a significant increase 
in AST activity in the serum of rats 12 hours after a single administration of 4 mL/kg 
CCl4 by gavage. In the same study, ALT levels were significantly increased over 
controls as early as 6 hours post-dosing. A study in female Wistar rats dosed orally with 
1.5 mL/kg CCl4 and autopsied at 0, 3, 6, 12, 48 and 72 hours after treatment revealed 
AST, ALT and GLDH levels peaked between 12 and 48 hours post-dosing (Teschke et 
al., 1983; Teschke et al., 1984).  
ALP is a non specific protein phosphatase and is mostly found in the bile canalicular 
membrane in hepatocytes (Alvaro et al., 2000; Chida and Taguchi, 2011). Increased 
serum levels of ALP are associated with obstructive liver disease and the increase in 
ALP serum level is a result of an inability of the liver to excrete excess ALP produced 
in other tissues such as bone and intestines (Talageri et al., 1951; Kaplan and Righetti, 
1970). In the present study, levels of ALP were statistically greater than control at 0.4 
mL/kg CCl4 (
*
P<0.05) and there appeared to be a dose-related trend (Table 3.3). In 
animals treated with 3.6 mL/kg CCl4 serum levels of the enzyme were over 3-times 
greater than control (
***
P<0.001). A study by Janakat and co-workers (2002) also 
reported increased serum ALP levels in male Wistar albino rats following the 
administration of a single i.p. dose of CCl4 at 2.0 mL/kg. 
TIMP-1 is involved in the regulation of MMPs, by inhibiting the proteolytic activity of 
these enzymes (Brew et al., 2000) which are responsible for the degradation of ECM 
(Murphy et al., 1991). Disruption of this equilibrium may result in conditions such as 
fibrosis where an uncontrolled turnover of matrix protein is present (Wight and Potter-
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Perigo, 2011; Siebuhr et al., 2012). The major sources for TIMP-1 production in liver 
fibrosis are activated HSC and Kupffer cells (Herbst et al., 1997; Wang et al., 2011). 
Therefore, TIMP-1 has been suggested to be a serum marker of liver fibrosis (Roderfeld 
et al., 2006). However, TIMP-1 was measured in the present acute dose study and levels 
were found to be increased in all CCl4-treated animals (Figure 3.2). At 0.8 mL/kg the 
mean value was 2-fold greater than control animals, and at 1.2 mL/kg and above the 
increase over control was statistically significant. At the highest dose level TIMP-1 was 
25-fold greater (
**
P<0.01). Herbst and colleagues (1997) investigated TIMP RNA 
expression in an acute rat model of CCl4 toxicity. Female Sprague-Dawley rats were 
treated i.p. with CCl4 at 1.25 mL/kg and autopsied at 0.5, 1, 3, 6, 12, 24, 48, or 72 hours 
after dosing. As early as 1 hour after a single dose of CCl4, TIMP RNA expression was 
shown to be activated in HSCs in the rat liver. Another study has demonstrated that 
increased expression of TIMP mRNA is present in CCl4-induced hepatic fibrosis 
(Iredale et al., 1996).  
In this current study serum MCP1 levels were significantly increased over controls 
(Table 3.3) at 1.6 mL/kg and above and at the highest dose level (3.6 mL/kg) there was 
a 25-fold increase (
***
P<0.001). Marra and colleagues (1993) described MCP1 as one of 
the most important chemotactic factors secreted by HSCs, which are responsible for 
ECM accumulation during chronic liver injury/disease (Marra et al., 1993). Data 
previously collected from both in vitro and in vivo studies suggests that HSCs are 
involved in the expression of MCP during both chronic and acute hepatic injury (Maher 
and McGuire, 1990; Czaja et al., 1994; Marra et al., 1998). In one study, MCP1 gene 
expression was induced 2 hours after CCl4 administration suggesting an important early 
role for MCP1 in the recruitment and activation of macrophages and monocytes 
following toxic insult to the liver (Czaja et al., 1994).  
AGP is a positive acute phase serum protein that is produced by the liver and secreted 
into the circulation in response to inflammation and infection (Fournier et al., 2000). 
Levels of AGP were greater in all CCl4-treated animals than in controls. However, the 
increases were only statistically significant at 2.0 mL/kg CCl4 and above. Increased 
AGP plasma levels have been reported following CCl4 administration and it appears 
that this increase may be related to the formation of reactive oxygen species but an 
exact mechanism for this has not yet been proposed. Goldberg et al., (1983) also 
reported increases in AGP plasma levels in Wistar rats following administration of 2.0 
mL/kg CCl4. 
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Lipocalin-2 is a 25-kDa glycoprotein (Kjeldsen et al., 1994). It has been found to be 
present in several tissues, such as the liver, kidneys, lungs, adipocytes and macrophages 
(Liu and Nilsen-Hamilton, 1995). Values of serum lipocalin-2 in this study were similar 
to control in the lower dose level groups. However, at 2.8 mL/kg CCl4 and above 
lipocalin-2 was significantly increased in treated animals compared to controls (Table 
3.3). Lipocalin-2 is highly expressed and released by the liver in response to 
inflammation (Liu and Nilsen-Hamilton, 1995; Flo et al., 2004). Borkham-Kamphorst et 
al. (2013) investigated the change in lipocalin-2 levels in a mouse model. In this study, 
mice were injected with a single dose of 0.8 mL/kg CCl4 intraperitoneally and autopsied 
at 48 hours post-dosing. This study by Borkham-Kamphorst demonstrated an increase 
in hepatic and serum lipocalin-2 levels following CCl4 administration and also evidence 
of a good degree of correlation between serum lipocalin-2 and serum AST and ALT 
levels. However, it has also been shown that in the event of renal toxicity lipocalin-2 is 
secreted by the thick ascending limb of the loop of Henle, distal tubule and convoluted 
tubule and excreted into the urine (Paragas et al., 2011). This suggests that lipocalin-2 is 
a potential biomarker of acute kidney injury which could predict the progression to 
chronic kidney disease (Bolignano et al., 2009). 
In the current study hepatic injury was confirmed by histopathological examination 
revealing hepatocellular changes associated with CCl4 administration at all dose levels. 
These changes consisted of vacuolation of centrilobular hepatocytes as well as the 
presence of hepatocyte necrosis. As the dose level increased the degree of injury 
increased; at 0.8 mL/kg only minimal centrilobular hepatocyte necrosis was present 
whereas at the highest dose level all animals had marked or very marked degeneration 
and necrosis (Figure 3.5, Figure 3.3). The centrilobular region is the area most 
susceptible to CCl4 due to the high concentration of cytochrome P-450 here, however, it 
has been reported that CCl4 does not affect all lobes of the liver equally. Matsubara and 
colleagues (1983) reported that CCl4-induced toxicity was greatest predominantly in the 
median lobe of the liver since this lobe has the highest concentration of cytochrome P-
450. The CCl4-induced microscopical changes reported in the present study compare to 
previous studies by Giffen et al., (2002) and Zira and colleagues (2013) who described 
hepatocellular degeneration and necrosis following the administration of CCl4 at 0.8 
mL/kg and 1 mL/kg to rats, respectively. 
At autopsy kidneys were removed and weighed; kidney weights were similar for control 
and CCl4-treated animals except for animals treated with CCl4 at 2.4 mL/kg (
*
P<0.05) 
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and 3.6 mL/kg (
**
P<0.01) (Figure 3.1 B). At these dose levels kidney weights were 
significantly greater than controls which may suggest the presence of kidney injury in 
these groups, but not in lower dose level groups. After a single administration of 3.6 
mL/kg CCl4 kidney weights were 22 % increased over control relative weights. Another 
study has also reported an increase in kidney weights in male Wistar rats dosed at 3 
mL/kg CCl4 of approximately 57 % (Khan et al., 2010). Smyth and colleagues (2008) 
reported significant increases in kidney weights in female Hanover-Wistar rats 
following a single administration of CCl4 at 1.2, 1.6 and 2.0 mL/kg (Smyth et al., 2008). 
At the highest dose level the relative kidney weights were heaviest and were 34 % 
increased over controls. 
In the present dose response study, analysis of serum urea and creatinine revealed that 
mean urea was greater in CCl4-treated animals than in controls at all dose levels but 
there was no dose-related trend (Table 3.3). Creatinine levels were similar to controls in 
all CCl4-treated groups apart from at the highest dose level where there was a 2.9-fold 
increase (
***
P<0.001). Increased urea and creatinine levels are suggestive of possible 
renal injury. Both urea and creatinine are freely filtered in the glomerulus. However, 
whereas creatinine undergoes tubular secretion, urea is not secreted but instead is 
reabsorbed by the renal tubules (Schrier, 2008). Decreased renal blood flow or 
compromised kidney function can cause a decrease in the glomerular filtration rate, and 
this will in turn result in increased serum creatinine and urea levels. Similar changes 
were previously reported in female Hanover-Wistar rats following a single 
administration of CCl4 at 1.2 mL/kg. At this dose level, histopathological examination 
of kidneys indicated kidney damage (Smyth et al., 2008).  
In the present study, urinary creatinine levels were significantly decreased over control 
at 2.8 and 3.2 mL/kg CCl4 (
**
P<0.01 and 
*
P<0.05, respectively) (Table 3.4). Decreased 
urinary creatinine levels are indicative of compromised kidney function and are often 
accompanied by increased serum creatinine. When the filtering capacity of the kidneys 
is affected, creatinine clearance is reduced; consequently, urinary creatinine levels are 
also decreased. In the present study, a statistically significant decrease in urinary 
creatinine was recorded at 2.8 and 3.2 mL/kg CCl4, and increased serum creatinine 
levels were also recorded at these dose levels even though the increase was not enough 
for statistical significance. This adds further evidence of CCl4-induced nephrotoxicity 
following the administration of 2.8 and 3.2 mL/kg CCl4 in this study. Total protein 
levels in the urine were significantly decreased in CCl4-treated animals at 0.8 mL/kg 
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and above compared to control rats (Table 3.4). Urinary albumin and glucose, however, 
were significantly increased over control at the highest dose level (3.6 mL/kg CCl4), but 
there was no evidence of a dose related effect (Table 3.4). Albumin is filtered from the 
blood in the kidneys and is almost completely reabsorbed in the proximal tubule 
(Lazzara and Deen, 2007). Albuminuria is therefore a consequence of damage to the 
proximal tubules. Glucose is not normally found in urine and is almost completely 
reabsorbed in the proximal tubule (Bishop et al., 1978). Therefore, the presence of 
glucose in the urine suggests a reduced tubular function (Wolf et al., 2009; Swain et al., 
2011). 
Data collected from urinary biomarkers provided an answer on a dose level at which 
CCl4-induced kidney toxicity was avoided. Changes to urinary creatinine, albumin and 
glucose levels suggested the presence of CCl4-induced renal damage at the highest dose 
levels. In the next Chapter we will assess the sensitivity of more specific and recently 
approved biomarkers for nephrotoxicity. However, in the present chapter, 
nephrotoxicity was confirmed by histopathological examination of tissue samples. 
Histopathological analysis of the kidneys revealed CCl4-related findings in a small 
proportion of the animals administered CCl4 at dose levels of 2.8 mL/kg and above 
(Table 3.6, Figure 3.4). These changes included granular casts in collecting ducts, 
dilatation of distal and/or collecting tubules, and minimal proximal tubular necrosis 
(Figure 3.4). In a study by Adams et al (1952) pathological effects in the kidneys were 
observed following exposure of Wistar rats by inhalation of 50 ppm CCl4. These 
changes included cloudy swelling of the tubular epithelium (Adams et al., 1952). Our 
results in the present study also compare with the study by Smyth et al., (2008) who 
described proximal tubular swelling and degeneration following administration of CCl4 
at 1.2, 1.6 and 2.0 mL/kg to female Hanover-Wistar rats. 
Histopathological examination of kidneys removed at autopsy was able to identify and 
confirm the threshold for CCl4-induced kidney toxicity in the male Hanover-Wistar rat. 
At concentrations equal to or greater than 2.8 mL/kg CCl4 there was microscopic 
evidence of renal damage. However, due to the great number of tissue samples 
generated in the study, kidneys from animals treated at 2.4 mL/kg were not assessed 
histopathologically for confirmation of nephrotoxicity. Therefore, we defined our 
optimal CCl4 dose level for inducing hepatotoxicity and not kidney toxicity as being 2.0 
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mL/kg, as at this concentration, there was no histopathological report of CCl4-induced 
renal damage. 
In the present study other organs including the adrenals, heart, lungs, pancreas, spleen, 
thymus, thyroid, testes and nasal cavity were evaluated for signs of CCl4-induced 
toxicity. A statistically significant decrease in the mean relative weight of the testes was 
recorded for animals treated with CCl4 at 2.8 mL/kg (20 % decrease; 
**
P<0.01) and at 
3.6 mL/kg (16 % decrease; 
*
P<0.05) (Table 3.2). However, histopathology revealed no 
abnormal findings in the testes in this study, apart from 1 rat at 3.6 mL/kg CCl4 with the 
presence of multinucleate spermatid giant cells. Manjrekar et al. (2008) previously 
described a decrease in the testes weight in albino Wistar rats following the 
administration of 0.5 mL/kg CCl4 by i.p. injection for 7 days. Histopathological 
examination of the testes showed tubular disorganisation and a reduced number of 
mature spermatozoa (Manjrekar et al., 2008). In another study, CCl4-induced changes in 
the spermatogenic cycle and degeneration in seminiferous tubules were described in the 
Hanover-Wistar rat treated with 0.25 mL/kg CCl4 intragastrically once a week for a 
period of 10 weeks (Horn et al., 2006). These reported findings in the testes were in a 
repeat dose study, whereas in the present study a single dose of CCl4 was administered. 
In the current study, CCl4-induced organ toxicity was present in the nasal cavity at all 
dose levels; the degree of severity increased with increasing dose of CCl4 (Table 3.7, 
Figure 3.5). The effects were confined to the olfactory epithelium in all treated animals 
except for 2 animals at 3.6 mL/kg CCl4 in which signs of respiratory epithelial 
ulceration were also present. CCl4 undergoes cytochrome P-450 2E1 metabolism and 
there are considerable levels of this CYP isoform in the nasal cavity (Boyd et al., 1980). 
However, in the present study, there was no evidence of dose-related effect. We 
hypothesise that the observed effect could be the result of gastroesophageal reflux 
during dosing, which has been shown to happen with the administration of oily 
preparations. Most studies investigating CCl4-induced injury to the respiratory tract are 
inhalation studies, and limited information is available regarding respiratory tract effects 
of oral administration of CCl4. Therefore, we consider this to be an interesting finding 
that could be further investigated.  
The main objective of this project was to identify urinary biomarkers of hepatic injury, 
therefore, urine samples collected during this dose response study were analysed by 1D 
1
H NMR and pattern recognition methods for identification of spectral regions which 
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related to metabolite resonances, and ultimately, metabolite concentrations, that varied 
between control and CCl4-treated samples. 
A PCA model of the spectra obtained for all urine samples was constructed to identify 
outliers and clustering trends. Samples were widely spread across the scores plot with 
no evident clustering patterns and no CCl4-induced metabolite changes were apparent 
(Figure 3.6).  
The same data was used to create an OPLS model (Figure 3.7) which revealed a better 
degree of sample separation along the first component compared to the PCA model 
(Figure 3.6). OPLS is a supervised pattern recognition method whereby, by introducing 
a new variable, we provide the model with a greater deal of information. OPLS models 
have the ability to separate the predictive variation, which is the correlated variation 
between the NMR spectral data and the CCl4 dose levels; from the orthogonal variation, 
which is the uncorrelated variation between the spectral data and the treatment 
concentration used. This property increases the potential for sample clustering 
compared to an unsupervised method, such as PCA. 
In the OPLS scores plot (Figure 3.8) it was clear that samples from animals treated with 
0.4, 0.8, 1.2 and 1.6 mL/kg CCl4 were clustered closer to the control group (left half of 
the scores plot), whereas samples from groups treated at 2.0, 2.4, 2.8, 3.2 and 3.6 mL/kg 
occupied the right half of the scores plot. This correlates well with the histopathological 
changes observed in the liver since, in general, mild and moderate changes were 
observed at 0.4 and 0.8 mL/kg, whereas a greater percentage of animals at the highest 
dose level groups showed marked/very marked changes (Table 3.5, Figure 3.3). In this 
study, histopathology analysis revealed kidney injury at 2.8 mL/kg CCl4 and above. 
However, samples from animals treated at 2.4 mL/kg were not histopathologically 
examined to confirm the absence of CCl4-induced kidney toxicity. Therefore, this dose 
level was excluded from the metabolomics-based investigation of urinary metabolites, 
and 2.0 mL/kg was determined to be the optimal CCl4 dose level where no 
nephrotoxicity was present in this study. This project was concerned with the 
identification of biomarkers of hepatotoxicity, therefore, in order to avoid identifying 
urinary metabolites which may be increased following nephrotoxicity, samples from 
animals treated with CCl4 at 2.4 mL/kg and above were removed from the analysis. 
Exclusion of these samples from the OPLS model (Figure 3.8 A) allowed much better 
cluster separation as potential confounding factors, such as urinary metabolites resulting 
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from CCl4-induced nephrotoxicity were eliminated. Also, by reducing the number of 
sample groups, we were able to increase the scores plot area available for positioning of 
sample points.  
The corresponding loadings plot (Figure 3.8 B) provides information on the spectral 
regions that are responsible for sample clustering along the first component t[1], which 
means that chemical shifts located on the right hand side of the loadings plot were 
related to samples located on the right hand side of the scores plot, and spectral regions 
located on the left hand side of the loadings plot were related to samples also located on 
the left hand side of the scores plot. However, as observed in the scores plot shown in 
Figure 3.8 A, the CCl4-treated groups were distributed along the whole extension of the 
first component, both on the left and right hand side of the scores plot, therefore 
compromising the interpretation of the loadings plot which did not allow differentiation 
of urinary metabolites between the different CCl4 treated groups.  
For improved cluster separation and metabolite identification, OPLS-DA models were 
used. It was decided from the histopathology data that 2.0 mL/kg CCl4 was the optimal 
dose level for inducing CCl4 hepatotoxicity without nephrotoxicity, therefore, an OPLS-
DA model of control and urine samples from rats treated at 2.0 mL/kg was constructed 
(Figure 3.10). The corresponding loadings plot and S-plot were used to determine the 
most relevant spectral regions and potential biomarkers were then identified (Table 3.9). 
Urinary levels of creatine and taurine were found to be increased in CCl4-treated 
animals. Increased urinary excretion of both creatine and taurine has been previously 
reported following hydrazine administration to rodents (Beckwith-Hall et al., 1998; 
Holmes et al., 2000; Nicholls et al., 2001). Urinary levels of taurine have also been 
found to be raised after CCl4 administration (Waterfield et al., 1991; Waterfield et al., 
1993). Taurine has been described as a specific urinary marker for hepatotoxicity 
(Waterfield et al., 1998) since it is mainly synthesised in the liver and it is thought that 
injury to the liver may result in leakage from the hepatocytes (Waterfield et al., 1993). 
Another possible reason for increased urinary taurine levels may be due to changes to 
the pool of cysteine, the precursor amino acid for taurine. CCl4-induced hepatotoxicity 
may cause an inhibition of protein synthesis which can result in increased levels of 
cysteine and consequently elevated synthesis of taurine (Timbrell et al., 1995). Taurine 
may also be consumed in the diet and is extensively reabsorbed in the kidneys 
(Jacobsen and Smith, 1968; Chesney, 1985). Consequently, nephrotoxicity could affect 
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the excretion of taurine in the urine. However, in this study we excluded urine samples 
from animals treated at higher dose levels of CCl4, therefore, the increase in the urinary 
levels of taurine is thought to be a result of CCl4-induced hepatotoxicity. Creatine is 
synthesised and metabolised in the liver (Waters et al., 2005) which suggests that the 
increase in creatine levels is likely to be a result of leakage from damaged hepatocytes 
(Waterfield et al., 1993). Alternatively, increased creatine may be due to increased 
cysteine synthesis since creatine is a by-product of cysteine synthesis (Clayton et al., 
2003; Clayton et al., 2004). 
A decrease in the resonances of hippurate at δ 7.74, 7.58, 7.54 and 3.86 was observed in 
animals treated with CCl4 in this study. Hippurate is formed when benzoate is 
metabolised by benzoyl-CoA synthetase to benzoyl-CoA, a process that requires ATP 
(Gatley and Sherratt, 1977). ATP depletion typically occurs during hepatic necrosis and 
therefore, may ultimately result in a decrease in the production of hippurate (Kim et al., 
2008b). Beckwith et al., (1998) described similar results in the urine of Sprague-Dawley 
rats following the administration of model hepatotoxins such as α-naphthyl 
isothiocyanate (ANIT), D-(+)-galactosamine hydrochloride (GaIN) and butylated 
hydroxytoluene (BHT) to Sprague-Dawley rats.  
Another finding from the present study was an increase in the resonances of metabolite 
peaks belonging to TCA cycle intermediates including citrate, 2-oxoglutarate and 
succinate and a decrease in the resonances of fumarate. Other groups have reported a 
decrease in the urinary levels of TCA cycle intermediates following administration of 
hepatotoxicants agents (Holmes et al., 2000; Nicholls et al., 2001). Studies have shown 
that when liver function is compromised acetyl-CoA is prevented from entering the 
TCA cycle, leading to a decrease in the levels of citrate, fumarate, succinate and 2-
oxoglutarate (Lu et al., 2010).  
At 2.0 mL/kg CCl4,
 1
H NMR creatinine resonances in this study appeared to be 
decreased in the urine of treated rats compared to control animals, but this decrease was 
not statistically significant. These results correlate with the urine chemistry 
measurements as shown in Table 3.4 which did not reveal a statistically significant 
difference at this CCl4 dose level. Nicholls et al. (2001) described a decrease in urinary 
creatinine levels following administration of hydrazine to male Hanover-Wistar rats. 
However, the authors did not report evidence of a hydrazine-induced effect in the 
kidneys. Creatinine is freely filtered in the glomerulus, therefore, a decreased level of 
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urinary creatinine has been described as a marker of impaired kidney function (Wu et 
al., 2005). At the optimal dose level for CCl4-induced hepatotoxicity in the present 
study (2.0 mL/kg), no histopathological evidence of kidney toxicity was recorded and 
this is in agreement with the 
1
H NMR data which did not reveal significant changes in 
urinary creatinine following the administration of 2.0 mL/kg CCl4. 
In this study, urinary TMAO levels were found to be decreased in the urine of rats 
treated with CCl4. Similar findings were reported by Nicholls et al. (2001) in an acute 
model of hydrazine-induced toxicity in the rat. TMAO results from the oxidation of 
trimethylamine, which in turn is derived from the metabolism of the nutrient choline. 
Choline is an essential nutrient and the liver is the main organ responsible for choline 
metabolism (Corbin and Zeisel, 2012). In cirrhotic livers, the conversion of methionine 
to S-adenosylmethionine (catalysed by S-adenosylmethionine synthetase), a precursor 
of choline, may be impaired, due to a deficiency in S-adenosylmethionine synthetase 
and therefore may act as the limiting step in choline metabolism (Duce et al., 1988; 
Lieber, 2002) which in turn would affect the production of TMAO. We suggest that the 
same pathway might be responsible for decreased urinary TMAO levels following a 
single administration of CCl4. 
Other chemical shift resonances changed in this study in response to CCl4-induced 
hepatic injury but the metabolites involved have yet to be identified. 
While interpreting the data resulting from the NMR analysis it is important to consider 
that in this preliminary NMR study, the pH of the urine samples was not adjusted, 
therefore the chemical shifts described for metabolites will vary slightly according to 
the pH of individual samples. Unlike other biofluids, such as plasma, which are under a 
tight homeostatic control, urine samples have different protein concentration, pH and 
ionic strength (Beckwith-Hall et al., 1998; Holmes et al., 2000; Bollard et al., 2005). 
Such differences are likely to affect the chemical shift of metabolites in the 
1
H NMR 
spectra due to changes in the equilibrium between acids and bases and in solute-solute 
interactions (Lauridsen et al., 2007; Schreier et al., 2013). In most studies the pH of 
urine samples is kept within a very tight interval by the addition of buffers such as 
sodium phosphate buffers (Holmes et al., 2000; Nicholls et al., 2001). Under normal 
physiological conditions the rat urine pH usually varies between 7.3 and 8.5 (Krinkle, 
2000). In the present study we carried out the analysis without adjusting the pH, which 
should be taken into account for future studies. However, since we are interested in 
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comparing control and CCl4-treated animals, we assume that differences in peaks 
intensities will not be affected and therefore, this should not have an impact in 
identifying differences in metabolites excretion in the urine.  
In the present study a rat model of acute hepatotoxicity was developed. The results 
revealed that hepatic injury occurs at 0.4 mL/kg CCl4 and above, whereas kidney injury 
was present at 2.8 mL/kg and above. Since histological examination was not carried out 
for kidneys at 2.4 mL/kg CCl4, it was decided in order to confidently stay below the 
threshold of nephrotoxicity the maximum dose level of CCl4 in future studies would be 
2.0 mL/kg. 1D 
1
H NMR analysis of urine samples collected during the study allowed 
the identification of possible urinary biomarkers of hepatotoxicity in the male Hanover-
Wistar rat following a single administration of CCl4. Some of the metabolites revealed 
in this study have yet to be identified. One of the most important characteristic of an 
ideal biomarker is that it should be sensitive to early changes in the liver and remain in 
the biofluid long enough to be detected. This will be examined closely in a time course 
study (Chapter 6) to investigate the pattern of change in metabolite levels as injury 
occurs and during the recovery/regeneration of liver period. Further, it would be 
interesting to determine if the same metabolite changes are present following chronic 
hepatic injury (Chapter 7). 
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CHAPTER FOUR 
Evaluation of biomarkers of nephrotoxicity 
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Chapter 4  
4.1 Introduction 
In this project CCl4 was used as the model toxicant to induce hepatotoxicity. CCl4 has 
also been shown to induce kidney damage at high dose levels via the production of free 
radicals following metabolism by cytochrome P-450 (Abraham et al., 1999). The high 
levels of cytochrome P-450 that can be found in the kidneys, particularly in the cells of 
the pars recta of the proximal and distal tubule, make these areas particularly vulnerable 
to damage (Cummings et al., 1999). Therefore, the kidneys are often listed as secondary 
organs of CCl4-induced toxicity (Deb and Chakravarty, 1962; Ogeturk et al., 2005; 
Makni et al., 2012).  
Additionally, the kidney is the primary organ involved in the clearance of endogenous 
waste products and in the excretion of chemicals from the body, making it particularly 
susceptible to injury by many toxicants (Perazella, 2009; Bonventre et al., 2010).  
It is vital in our urinary biomarker studies that we are able to reliably detect even low 
degrees of nephrotoxicity in our CCl4-liver model. Therefore, in this Chapter, the 
commonly used and recently approved nephrotoxicity biomarkers will be evaluated for 
sensitivity. 
HCBD was used as a model compound to induce nephrotoxicity in this Chapter. HCBD 
is known to cause degeneration/necrosis specifically to the pars recta of the renal 
proximal tubule in the rat (Lock and Ishmael, 1979; Ishmael et al., 1982; Hook et al., 
1983; Cristofori et al., 2007). 
The mechanism by which HCBD induces injury involves hepatic conjugation with 
glutathione in a reaction catalysed by glutathione-S-transferase (GST). This reaction 
results in the formation of metabolites, such as S-(pentachlorobutadienyl)-glutathione 
which are then further transformed to S-(pentachlorobutadienyl)-L-cysteine (Nash et al., 
1984). The latter is transported to the kidneys where it accumulates and where it 
undergoes further reactions leading to the production of a reactive thiol by renal 
cysteine conjugate β-lyase. This highly reactive thiol intermediate may bind to DNA, 
proteins and macromolecules and is thought to be the responsible agent for the 
nephrotoxic effect of HCBD (Birner et al., 1995; Birner et al., 1998). Although cysteine 
β-lyase is mainly found in the proximal tubule, particularly in the S3 segment, it is also 
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present in the liver, where it can therefore, induce injury via the formation of the 
reactive thiol (Tateishi et al., 1978). Hence the importance given in the present study to 
measuring markers of liver injury, to guarantee there is no hepatotoxicity following 
HCBD administration. 
Traditional markers to detect nephrotoxicity include serum creatinine and urea. 
Creatinine (113 kDa) is a product of muscle creatine metabolism. Serum creatinine is 
freely filtered by the glomerulus and undergoes tubular secretion. Urea (60 kDa) is the 
primary metabolite derived from dietary protein catabolism. Serum urea is also freely 
filtered by the glomerulus; however, it is reabsorbed by the renal tubules. It is estimated 
that approximately 40 % of the urea filtered in the glomerulus is reabsorbed in the 
proximal tubule. Therefore, the amount of urea excreted in the urine should not exceed 
60 % of the filtered urea (Popovtzer et al., 1971). 
The measurement of urinary creatinine is used in the calculation of creatinine clearance 
which in turn is used to estimate the glomerular filtration rate. A decrease in the 
glomerular filtration rate, that is, the rate at which blood flows through the kidneys, will 
result in increased levels of serum creatinine and urea (Schrier, 2008). Serum creatinine 
and urea values often remain within the normal range until greater than 50 % of the 
renal function is affected. Therefore, urea and creatinine have been shown to lack 
sensitivity to kidney injury, and significant changes usually only occur when there is 
more severe kidney injury (Dharnidharka et al., 2002; Dieterle et al., 2010).  
Recently, the Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA), approved the voluntary introduction of a panel of biomarkers for drug-
induced renal toxicity in nonclinical and clinical drug development studies in response 
to the lack of reliable biomarkers (FDA, 2008). These include KIM-1, albumin, 
clusterin, trefoil factor-3 (as biomarkers of drug-induced acute kidney tubular 
alterations) and total protein, β-2 microglobulin and cystatin-C (biomarkers of acute 
drug-induced glomerular alterations/injury and impairment of renal tubular 
reabsorption) (FDA, 2008). 
Limited data exists on the sensitivity of these biomarkers; a good kidney biomarker will 
be sensitive to early changes to the kidney pathology and remain in the biofluid long 
enough to be detected.  
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In this Chapter, two studies were carried out to extensively characterise traditional and 
novel serum, urinary and gene expression markers of nephrotoxicity following HCBD-
induced nephrotoxicity and to correlate these with changes in renal histopathology to 
determine the sensitivity to severity of injury. The first study was a dose response study, 
in which a single dose of HCBD was administered to Hanover-Wistar rats at a range of 
dose levels from 5 to 90 mg/kg to investigate the sensitivity of the biomarkers. The 
second study was a time course study, in which animals received a single dose of 
HCBD (at a dose level as determined by the dose-response study) and biomarker 
measurements were carried out at various time points up to 28 days post-dosing. This 
experiment evaluated the biomarker levels as injury was induced and as recovery 
occurred. 
In summary, the main goal of the dose response and time course study described in this 
Chapter was to characterise a panel of renal biomarkers. The information collected 
would be used in our future CCl4 liver injury studies to rule out potential CCl4-induced 
kidney injury by evaluating the most reliable panel of nephrotoxicity biomarkers.  
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4.2 Animal experimental design 
4.2.1 Dose response study 
Sixty male Hanover-Wistar rats (mean body weight 224.0 ± 5.58 g) were divided into 
eight groups (n=6) and dosed intraperitoneally with HCBD at 0 (controls), 5, 10, 15, 20, 
25, 30, 35, 45 and 90 mg/kg in a total volume not exceeding 0.3 mL per animal. The 
vehicle for HCBD was corn oil and control animals were dosed intraperitoneally with 
equivalent volumes of corn oil. After dosing, animals were immediately placed in 
metabolism cages for the collection of 24 hour urine samples. During this period 
animals had access to water but not diet. Urine samples were collected over ice and 
stored at -80 ºC for further analysis. All animals were weighed before dosing, before 
being placed in metabolism cages and at 24 hours post-dosing, just prior to autopsy. 
At autopsy (24 hours after dosing) blood was taken for the preparation of serum which 
was stored at -80 ºC until future analysis. The liver and the kidneys were removed and 
weighed. For gene expression analysis a section was cut from the left lobe of the liver 
and from the left kidney, placed in RNALater tubes and stored at 4 ºC until analysis. 
The remainder of the left kidney and liver, plus the right kidney were placed in fixative 
as described in Section 2.8. 
4.2.2 Time course study 
One hundred and twenty male Hanover-Wistar rats (mean body weight 215.3 ± 5.14 g) 
were divided into ten groups (n=12). At time 10:00 hr on day 1 of the study, six animals 
in each group were dosed with corn oil (controls) (rats 1-6) (60 animals in total) and six 
animals in each group were dosed with HCBD at 45 mg/kg (rats 7-12) (60 animals in 
total) by i.p. injection. For all animals, a constant dosing volume of approximately 0.3 
mL was administered and animals were weighed prior to dosing. After dosing, all rats 
were returned to their communal cages where they had access to diet and water ad 
libitum.  
At 16:00 hr on the day of dosing (i.e., 6 hours post-dosing), 6 controls and 6 treated 
animals (group 1) were weighed and placed in metabolism cages for the collection of 18 
hour urine samples during which period animals had access to water but not diet. At 
10:00 hr the following day (24 hours post-dosing) this group of animals were removed 
from the metabolism cages and autopsied (day 1 post-dosing). At 16:00 hr on day 1 
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post-dosing, a second group of animals (group 2) were weighed and placed in 
metabolism cages for 18 hour urine collection. These animals were autopsied at 10:00 
hr the following day (day 2 post-dosing). This process was repeated for the remaining 
groups of animals to collect data at days 3, 4, 5, 6, 7, 10, 14 and 28 post-dosing.  
All urine samples were collected over ice and stored at -80 ºC for future analysis. At 
each autopsy blood was taken for the preparation of serum and stored at -80 ºC until 
analysis. The liver and the kidneys were removed and weighed. For gene expression 
analysis a section was cut from the right kidney, placed in RNALater tubes and stored at 
4 ºC until analysis. The remainder of the right kidney and liver, plus the left kidney 
were placed in fixative as described in Section 2.8. 
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4.3 Results for the dose response study 
4.3.1 Observations during the study 
No abnormal observations were noted during the dosing period in this study. During the 
autopsy some of the livers and kidneys from animals treated at 90 mg/kg were paler in 
colour when compared to control organs. No other abnormal observations were 
recorded. 
4.3.2 Body weight data 
Table 4.1 shows the change in body weight (for both control and HCBD-treated 
animals) during the 24 hour period while the rats were in the metabolism cages. All 
animals lost weight during the metaboling period. However, there did not appear to be a 
dose-related effect on body weight loss. Animals in the 10 mg/kg HCBD group lost the 
most weight (25.15 g compared to 18.10 g in the control group; 
**
P<0.01). 
Table 4.1 Body weight change for male Hanover-Wistar rats treated with increasing doses of 
HCBD during a 24 hour period in metabolism cages. Animals were dosed with vehicle (control, 0 
mg/kg) or HCBD by intraperitoneal injection and placed individually in metabolism cages for the 
collection of 24 hour urine samples as described in Section 4.2.1. Animals had access to water but not diet 
while in the metabolism cages. Weight changes are shown as mean and SD of 6 animals per group. 
Changes in body weight that are statistically different to the change for control animals by one-way 
ANOVA test are shown: 
*
P<0.05; 
**
P<0.01. 
 
Dose level of HCBD 
(mg/kg) 
Mean (SD) change in 
body weight (g) 
0 -18.10 (8.74) 
5 -18.35 (2.45) 
10 -25.15
**
 (1.08) 
15 -22.00 (2.02) 
20 -22.73 (1.37) 
25 -24.63
*
 (1.55) 
30 -20.38 (2.30) 
35 -21.53 (2.85) 
45 -25.03
**
 (2.32) 
90 -20.53 (2.65) 
 
 144 
4.3.3 Liver weights 
Livers from animals treated at the highest HCBD dose level (90 mg/kg) were 
significantly increased over controls (40.72 g/kg BW and 35.38 g/kg BW, for HCBD-
treated animals and control rats respectively; 
**
P<0.01). At all other HCBD dose levels 
liver weights were similar to controls (Figure 4.1 A). 
4.3.4 Kidney weights 
The mean relative kidney weights for rats treated with HCBD at 5, 10 and 15 mg/kg 
were similar to controls (Figure 4.1 B) whereas at 20 mg/kg HCBD, relative kidney 
weights were approximately 10 % lower than controls (
*
P<0.05). However, at 90 
mg/kg, relative kidney weights were 1.2-fold greater than controls (5.06 g/kg BW and 
4.23 g/kg BW respectively; 
***
P<0.001). There was no clear dose response relationship. 
A 
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B 
 
Figure 4.1 Relative liver (A) and kidney (B) weights from male Hanover-Wistar rats treated with 
increasing doses of HCBD. Animals were dosed with vehicle (control, 0 mg/kg) or HCBD by 
intraperitoneal injection. At 24 hours post-dosing animals were killed, livers and kidneys were removed 
and weighed. The kidney weight was expressed as a mean of the left and right kidneys. Results are shown 
as mean organ weight per kg body weight (BW) with SD indicated by vertical bars of 6 animals per 
group. Relative organ weights that differ significantly by one-way ANOVA test from control values are 
shown:
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
4.3.5 Serum clinical chemistry 
Serum levels of ALT, AST and GLDH were measured in samples from rats treated with 
HCBD at 0 (controls), 5, 10, 15, 20, 25, 30, 35, 45 and 90 mg/kg. These are traditionally 
used as serum parameters of liver injury and were measured to guarantee that no 
hepatotoxicity was present as the liver may be a secondary site for HCBD-induced 
damage.  
ALT and GLDH were significantly increased over controls at the highest dose level (90 
mg/kg); ALT was 1.85-fold increased (
**
P<0.01), whereas GLDH was 4.08-fold 
increased (
***
P<0.001) above controls (Figure 4.2).  
Mean levels for ALP did not show evidence of a treatment-related effect except in the 
serum from animals treated at the highest HCBD dose level (90 mg/kg); enzyme 
activity was approximately twice as great as the activity measured in the serum from 
vehicle-treated (control) animals (425.50 and 831.17 U/L for control and HCBD-treated 
animals respectively; 
***
P<0.001) (Table 4.2). 
*** 
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Measurement of other serum clinical chemistry parameters, such as urea, creatinine, 
glucose, albumin and total protein was performed to evaluate kidney function. Serum 
urea levels were significantly decreased at 5, 20 and 25 mg/kg HCBD (
*
P<0.05, 
**
P<0.01 and 
*
P<0.05, respectively) but at 90 mg/kg they were 3-fold greater than 
controls (21.58 and 8.08 mmol/L respectively; 
***
P<0.001) (Table 4.2). Creatinine 
levels were similar to controls at most HCBD dose levels but at 45 and 90 mg/kg 
HCBD, levels were significantly increased (1.8-fold and 5.7-fold respectively). Glucose 
levels in the serum did not follow a clear HCBD dose-related trend but were 
significantly decreased at 10, 20, 35 and 90 mg/kg HCBD (Table 4.2). Albumin and 
total protein mean values were similar to controls at all dose levels (Table 4.2). 
 
 
Figure 4.2 Serum ALT, AST and GLDH levels for male Hanover-Wistar rats treated with 
increasing doses of HCBD. Animals were dosed with vehicle (control, 0 mg/kg) or HCBD by 
intraperitoneal injection. At 24 hours post-dosing, serum was collected as described in section 4.2.1 and 
enzymes were assayed as described in Section 2.7. Values are the means with SD indicated by vertical 
bars of 6 animals per group. Values that differ significantly from controls by one-way ANOVA test are 
shown: 
**
P<0.01; 
***
P<0.001 
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Table 4.2 Serum clinical chemistry parameters for male Hanover-Wistar rats treated with increasing doses of HCBD. Animals were treated with vehicle (control, 0 mg/kg) or 
HCBD by intraperitoneal injection. At 24 hours post-dosing, serum was collected as described in Section 4.2.1 and serum biomarkers were assayed as described in Section 2.7. 
Values are the means and SD of 6 animals per group. Values that differ significantly from controls by one-way ANOVA test are shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
 
Serum 
parameters 
HCBD dose level (mg/kg) 
0 5 10 15 20 25 30 35 45 90 
ALP 
(U/L) 
425.50 
(111.67) 
397.50 
(61.80) 
426.00 
(74.45) 
358.50 
(80.52) 
374.50 
(45.28) 
343.00 
(36.44) 
424.00 
(48.97) 
446.17 
(114.03) 
469.83 
(115.81) 
831.17
***
 
(169.22) 
Urea 
(mmol/L) 
8.08 
(1.71) 
6.33
*
 
(0.50) 
7.63 
(0.61) 
6.82  
(1.18) 
5.82
**
 
(0.53) 
5.88
*
 
(0.85) 
8.60 
(1.81) 
6.78 
(1.47) 
9.57 
(2.06) 
21.58
***
 
(3.83) 
Creatinine 
(µmol/L) 
23.33 
(3.14) 
22.00 
(0.89) 
26.50 
(1.87) 
23.17 
(2.32) 
25.83 
(1.60) 
25.67 
(2.66) 
26.33 
(4.50) 
29.67 
(7.63) 
42.00
**
 
(19.83) 
133.50
***
 
(38.81) 
Glucose 
(mmol/L) 
5.84 
(0.59) 
4.91 
(0.92) 
2.95
***
 
(0.38) 
6.06  
(1.40) 
3.90
**
 
(0.77) 
4.41 
(0.74) 
6.40 
(1.03) 
3.24
***
 
(0.37) 
4.56 
(1.12) 
4.41
*
 
(1.21) 
Albumin 
(g/L) 
32.67 (67 
(0.82) 
32.83 
(0.75) 
33.33 
(0.82) 
33.33 
(0.82) 
32.67 
(0.52) 
32.50 
(1.38) 
32.83 
(0.75) 
32.83 
(1.17) 
33.17 
(0.75) 
31.67 
(1.75) 
Total protein 
(g/L) 
53.00 
(1.67) 
53.17 
(1.17) 
55.33 
(1.37) 
54.33 
(1.21) 
54.33 
(1.21) 
53.67 
(1.97) 
53.33 
(1.51) 
54.17 
(1.72) 
54.00 
(1.10) 
50.50 
(3.56) 
 
APL: alkaline phosphatase.  
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4.3.6 Urinary biomarkers of kidney injury 
Mean urinary levels of α-GST and GST Yb1 for HCBD-treated animals were increased 
over controls at all dose levels. However, the differences were only statistically 
significant at 20 mg/kg and above for α-GST and at 10 mg/kg and above for GST Yb1. 
There was a general dose-related trend for both. At 90 mg/kg HCBD, α-GST excretion 
was 649-fold greater in HCBD-treated animals compared to controls, whereas the 
increase for GST Yb1 corresponded to a 7-fold increase over controls (Table 4.3). 
There were no significant changes in the levels of urinary osteopontin following 
HCBD-treatment. Lipocalin-2 levels were significantly decreased at 30 mg/kg HCBD 
(
*
P<0.05), but no other significant differences were present (Table 4.3). 
Urinary β-HBA was increased at all dose levels but only significantly at 10 mg/kg 
HCBD and above; there appeared to be a dose-dependent increase. Levels were 3.3-fold 
greater than controls in the 10 mg/kg group, whereas at 90 mg/kg the fold increase was 
approximately 31-fold (
***
P<0.001) (Table 4.3). Acetoacetate levels in urine showed no 
evidence of an HCBD treatment-related change at the lower dose levels. However, at 35 
mg/kg HCBD and above, there was a significant increase in acetoacetate levels. In the 
highest dose group (90 mg/kg) the mean acetoacetate value was 55.47 µmol/c.p. in 
comparison to 0.10 µmol/c.p. for controls which corresponded to a 554.7-fold increase 
(
***
P<0.001) (Table 4.3). 
Urinary creatinine was significantly increased over controls at most HCBD dose levels 
(10, 15, 20, 25, 30 and 35 mg/kg HCBD). Levels appeared to increase with increasing 
HCBD dose level to a maximum at 20 mg/kg, after which there was a gradual decrease 
in urinary creatinine levels. At 90 mg/kg HCBD, urinary creatinine was decreased to 
approximately 70 % of the control values (27.12 µmol/c.p. and 39.88 µmol/c.p., for 
HCBD-treated and control animals, respectively; 
***
P<0.001) (Table 4.3). Urinary 
excretion of glucose was similar to controls at all dose levels up to and including 30 
mg/kg HCBD. At 35 mg/kg HCBD there was a 2.7-fold increase in urinary glucose but 
this was not statistically significant. In animals treated with 45 mg/kg and 90 mg/kg 
HCBD mean glucose levels in the urine were approximately 19- and 103-fold greater 
than controls, respectively (
***
P<0.001) (Table 4.3). 
Urinary levels of clusterin were only significantly different from controls at 90 mg/kg 
HCBD (highest dose level). At this dose level, the mean clusterin level in the urine of 
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HCBD-treated animals was 462.78 ng/c.p., whereas in control animals the level was 
61.91 ng/c.p., thus representing an 8-fold increase (
***
P<0.001). KIM-1 values were 
similar to control in the urine from animals treated with HCBD at 5, 10 and 15 mg/kg 
but were significantly increased at 20 mg/kg and higher (Table 4.3). However, the KIM-
1 concentration at the highest HCBD dose does not fit a dose related trend. 
Total protein was increased in the urine of HCBD-treated animals at 15 mg/kg and 
above to a maximum of approximately 5-fold at the highest HCBD dose (Table 4.3). 
Albumin was significantly greater than controls at 20 mg/kg HCBD and above (Table 
4.3). At the highest HCBD dose level the mean albumin concentration in the urine was 
17.45 mg/c.p., representing a 134-fold increase over control (
***
P<0.001). 
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Table 4.3 Urinary biomarkers in male Hanover-Wistar rats treated with increasing doses of HCBD. Rats were treated with vehicle (control, 0 mg/kg) or HCBD by 
intraperitoneal injection and urine was collected for 24 hours as described in section 4.2.1. Biomarkers were assayed as described in Section 2.7. Values are the means and SD of 6 
animals per dose level group and are expressed as c.p. (collection period, 24 hours). Values that differ significantly by one-way ANOVA test from controls are shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
 
 
Urinary 
parameters 
HCBD dose level (mg/kg) 
0    5         10 15 20 25 30 35 45 90 
α-GST 
 (ng/c.p.) 
537.59 
(228.62) 
765.59 
(245.21) 
2182.13 
(1108.45) 
5391.33 
(2927.94) 
17961.58
**
 
(8854.04) 
25684.65
**
 
(20354.78) 
38617.67
***
 
(16212.37) 
86390.53
*
 
(85383.66) 
142453.80
***
 
(122150.47) 
348893.83
***
 
(78878.72) 
GST Yb1 
(ng/c.p.) 
82.48 
(51.48) 
90.67 
(25.90) 
171.67
*
 
(48.86) 
292.56
***
 
(92.18) 
287.28
***
 
(31.30) 
319.53
***
 
(106.42) 
244.67
***
 
(102.99) 
454.74
***
 
(336.09) 
388.52
***
 
(146.91) 
572.55
***
 
(224.68) 
Osteopontin 
(ng/c.p.) 
33.75 
(24.25) 
44.32 
(23.00) 
40.54 
(19.19) 
37.33 
(14.70) 
39.37 
(20.48) 
38.54 
(11.91) 
39.58 
(11.91) 
50.88 
(16.53) 
53.69 
(23.04) 
54.12 
(37.13) 
Lipocalin-2 
(ng/c.p.) 
8028.38 
(2731.95) 
5859.20 
(2428.48) 
7780.25 
(6013.78) 
4660.00 
(2204.25) 
4424.25 
(1113.63) 
5560.83 
(3643.41) 
3792.97
* 
(978.24) 
7159.17 
(3260.80) 
5890.45 
(1610.70) 
7505.00 
(2679.98) 
β-HBA  
(µmol/c.p.) 
5.17 
(1.72) 
9.34 
(3.14) 
17.07
**
 
(7.63) 
46.18
***
 
(11.14) 
50.66
***
 
(14.16) 
47.35
***
 
(11.60) 
54.85
***
 
(9.15) 
73.70
***
 
(41.24) 
106.51
***
 
(71.52) 
161.29
***
 
(81.37) 
Acetoacetate 
( µmol/c.p.) 
0.10 
(0.17) 
0.09 
(0.14) 
0.19 
(030) 
0.41 
(0.55) 
0.04 
(0.10) 
0.15 
(0.29) 
0.54 
(1.01) 
13.56
**
 
(17.16) 
38.71
***
 
(38.45) 
55.47
***
 
(50.62) 
Creatinine 
(µmol/c.p.) 
39.88 
(5.95) 
41.38 
(2.94) 
49.78
**
 
(2.47) 
53.34
***
 
(4.12) 
58.10
***
 
(3.73) 
54.55
***
 
(4.64) 
47.84
*
 
(5.21) 
47.31
*
 
(4.77) 
38.53 
(1.41) 
27.12
***
 
(4.16) 
Glucose 
(µmol/c.p.) 
4.80 
(0.77) 
6.09 
(1.25) 
5.73 
(0.90) 
6.71 
(1.82) 
5.41 
(1.02) 
5.99 
(0.57) 
4.94 
(0.91) 
13.02 
(14.16) 
90.77
***
 
(98.62) 
496.25
***
 
(235.37) 
Clusterin 
(ng/c.p.) 
61.91 
(27.28) 
58.50 
(12.53) 
63.05 
(29.75) 
80.80 
(45.49) 
48.92 
(16.52) 
49.28 
(12.91) 
42.90 
(16.02) 
80.57 
(64.10) 
150.74 
(121.23) 
462.78
***
 
(161.84) 
KIM-1 
(ng/c.p.) 
8.57 
(1.90) 
9.49 
(1.49) 
12.78 
(1.22) 
15.55 
(3.23) 
22.60
**
 
(6.87) 
27.89
**
 
(12.91) 
34.43
***
 
(19.18) 
35.23
***
 
(24.93) 
57.69
***
 
(41.75) 
37.17
***
 
(20.19) 
Total protein 
(mg/c.p.) 
6.52 
(2.62) 
8.79 
(1.89) 
8.37 
(1.87) 
11.65
*
 
(4.41) 
11.01
*
 
(2.39) 
13.62
**
 
(1.98) 
10.39 
(3.02) 
13.95
**
 
(5.03) 
18.22
***
 
(1.01) 
33.49
**
 
(9.86) 
Albumin 
(mg /c.p.) 
0.13 
(0.02) 
0.20 
(0.08) 
0.17 
(0.06) 
0.28 
(0.09) 
0.56
*
 
(0.20) 
1.01
**
 
(0.63) 
1.26
**
 
(0.76) 
3.63
***
 
(2.30) 
7.12
***
 
(6.53) 
17.45
***
 
(5.22) 
  
α-GST: α-glutathione-S-transferase; GST Yb1: glutathione-S-transferase Yb1; KIM-1: kidney injury molecule-1, β-HBA: β-hydroxybutyrate.  
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4.3.7 Liver gene expression 
The liver is responsible for the primary metabolism of HCBD. Therefore, gene 
expression analysis of the liver was performed to track the interplay of changes between 
the liver and the kidney, based on the metabolism and potential toxic effects of HCBD. 
Liver gene expression data was only collected from animals at 0, 5, 10, 15, 20, 30, 45 
and 90 mg/kg due to the large number of samples generated during the study (Table 
4.4). Genes were separated according to functional category: xenobiotic metabolism, 
oxidative stress, inflammation and regeneration/repair.  
Significant upregulation of most of the genes involved in xenobiotic metabolism was 
noted in the livers of animals treated with HCBD. Epoxide hydrolase (microsomal) 1 
(EPHX1), UDP glucuronosyltransferase 1A6 (UGT1A6), glutathione S-transferase 
isoform mu 3 (GSTM4), cytochrome P-4502C (CYP2C) and glutathione S-transferase 
Yc2 subunit (alpha 3) GSTA3 were upregulated at all HCBD dose levels, whereas 
cytochrome P-4501A1 (CYP1A1) was downregulated in HCBD-treated animals, 
although this downregulation was only significant at 45 and 90 mg/kg HCBD.  
There was also significant upregulation in the expression of markers of oxidative stress. 
Glutamate-cysteine ligase, catalytic subunit (GCLC), glutathione reductase (GSR) and 
thioredoxin reductase 1 (TXRND1), were increased at all HCBD dose levels and 
showed evidence of a dose-related response (Table 4.4). 
Inflammatory markers such as kininogen 1 (KNG1) and tissue inhibitor of 
metalloproteinase 1 (TIMP-1), were downregulated in the livers of animals treated with 
HCBD (Table 4.4). TIMP-1 was significantly downregulated at 45 mg/kg HCBD 
(
*
P<0.05). Lipocalin-2 appeared to be upregulated at 10 mg/kg and 30 mg/kg HCBD but 
this was not statistically significant. However, at 15, 20, 45 and 90 mg/kg HCBD, 
lipocalin-2 expression in the liver was downregulated.  
At the highest HCBD-dose level there was significant upregulation of annexin A7 
(ANXA7) and crystalline, αB (CRYAB) which are genes involved in regeneration and 
repair. Other genes in this category including COL1A1, GPNMB and also ANXA7 at 
lower HCBD dose levels (5, 10, 15, 120 mg/kg) were downregulated compared to 
control animals (Table 4.4). 
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Table 4.4 Liver gene expression in male Hanover-Wistar rats treated with increasing doses of HCBD. Rats were treated with vehicle (control, 0 mg/kg) or HCBD by 
intraperitoneal injection. At autopsy, 24 hours post-dosing, liver expression was measured as described in Section 2.9. Results are represented as copy number [x10
3
/2 ng cDNA]. 
Values are the means and SD of 6 animals per dose level group. Values that differ significantly by one-way ANOVA test from controls are shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
 
  
HCBD dose level (mg/kg) 
Functional category/gene name symbol 0 5 10 15 20 30 45 90 
Xenobiotic metabolism  
         
Epoxide hydrolase 1 (microsomal)  EPHX1 298 (92) 534
**
 (115) 978
***
 (251) 1576
***
 (323) 1749
***
 (633) 1771
***
 (506) 2832
***
 (1796) 7399
***
 (2718) 
UDP glucuronosyltransferase 1A6  UGT1A6 29 (5) 60
***
 (15) 102
***
 (43) 158
***
 (29) 163
***
 (25) 242
***
 (58) 217
***
 (129) 570
***
 (177) 
Glutathione S-transferase  
isoform mu 3  
GSTM4 658 (74) 923
***
 (114) 1340
***
 (234) 1975
***
 (395) 1892
***
 (392) 2466
***
 (586) 2543
***
 (1055) 5469
***
 (756) 
Cytochrome P450 2C  CYP2C 549 (124) 1029
*
 (369) 903
**
 (222) 1398
***
 (334) 1166
**
 (429) 1309
***
 (498) 996
**
 (364) 974
**
 (323) 
Glutathione S-transferase Yc2 subunit 
(alpha 3)  
GSTA3 13 (7) 37
**
 (10) 52
**
 (34) 75
***
 (21) 84
***
 (41) 154
***
 (63) 208
***
 (99) 486
*** 
(122) 
Cytochrome P450 1A1  CYP1A1 9 (10) 8 (7) 4 (4) 3 (2) 6 (8) 6 (2) 2
*
 (1) 2
*
 (3) 
ATP-binding cassette, subfamily C  
member3  
ABCC3 4 (1) 4 (1) 5 (3) 5 (4) 3 (1) 10
*
 (7) 26
**
 (16) 134
***
 (45) 
NAD (P)H dehydrogenase, quinone 1  NQO1 28 (19) 47 (22) 47 (24) 68
*
 (22) 107
***
 (29) 110
**
 (61) 101
*
 (77) 196
***
 (86) 
Oxidative stress           
Glutamate-cysteine ligase, catalytic 
subunit  
GCLC 56 (12) 75
*
 (11) 106
**
 (30) 140
***
 (31) 118
**
 (41) 156
***
 (61) 183
***
 (59) 247
***
 (105) 
Glutathione reductase  GSR 100 (19) 129
*
 (19) 169
***
 (31) 195
***
 (27) 205
***
 (34) 237
***
 (33) 287
***
 (130) 497
***
 (94) 
Thioredoxin reductase 1  TXNRD1 108 (18) 153
**
 (19) 190
***
 (36) 206
***
 (25) 216
***
 (20) 291
***
 (35) 305
***
 (122) 691
***
 (187) 
Glucose-6-phosphate dehydrogenase  G6PDX 17 (4) 13 (4) 13
*
 (3) 10
***
 (1) 12
**
 (1) 11
**
 (2) 10
**
 (2) 27 (13) 
Heme oxygenase (decycling) 1  HMOX1 93 (16) 117 (36) 100 (29) 73 (27) 96 (43) 417
**
 (344) 158 (120) 320
**
 (182) 
Inflammation           
Chemokine (C-C motif) ligand 2  CCL2 0.6 (0.7) 0.8 (0.5) 1.0 (0.7) 1.2 (1.1) 0.7 (0.3) 1.1 (0.6) 0.5 (0.3) 0.8 (0.7) 
Interleukin-1beta  IL1B 6.4 (5.7) 7.4 (3.0) 4.9 (3.2) 3.0 (1.0) 4.3 (0.7) 4.4 (1.5) 2.6 (0.5) 3.7 (1.1) 
Kininogen 1  KNG1 12887 (4615) 10285 (5194) 9800 (3977) 5715
**
 (1519) 10620 (5291) 12551 (7313) 6376
**
 (1538) 9324 (996) 
Tissue inhibitor of metalloproteinase 1  TIMP1 19 (10) 18 (11) 18 (9) 16 (8) 11 (5) 14 (6) 10
*
 (3) 12 (3) 
Lipocalin-2  LCN2 310 (237) 105 (129) 1128 (2577) 15
***
 (7) 73
*
 (115) 653 (946) 115
*
 (187) 32
**
 (18) 
Regeneration/repair           
Annexin A7  ANXA7 23 (3) 18
*
 (3) 21 (6) 18
*
 (3) 21 (3) 23 (4) 24 (7) 39
***
 (6) 
Crystallin, alpha B  CRYAB 2.6 (0.5) 2.8 (0.6) 2.9 (0.2) 2.7 (0.5) 2.8 (0.6) 2.7 (0.4) 3.0 (0.4) 3.8
**
 (0.3) 
Collagen, type 1, alpha 1  COL1A1 21 (2) 21 (2) 20 (4) 13
***
 (3) 13
**
 (4) 14
**
 (4) 17 (5) 19 (3) 
Glycoprotein (transmembrane) nmb  GPNMB 21 (10) 19 (7) 19 (9) 11
**
 (2) 14 (4) 11
*
 (4) 10
**
 (1) 11
*
 (4) 
Matrix metallopeptidase 12  MMP12 0.1 (0.1) 0.1 (0.1) 0.1 (0.0) 0.1 (0.1) 0.1 (0.1) 0.1 (0.1) 0.1 (0.1) 0.1 (0.1) 
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4.3.8 Kidney gene expression 
Table 4.5 shows the mean values for gene expression in the kidney of the male 
Hanover-Wistar rats treated with vehicle (controls) or HCBD at 5, 10, 15, 20, 30, 45 
and 90 mg/kg HCBD and autopsied 24 hours post-dosing.  
Twenty four hours after HCBD administration, there was significant upregulation of 
some of the genes involved in xenobiotic metabolism in all treated animals, e.g. 
EPHX1, UGT1A6, GSTA3, ABCC3 and NQO1 (Table 4.5). ABCC3, EPHX1 and 
NQO1 mRNA increased in a dose-related manner and at the highest dose level (90 
mg/kg HCBD) mRNA levels had increased 7-, 24- and 28-fold respectively 
(
***
P<0.001). Levels of CYP2C mRNA were downregulated at all HCBD dose levels 
compared to controls. This downregulation was statistically significant at 10, 15, 30, 45 
and 90 mg/kg HCBD. CYP1A1 expression was significantly downregulated at 90 
mg/kg (
***
P<0.001) (Table 4.5). 
In the oxidative stress category, all genes, except for GCLC were significantly 
upregulated in the kidneys at all HCBD dose levels. Glucose-6-phosphate 
dehydrogenase (G6PDX) and heme oxygenase (decycling) 1 (HMOX1) showed a dose-
related response (Table 4.5). GCLC was significantly downregulated in comparison to 
control animals at 30 mg/kg and above. 
All inflammatory genes were significantly upregulated in the kidneys from animals 
treated with HCBD at the highest dose level (90 mg/kg) (
***
P<0.001) (Table 4.5). 
However, lipocalin-2 was also significantly downregulated at 5 and 15 mg/kg HCBD 
(
*
P<0.05) (Table 4.5). 
In the category of regeneration/repair, KIM-1 was the most sensitive marker with 
changes in expression at the lowest dose level (5 mg/kg HCBD) and was upregulated at 
all dose levels in a dose-related manner. CRYAB was upregulated at 10 mg/kg and 
above, except at 90 mg/kg when it was significantly downregulated. ANXA7 mRNA 
levels were increased at 20 mg/kg HCBD and above, whereas GPNMB only showed 
statistical changes at the highest dose levels (45 and 90 mg/kg HCBD). Matrix 
metallopeptidase 12 (MMP12) was significantly upregulated at 20 mg/kg and 90 mg/kg 
and COL1A1 was downregulated at 15, 20 and 30 mg/kg. 
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Table 4.5 Kidney gene expression in male Hanover-Wistar rats treated with increasing doses of HCBD. Rats were treated with vehicle (control, 0 mg/kg) or HCBD by 
intraperitoneal injection. At autopsy, 24 hours post-dosing, kidney expression was measured as described in Section 2.9. Results are represented as copy number [x10
3
/2 ng cDNA]. 
Values are the means and SD of 6 animals per dose level group, except at 20 mg/kg HCBD when n=5. Values that differ significantly by one-way ANOVA test from controls are 
shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
 
  
HCBD dose level (mg/kg) 
Functional category/gene name symbol 0 5 10 15 20 30 45 90 
Xenobiotic metabolism 
         
Epoxide hydrolase 1 (microsomal) EPHX1 495 (96) 1466
***
 (348) 3009
***
 (988) 3815
***
 (685) 6250
***
 (1011) 6043
***
 (1459) 5423
***
 (1629) 11665
***
 (2596) 
UDP glucuronosyltransferase 1A6 UGT1A6 188 (40) 632
***
 (91) 801
***
 (136) 858
***
 (45) 1047
***
 (150) 918
***
 (73) 721
***
 (83) 720
***
 (147) 
Glutathione S-transferase 
isoform mu 3 
GSTM4 44 (12) 58 (11) 60
*
 (11) 64
**
 (8) 78
**
 (7) 75
*
 (25) 84
**
 (22) 197
***
 (72) 
Cytochrome P450 2C CYP2C 60 (36) 35 (25) 18
*
 (12) 17
**
 (6) 30 (27) 22
*
 (15) 7
**
 (7) 0
***
 (0) 
Glutathione S-transferase Yc2 subunit 
(alpha 3) 
GSTA3 30 (6) 83
***
 (17) 123
***
 (26) 147
***
 (26) 174
***
 (32) 196
***
 (25) 156
***
 (25) 171
***
 (40) 
Cytochrome P450 1A1 CYP1A1 55.3 (22.4) 80.1 (50.8) 77.3 (43.8) 84.7 (28.9) 52.1 (36.5) 78.3 (48.7) 23.4 (24.7) 0.2
***
 (0.1) 
ATP-binding cassette, subfamily C 
member3 
ABCC3 13 (2) 19
**
 (4) 28
***
 (5) 31
***
 (4) 44
***
 (5) 47
***
 (6) 44
*** 
(14) 82
***
 (12) 
NAD (P)H dehydrogenase, quinone 1 NQO1 5 (1) 32
***
 (13) 46
***
 (12) 60
***
 (15) 108
***
 (35) 105
***
 (44) 111
***
 (57) 140
***
 (28 ) 
Oxidative stress          
Glutamate-cysteine ligase, catalytic subunit GCLC 3027 (361) 3184 (265) 3107 (222) 3012 (224) 3169 (187) 2396
*
 (495) 1923
***
 (584) 742
***
 (154) 
Glutathione reductase GSR 476 (83) 657
**
 (64) 746
***
 (72) 770
***
 (83) 854
***
 (91) 827
***
 (62) 735
***
 (103) 944
***
 (89) 
Thioredoxin reductase 1 TXNRD1 235 (62) 364
**
 (42) 541
***
 (111) 670
***
 (311) 750
***
 (69) 845
***
 (68) 767
***
 (268) 1331
***
 (197) 
Glucose-6-phosphate dehydrogenase G6PDX 67 (9) 109
***
 (21) 151
***
 (26) 180
***
 (23) 261
***
 (34) 262
***
 (14) 248
***
 (89) 458
***
 (55) 
Heme oxygenase (decycling) 1 HMOX1 20 (5) 46
***
 (6) 110
***
 (54) 176
***
 (45) 272
***
 (95) 498
***
 (181) 709
***
 (473) 679
***
 (224) 
Inflammation          
Chemokine (C-C motif) ligand 2 CCL2 1.7 (1.0) 1.4 (0.7) 1.4 (1.4) 0.9 (0.4) 2.4 (1.9) 2.4 (1.2) 2.4 (1.7) 12.3
***
 (2.2) 
Interleukin-1beta IL1B 2.7 (0.9) 2.9 (0.9) 2.7 (1.6) 2.4 (0.4) 4.1
*
 (0.8) 2.8 (0.5) 4.8 (2.8) 9.9
***
 (1.8) 
Kininogen 1 KNG1 14 (7) 10 (3) 11 (3) 11 (1) 17 (4) 22
*
 (4) 43 (32) 194
***
 (39) 
Tissue inhibitor of metalloproteinase 1 TIMP1 28 (31) 15 (8) 21 (13) 12 (4) 18 (7) 18 (5) 43 (27) 322
***
 (224) 
Lipocalin-2 LCN2 28 (10) 18
*
 (3) 24 (8) 18
*
 (2) 25 (7) 35 (18) 109 (76) 1036
***
 (637) 
Regeneration/repair          
Kidney injury molecule-1 KIM-1 0.2 (0.0) 0.4
*
 (0.2) 1.5
***
 (0.6) 2.5
***
 (0.6) 11.9
***
 (7.1) 28.2
***
 (14.2) 52.4
***
 (40.4) 84.6
***
 (25.9) 
Annexin A7 ANXA7 60 (9) 59 (3) 69 (4) 68 (9) 90
**
 (14) 98
***
 (10) 95
*
 (31) 174
***
 (22) 
Crystallin, alpha B CRYAB 635 (93) 775 (109) 970
**
 (208) 1108
***
 (183) 1208
**
 (322) 1062
**
 (256) 1023
*
 (301) 373
*** 
(104) 
Collagen, type 1, alpha 1 COL1A1 159 (37) 185 (44) 158 (78) 116
**
 (32) 141
*
 (13) 108
**
 (16) 226 (77) 327 (130) 
Glycoprotein (transmembrane) nmb GPNMB 2.2 (0.9) 1.9 (0.9) 1.7 (0.5) 1.6 (0.4) 2.1 (0.5) 2.3 (0.6) 6.3
*
 (3.7) 22.5
***
 (8.2) 
Matrix metallopeptidase 12 MMP12 0.3 (0.1) 0.2 (0.1) 0.3 (0.1) 0.3 (0.1) 0.5
*
 (0.2) 0.4 (0.2) 0.6 (0.3) 2.1
***
 (1.2) 
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4.3.9 Histopathology 
Due to the large number of tissue samples generated during this study livers and kidneys 
from rats treated at 25 and 35 mg/kg HCBD were not histologically examined. 
Table 4.6 shows the number of animals in each dose level group showing pathological 
changes to the kidney.  
Histological examination of the kidneys did not reveal HCBD-induced degenerative 
changes at 5 mg/kg (Figure 4.3 C). At 10 mg/kg HCBD (Figure 4.3 E), however, there 
was minimal degeneration which consisted of individual degenerate cells, and at 15 
mg/kg and above there appeared to be a dose-related increase in the severity of the 
degenerative changes. In animals dosed at 20 mg/kg HCBD there were clusters of two 
to four degenerate cells with pyknotic nuclei (Figure 4.3 G), and at the highest dose 
level (90 mg/kg) there was hypereosinophilia and loss of cellular and nuclear detail in 
marked numbers of proximal tubular epithelial cells (Figure 4.3 I). All tubules in the S3 
segment were affected. 
At 5 mg/kg HCBD there was an increase in the number of hyaline droplets in the 
convoluted tubules proximal to the S3 segment and also an increase in the number of 
animals where hyaline droplets were reported compared to the control group (Figure 4.3 
D). Hyaline droplets result from the accumulation of α-2µ globulin, are most often seen 
in the proximal convoluted tubules and may occur as a result of HCBD administration 
(Cristofori et al., 2013). At 10 mg/kg HCBD there was evidence of small hyaline 
droplets affecting multiple tubules (Figure 4.3 F) and at 20 and 90 mg/kg HCBD there 
were high numbers of hyaline droplets in the majority of the tubules (Figure 4.3 H and J 
respectively). At higher HCBD dose levels there appeared to be a dose-related increase 
in the severity of hyaline droplet formation (Figure 4.3 B, D, F, H and J). 
There were no HCBD treatment-related morphological changes findings in the liver at 
any dose level (data not shown). 
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Table 4.6 Histopathological findings in the kidneys of male Hanover-Wistar rats treated with 
increasing doses of HCBD. Animals were dosed with vehicle (control, 0 mg/kg) or HCBD by 
intraperitoneal injection and autopsied at 24 hours post-dosing as described in Section 4.2.1. Six animals 
per group were examined. Each column represents the number of animals in that dose group showing the 
pathological changes described in the rows. 
 
 HCBD dose level (mg/kg) 
0 5 10 15 20 30 45 90 
No abnormality detected  
 6 6 1 0 0 0 0 0 
Degeneration 
Minimal 0 0 5 4 1 0 0 0 
Mild 0 0 0 2 3 1 2 0 
Moderate 0 0 0 0 2 5 1 0 
Marked 0 0 0 0 0 0 3 1 
Very marked 0 0 0 0 0 0 0 5 
No abnormality detected  
 4 0 0 0 0 0 0 0 
Hyaline droplets         
Minimal 2 2 0 0 0 0 0 0 
Mild 0 4 6 5 4 4 3 3 
Moderate 0 0 0 1 2 2 3 3 
 
 
 
A B
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Figure 4.3 Histology of renal medulla sections from male Hanover-Wistar treated with increasing 
doses of HCBD. Original magnification of all images, x 200. At autopsy, 24 hours post-dosing, kidney 
samples were collected and processed for histopathological examination as described in Section 2.8. 
Sections A, C, E, G and I, were subjected to H&E staining; sections B, D, F, H and J, were subjected to 
chromotrope-aniline-blue staining (CAD) (hyaline droplets). Each panel shows a representative section 
from one of six animals per dose. Rats were treated with HCBD at doses of 0 mg/kg (control; sections A, 
B), 5 mg/kg (sections C, D: absence of histopathological changes (C); accumulation of low number of 
hyaline droplets (D)), 10 mg/kg (sections E, F: occasional degenerate cell (E); small scattered hyaline 
droplets (F)), 20 mg/kg (sections G, H: clusters of 2 to 4 degenerate cells (G); high number of variable 
size hyaline droplets (H)) and 90 mg/kg (I, J: loss of cellular and nuclear detail (I); high number of 
hyaline droplets (J)).  
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4.4 Results for the time course study 
In this experiment sixty animals were administered with a single dose of HCBD at 45 
mg/kg and sixty animals were dosed with vehicle (controls). Six HCBD-treated rats and 
six control animals were autopsied at days 1, 2, 3, 4, 5, 6, 7, 10 and 28 after dosing. This 
dose level was chosen based on the results from the dose response study, since this dose 
level produced consistent histopathological evidence of proximal tubular degeneration. 
4.4.1 Observations during the study 
During the post-dosing period observations were recorded at each autopsy time point. 
After 1, 2, 3, 4 and 5 days of receiving a single dose of HCBD, the kidneys from 
HCBD-treated rats appeared enlarged and paler in colour when compared to control rats 
at the same time point. No other abnormalities were recorded. 
4.4.2 Nonresponders 
During the course of this study, 6 rats out of the 60 treated with HCBD, were considered 
to have been mis-dosed since they did not show any HCBD-related effects. One animal 
per group at days 2, 3, 5 and 7 post-dosing and 2 animals on day 6 post-dosing were 
considered to be mis-dosed. Histopathology examination of these animals revealed no 
evidence of proximal tubular injury and thus data from these rats was not included in 
the results section. 
4.4.3 Body weights  
Table 4.7 shows the change in body weight (for both control and HCBD-treated 
animals) while the animals were in the metabolism cages for 18 hour urine collection 
prior to autopsy at each time point. Animals lost weight while in the metabolism cages. 
There was no clear evidence of a HCBD-treatment related effect on body weight loss at 
any of the time points studied. 
 
 159 
Table 4.7 Body weight change for male Hanover-Wistar rats treated with a single dose of vehicle 
(control) or HCBD at 45 mg/kg during an 18 hour period in metabolism cages. Animals were dosed 
by intraperitoneal injection and placed individually in metabolism cages for the collection of 18 hour 
urine samples as described in Section 4.2.2. Animals had access to water but not diet while in the 
metabolism cages. Values are means and SD of at least 4 animals at each time point (as described in 
Section 4.4.2) and indicate change in body weight. Values that are different from corresponding controls 
at the respective time point by Students’ t-test are shown: *P<0.05. 
 
 
 
Mean (SD) change in body weight (g) 
Time (days after 
dosing) 
          0 mg/kg HCBD 45 mg/kg HCBD 
1 -14.65 (1.26) -17.12
*
 (2.12) 
2 -15.77 (1.75) -14.72 (1.63) 
3 -18.20 (2.75) -21.42 (2.38) 
4 -18.15 (1.75) -15.75 (2.80) 
5 -18.22 (2.03) -15.20
*
 (2.47) 
6 -18.75 (2.81) -17.97 (3.71) 
7 -19.10 (2.43) -20.42 (2.27) 
10 -22.70 (2.51) -20.30 (2.59) 
14 -18.27 (0.90) -18.72 (3.82) 
28 -17.85 (2.05) -20.13 (1.78) 
 
4.4.4 Liver weights 
Relative liver weights were calculated as preliminary indicators of potential HCBD-
induced hepatotoxicity. Relative liver weights for HCBD-treated rats were significantly 
increased over the respective controls on days 1, 2, 3 and 4 post-dosing (Figure 4.4 A). 
After this time point there were no significant differences between control and HCBD-
treated liver weights. 
4.4.5 Kidney weight 
Relative kidney weights for vehicle-treated (controls) and HCBD-treated animals are 
shown in Figure 4.4 B. Kidney weights were significantly increased over controls at 
days 1, 2, 3, 4 and 5 after dosing. At day 4 following a single dose of HCBD, kidneys 
from HCBD-treated animals were 40 % increased over controls (
***
P<0.001). From day 
6 onwards there was no difference between control and kidneys from HCBD-treated 
animals. 
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A
 
B  
 
Figure 4.4 Relative liver (A) and kidney (B) weights from male Hanover-Wistar rats treated with a 
single dose of vehicle (control) or HCBD at 45 mg/kg and sampled at various time points post-
dosing. Animals were dosed on day 0 and autopsied at several time points following treatment. At 
autopsy animals were killed, livers and kidneys were removed and weighed. The kidney weight was 
expressed as a mean of the left and right kidneys. Results are shown as mean body weight per kg body 
weight (BW) with SD indicated by vertical bars of at least 4 animals at each time point (as described in 
Section 4.4.2). Values that differ significantly from corresponding controls at the respective time points 
by Students’ t-test are shown: *P<0.05; **P<0.01; ***P<0.001. 
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4.4.6 Serum clinical chemistry 
Serum ALT, AST, GLDH and ALP were measured in control (vehicle-treated animals) 
and HCBD-treated rats at day 1 to 28 post-dosing. Levels of these enzymes revealed no 
clear HCBD-treatment related effects with time (Figure 4.5). Mean ALT values were 
decreased by 30 % compared to the respective controls at day 4 post-dosing but not at 
any other time points. Serum GLDH was significantly increased over controls on days 2 
and 3 post-dosing. No other differences were noted.  
Serum levels of urea, albumin, glucose and total protein were measured in this study but 
there were no significant changes between control and HCBD-treated animals at any 
time point (Table 4.8).  
Creatinine levels in the serum, however, were approximately 2-fold increased over 
concurrent controls on days 1 and 2 post-dosing. At all later time points there was no 
difference between creatinine levels in control and HCBD-treated rats (Table 4.8). 
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Figure 4.5 Serum ALT (A), AST (B), GLDH (C) and ALP (D) levels for male Hanover-Wistar rats 
treated with a single dose of vehicle (control) or HCBD at 45 mg/kg and sampled at various time 
points post-dosing. Animals were dosed on day 0 and autopsied at several time points following 
treatment. At autopsy serum was collected according to section 4.2.2 and enzymes were assayed as 
described in Section 2.7. Values are means with SD indicated by vertical bars of at least 4 animals at each 
time point (as described in Section 4.4.2). Values that differ significantly from corresponding controls at 
the respective time points by Students’s t-test are shown:*P<0.05; **P<0.01. 
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Table 4.8 Serum clinical chemistry parameters levels for male Hanover-Wistar rats treated with a single dose of vehicle (control) or HCBD at 45 mg/kg and sampled at 
various time points post-dosing. Animals were dosed on day 0 and autopsied at several time points following treatment. At autopsy serum was collected according to section 4.2.2 
and enzymes were assayed as described in Section 2.7. Values are means and SD of at least 4 animals at each time point (as described in Section 4.4.2). Values that differ 
significantly from corresponding controls at the respective time points by Students’s t-test are shown:*P<0.05. C: control, T: treated. 
 
Serum 
parameters 
 Time (days post-dosing) 
 1 2 3 4 5 6 7 10 14 28 
Urea 
(mmol/L) 
C 
7.80 
(0.75) 
7.17 
(0.74) 
9.72 
(0.85) 
8.02 
(0.62) 
7.67 
(0.90) 
7.55 
(1.12) 
6.47 
(0.70) 
10.62 
(1.53) 
6.53 
(1.14) 
7.68 
(1.36) 
T 
9.27 
(2.37) 
10.12 
(3.61) 
10.88 
(1.68) 
8.22 
(1.71) 
6.88 
(0.60) 
7.40 
(0.83) 
7.26 
(1.01) 
10.12 
(1.02) 
7.82 
(1.06) 
7.90 
(1.16) 
Albumin 
(g/L) 
C 
34.00 
(1.67) 
33.00 
(1.67) 
33.17 
(1.17) 
33.17 
(0.75) 
34.00 
(1.26) 
33.00 
(1.10) 
33.83 
(1.47) 
32.50 
(0.55) 
32.33 
(1.51) 
34.67 
(1.75) 
T 
33.33 
(0.82) 
33.60 
(1.14) 
32.60 
(1.95) 
33.17 
(0.98) 
34.60 
(0.89) 
33.25 
(2.36) 
32.60 
(1.52) 
32.67 
(1.21) 
33.50 
(1.64) 
34.67 
(1.75) 
Glucose 
(mmol/L) 
C 
3.77 
(1.00) 
4.76 
(0.79) 
7.27 
(2.49) 
8.36 
(0.72) 
4.84 
(1.37) 
4.11 
(1.46) 
4.30 
(1.09) 
7.40 
(0.42) 
4.19 
(0.84) 
6.65 
(1.23) 
T 
2.85 
(0.77) 
4.12 
(0.96) 
7.27 
(0.93) 
8.61 
(0.45) 
5.13 
(0.70) 
3.90 
(1.19) 
5.56 
(1.44) 
7.44 
(0.31) 
3.86 
(1.26) 
6.20 
(1.10) 
Total protein 
(g/L) 
C 
55.50 
(2.51) 
54.17 
(1.72) 
56.17 
(1.94) 
53.67 
(1.03) 
55.00 
(2.28) 
52.83 
(2.23) 
54.33 
(2.16) 
53.17 
(0.98) 
52.83 
(2.04) 
55.50 
(3.62) 
T 
53.67 
(1.63) 
54.00 
(2.00) 
53.20 
(2.95) 
53.17 
(1.60) 
55.20 
(1.92) 
54.00 
(3.83) 
53.60 
(0.89) 
54.17 
(1.94) 
54.33 
(2.58) 
57.50 
(4.14) 
Creatinine 
(µmol/L) 
C 
25.00 
(1.79) 
26.00 
(1.90) 
29.17 
(2.48) 
22.17 
(1.33) 
23.33 
(2.42) 
22.00 
(3.41) 
23.00 
(2.00) 
24.67 
(1.21) 
24.33 
(2.58) 
29.33 
(2.73) 
T 
48.67
*
 
(22.92) 
50.60
*
 
(26.81) 
34.60 
(13.61) 
23.83 
(4.26) 
23.40 
(1.67) 
25.00 
(1.41) 
25.20 
(1.79) 
25.00 
(1.41) 
25.00 
(6.39) 
31.83 
(2.79) 
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4.4.7 Urinary biomarkers of kidney injury 
Levels of the same urinary biomarkers that were measured in the dose response study in 
this Chapter (Section 4.3) were measured to assess the sensitivity of the markers at 
various time points after the induction of acute kidney injury.  
Urinary α-GST and GST Yb1 both peaked at 24 hours (day 1) following a single dose 
of HCBD at 45 mg/kg (an approximate 357- and 17-fold increase was measured for α-
GST and GST Yb1 respectively; 
***
P<0.001). From day 2 post-dosing, levels of both 
enzymes gradually declined with time, but were still significantly elevated over controls 
at day 4 post-dosing. However, at day 5 post-dosing, α-GST levels in HCBD-treated 
animals were significantly lower than the concurrent controls (
*
P<0.05), whereas GST 
Yb1 was similar to control (Table 4.9). 
Urinary osteopontin was significantly increased over controls at days 2 to 5 post-dosing 
and also at day 7 (Table 4.9). 
Lipocalin-2 was significantly decreased in HCBD-treated animals compared to controls 
on day 3 post-dosing (
*
P<0.05), however, the mean control value was much greater at 
this time point than the control lipocalin-2 values at the other time points. This was due 
to 2 animals in the group having elevated serum levels of lipocalin-2 (when compared 
to the lowest value in the group, these 2 animals showed an approximate 2.5-fold 
increase). At other time points in the study, there appeared to be no evidence of an 
HCBD-related effect on lipocalin-2 (Table 4.9). 
Urinary creatinine levels showed no evidence of an HCBD-treatment related effect apart 
from a significant decrease in the treated animals at day 6 (43.00 and 38.25 µmol/c.p. 
for control animals and HCBD-treated rats respectively) (
*
P<0.05) (Table 4.9). Urinary 
glucose was significantly increased in HCBD-treated animals at the first time point (day 
1) and up to day 4 post-dosing (inclusively) (Table 4.9). 
Clusterin was significantly increased over controls at days 1, 4, 5 and 7 after HCBD-
treatment; there were also increases at days 2 and 3 but these were not statistically 
significant (Table 4.10). The greatest fold increase was measured on day 4 post-dosing 
(6.5-fold increase over concurrent controls; 
***
P<0.001). Levels for KIM-1 were 
significantly increased in HCBD-treated rats from day 1 to 7 post-dosing. KIM-1 levels 
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in urine peaked on day 4, at which time point an approximate 84-fold increase was 
reported over concurrent controls (5.42 and 454.01 ng/c.p.) (
***
P<0.001) (Table 4.10). 
Urinary total protein was significantly increased in HCBD-treated animals at the first 
time point (day 1) and up day 4 post-dosing (inclusively). Total protein levels peaked on 
day 1 (24 hours post-dosing) (
***
P<0.001). 
Albumin was 156-fold increased over concurrent controls on day 1 post-dosing, and 
remained significantly increased at days 2, 3, 4 and 5 post-dosing. However, 7 days 
after HCBD-treatment, mean albumin levels were decreased when compared to the 
respective controls (
*
P<0.05) (Table 4.10). At all other time points urinary albumin for 
HCBD-treated animals was similar to controls. 
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Table 4.9 Urinary levels of α-GST, GST Yb1, osteopontin, lipocalin-2, creatinine and glucose for male Hanover-Wistar rats treated with a single dose of vehicle (control) 
or HCBD at 45 mg/ kg and sampled at various time points post-dosing.
 
Animals were dosed on day 0 and autopsied at several time points following treatment. Urine was 
collected for 18 hours prior to autopsy at each time point and analysed as described in Section 4.2.2. Values are means and SD of at least 4 animals at each time point (as described in 
Section 4.4.2) and are expressed as c.p. (collection period, 18 hours). Values that differ significantly from corresponding controls at the respective time points by Students’s t-test are 
shown:
 *
P<0.05; 
**
P<0.01; 
***
P<0.001. C: control, T: treated. 
Urinary 
parameters 
Time (days) 
1 2 3 4 5 6 7 10 14 28 
α-GST 
(ng/c.p.) 
C 
504.81 
(381.55) 
347.91 
(166.50) 
836.71 
(279.54) 
459.88 
(153.93) 
619.37 
(280.95) 
622.97 
(456.92) 
926.04 
(290.47) 
456.93 
(149.47) 
782.62 
(313.00) 
1677.10 
(743.08) 
T 
180179.28
*** 
 (125447.39)
 
31051.80
*** 
(19835.69)
 
5552.50
***
 
(2325.36) 
1202.20
***
 
(265.63) 
301.00
*
 
(106.14) 
516.43 
(209.97) 
615.12 
(233.18) 
565.94 
(1335.61) 
835.77 
(180.34) 
1604.55 
(524.74) 
GST Yb1 
(ng/c.p.) 
C 
38.91 
(19.61) 
34.44 
(25.46) 
79.03 
(40.13) 
38.52 
(9.45) 
43.38 
(31.79) 
39.21 
(18.05) 
105.96 
(50.27) 
46.09 
(17.41) 
78.91 
(37.11) 
155.93 
(36.23) 
T 
640.83
***
 
(271.43) 
345.25
***
 
(176.50) 
359.33
***
 
(103.25) 
111.67
**
 
(39.32) 
45.48 
(17.58) 
44.54 
(24.99) 
63.19 
(23.44) 
81.35
*
 
(3.64) 
72.82 
(17.31) 
179.24 
(61.64) 
Osteopontin 
(ng/c.p.) 
C 
21.60 
(10.58) 
17.56 
(9.45) 
23.87 
(6.31) 
14.02 
(4.23) 
21.56 
(9.87) 
14.58 
(5.06) 
40.19 
(11.85) 
37.88 
(12.30) 
39.27 
(11.07) 
28.02 
(6.81) 
T 
32.61 
(17.10) 
63.79
**
 
(45.56) 
90.86
***
 
(49.25) 
92.33
***
 
(16.66) 
58.26
**
 
(18.33) 
24.08 
(11.00) 
67.56
*
 
(17.43) 
41.04 
(12.28) 
29.02 
(11.80) 
38.95
*
 
(7.23) 
Lipocalin-
2 
(ng/c.p.) 
C 
3394.52 
(1461.95) 
4558.70 
(1797.72) 
8024.93 
(3348.34) 
6426.62 
(3456.35) 
3871.45 
(901.47) 
2689.30 
(329.85) 
4529.62 
(657.45) 
3793.58 
(1255.27) 
2829.77 
(966.21) 
3255.00 
(602.18) 
T 
5492.22 
(3696.26) 
3421.98 
(1574.78) 
4263.62
*
 
(346.09) 
5568.55 
(1047.33) 
3354.32 
(503.13) 
2209.35 
(516.90) 
4230.86 
(638.72) 
4012.78 
(1317.64) 
2105.25 
(382.96) 
2681.78 
(637.14) 
Creatinine 
(µmol/c.p.) 
C 
36.17 
(3.92) 
32.17 
(7.36) 
48.33 
(2.73) 
35.83 
(1.72) 
30.67 
(5.28) 
43.00 
(2.97) 
45.50 
(1.52) 
46.00 
(9.17) 
49.83 
(11.53) 
69.83 
(13.70) 
T 
32.17 
(2.23) 
32.00 
(9.00) 
53.00 
(4.12) 
37.33 
(3.27) 
29.80 
(2.05) 
38.25
*
 
(2.99) 
44.20 
(5.40) 
47.67 
(4.23) 
47.00 
(5.37) 
69.67 
(2.66) 
Glucose 
(µmol/c.p.) 
C 
3.50 
(0.55) 
3.33 
(1.03) 
3.67 
(0.52) 
4.33 
(1.03) 
3.33 
(0.82) 
4.83 
(0.75) 
4.00 
(0.63) 
6.33 
(1.75) 
4.67 
(1.37) 
5.00 
(1.10) 
T 
105.67
*
 
(151.79) 
170.40
**
 
(144.94) 
57.40
*
 
(56.81) 
22.00
***
 
(18.42) 
8.20 
(10.52) 
4.00 
(0.82) 
3.60 
(0.55) 
7.17 
(1.83) 
3.67 
(0.52) 
5.67 
(1.03) 
 
α-GST: α-glutathione-S-transferase; GST Yb1: glutathione-S-transferase Yb1.  
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Table 4.10 Urinary levels clusterin, KIM-1, total protein and albumin for male Hanover-Wistar rats treated with a single dose of vehicle (control) or HCBD at 45 mg/ kg 
and sampled at various time points post-dosing. Animals were dosed on day 0 and autopsied at several time points following treatment. Urine was collected for 18 hours prior to 
autopsy at each time point and analysed as described in Section 4.2.2. Values are means and SD of at least 4 animals at each time point (as described in Section 4.4.2) and are 
expressed as c.p. (collection period, 18 hours). Values that differ significantly from corresponding controls at the respective time points by Students’s t-test are shown: *P<0.05; 
**
P<0.01; 
***
P<0.001. C: control, T: treated. 
 
            Urinary 
parameters 
Time (days) 
             1            2          3          4       5      6   7   10 14 28 
Clusterin 
(ng/c.p.) 
C 
82.96 
(29.43) 
141.48 
(55.51) 
125.29 
(19.43) 
104.98 
(22.32) 
90.28 
(12.30) 
190.84 
(123.07) 
82.64 
(34.16) 
110.13 
(26.91) 
83.62 
(45.39) 
85.66 
(22.51) 
T 
329.02
*
 
(372.02) 
299.52 
(212.95) 
290.20 
(182.21) 
682.93
***
 
(242.13) 
346.26
**
 
(175.45) 
198.38 
(93.74) 
200.73
**
 
(50.34) 
133.98 
(17.11) 
96.17 
(45.07) 
92.45 
(29.03) 
KIM-1 
(ng/c.p.) 
C 
4.56 
(1.02) 
3.73 
(0.46) 
4.80 
(0.78) 
5.42 
(0.91) 
4.81 
(1.17) 
5.21 
(1.28) 
7.28 
(0.53) 
9.72 
(1.99) 
6.57 
(1.64) 
6.35 
(0.97) 
T 
32.02
***
 
(15.40) 
360.53
*** 
(144.26) 
233.07
***
 
(125.15) 
454.01
***
 
(148.65) 
124.37
*** 
(100.54) 
13.76
**
 
(4.66) 
14.81
***
 
(1.29) 
10.25 
(1.18) 
6.81 
(2.08) 
7.10 
(1.74) 
Total protein 
(mg/c.p.) 
C 
4.17 
(0.54) 
4.83 
(2.85) 
5.88 
(1.48) 
5.23 
(1.54) 
5.23 
(1.01) 
9.30 
(1.33) 
7.12 
(1.99) 
5.03 
(1.58) 
7.08 
(2.22) 
9.10 
(3.45) 
T 
18.12
***
 
(8.79) 
12.10
**
 
(3.08) 
11.40
***
 
(1.83) 
9.45
**
 
(1.28) 
5.76 
(1.71) 
6.75
**
 
(0.97) 
5.88 
(2.09) 
5.23 
(1.33) 
5.92 
(1.06) 
7.93 
(1.04) 
Albumin 
(mg /c.p.) 
C 
0.07 
(0.08) 
0.07 
(0.03) 
0.08 
(0.02) 
0.15 
(0.10) 
0.07 
(0.03) 
0.10 
(0.03) 
0.13 
(0.05) 
0.79 
(0.64) 
0.12 
(0.04) 
0.16 
(0.06) 
T 
10.94
***
 
(6.51) 
9.45
***
 
(5.61) 
1.25
*
 
(0.92) 
3.09
***
 
(2.46) 
0.76
*
 
(0.82) 
0.07 
(0.01) 
0.08
*
 
(0.04) 
0.53 
(0.54) 
0.16 
(0.04) 
0.14 
(0.04) 
 
KIM-1: kidney
 
injury molecule-1. 
 
 168 
 
4.4.8 Gene expression 
In the dose response study in this Chapter most of the changes in gene expression 
markers for the liver corresponded to genes involved in xenobiotic metabolism and 
oxidative stress. This reflects the metabolism of HCBD in the liver with the production 
of a toxic metabolite in the kidneys and did not indicate a toxic response. Therefore, in 
the present study, it was not considered necessary to carry out gene expression analysis 
of the liver. 
Table 4.11 shows the gene expression data in the kidneys of the male Hanover-Wistar 
rats treated with vehicle (controls) or a single dose of 45 mg/kg HCBD and autopsied at 
day 1 to 28 post-dosing. Three HCBD-treated animals and 3 concurrent control animals 
were randomly selected at each time point. 
Twenty four hours after HCBD administration (day 1), there was significant 
upregulation of all the genes involved in xenobiotic metabolism, except CYP1A1 and 
CYP2C which were downregulated. NQO1 was upregulated 26-fold compared to 
controls at the same time point (
***
P<0.001). EPHX1 mRNA was approximately 15-fold 
greater than concurrent controls (
***
P<0.001) (Table 4.11). ABCC3, GSTM4, GSTA3 
and UGT1A6 were also significantly upregulated over controls at day 1 post-dosing but 
fold increases recorded were smaller (4.1-fold for ABCC, 3.3- for GSTM4 and 5-fold 
for both GSTA3 and UGT1A6 respectively; 
**
P<0.01). All of these genes remained 
upregulated at days 2 and 3 and most had returned to normal expression levels by day 4 
post-dosing. 
The expression of CYP1A1 appeared to be downregulated at all time points but the only 
statistically significant differences were noted on days 5 and 7 post-dosing. CYP2C 
expression remained downregulated until day 10 post-dosing but this was not 
statistically significant on day 6.  
In the category of oxidative stress, G6PDX, GSR, HMOX1 and TXNRD1 mRNA levels 
were significantly increased over concurrent controls from day 1 to day 3 post-dosing. 
GCLC was the only gene in this category to be downregulated when compared to 
control animals; however, this downregulation was not statistically significant (Table 
4.11). 
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The inflammatory gene LCN2 was upregulated as early as day 2 after dosing (
**
P<0.01) 
and remained significantly upregulated up to and including day 5 post-dosing. 
Expression levels of LCN2 were also significantly upregulated on day 7 and 14 post-
dosing. Also in this category, TIMP1 was upregulated on day 1 and 2 post-dosing and 
also on days 4 and 5 post-dosing. 
In the functional category of regeneration and repair ANXA7, COL1A1, CRYAB, 
KIM-1 and MMP12 were all significantly upregulated on day 1 post-dosing. The fold 
increase in mRNA expression at 24 hours following a single dose of 45 mg/kg HCBD 
was greatest for KIM-1 (242-fold increase, 
***
P<0.001) and expression of this gene 
remained upregulated until day 5 after dosing, and on day 7 and day 10 post-dosing. 
ANXA7 was upregulated between days 1 and 4 post-dosing; expression of this gene 
was highest on day 2 post-dosing (
***
P<0.001). 
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Table 4.11 Kidney gene expression in male Hanover-Wistar rats treated with a single dose of vehicle (control) or HCBD 45 mg/ kg and sampled at various time points 
post-dosing. Animals were dosed on day 0 and autopsied at several time points following treatment. At autopsy, kidney expression was measured as described in Section 2.9. Results 
are represented as copy number [x10
3
/5 ng cDNA]. Values are the means and SD of 3 animals per dose level group. Values that differ significantly from corresponding controls at 
the respective time points by Students’ t-test are shown: *P<0.05; **P<0.01; ***P<0.001. Control values are only shown for day 1 post-dosing. 
   Days post-dosing 
Functional category/gene name symbol 
Control 
(Day 1) 
1 2 3 4 5 6 7 10 14 28 
Xenobiotic metabolism             
Cytochrome P450 1A1 CYP1A1 111.8 (37.5) 34.5 (34.8) 13.7 (16.5) 15.8 (25.2) 3.2 (2.8) 2.7
*
 (4.3) 19.9 (6.5) 6.7
*
 (4.4) 55.3 (26.9) 24.4 (31.4) 56.1 (36.3) 
Cytochrome P450 2C CYP2C 56.9 (20.5) 8.6
*
 (9.4) 1.1
**
 (1.0) 6.5
**
 (5.3) 3.7
**
 (5.2) 0.6
*
 (1.0) 22.6 (1.0) 11.8
*
 (18.1) 25.3
*
 (14.0) 77.3 (31.7) 237.4 (26.0) 
NAD (P)H dehydrogenase, quinone 1 NQO1 10.6 (3.0) 263.1
***
 (51.2) 115.4
***
 (39.2) 74.3
***
 (6.5) 15.4 (3.0) 24.9
*
 (2.3) 21.5 (8.8) 14.0 (2.5) 9.1 (0.3) 11.7
*
 (0.8) 9.7 (1.8) 
ATP-binding cassette, subfamily C 
member3 
ABCC3 18.5 (4.8) 75.9
**
 (21.3) 48.0
**
 (7.2) 32.3
*
 (2.8) 22.0 (3.7) 24.1 (2.4) 21.9 (1.2) 24.1
**
 (2.1) 24.1 (2.2) 27.0 (0.9) 22.4 (4.1) 
Glutathione S-transferase 
isoform mu 3 
GSTM4 52.9 (1.7) 174.0
**
 (41.6) 150.3
**
 (31.1) 175.3
**
 (20.8) 80.4 (19.8) 79.4 (24.6) 70.7 (12.6) 61.2 (11.8) 131.9 (38.6) 70.8 (3.5) 62.5 (17.6) 
Glutathione S-transferase Yc2 subunit 
(alpha 3) 
GSTA3 67.6 (22.3) 334.4
**
 (80.3) 300.4
**
 (90.2) 202.2
**
 (57.6) 72.9 (14.5) 94.7
*
 (10.5) 92.0 (12.2) 50.8 (12.4) 44.7 (2.6) 58.0 (13.8) 59.3 (7.2) 
UDP glucuronosyltransferase 1A6 UGT1A6 241.3 (74.3) 1241.2
**
 (55.4) 971.3
***
 (167.9) 660.0
**
 (102.4) 322.3
*
 (15.1) 325.5 (71.6) 322.3 (104.5) 273.2 (66.3) 143.1
**
 (13.3) 263.3
*
 (17.2) 254.5
*
 (28.6) 
Epoxide hydrolase 1 (microsomal) 
EPHX1 635.6  
(113.0) 
9486.9
***
 
(1805.4) 
4397.5
*** 
 (1326.1) 
2094.8
**
  
(618.7) 
701.3  
(60.8) 
693.7 
 (115.1) 
709.4  
(97.6) 
620.8  
(36.8) 
561.1 
 (72.1) 
796.7  
(131.9) 
697.1  
(81.3) 
Oxidative stress             
Glucose-6-phosphate dehydrogenase G6PDX 79.2 (9.9) 379.7
***
 (52.7) 307.9
**
 (67.9) 193.1
**
 (3.2) 123.1 (9.9) 110.4 (32.7) 105.0
*
 (4.3) 102.0 (20.2) 90.4 (12.7) 116.5 (9.0) 114.2 (13.3) 
Glutathione reductase GSR 551.3 (67.7) 1134.8
**
 (114.2) 934.7
***
 (53.0) 810.3
**
 (22.0) 566.6 (49.7) 584.7 (127.8) 684.7 (117.8) 631.6 (49.3) 684.0 (97.7) 712.0 (79.4) 593.4 (122.7) 
Heme oxygenase (decycling) 1 HMOX1 12.8 (2.4) 614.2
***
 (230.1) 194.9
***
 (55.6) 58.8
**
 (15.4) 33.2
*
 (7.5) 32.9 (11.5) 15.6 (0.5) 21.7 (7.5) 16.4 (2.2) 18.9 (2.9) 16.1 (2.2) 
Thioredoxin reductase 1 TXNRD1 293.9 (26.4) 1125.0
***
 (242.4) 729.3
**
 (112.2) 586.4
***
 (32.0) 330.4 (17.4) 322.6 (29.2) 371.0 (27.9) 318.0 (36.7) 301.0 (24.2) 373.6 (48.0) 363.2 (36.8) 
Glutamate-cysteine ligase, catalytic 
subunit 
GCLC 4372.3 
  (1050.1) 
2642.2  
(837.4) 
2350.6  
(996.6) 
2323.7  
(1313.9) 
1607.9
** 
 (636.8) 
1235.6  
(584.3)
**
 
2820.7  
(342.4) 
2968.8
**
  
(436.2) 
4754.8  
(1426.3) 
6049.5  
(1761.1) 
6436.0  
(410.9) 
Inflammation             
Lipocalin-2 LCN2 22.1 (4.6) 186.6 (218.2) 139.2
**
 (47.2) 183.0
*
 (137.7) 226.0
**
 (74.2) 293.7
*
 (256.0) 45.9 (1.3) 58.0
*
 (15.8) 42.5 (5.5) 37.3
*
 (4.6) 31.7 (11.1) 
Chemokine (C-C motif) ligand 2 CCL2 4.5 (1.3) 17.4 (13.7) 11.9 (5.1) 14.7 (7.0) 16.4 (4.7) 12.8 (11.4) 4.7 (0.1) 5.9 (2.1) 9.5 (2.6) 10.3 (8.5) 7.6 (0.6) 
Kininogen 1 KNG1 19.7 (5.8) 106.4 (98.4) 87.4
*
 (40.3) 46.6 (26.3) 43.0 (28.9) 54.0 (51.0) 15.6 (1.2) 15.9 (7.1) 15.2 (3.7) 13.9 (3.5) 14.7 (1.5) 
Tissue inhibitor of metalloproteinase 1 TIMP1 11.7 (3.0) 84.7
*
 (62.8) 62.3
*
 (18.7) 75.0 (48.0) 81.8
*
 (26.4) 57.7
*
 (30.7) 32.2 (21.7) 29.6 (16.9) 32.4 (5.5) 22.2 (5.4) 18.6 (4.9) 
Regeneration/repair             
Annexin A7 ANXA7 78.1 (15.5) 158.4
*
 (44.3) 186.9
***
 (10.5) 163.0
*
 (27.8) 131.0
**
 (11.5) 121.6 (24.7) 99.4 (15.6) 104.6 (16.2) 104.4 (9.4) 109.9 (5.9) 99.4 (7.8) 
Collagen, type 1, alpha 1 COL1A1 133.6 (28.5) 221.7
*
 (32.2) 213.5 (61.7) 339.9 (122.0) 737.7 (502.7) 578.5
**
 (110.8) 262.8 (104.0) 322.8 (148.5) 265.8 (94.9) 291.5 (78.0) 120.1 (30.1) 
Crystallin, alpha B CRYAB 1060.1 (82.3) 1567.4
*
 (234.8) 1282.9 (152.4) 647.3 (295.5) 507.4
**
 (109.5) 461.9
*
 (175.1) 727.0 (63.4) 625.9
*
 (126.6) 831.8 (71.9) 968.6 (262.2) 1009.9 (37.7) 
Kidney injury molecule-1 KIM-1 0.2 (0.0) 48.3
***
 (33.6) 65.2
***
 (11.5) 79.8
***
 (43.3) 59.1
***
 (24.7) 33.2
***
 (26.0) 3.9 (0.5) 3.0
***
 (0.4) 1.4
*
 (0.8) 0.8 (0.6) 0.6 (0.5) 
Matrix metallopeptidase 12 MMP12 0.2 (0.0) 1.6
**
 (0.7) 1.6 (0.2) 1.0
*
 (0.4) 1.2 (0.6) 0.7 (0.3) 0.2 (0.1) 0.4 (0.1) 1.6 (0.6) 0.9 (0.2) 1.0 (0.8) 
Glycoprotein (transmembrane) nmb GPNMB 2.3 (1.0) 13.8 (8.1) 15.1
**
 (3.1) 17.8 (9.9) 22.8
**
 (5.1) 24.8
*
 (12.0) 7.5 (2.7) 10.6
***
 (0.9) 6.6 (1.8) 5.5 (0.2) 3.3 (0.4) 
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4.4.9 Histopathology 
Histological examination of the kidneys following a single administration of 45 mg/kg 
HCBD revealed evidence of degeneration and regeneration in the S3 segment of the 
proximal renal tubules 
Table 4.12 shows the number of animals at each time point that demonstrated 
histopathological changes to the kidneys. There were signs of degeneration from day 1 
to day 3 post-dosing (Table 4.12, Figure 4.6 B, C and D). On day 1 post-dosing there 
was evidence of tubular degeneration and hypereosinophilia, which was also observed 
on day 2. On day 3, there were focal areas of degeneration (labelled with (*) in Figure 
4.6 B, C and D). However, the severity of degeneration changed with time; no animals 
on day 1 displayed evidence of marked degeneration, whereas on day 2, 3 out of the 5 
animals examined had marked degeneration and 1 out of 5 on day 3 showed marked 
degeneration. After day 3, no animals were found to have histopathological evidence of 
degeneration.  
Regeneration of the S3 segment of the proximal tubule was first observed on day 2 post-
dosing (5 out of 5 animals at that time point) but was only moderate or marked. 
Regeneration is labelled with (†) in Figure 4.6 C and D. At days 4 and 5 post-dosing all 
animals showed very marked signs of regeneration suggesting that regeneration peaked 
at these time points. Figure 4.6 C shows mitotic figures evidenced with arrows and 
eosinophilic proteinaceous debris in the tubule lamina (+). By day 10 most animals were 
only showing minimal or mild signs of regeneration and tubules had a morphologic 
appearance almost similar to control. 
Kidneys from control animals and livers from all animals did not reveal any evidence of 
HCBD-treatment related effect at any of the time points in this study.  
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Table 4.12 Histopathological findings in the kidneys of male Hanover-Wistar rats treated with a 
single dose of vehicle (control) or HCBD at 45 mg/kg and sampled at various time points post-
dosing. Animals were dosed on day 0 and autopsied at several time points following treatment. Each 
column represents the number of animals in that dose group showing the pathological changes described 
in the rows. A minimum of at least 4 animals was examined at each time point (as described in Section 
4.4.2). 
 Time (days post-dosing) 
1 2 3 4 5 6 7 10 14 28 
No degenerative abnormality 
detected  
  
 0 0 0 6 5 4 5 6 6 6 
Minimal 2 0 0 0 0 0 0 0 0 0 
Mild 2 0 2 0 0 0 0 0 0 0 
Moderate 2 2 2 0 0 0 0 0 0 0 
Marked 0 3 1 0 0 0 0 0 0 0 
Very marked 0 0 0 0 0 0 0 0 0 0 
No regenerative abnormality  
detected  
 6 0 0 0 0 0 0 1 2 4 
Minimal 0 0 2 0 0 0 0 5 1 2 
Mild 0 0 0 0 0 0 0 0 3 0 
Moderate 0 1 0 0 0 1 1 0 0 0 
Marked 0 4 3 0 0 2 0 0 0 0 
Very marked 0 0 0 6 5 1 4 0 0 0 
 
A B
C D
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G H
 
Figure 4.6 Histology of renal cortex sections from male Hanover-Wistar rats treated with a single 
dose of vehicle (control) or HCBD at 45 mg/kg and sampled at various time points. Original 
magnification of all images, x 200; H&E. Animals were dosed on day 0 and autopsied at several time 
points following treatment. Rats were dosed by intraperitoneal injection and autopsied at various time 
points post-dosing. At autopsy kidney samples were collected and processed for histopathological 
examination as described in Section 2.8. (A) control rat at day 1; (B) HCBD-treated day 1: tubular 
degeneration and hypereosinophilia (*); (C) HCBD-treated day 2: degeneration (*) and areas of 
regeneration (†); (D) HCBD-treated day 3: focal areas of degeneration (*); (E) HCBD-treated day 4: 
marked regeneration with the majority of tubules displaying increased basophilia, increased nuclear and 
cellular size, mitotic figures (arrows) and eosinophilic proteinaceous debris in the tubule lamina (+); (F) 
HCBD-treated day 5: continued regeneration; (G) HCBD-treated day 6: less evidence of regeneration; (H) 
HCBD-treated day 10: normal appearance of renal medulla. 
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4.5 Discussion 
The first objective of the dose response study presented in this Chapter was to define a 
dose level of HCBD that induced nephrotoxicity in the male Hanover-Wistar rat and use 
this in a second experiment, a time course study, to evaluate the sensitivity of a range of 
urinary biomarkers for kidney injury.  
In the dose response study animals were dosed with HCBD at dose levels ranging from 
5 to 90 mg/kg. 
HCBD undergoes primary metabolism in the liver to form a glutathione conjugate prior 
to secondary metabolism in the kidney. The kidneys are the main target organ for 
HCBD-induced toxicity, however, it has been reported that the liver also has the 
enzyme cysteine β-lyase, and therefore, is capable of producing the toxic compound 
responsible for HCBD-induced toxicity (Tateishi et al., 1978; Stevens, 1985a; Stevens, 
1985b). Therefore, in the present studies, great importance was given to guarantee that 
the liver did not show evidence of an HCBD-induced toxic effect.  
In this dose response study, relative liver weights, as recorded at autopsy, were 
significantly increased over controls at the highest HCBD dose level, but were similar 
to controls at all other dose levels (Figure 4.1 A). In a previous study by Lock et al., 
(1981) male rats administered with a single i.p. injection of 300 mg/kg HCBD had 
heavier livers than control animals and this was associated with an increase in the liver 
water content. Similar results were reported in another study by Lock and co-workers 
(1985) when male Alderley Park mice were administered with HCBD at 100 and 200 
mg/kg. Liver weights were increased at 24 hours post-dosing which was accompanied 
by an increase in the liver water content. Histological evaluation of the liver revealed 
cytoplasmic vacuolation of the periportal hepatocytes. 
Serum ALT, AST and GLDH activity were measured as indicators of hepatic injury, 
however, the only changes were an increase in ALT and GLDH at the highest dose level 
(90 mg/kg HCBD) (Figure 4.2). In the study by Lock and colleagues (1985), a 
significant increase in ALT activity was reported at 4 and 8 hours following 
administration of 50 mg/kg HCBD to mice but by 16 hours post-dosing levels had 
returned to normal. These were also the time points when the first ultrastructural 
changes were reported in the liver which consisted of disorganisation and swelling of 
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the rough endoplasmic reticulum particularly in the centrilobular hepatocytes (4 hours 
post-dosing). At 8 hours post-dosing there was evidence of mitochondrial swelling in 
periportal hepatocytes whereas at 16 hours after HCBD administration there was 
mitochondrial swelling and proliferation of smooth endoplasmic reticulum in periportal 
hepatocytes. However, in the present study, no evidence was found of an HCBD-
induced toxic effect in the liver at any of the dose levels used. 
Gene expression data analysis of the liver (Table 4.4) revealed significant upregulation 
of all genes involved in xenobiotic metabolism at the lowest dose level (5 mg/kg), 
except for ABCC3, CYP1A1 and NQO1. EPHX1, GSTM4 and GSTA3 mRNA levels 
were significantly increased following the administration of HCBD (1.8-, 1.4- and 2.8-
fold respectively). NQO1 mRNA was 2.1-fold upregulated over controls but this change 
was not statistically significant. Epoxides react with nucleophilic molecules such as 
DNA, RNA and proteins and the enzyme epoxide hydrolase (EPHX1) converts the 
epoxide into a more excretable molecule (Archer, 1997). NQO1 is induced by oxidative 
stress and combats oxidative stress by catalysing the conversion of quinone to 
hydroquinone suppressing the formation of the reactive hemiquinone (Nioi and Hayes, 
2004). GSTs are enzymes involved in the first step of the metabolism of HCBD, which 
involves the conjugation of reduced glutathione to organic molecules during the 
detoxification process which occurs in the liver (Mannervik et al., 1985). Therefore, the 
increase in gene expression reflects the increased xenobiotic metabolising activity of the 
liver in the presence of HCBD.  
In the category of oxidative stress, the first genes to show evidence of statistically 
significant upregulation were GLCL, GSR and TXRND1 with an average 1.3-fold 
increase in mRNA levels over control values (Table 4.4). HMOX1 upregulation did not 
occur at the lower dose levels but expression was maximal at 30 mg/kg HCBD. At this 
dose level HMOX1 mRNA was found to be upregulated to approximately 4.5-fold.  
Inflammatory and regeneration/repair gene expression changes in the liver did not show 
evidence of a dose-related effect. Thus, gene expression changes in the liver reflect the 
primary metabolism of HCBD prior to the production of a toxic metabolite in the 
kidney (Table 4.4). 
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Histopathological examination of the liver sections from this study confirmed the 
absence of morphologic changes consistent with HCBD-administration at any dose 
level. 
In the current dose response study the relative kidney weights were approximately 1.2-
fold increased over control animals at the highest HCBD dose level (Figure 4.1 B). 
Lock and colleagues (1981) also reported a significant increase in the relative kidney 
weight at 24 hours following the administration of a single dose of 300 mg/kg HCBD. 
Lock et al., (1981) suggested the increased weight was associated with an increase in 
tissue water content. In another study, 28 and 63 day old male and female rats were 
administered with a single dose of HCBD at 25, 50 and 100 mg/kg and the relative 
kidney weights were shown to be significantly increased over controls (Kuo and Hook, 
1983). In our study we did not see an increase in kidney weights below 90 mg/kg. 
Routine clinical chemistry revealed significant increases in serum creatinine and urea 
levels following the administration of HCBD at 45 and 90 mg/kg (
**
P<0.01 and 
***
P<0.001, respectively) (Table 4.2); this suggests the presence of kidney injury at 
these dose levels. In another study, Lock and Ishmael (1979) administered HCBD at 
100, 200 and 300 mg/kg to male Alderley Park albino rats and found a statistically 
significant increase in the serum urea concentration. Significant increases in urea and 
serum creatinine were also reported following a single administration of HCBD at 100 
mg/kg to male Wistar rats (Chiusolo et al., 2010). Sedeghnia et al., (2013) described an 
increase in the mean urea and creatinine serum levels at 24 hours following the 
administration of 100 mg/kg HCBD to female Wistar rats. The results from our study 
suggest that serum creatinine and urea may not be very sensitive in response to kidney 
injury, since they were similar to control levels at the lowest dose levels, and did not 
appear to correlate with the histopathology data which showed evidence of degeneration 
following administration of 10 mg/kg HCBD and above. 
Urinary levels of the cytosolic enzymes α-GST and GST Yb1 were significantly raised 
over control animals at 20 and 10 mg/kg HCBD, respectively (Table 4.3). There also 
appeared to be a dose-dependent relationship, with a 33.4- and a 2.08-fold increase for 
α-GST (at 20 mg/kg) and GST Yb1 (at 10 mg/kg) over controls, respectively (Table 
4.3). Pinches et al. (2012) measured urinary biomarker levels following a single dose of 
0.1, 1 or 2.5 mg/kg cisplatin to male and female Hanover-Wistar rats. They found that 
α-GST and GST Yb1 did not appear to be more sensitive than traditional markers such 
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as serum urea and creatinine. The results also indicated that increases in α-GST may be 
influenced by the sex of the animals (Pinches et al., 2012).  
The increase in urinary α-GST and GST Yb1 following renal injury is due to cellular 
damage resulting in the enzymes being released from tubular epithelial cells and into the 
tubular lumen (Harrison et al., 1989). α-GST is located in the epithelial cells of the 
proximal renal tubules, whereas GST Yb1 can be predominantly found in the epithelial 
cells of the distal renal tubules (Rozell et al., 1993; Otieno et al., 1997). However, in 
this study, histological examination revealed HCBD-induced injury mainly to the S3 
segment of the proximal tubule (Figure 4.3). Additionally, it is thought that there was 
some degree of cross-reactivity in the GST Yb1 assay with α-GST due to a lack of 
antibody specificity, particularly at dose levels up to 15 mg/kg HCBD. α-GST is known 
to cross-react with the MSD GST Yb1 assay by 7.22 % (Argutus, 2010). Therefore, 
increases in the urinary excretion of GST Yb1 should be interpreted with caution. 
No evidence of a dose-related effect was recorded for the urinary levels of osteopontin 
suggesting this to be a less sensitive biomarker. Lipocalin-2 excretion in the urine was 
not increased in HCBD-treated animals at any HCBD dose levels (at 30 mg/kg HCBD 
there was a significant decrease) (Table 4.3). In a previous study by Swain et al., (2011), 
with female rats dosed with HCBD at 0, 90 and 135 mg/kg, urinary lipocalin-2 was 
found to be significantly increased over controls at both HCBD dose levels. However, 
these dose levels were greater than the HCBD concentrations administered in our 
current dose response study and this may account for the differences in urinary levels of 
lipocalin-2. The usefulness and specificity of lipocalin-2 as a urinary marker for renal 
damage may be compromised by the fact that this protein is released by the liver in 
response to inflammation (Liu and Nilsen-Hamilton, 1995) and has been previously 
shown to be increased following CCl4-induced liver toxicity (Smyth et al., 2009b; 
Borkham-Kamphorst et al., 2013). 
Urinary β-HBA levels were significantly increased over controls at 10 mg/kg HCBD 
(3.3-fold) and remained elevated at all other HCBD dose levels, peaking at 90 mg/kg 
HCBD (31-fold increase, 
***
P<0.001) (Table 4.3). β-HBA is a ketone body which is 
produced in the liver, mainly from fatty acid metabolism. Increased levels of β-HBA 
have been previously reported in the urine of rats following administration of 100 
mg/kg HCBD (Berndt and Mehendale, 1979; Davis et al., 1980). Gartland et al, (1989) 
investigated the effect on β-HBA urinary levels following the administration of 3 
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nephrotoxicant agents, including HCBD. The increase in β-HBA levels was only 
observed after HCBD administration. In the present study, acetoacetate urinary levels 
were significantly increased over controls at 35 mg/kg HCBD and there appeared to be 
a dose-related increase (Table 4.3); acetoacetate is also a ketone body. Increased urinary 
levels of ketone bodies generally indicate a state of diabetic ketoacidosis. 
HCBD has also been previously shown to cause lactic aciduria. This may occur as a 
consequence of damage to the proximal tubules which may result in decreased 
reabsorption of lactic acid in this segment of the kidneys (Hohmann et al., 1974; 
Gartland et al., 1989). A study by Xu et al., (2008) revealed that administration of 
cisplatin and gentamicin also resulted in an increase in urinary levels of β-HBA and 
acetoacetate. The authors suggest that the lactic aciduria and ketonuria observed may be 
a consequence of a reduction in the number of functional tubule transporters in kidney 
cells rather than a perturbation of the metabolic pathway. We, therefore, hypothesise 
that the mechanism for ketonuria observed in this study, may be due to a HCBD-
induced reduction in the number of membrane transporters in the proximal tubule.  
Creatinine was the most sensitive of the traditional urinary markers of kidney injury. 
Urinary creatinine was significantly decreased compared to control rats at the highest 
HCBD dose level (90 mg/kg) (Table 4.3; 
***
P<0.001). In acute kidney injury, the 
glomerular filtration rate will be reduced, resulting in a decrease in the creatinine 
clearance and consequently, in reduced urinary creatinine levels (Mitch and Walser, 
1978). Decreased urinary creatinine has been previously reported following the 
administration of 10 mg/kg cisplatin to rodents (Bulacio and Torres, 2013).  
Urinary glucose levels were only significantly increased over control at 40 mg/kg 
HCBD (approximate 20-fold increase; 
***
P<0.001). Glucose is not normally found in 
urine so the presence of glucose suggests a reduced tubular function (Wolf et al., 2009; 
Swain et al., 2011). In a previous study investigating the effect of HCBD in female rats, 
urinary glucose was found to be significantly increased over control levels at 90 (218-
fold increase) and 135 mg/kg (210-fold increase) (Swain et al., 2011). Berndt et al., 
(1979) also reported increased urinary glucose levels following the administration of 
100 mg/kg HCBD to male Sprague-Dawley rats. 
Urinary clusterin was only significantly increased over controls at the highest dose level 
(90 mg/kg HCBD), whereas KIM-1 urinary levels were significantly increased over 
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controls at dose levels of 20 mg/kg HCBD (2.6- fold increase; 
**
P<0.01) and above 
(
***
P<0.001) (Table 4.3). Increased urinary levels of clusterin and KIM-1 were also 
reported by Swain and colleagues following HCBD-induced acute nephrotoxicity 
(Swain et al., 2011). Clusterin had a molecular weight of 76-80 kDa and has been 
described as having anti-apoptotic functions, however, the exact mechanism is still 
unknown (Rosenberg and Silkensen, 1995). Appearance of clusterin in the urine has 
been shown to be accompanied by renal damage (Dieterle et al., 2010).  
KIM-1 is predominantly found in proximal epithelial cells of the S3 segment and is 
considered to be involved in the phagocytosis of apoptotic cells in the renal tubular 
lumen (Ichimura et al., 2008). Increased urinary KIM-1 has been reported following 
exposure to several nephrotoxicants, including folic acid and cisplatin (Ichimura et al., 
2004; Vaidya et al., 2006). In a study by Vaidya et al. (2010) KIM-1 was shown to be 
increased in the urine as early as 3 hours after renal injury was induced suggesting it to 
be a sensitive marker.  
The first significant change in mean total protein levels in the urine was detected at 15 
mg/kg HCBD when an approximate 2-fold increase over controls was observed 
(
*
P<0.05). Proteinuria is often used as a marker of nephropathy as kidney injury may 
lead to renal failure resulting in increased protein levels in the urine (Shihabi et al., 
1991). Increased urinary total protein was previously reported following HCBD 
administration to rats (Berndt and Mehendale, 1979; Swain et al., 2011). 
Urinary albumin was 4.3-fold increased over controls at 20 mg/kg HCBD (
*
P<0.05) 
(Table 4.3). Urinary albumin is considered to be a marker of both proximal tubular 
function and glomerular integrity (Swain et al., 2011). Albumin that is filtered from the 
blood is almost completely reabsorbed by the proximal tubule (Lazzara and Deen, 
2007). Therefore, injury to the proximal tubules may result in albuminuria. Increased 
urinary albumin levels were reported by Swain and colleagues (2011) in a model of 
HCBD-induced renal damage. 
The results of the present dose response study suggest the most sensitive urinary 
biomarker of HCBD-induced injury to be β-HBA and GST Yb1 (significantly increased 
at 10 mg/kg HCBD), followed by α-GST (significantly increased at 20 mg/kg HCBD). 
At 10 mg/kg HCBD, GST Yb1 was 2-fold increased over control whereas the increase 
for α-GST was 4-fold. However, due to a great standard deviation in the groups the 
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increase in α-GST urinary levels was not enough to show statistical significance. 
Additionally, the results from GST Yb1 may be due to a cross reaction with α-GST as 
discussed previously, and therefore should be interpreted with caution. The changes in 
β-HBA levels are thought to be a HCBD-specific nephrotoxic effect and therefore may 
not be useful for evaluating any potential CCl4-induced nephrotoxicity in our future 
studies.  
Gene expression analysis was carried out on the kidney samples in this study (Table 
4.5). Changes to genes involved in xenobiotic metabolism and oxidative stress were 
seen at the lowest dose level. NQO1 mRNA expression showed the greatest fold change 
at 5 mg/kg HCBD which corresponded to a 6.4-fold increased compared to controls. 
NQO1 is an enzyme that is induced by oxidative stress and has been shown to be 
upregulated following the induction of renal toxicity (Nioi and Hayes, 2004, Zhu et al., 
2008). In a previously reported dose response study, NQO1 was also found to be 
significantly upregulated in the kidney following the administration of 90 and 135 
mg/kg HCBD to female Hanover-Wistar rats (Swain et al., 2011). The upregulation in 
NQO1 levels appears to be related to the mechanism of action for HCBD which 
involves the production of reactive oxygen species following activation by β-lyase 
(Scatena et al., 2007). GSTA3 and GSTM4 were significantly upregulated at 5 and 10 
mg/kg HCBD. In a previous study by Swain et al., (2011) in female rats, both GSTM4 
and GSTA3 mRNA levels were significantly upregulated following the administration 
of 90 mg/kg HCBD (3.7 and 2.5-fold respectively). 
In the oxidative stress functional category, the greatest change in gene expression in the 
kidney was noted for HMOX1. The first significant change was present at 5 mg/kg 
HCBD and there was evidence of a clear dose-related increase in mRNA levels. 
HMOX1 is located in the proximal and distal tubules of the rat kidney (da Silva et al., 
2001) and is involved in protecting the kidneys against oxidative stress. HMOXI also 
acts to degrade the heme derived from haemoglobin and cytochrome molecules 
resulting in the production of bilirubin which has antioxidant properties via the 
scavenging of reactive oxygen species (Abraham and Kappas, 2005). Previous studies 
have shown that the metabolite formed by cysteine β-lyase in the kidneys has the ability 
to interact with components of the inner mitochondrial membrane causing uncoupling 
of oxidative phosphorylation (Wallin et al., 1987). This leads to the generation of 
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reactive oxygen species which will be responsible for the increase in oxidative stress 
(Wallace, 1999). 
Changes in the expression of genes involved in the inflammation process were only 
present at the highest dose level (90 mg/kg HCBD) suggesting a lack of inflammatory 
response following HCBD administration. 
In this study, the most sensitive gene for HCBD-induced kidney injury was KIM-1; the 
expression of KIM-1 was significantly upregulated at 5 mg/kg HCBD (
*
P<0.05) and 
there was evidence of a dose-dependent increase. The greatest fold increase was also 
seen for KIM-1 expression and corresponded to a 423-fold increase over controls at the 
highest dose level (90 mg/kg HCBD). A previous study in male rats treated with 
different nephrotoxicant agents: chromate (S1-S2 segment specific), cephaloridine (S2 
segment specific) and HCBD (S3 segment specific), revealed significant upregulation of 
KIM-1 expression in toxin-treated rats (Chiusolo et al., 2010). 
Histopathological examination of the kidneys revealed the presence of HCBD 
treatment-related findings in the treated animals consistent with injury to the S3 
segment of the nephron (Table 4.6). Evidence of degeneration was present at 10 mg/kg 
HCBD; this was also the first dose level at which the urinary biomarkers measured were 
significantly increased over control (Table 4.3). At 10 mg/kg there was minimal 
degeneration of individual cells followed by increased severity of degenerative changes 
with increasing HCBD dose level. Degenerating cells showed an irregular outline, 
condensed cytoplasm with swollen mitochondria; the nuclear outline was also irregular 
and in some cells the nucleus was pyknotic. These observations are in agreement with 
the findings described in the literature for HCBD-induced tubular degeneration (Ishmael 
et al., 1982). This dose-related response was also apparent in the urinary biomarkers, for 
e.g., α-GST and β-HBA. Histopathologically, there was an increase in the number of 
hyaline droplets present in the convoluted tubules proximal to the S3 segment at 5 
mg/kg HCBD, and both the number of droplets and the number of animals affected 
appeared to increase with increasing dose level of HCBD. Therefore, hyaline droplet 
accumulation was detected at a lower dose level than the first signs of degeneration and 
also changes to the urinary biomarkers (10 mg/kg HCBD). However, KIM-1 gene 
expression was upregulated at 5 mg/kg. Hyaline droplet accumulation has been reported 
by several authors following HCBD administration (Bouthillier et al., 1991; Pahler et 
al., 1997; Cristofori et al., 2013). 
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Hyaline droplets are frequently observed in the proximal renal tubules of male rats 
(Swenberg, 1993). The development of these hyaline droplets is related to the presence 
of α-2µ globulin which is synthesised in the liver of the male rat, secreted into the 
plasma and filtered by the glomerulus and is subject to androgenic control (Roy et al., 
1966; Pahler et al., 1997; Hard, 2008; Swain et al., 2011). Approximately 50 % of the α-
2µ globulin that is present in the glomerular filtrate is reabsorbed in the proximal tubule 
and the remaining α-2µ globulin is excreted in the urine (Swenberg, 1993). This 
reabsorption occurs by endocytosis followed by hydrolytic digestion inside lysosomes 
(Swenberg, 1993). Accumulation of hyaline droplets is the first step in α-2µ globulin 
nephropathy (Cristofori et al., 2013). The lesion begins with individual cell necrosis and 
the formation of granular casts and may progress to renal tumour (Swenberg, 1993; 
Cristofori et al., 2013). HCBD has been shown to bind to α-2µ globulin, therefore, 
inhibiting its degradation in the lysosomes, which then leads to degeneration and cell 
necrosis (Lehman-McKeeman et al., 1990). 
In the current dose response study, we wished to evaluate a panel of urinary and gene 
expression biomarkers with regards to sensitivity. The purpose of this study was to 
identify the most sensitive kidney biomarkers. At higher dose levels, CCl4 is known to 
induce nephrotoxicity and the effect on the kidney after chronic dosing is not well 
documented, thus we wished to determine the most ideal and sensitive kidney 
biomarkers to use in our future studies so that we can rule out CCl4-induced 
nephrotoxicity. The results of the dose response study suggest that the most sensitive 
urinary biomarkers are α-GST and albumin (significantly increased at 20 mg/kg and 
displaying the greatest fold changes), followed by KIM-1. KIM-1 gene expression was 
upregulated at the lowest dose level suggesting this to be the most sensitive marker 
from invasive sample collection. 
In this Chapter, we chose 45 mg/kg as the dose level to use for our time course study 
since in the dose response study histopathological proximal tubular degeneration was 
present in animals treated with HCBD at this dose level. Histopathological examination 
of the livers revealed no changes consistent with HCBD-induced hepatotoxicity at any 
of the dose levels used in the dose response study. However, relative liver weights were 
significantly increased after administration of HCBD at 90 mg/kg (Figure 4.1 A) and 
serum ALT and GLDH were also significantly increased over control at the highest 
dose level (Figure 4.2).  
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In the time course study, 6 out of 60 animals, did not appear to respond to HCBD 
treatment and there was no evidence of injury to the proximal tubules, therefore, data 
from these animals was excluded from analysis. Mis-dosing of animals via the i.p. route 
has been previously documented and may account for a 11 to 20 % failure rate (Lewis et 
al., 1966).  
At autopsy, liver weights from HCBD-treated animals were significantly increased over 
controls from day 1 to day 4 post-dosing (Figure 4.4 A). Lock et al. (1982) reported a 
significant increase in the relative liver weight of HCBD-treated animals at 300 mg/kg 
within 24 hours of dosing, which was associated with an increase in the liver water 
content. However, Kuo and Hook (1983) described no change to liver weight following 
the administration of 25, 50 and 100 mg/kg HCBD. 
GLDH was the only serum enzyme to be significantly increased over controls (days 2 
and 3) (Figure 4.5 C) and histopathological examination of the liver revealed no 
structural changes. These results suggest the absence of a HCBD-induced injury to the 
liver.  
The same urinary biomarkers that were measured in the dose response study were 
evaluated in this time course study to record changes with time as renal proximal tubule 
injury is induced and recovery occurs (Table 4.9, Table 4.10). α-GST and GST Yb1 
appeared to be sensitive urinary markers (356.9- and 16.5-fold increased over controls 
respectively); peaking on day 1 post-dosing and remaining significantly elevated over 
concurrent controls up to day 4 post-dosing (Table 4.9). In another study by Gautier et 
al., (2010), urinary excretion of α-GST was increased in animals dosed at 3 mg/kg 
cisplatin on days 3 and 5 after dosing and correlated well with the histopathology data 
showing moderate or marked necrosis of the S3 segment. They also found α-GST to be 
increased over controls to a greater extent and at earlier time points than the other 
urinary markers tested (serum creatinine, urea, NAG and total protein). Kharasch et al. 
(1997) also described α-GST as the most sensitive urinary marker of proximal tubular 
cell necrosis. In the present study, there was a good degree of correlation between 
urinary α-GST and the histopathology evidence of HCBD-induced nephrotoxicity. 
Maximum levels of α-GST were present on day 1 post-dosing representing degeneration 
of the tubules. 
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Urinary osteopontin was significantly raised over control levels at days 2, 3, 4, 5 and 7 
post-dosing (Table 4.9). The fold increase was greatest on day 4 (7-fold) which suggests 
that osteopontin is a marker of epithelial regeneration since on day 4 post-dosing all 
animals showed very marked evidence of regeneration. However, the fold changes in 
this study revealed osteopontin to be less sensitive than KIM-1 as a marker of 
regeneration. In fact, urinary KIM-1 peaked at day 4 post-dosing at which time point it 
was 84-fold increased over control (Table 4.9). Also, in the previous dose response 
study, no changes were recorded for urinary osteopontin at 24 hours post-dosing. This 
fact adds further evidence that osteopontin is likely to be a marker of regeneration rather 
than degeneration.  
In a study carried out by Pinches et al., (2012) male and female rats were administered a 
single dose of cisplatin and increased urinary osteopontin was observed on day 5 post-
dosing. Osteopontin is expressed in the healthy kidney; reports regarding its localisation 
are contradictory with some authors reporting that it is normally present at the apical 
surface of cells in the distal nephron (Verhulst et al., 2002) and others reporting 
osteopontin to be present in the proximal tubules (Mark et al., 1988). Osteopontin has 
been shown to be expressed by macrophages. It is involved in cellular functions such as 
cell adhesion, migration and regulation of inflammatory responses of macrophages, by 
promoting their migration and retention at sites of acute and chronic inflammation 
(Lund et al., 2009). However, in the present study histopathological examination 
revealed injury predominantly to the S3 segment of the proximal tubules and therefore, 
we suggest that the increase in urinary osteopontin is likely to be mainly due to release 
from proximal tubular cells. The association of osteopontin with regeneration of tubular 
cells has been previously described by Xie et al. (2001a) following the administration of 
gentamicin. The mechanism is not yet fully described but it appears that osteopontin has 
the ability to interact with CD44 which is a widely distributed cell receptor and is 
thought to interact with hyaluronic acid. By interacting with CD44, osteopontin blocks 
the binding site for hyaluronic acid and therefore blocks its inhibition of cell growth and 
differentiation (Xie et al., 2001a). Persy and colleagues (1999) also reported an 
association between osteopontin staining in the proximal tubules and evidence of 
morphologic regeneration. During the period of tubular injury the authors observed loss 
of brush border of tubular cells. During regeneration, however, the tubular basement 
membrane became lined with a flat epithelium and there was restoration of the brush 
border by tubular cells (Persy et al., 1999). 
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Lipocalin-2 excretion in the urine was not significantly increased following treatment 
with HCBD at 45 mg/kg at any time point (Table 4.9). However, analysis of the gene 
expression data, revealed LCN-2 mRNA in the kidney to be significantly upregulated 
on days 2 to 5, 7 and 14 post-dosing (Table 4.11). In the dose response study in this 
Chapter there was no evidence of an effect on the urinary lipocalin-2 levels with HCBD 
administration. However, others have reported significant increases to urinary lipocalin-
2 in response to kidney injury. Swain et al., (2011) reported increases to urinary 
lipocalin-2, 24 hours after a single dose of 120 mg/kg HCBD to female rats, whereas in 
a study in mice (Mishra et al., 2004) urinary levels of lipocalin-2 increased with time 
following the administration of 20 mg/kg and were maximal at 48 hours post-dosing. 
In the dose response study described in this Chapter, urinary creatinine was significantly 
increased over control at 10 mg/kg HCBD and then at dose levels above 20 mg/kg 
HCBD urinary creatinine appeared to decrease with increasing dose level (Table 4.3). In 
this time course study there was no effect on urinary creatinine levels suggesting this to 
be an insensitive unreliable marker of nephrotoxicity.  
Glucose levels in the urine were significantly increased over controls at day 1 and 
remained elevated until day 4 (Table 4.9). On day 1 post-dosing the fold increase over 
concurrent controls was approximately 30, but maximal levels were reached on day 2 
post-dosing (170.40 µmol/c.p. compared to 3.33 µmol/c.p. for control animals, which 
corresponded to a 51.2-fold increase). Pinches et al., (2012) also reported significant 
increases in urinary glucose following the administration of cisplatin and found good 
correlation between increased levels of glucose in the urine and the degree of proximal 
tubular necrosis. However, in the dose response study, there was no evidence of an 
HCBD effect on glucose levels in the urine at dose levels below 45 mg/kg (Table 4.3). 
Therefore, it could be suggested that the increase in urinary glucose may be the result of 
loss of functional capacity of the kidneys, as a result of more severe injury.  
Urinary clusterin levels were highest on day 4 and 5 post-dosing. At these time points 
mean levels were 6.5- and 3.8-fold increased over concurrent controls (Table 4.10). 
Another research group has reported increases in urinary clusterin in Hanover-Wistar 
rats at days 3 and 5 following cisplatin-induced nephrotoxicity (Gautier et al., 2010). 
The temporal pattern for clusterin may therefore reflect its antiapoptotic properties 
(Rosenberg and Silkensen, 1995). It has been suggested that clusterin may be induced to 
promote cell interactions since one of the first steps in the apoptotic pathway is loss of 
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cell contacts (Rosenberg and Silkensen, 1995). Hidaka et al. (2002) reported that 
clusterin reaches maximum concentration 2 days after an ischemic insult. The S3 
segment is the portion of the nephron most susceptible to ischemia, and the authors of 
this study suggested that the majority of the clusterin detected in the urine comes from 
the cellular debris in the S3 segment of the proximal tubule. Dieterle et al., (2010) have 
also described a good degree of correlation between urinary clusterin levels and 
proximal tubular injury. In the present study, we also consider the source of clusterin to 
be the proximal renal tubular epithelium. 
KIM-1 urinary excretion was significantly increased on day 1 post-dosing, with a 7-fold 
increase over controls (
***
P<0.001) and mean levels remained significantly elevated up 
to day 7 post-dosing (Table 4.10). However, the greatest fold increase was noted on day 
4 post-dosing (83.8-fold; 
***
P<0.001), which was the time point when histopathology 
examination revealed very marked evidence of regeneration in 6 out of 6 HCBD-treated 
animals. Swain et al., (2011) dosed female rats with 120 mg/kg HCBD and sampled at 
various time points. Urinary KIM-1 was significantly increased over controls on day 1 
post-dosing (7-fold increase) but the greatest fold change was seen on day 4 following 
HCBD treatment when a 33-fold increase was recorded. In a study by Vaidya et al., 
(2010) urinary KIM-1 levels were increased as early as 3 hours in a model of kidney 
tubular damage. These studies suggest KIM-1 to be a sensitive urinary marker to both 
tubular degeneration and the regeneration/recovery period. 
Mean albumin levels in the urine were significantly increased over controls at day 1 
(156-fold) and remained elevated until day 5, respectively (Table 4.10). This suggests 
albumin is a sensitive and specific marker for detection of early stages of renal injury 
and this correlated well with the histopathology showing injury at these time points. 
Gene expression analysis revealed upregulation of several genes involved in the 
metabolism of xenobiotics and oxidative stress, particularly on day 1 post-dosing (Table 
4.11). These include the increased expression of NQO1 (detoxification gene). NQO1 is 
a gene that encodes a cytosolic flavoenzyme which plays a role in the mechanism of 
defence by preventing the production of reactive oxygen species (Ross, 2004; Vasiliou 
et al., 2006). The expression of the NQO1 is increased by oxidative stress (Nioi and 
Hayes, 2004) and it has been detected at high concentrations in the rat liver (Sharkis and 
Swenson, 1989). NQO1 protects the kidneys from both oxidative and inflammatory 
stress (Bolati et al., 2013). The mechanism for HCBD-induced injury involves the 
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formation of reactive thiols after activation by the enzyme β-lyase, thus causing 
oxidative stress (Scatena et al., 2007). In experiment 1 (dose response study) levels of 
NQO1 were upregulated at an HCBD dose level of 5 mg/kg and NQO1 has been 
previously reported to be upregulated following 1,2-dithiole-3-thione-induced renal 
injury (Zhu et al., 2008). NQO1 appears to be a sensitive marker for early signs of 
kidney injury. EPHX1 expression was maximal on day 1 post-dosing in the current time 
course study (14-fold upregulated when compared to concurrent controls). This result 
compares to the previous dose response study, where a 10-fold upregulation was noted 
over control animals. Epoxide hydrolases are predominantly found in the liver, kidney 
and testes. Epoxides can be formed by action of cytochrome P-450 and have the ability 
to bind to macromolecules such as DNA, RNA and proteins and are thought to be 
responsible to the carcinogenic properties of many compounds. Epoxide hydrolases act 
by converting the epoxides into more excretable forms (Archer, 1997). 
Cytochrome P450 2C was downregulated from day 1 to day 5 post-dosing; this gene 
was also downregulated in experiment 1. Zordoki et al., (2011) found the expression of 
cytochrome P-450 2C to be decreased in the male rat kidney following the induction of 
injury by doxorubicin. Doxorubicin is known to cause nephrotoxicity by increasing 
capillary permeability and glomerular atrophy (Zordoky et al., 2011).  
HMOX1 was increased in expression by 48-fold on day 1 and was significantly 
increased until day 4 post-dosing. HMOX1 is involved in protecting the kidneys against 
oxidative stress by the production of bilirubin which has anti-inflammatory properties 
(Abraham and Kappas, 2005). HMOX1 has been previously reported to be upregulated 
following the induction of kidney injury (Nath, 2006; Takahashi et al., 2004). In a study 
by Rokushima et al. (2008) cephaloridine was administered to male rats to induce 
kidney injury. This group found HMOX1 to be upregulated at 24 hours following 
treatment and the authors suggested HMOX1 as a potential nephrotoxicity biomarker. 
In the dose response study described earlier in this Chapter, HMOX1 expression was 
upregulated at a dose level of 5 mg/kg HCBD and above, but this upregulation was only 
statistically significant at 30 and 90 mg/kg HCBD. Other genes in this category for 
which mRNA expression was upregulated include GSR and TXNRD1. Overall, these 
changes reflect the mechanism for HCBD-induced injury. 
 188 
 
Lipocalin-2 mRNA levels (functional category of inflammation) were upregulated from 
day 2 to 5, and on day 7 and 14 post-dosing. However, no correlation was apparent with 
urinary biomarker levels. 
In the category of regeneration and repair, upregulation of gene transcription was seen 
for all genes, except GPNMB, as early as day 1 post-dosing. This preceded the first 
pathological sign of regeneration which were only noted on day 2 post-dosing and were 
maximal at day 4. KIM-1 mRNA expression was increased from day 1 to 5 and on day 
7 and 10, and was maximal on day 3 post-dosing. This correlated with the urinary 
changes recorded for KIM-1 for which peak levels were seen at day 4, but remained 
significantly increased up to and including day 7 post-dosing. It appeared that the 
upregulation seen in mRNA levels occurred before the highest urinary concentration 
was recorded.  
In the HCBD studies in this Chapter, we were able to characterise a wide panel of serum 
and urinary markers for injury to the proximal tubule of the kidneys. The changes in 
biomarker levels were correlated with histopathological evidence of kidney toxicity. In 
our CCl4-induced hepatic injury studies we are aware that CCl4 also causes 
nephrotoxicity at higher dose levels. Therefore, we need to be able to detect even very 
low degrees of kidney injury if we are to have confidence that any urinary metabolite 
markers we identify are a result of hepatic injury and not of both liver and kidney 
toxicity. The combined interpretation of the data collected from both the dose response 
and time course study has revealed α-GST and albumin to be the most sensitive urinary 
biomarkers followed by KIM-1. However, histological evidence of hyaline droplet 
formation was seen even before changes to urinary markers were reported, at a dose 
level of 5 mg/kg HCBD. At this dose level gene expression data was more sensitive 
than any of the urinary markers, however, this data is collected after autopsy and 
therefore they are not non-invasive markers. 
With regards to temporal changes following acute injury it was shown that α-GST, 
albumin, KIM-1, glucose, clusterin and osteopontin may be reliable markers for 
proximal tubular injury, degeneration and regeneration to normal function. In terms of 
gene expression data, NQO1 and HMOX1 showed upregulation in comparison to the 
concurrent controls and this was associated with proximal tubular injury whereas, KIM-
1 and ANXA7 expression coincided with evidence of proximal tubular regeneration. 
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These markers will be of great use in our future CCl4 studies and will be used in 
Chapters 5, 6 and 7. 
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CHAPTER FIVE 
Studies to determine the change in urinary metabolites with increasing age of the 
male rat; the age at which sexual maturity is reached and comparison of 
metabolomic changes to the urine following CCl4-induced hepatic injury in the 
pre- and post-sexually mature rat 
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Chapter 5  
5.1 Introduction 
In our previous liver studies in Chapter 3, we used animals approximately 7 weeks old 
and consequently developed our hepatic model in animals of this age. However, a 
number of physiological factors and conditions are known to have an effect on 
hepatocyte enzyme induction such as the hormonal status, gender, age, nutritional status 
and infection (Bollard et al., 2005; Maronpot et al., 2010). Age-related differences in 
susceptibility to drugs and toxicants have been proposed to be due to either 
toxicokinetic or toxicodynamic processes. This includes differences in absorption, 
distribution, biotransformation and excretion of xenobiotics, as well as differences in 
the sensitivity of the affected tissues (Klaassen, 1972; Klaassen, 1973; Birnbaum, 
1991). For example, it has been previously reported that the rat liver has increased 
susceptibility to ethanol toxicity as the animals get older and also that the kidneys from 
old animals are more sensitive to ischemia than the kidneys from younger animals 
(Miura et al., 1987; Rikans et al., 1999). Therefore, the age of the animals used in our 
studies should be carefully considered if these factors are to be taken into account. CCl4 
is metabolised by cytochrome P-450 to the trichloromethyl free radical and if this step is 
affected by age the induction of hepatic injury will also be affected. 
Previous investigative studies have focused on the hepatic expression and activity of 
cytochrome P-450 enzymes, which in turn is dependent on the development of sexual 
maturity. In this Chapter we focused on determining the age at which male Hanover-
Wistar rats become sexually mature. This information was then used in a comparative 
study of the effects of a single dose of CCl4 at 1.2 mL/kg, in 7 week old rats (pre-
maturity) and in 13 week old rats (post-maturity).  
As mentioned above, the hormonal status of the animal is thought to have an effect on 
enzyme induction (Marshall and McLean, 1969; Waxman et al., 1985). The animals we 
used in previous studies were 7 weeks old which is likely to be prior to sexual maturity 
of the rat. When the male rat becomes sexually mature and thus fully fertile, there will 
be a dramatic change to the hormone levels, in particular to testosterone levels 
(Ghanadian et al., 1975; Fujita et al., 1990; Chen et al., 1994). A change in sexual 
hormone levels is likely to result in changes to the urinary metabolome. 
 192 
 
Consequently, in this Chapter we conducted a series of experiments investigating the 
development of sexual maturity in the male rat, and changes to the urine metabolite 
profile as the animal ages. Additionally, we determined if animals both pre- and post-
sexual maturity have different urinary metabolite profiles following the induction of 
CCl4-induced hepatic injury.  
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5.2 Animal experimental design 
In this Chapter, 3 animal studies were carried out: a growth curve study investigating 
metabolite changes in the rat urine with age, a sexual maturity study, and a CCl4 
comparative study in young and older fertile animals.  
5.2.1 Experiment 1: Growth curve study 
Twenty male Hanover-Wistar rats (mean body weight 48.0 ± 3.46 g) at 22 days of age 
were divided into groups of 5 in communal cages with free access to water and diet ad 
libitum. Ten animals were kept in the communal cages throughout the whole study and 
weighed 3 times a week for a period of 10 weeks. The remaining 10 animals were 
weighed 3 times a week and metaboled for 24 hour urine collection every two weeks at 
26, 40, 54, 68, 84 and 91 days of age with access to water but not diet.  
5.2.2 Experiment 2: Sexual maturity study 
Thirty six male Hanover-Wistar rats (mean body weight 53.93 ± 6.97 g) were housed in 
groups of 6 animals. Animals were weighed 3 times a week and autopsied at 24, 33, 52, 
63, 77 and 90 days. At autopsy, testes and epididymides were removed and taken into 
Bouin’s fixative and processed as described in Section 2.8. 
5.2.3 Experiment 3: Studies comparing the urinary metabolome following 
CCl4–induced hepatic toxicity in animals at 7 and 13 weeks of age  
The toxicological effects of a single CCl4 administration were investigated in the male 
Hanover-Wistar rat at 7 weeks (pre-sexual maturity) and 13 weeks (post-sexual 
maturity) of age. 
For the 7 week old study, 20 male Hanover-Wistar rats (mean body weight 221.7 ± 12.1 
g) were divided into 2 groups (n=10) and dosed with CCl4 by gavage at 0 (controls) and 
1.2 mL/kg. Control animals were dosed with equivalent volumes of corn oil. After 
dosing, animals were returned to their communal cages for 6 hours with access to water 
and food ad libitum. At 6 hours post-dosing they were placed in individual metabolism 
cages for the collection of 18 hour urine samples (6 to 24 hours post-dosing). While in 
the metabolism cages animals had access to water but not diet. 
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A second group of 20 animals at 13 weeks of age were dosed with CCl4 at 0 (controls) 
and 1.2 mL/kg. Immediately after dosing, animals (mean body weight 358.6 ± 25.8 g) 
were placed in metabolism cages for the collection of 24 hour urine samples.  
For both groups of animals urine samples were collected over ice and stored at -80 ºC 
for future analysis. All animals were weighed before dosing, before being placed in 
metabolism cages and at 24 hours post-dosing, just prior to autopsy.  
At autopsy (24 hours after dosing) blood was taken for the preparation of serum which 
was stored at -80 ºC until analysis. The liver and kidneys were removed and placed in 
10.5% (v/v) phosphate buffered formalin fixative and processed as described in Section 
2.8.  
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5.3 Growth curve study 
5.3.1  Body weights 
Figure 5.1 shows the growth curve of male Hanover-Wistar rats between 3 and 13 
weeks of age. Both groups of animals (those in communal cages and those metaboled at 
regular intervals) gained weight at a steady rate. Rats in the group which were 
metaboled every 2 weeks lost weight during the 24 hours in metabolism cages (arrows 
in Figure 5.1 indicate the time points). However, the animals regained this weight 
shortly after return to communal cages and the overall rate of weight gain was not 
affected. By the end of the 10 week period both groups of animals had similar body 
weights (368.68 g and 348.77 g for control and metaboled animals, respectively). 
 
Figure 5.1 Increase in body weight from 3 to 13 weeks of age for Hanover-Wistar rats. Animals (   ) 
were placed in metabolism cages for 24 hours on 6 occasions (indicated by arrows) and at all other times 
housed in communal cages as described in Section 5.2.1. Animals represented by (    ) were housed in 
communal cages for the whole study. Values are the means with SD indicated by vertical bars of 10 
animals per group. 
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5.3.2 Urine output and water consumption for animals in metabolism 
cages 
Mean urine output was recorded hourly during each 24 hour period in the metabolism 
cages (Table 5.1). 
Great variation, as shown by the large standard deviations, was noted between the urine 
volume produced by individual animals and this was consistent throughout the study. 
The same was observed for water consumption during the same period. There was a 
tendency for water consumption and urine production to increase with age up until 68 
and 84 days old. 
Table 5.1 Urine output and water consumption in male Hanover-Wistar rats during a 24 hour 
period in metabolism cages at different ages. Animals were placed in metabolism cages for 24 hours on 
6 occasions (26, 40, 54, 68, 84 and 91 days of age) and at all other times housed in communal cages as 
described in Section 5.2.1. Urine production and water consumption were measured every hour, starting 
at 12.00 h. Values are the means and SD of 10 animals per group. 
 
Age 
(days) 
Mean total urine  
volume (SD) over 24 h (mL) 
Mean total water consumption 
(SD) over 24 h (mL) 
26 4.45 (1.97) 8.72 (9.78) 
40 12.45 (3.04) 10.55 (4.05) 
54 17.06 (4.51) 14.16 (6.06) 
68 20.65 (5.40) 12.25 (5.21) 
84 19.61 (5.69) 15.34 (5.62) 
91 18.96 (7.99) 13.11 (7.43) 
 
5.3.3 Urine clinical chemistry 
Urine samples collected during this study were analysed for levels of kidney biomarkers 
to determine control levels as the animals aged. 
Levels of urinary α-GST were significantly increased between 26 and 40 days old 
(
***
P<0.001), however, there was a very dramatic increase between 54 and 68 days of 
age (Figure 5.2 A). At 68 days of age the mean value was 910.50 ng/c.p. compared to 
56.06 ng/c.p. for 54 day old rats, representing an approximate 16-fold increase 
(
***P<0.001). After 68 days, levels decreased slightly but α-GST at 91 days remained 
over 50-fold greater than urinary levels in 26 days old rats. 
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Mean urinary GST Yb1 followed the same trend as α-GST. GST Yb1 increased slightly 
with age in animals up to 54 days old; however, at 68 days old there was a dramatic 
increase followed by a plateau at 84 and 91 days old. Values for GST Yb1 were 16.41 
and 82.24 ng/c.p. for animals at 54 and 68 days of age respectively (5-fold increase; 
***
P<0.001) (Figure 5.2 B).  
Mean KIM-1 urinary values were significantly increased in 40 and 54 day old rats 
compared to the respective previous time points (
***
P<0.001) (Table 5.2). The highest 
measurement was 13.79 ng/c.p. for animals at 54 days old. After day 54, urinary KIM-1 
levels appeared to decrease slightly, however, this decrease was not statistically 
significant. Microalbumin (MALB) and osteopontin both appeared to follow the same 
trend as KIM-1 and both peaked at 54 days into the study and then showed a decrease 
with age. 
RPA1 and clusterin increased as the animals aged. At 91 days the mean urinary RPA1 
value was almost 6-fold greater than at 26 days of age (41.81 ng/c.p. and 7.63 ng/c.p. 
respectively), whereas clusterin was approximately 5-fold increased in the urine of rats 
at 91 days old compared to at 26 days old (Table 5.2).  
Urinary NAG and lipocalin-2 increased with increasing age and reached maximum 
levels at 68 days old after which the levels stabilised (Table 5.2). At 68 days mean 
values were 206.30 mU/c.p. and 4503.31 ng/c.p. for NAG and lipocalin-2, respectively. 
Creatinine was also measured in the urine of rats during this study. Mean values 
increased steadily with age and at 91 days urinary creatinine was 8.6-fold greater than at 
26 days. However, values were only statistically significant at 40, 54 and 68 days (Table 
5.2).  
Total protein concentration followed the same trend as α-GST and GST Yb1 (Table 
5.2). Mean values increased slightly up to day 54, but a dramatic increase was seen at 
68 days. At 84 and 91 days of age a slight decrease was observed. Glucose levels 
increased with age and peaked in the urine of 91 days old animals. 
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Figure 5.2 Urinary α-GST (A) and GST Yb1 (B) for male Hanover-Wistar rats at different ages. 
Animals were placed in metabolism cages for 24 hour urine collection on 6 occasions (26, 40, 54, 68, 84 
and 91 days of age) and at all other times housed in communal cages as described in Section 5.2.1 Assays 
were carried out according to the methods described in Section 2.7. Values are means with SD indicated 
by vertical bars of 10 animals per group. Values that differ significantly from previous time point by 
Students’ t-test are shown: ***P<0.001. 
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Table 5.2 Urinary clinical chemistry parameters for male Hanover-Wistar rats at different ages. 
Animals were placed in metabolism cages for 24 hour urine collection on 6 occasions (26, 40, 54, 68, 84 
and 91 days of age) and at all other times housed in communal cages as described in Section 5.2.1. 
Assays were carried out according to the methods described in Section 2.7. Values are means and SD of 
10 animals per group. Values that differ significantly from previous time by Students’ t-test are shown: 
*
P<0.05;
 ***
P<0.001. 
 
KIM-1: kidney
 
injury molecule-1; MALB: microalbumin; RPA-1: renal papillary antigen-1; NAG: NAG: 
N-acetyl-D-glucosamine.  
5.3.4 Testosterone levels in urine 
Testosterone levels were measured in the urine of rats at 26, 40, 54, 68, 84 and 91 days 
of age (Figure 5.3). Testosterone is a measure of sexual maturity (Lee et al., 1975). 
Mean testosterone values at each time point are shown in Figure 5.3. Between days 26 
and 54 there was a modest increase in testosterone values (1.89 to 5.93 ng/c.p. 
respectively) with a significant increase between days 26 and 40 (
***
P<0.001). 
However, between days 54 and 68 there was an approximate 6-fold increase. Values 
were further increased between days 68 and 84 (a fold difference of 1.44-fold) to a 
mean urinary testosterone level of 49.95 ng/c.p. At 91 days old there was a slight non-
significant decrease to 45.99 ng/c.p. 
Urinary 
parameters 
Days of age 
26 40 54 68 84 91 
KIM-1 
(ng/c.p.) 
3.86 
(1.90) 
9.82
***
 
(1.84) 
13.79
***
 
(3.05) 
12.65 
(3.10) 
11.05 
(2.59) 
10.66 
(2.76) 
MALB 
(mg/c.p.) 
0.09 
(0.05) 
0.25
***
 
(0.11) 
0.35
***
 
(0.13) 
0.26
*
 
(0.11) 
0.23 
(0.08) 
0.22 
(0.08) 
Osteopontin 
(ng/c.p.) 
21.62 
(12.24) 
54.95
*** 
(15.33) 
73.01
***
 
(22.07) 
53.21
* 
(13.03) 
41.48
*
 
(9.41) 
42.37 
(8.28) 
RPA1 
(ng/c.p.) 
7.63 
(4.29) 
19.66
***
 
(4.96) 
26.25
***
 
(7.46) 
31.97
*
 
(10.75) 
40.96
**
 
(12.36) 
41.81 
(12.08) 
Clusterin 
(ng/c.p.) 
24.13 
(12.78) 
63.19
*** 
(17.84) 
83.88
** 
(24.91) 
109.8
*
 
(41.52) 
126.14 
(59.79) 
126.21
 
 (53.19) 
NAG 
(mU/c.p.) 
46.70 
(20.34) 
123.30
***
 
 (23.26) 
166.50
*** 
 (19.17) 
206.30
* 
 (49.78) 
205.10 
 (36.66) 
205.00 
 (51.44) 
Lipocalin-2 
(ng/c.p.) 
1184.93  
(536.19) 
3204.46
***
 
(996.43) 
4228.15
** 
(1304.66) 
4503.31 
(1099.70) 
4382.22 
(1591.45) 
4374.74 
(2029.94) 
Creatinine 
(µmol/c.p.) 
10.60 
(4.38) 
27.20
***
 
(3.36) 
37.70
***
 
(5.27) 
78.60
***
 
(16.11) 
88.90 
(14.81) 
91.30 
(18.82) 
Total protein 
(mg/c.p.) 
0.69 
(0.33) 
1.79
***
 
(0.45) 
2.46
***
 
(0.62) 
11.60
***
 
(2.97) 
11.14 
(4.39) 
10.43 
(4.88) 
Glucose 
(µmol/c.p.) 
1.60 
(0.84) 
4.00
***
 
(1.05) 
5.60
***
 
(1.26) 
7.20
*
 
(1.99) 
7.00 
(1.15) 
7.20 
(1.87) 
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Figure 5.3 Urinary testosterone for male Hanover-Wistar rats at different ages. Animals were placed 
in metabolism cages for 24 hour urine collection on 6 occasions (26, 40, 54, 68, 84 and 91 days of age) 
and at all other times housed in communal cages as described in Section 5.2.1. Testosterone assay was 
carried out according to the methods described in Section 2.7. Values are means with SD indicated by 
vertical bars of 10 animals per group. Values that differ significantly from previous time point by 
Students’ t-test are shown: **P<0.01; ***P<0.001. 
5.3.5 1D 1H NMR spectrometry  
Urine samples were collected from 10 male Hanover-Wistar rats at 26, 40, 54, 68, 84 
and 91 days of age and prepared as described in Section 2.10 for metabolite analysis by 
1D 
1
H NMR. 
A PCA scores plot for these samples is shown in Figure 5.4 A. Outliers in the scores 
PCA plot and outliers in individual OPLS-DA models (Figure 5.5) were excluded from 
analysis.  
There was a great degree of overlap between samples from animals at 26, 40, 54, 68 and 
91 days of age, all located on the left hand side of the plot. However, a separate sample 
cluster was visible on the right upper quadrant of the scores plot. These spots 
represented urine samples collected from 84 day old rats. This PCA analysis suggests 
the presence of age-related urinary metabolite differences in rats at 84 days old 
compared to the other time points. 
The separation of samples from rats at 84 days old from those at other time points was 
further confirmed by OPLS analysis (Figure 5.4 B). The OPLS demonstrated an age-
dependent shift of samples along the discriminating component t[1] to the right hand 
*** ** 
*** 
** 
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side of the scores plot. All samples appeared to follow the shift with time apart from 
urine samples collected from animals at 84 days of age which occupied a different 
position on the scores plot.  
A 
 
 
B 
 
 
Figure 5.4 PCA scores plot (A) and OPLS scores plot (B) from models derived from 1D 
1
H NMR 
spectral data of urine samples from male Hanover-Wistar rats at different ages. Animals were 
placed in metabolism cages for 24 hour urine collection on 6 occasions (26, 40, 54, 68, 84 and 91 days of 
age) as described in Section 5.2.1. Each spot in the score plot represents one urine sample. (A) R
2
X (cum) 
= 0.961, Q
2
 (cum) = 0.834; (B) R
2
X (cum) = 0.821, Q
2
 = 0.887. Arrow represents direction of movement. 
Circled spots correspond to urine samples collected from 84 days old rats. 
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To further investigate the differences between urine samples collected from animals at 
consecutive time points, individual OLPS-DA models were performed based on the 
urine 1D 
1
H NMR spectra of animals at 26 and 40, 40 and 54, 54 and 68, 68 and 84, and 
84 and 91 days old rats (Figure 5.5). In the OPLS-DA scores plot, separation across the 
discriminating component t[1] relates to changes in metabolite levels between groups 
due to increasing age of the animals, whereas separation along the orthogonal 
component relates to changes in metabolite levels within groups, i.e., that are not the 
result of age differences. Clear cluster separation was observed along the discriminating 
component t[1] between rats belonging to each 2 consecutive age groups showing a 
change in metabolites with age. 
However, since Figure 5.4 B revealed that urine samples from rats at 84 days old were 
very different to those at the other time points, further investigation was required to 
attempt to identify some of the metabolites responsible for this difference. The OPLS-
DA scores plots for samples at 68 and 84 days of age (Figure 5.5 D) and 84 and 91 days 
of age (Figure 5.5 E) show a good separation between samples. The corresponding 
loadings plots are shown in Figure 5.6 A and B. The chemical shifts that are labelled in 
the loadings plots were selected based on the combined interpretation of the S-plot and 
the VIP plot (data not shown) and thought to contribute the most to the separation of 
samples at 84 days from all other samples. Integrated regions corresponding to these 
chemical shifts were statistically analysed using a Student’s t-test as described in 
Section 2.11. Chemical shifts and spectral regions were then identified by visual 
analysis of spectral data, and by comparison with chemical shifts and signal multiplicity 
described in previously published literature.  
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Figure 5.5 Scores plots from OPLS-DA models derived from 1D 
1
H NMR spectral data of urine 
samples from male Hanover-Wistar rats at different ages. Animals were placed in metabolism cages 
for 24 hour urine collection on 6 occasions (26, 40, 54, 68, 84 and 91 days of age) as described in Section 
5.2.1. (A) 26 and 40 days; (B) 40 and 54 days; (C) 54 and 68 days; (D) 68 and 84 days; (D) and 84 and 91 
days. Each spot in the score plot represents one urine sample. 
 
A B 
C D 
E 
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A 
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Figure 5.6 OPLS-DA loadings plots from OPLS-DA models derived from 1D 
1
H NMR spectral data 
of urine samples from male Hanover-Wistar rats at different ages. Animals were placed in 
metabolism cages for 24 hour urine collection on 6 occasions (26, 40, 54, 68, 84 and 91 days of age) as 
described in Section 5.2.1. (A) 68 and 84 days (R
2
X (cum) = 0.949, Q
2
 = 0.958); (B) and 84 and 91 days 
(R
2
X (cum) = 0.877, Q
2
 = 0.858). Each spot in the loadings plot represents a NMR variable labelled as 
chemical shift in ppm.  
Identification of the chemical shifts and statistical testing of integral values at all time 
points revealed the main metabolites showing changes with increasing age of the rat 
(Table 5.3). Rats at 40 days of age excreted significantly greater levels of creatinine, 
creatine, 2-oxoglutarate, citrate and succinate than at 26 days old. Rats at 54 days of age 
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excreted greater levels of creatinine and 2-oxoglutarate compared to 40 days old 
animals. However, spectral signals for citrate, succinate, creatine and taurine were 
decreased in the urines at this time point and the decrease for creatine was statistically 
significant. Animals at 68 days of age excreted significantly greater levels of creatinine 
and taurine compared to 54 days old rats. However, succinate, citrate, 2-oxoglutarate 
and creatine were decreased with respect to the previous time point.  
From the analysis of the loadings plots for 68 and 84 and 84 and 91 days in Figure 5.6 
A and B, it appeared that, at 84 days of age, most of the chemical shifts showed positive 
loadings for PC1, whereas most of the labelled chemical shifts identified in the loadings 
plot in Figure 5.6 B (84 and 91 days) showed negative loadings for PC1. This 
demonstrates that the integral intensities of most chemical shift regions were increased 
in the urine samples from 84 days old rats in comparison to younger animals (68 days 
old) and older animals (91 days old). At 84 days it would appear that most metabolites 
were present in the highest concentration in the rat urine. 
Table 5.3 OPLS-DA detected 1D 
1
H NMR chemical shifts responsible for the separation of 1D 
1
H 
NMR derived spectra from the urine of male Hanover-Wistar rats at different ages. Animals were 
placed in metabolism cages for 24 hour urine collection on 6 occasions (26, 40, 54, 68, 84 and 91 days of 
age) as described in Section 5.2.1. Chemical shifts were statistically compared by means of a Students’ t-
test. Values that differ significantly from the previous time point are shown 
*
P<0.05; 
**
P<0.01; 
***
P<0.001.  
  
Change in metabolite concentration with age in days 
(increase (+); decrease (-)) 
Chemical 
shift (δ), 
multiplicity 
Endogenous 
metabolites 
40 54 68 84 91  
8.46-8.50 (s) formate - + - - + 
7.70-7.74 (d) hippurate - + + - + 
7.62-7.66 (t) hippurate + + + - + 
7.54-7.58 (t) hippurate  + + + - + 
4.06-4.10 (s) creatinine +
** 
+ +
**
 +
***
 -
***
 
3.98-4.02 (d) hippurate + - - + - 
3.94-3.98 (s) creatine +
*
 -
*
 - +
**
 -
**
 
3.42-3.46 (t) taurine + + +
***
 +
*
 -
**
 
3.26-3.30 (t) taurine - - +
***
 +
*
 -
*
 
3.06-3.10 (s) creatinine +
**
 + +
**
 +
***
 -
***
 
2.98-3.02 (t) 2-oxoglutarate +
**
 + - +
**
 -
**
 
2.70-2.74 (d) citrate +
**
 - - + -
**
 
2.54-2.58 (d) citrate + - - +
*
 -
**
 
2.42-2.46 (t) 2-oxoglutarate +
**
 + - +
**
 -
**
 
2.38-2.42 (s) succinate + - - + - 
 
S, singlet; d, doublet; t, triplet
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5.4 Sexual maturity study 
In order to investigate if the development of sexual maturity of the Hanover-Wistar was 
a contributor to the changes in urinary proteins and metabolites with age, a group of 36 
animals was sampled every week between the age of 24 and 90 days for histological 
examination of relevant tissues. 
5.4.1 Body weights 
Rats were weighed 3 times a week for the duration of the study and the body weight 
growth curve followed a similar trend to that observed previously (Figure 5.1). 
5.4.2 Testes weight 
Figure 5.7 A shows the mean relative weight for the right and left testes for 6 animals at 
each autopsy. Mean relative weights increased up to 52 days (
***
P<0.001 compared to 
weights at 33 days old). In 24 day old rats the relative weight for the testes was 3.76 
g/kg whereas in 52 day old rats the testes weighed 5.52 g/kg, representing a 1.5-fold 
increase. After this time point there were no further increases in testes weight and there 
appeared to be a decrease in weight at 91 days. However, this is due to one animal 
having significantly lighter testes than the rest of the animals in the same group thus 
contributing to the large standard deviation. 
5.4.3 Epididymides weight 
At autopsy, epididymides were collected and relative weights were calculated and 
recorded. Epididymides weight was expressed as a mean of right and left epididymides. 
Relative weights increased up to day 77 when they were over 3 times heavier than at 24 
days (6.26 and 1.27 g/kg BW, respectively). At 90 days of age relative weights were 
approximately 25 % less than at the previous time point (Figure 5.7 B). This was due to 
one animal that had lighter epididymides than the rest of the group. 
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A 
 
B 
 
Figure 5.7 Relative testes (A) and epididymides (B) weights for male Hanover-Wistar rats at 
different ages. Animals were housed in communal cages and autopsied at the time points shown as 
described in Section 5.2.2. Values are means of relative organ weight expressed as g per kg body weight 
(BW) with SD indicated by vertical bars of 6 animals per group. Both the testes and the epididymides 
weights were expressed as a mean of both the right and left organs. Organ weights that differ significantly 
from previous time point by Students’ t-test are shown: *P<0.05, **P<0.01, ***P<0.001. 
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5.4.4 Histopathology 
Tissue samples collected at autopsy were further processed for histological examination 
(Figure 5.8).  
At 52 days, the seminiferous epithelium demonstrated all of the normal stages of 
spermatogenesis, and the epididymides contained sperm. However, the sperm count was 
lower than that found in a fully mature animal. Therefore animals were considered to be 
sexually mature at 52 days old as they produced viable sperm, but were not considered 
to be fully fertile adults.  
At 63 days of age, animals were considered to be fully fertile as the number of sperm 
present in the epididymides was much greater than at 52 days (Table 5.4). Samples 
taken on or after day 77 revealed full maturity of the testes and a normal complement of 
sperm in the epididymides. Apart from one animal, killed on day 90, with extensive 
bilateral atrophy of the testes and aspermia of the epididymides, no remarkable 
pathological changes were recorded in any of the samples. 
 
 
spermatogonia
10 spermatocyte
cell division
degenerating spermatocytes
A B 
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Figure 5.8 Histology of the seminiferous tubules in the testes and epididymides of male Hanover-
Wistar rats at different ages. Original magnification A and E, x 100; B, C, D and F, x 200. H&E. 
Animals were housed in communal cages and autopsied at the time points described in Section 5.2.2. At 
autopsy, the seminiferous tubules and the testes were collected and processed for histopathological 
examination as described in Section 2.8. (A) 24 day old rat: seminiferous tubules appear very similar; (B) 
24 day old rat: seminiferous tubules showing spermatogonia and spermatocytes; (C) 33 day old rat: 
seminiferous tubules showing the beginning of spermatid development; (D) 52 day old rat: seminiferous 
tubules showing spermatozoa but in low levels; (E) 63 day old rat: seminiferous tubules showing similar 
appearance to testes at day 52; (F) 63 day old rat: epididymides showing full complement of sperm. 
Table 5.4 Elongating spermatids and presence of sperm in epididymides with increasing age of 
male Hanover-Wistar rat. Animals were housed in communal cages and autopsied at 24, 33, 52, 63, 77 
and 90 days as described in Section 5.2.2. At autopsy, the seminiferous tubules and the testes were 
collected and processed for histopathological examination as described in Section 2.8. 
 
Age 
(days) 
Testes with elongating spermatids 
present 
Epididymides (spermatozoa 
present in cauda) 
24 No No 
33 A few No (minimal cell debris present) 
52 Yes Yes (in low numbers) 
63 Yes Yes 
77 Yes Yes 
90 Yes Yes 
C 
spermatogonia
10 spermatocyte
round spermatid
elongating spermatid
D 
F E 
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5.5 Comparison of metabolomic changes to the urine following CCl4-induced 
hepatic injury in the pre- and post-sexually mature rat 
In experiment 1 in this Chapter, levels of urinary testosterone suggest that sexual 
maturity occurred between 54 and 68 days, since between these time points the greatest 
fold-increase was observed. Histopathological results from experiment 2 indicate that 
sexual maturity occurs between 52 and 63 days. Therefore, this study examines rats at 7 
weeks (49 days) to represent immature rats, and animals at 13 weeks (91 days) to 
represent post-sexually mature rats.  
5.5.1 Observations during the study 
No abnormal observations were recorded during the study. However, at autopsy, livers 
from both 7 and 13 week old CCl4-treated animals appeared paler in colour when 
compared to control livers.  
5.5.2 Liver weights 
Liver weights were significantly increased over controls in both groups of CCl4-treated 
animals (7 week old and 13 week old) (
***
P<0.001) (data not shown). 
5.5.3 Kidney weights 
Kidney weights were significantly decreased compared to control values in the animals 
dosed with 1.2 mL/kg CCl4 at 7 weeks old (mean relative weights were 3.83 and 3.60 
g/kg BW for control and 1.2 mL/kg CCl4-treated animals respectively; 
*
P<0.05). 
However, no CCl4-treatment related effect was evident in the relative kidney weight in 
older animals (13 week old) (data not shown).  
5.5.4 Serum clinical chemistry 
Figure 5.9 and Figure 5.10 show that serum ALT and AST were significantly increased 
in all rats following treatment with 1.2 mL/kg CCl4. In younger animals (7 weeks) there 
was a 7.91- and a 3.25-fold increase over control levels for ALT (
***
P<0.001) and AST 
(
**
P<0.01), respectively (Figure 5.9). Whereas, in 13 week old rats, much greater fold 
increases were measured (Figure 5.10). Control mean values were 64.50 and 187.40 
U/L whereas levels in the serum of treated animals were 2116.20 and 1792.50 U/L for 
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ALT and AST, respectively. This represented a 33-fold increase over controls for ALT 
(
*
P<0.05) and an approximate 10-fold increase over control values for AST (
*
P<0.05). 
In 7 week old rats mean serum levels of GLDH were 22-fold increased in CCl4-treated 
rats compared to vehicle-treated animals (
***
P<0.001), whereas in older animals (13 
weeks) the increase recorded for serum GLDH levels was 42-fold (
**
P<0.01) (Figure 
5.9, Figure 5.10). 
ALP also increased after dosing with CCl4 from 541.10 U/L to 719.30 U/L in 7 week 
old rats (1.33-fold increase; 
*
P<0.05), and from 207.70 U/L to 322.70 U/L in 13 week 
old rats (1.55-fold increase; 
***
P<0.001) (Table 5.5, Table 5.6). 
For animals at 7 weeks of age all other parameters were similar for control and CCl4-
treated animals, except for urea which was significantly increased above controls 
following CCl4 administration (1.53-fold increase; 
***
P<0.001). However, in older 
animals (13 weeks) serum albumin and creatinine were significantly increased 
following treatment with CCl4, whereas glucose was statistically significantly decreased 
in the serum of CCl4-treated rats (7.73 and 5.70 mmol/L for vehicle and CCl4-treated 
animals, respectively; 
***
P<0.001). Serum urea was significantly raised above controls 
for CCl4-treated animals in both age groups (1.70-fold increase; 
***
P<0.001) (Table 5.5, 
Table 5.6). 
 
 212 
 
 
Figure 5.9 Serum ALT, AST and GLDH levels for 7 week old male Hanover-Wistar rats treated 
with vehicle (control) or CCl4 at 1.2 mL/kg. Animals were dosed by gavage. At 24 hours post-dosing 
serum was collected as described in Section 5.2.3 and enzyme assays were carried out as described in 
Section 2.7. Values are the means with SD indicated by vertical bars of 10 animals per group. Values that 
differ significantly from controls by Students’ t-test are shown:  **P<0.01; ***P<0.001. 
 
Figure 5.10 Serum ALT, AST and GLDH levels for 13 week old male Hanover-Wistar rats treated 
with vehicle (control) or CCl4 at 1.2 mL/kg. Animals were dosed by gavage. At 24 hours post-dosing 
serum was collected as described in Section 5.2.3 and enzyme assays were carried out as described in 
Section 2.7. Values are the means with SD indicated by vertical bars of 10 animals per group. Values that 
differ significantly from controls by Students’ t-test are shown: *P<0.05; **P<0.01. 
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Table 5.5 Serum clinical chemistry parameters for 7 week old rats treated with vehicle (control) or 
CCl4 at 1.2 mL/kg. Animals were dosed by gavage. At 24 hours post-dosing serum was collected as 
described in Section 5.2.3 and enzyme assays were carried out as described in Section 2.7. Values are 
means and SD of 10 animals per group. Values that differ significantly from controls by Students’ t-test 
are shown: 
*
P<0.05; 
***
P<0.001. 
 
Serum parameters 
CCl4 dose level (mL/kg) 
                 0 1.2 
ALP 
(U/L) 
541.10 
(187.37) 
719.30
*
 
(142.73) 
Albumin 
(g/L) 
35.89 
(1.22) 
36.74 
(0.80) 
Creatinine
 
(µmol/L) 
23.60 
(2.46) 
26.70 
(3.56) 
Glucose 
(mmol/L) 
5.51 
(1.31) 
5.30 
(0.69) 
Urea 
(mmol/L) 
6.14 
(1.04) 
9.37
***
 
(0.92) 
Total protein 
(g/L) 
55.50 
(1.51) 
55.80 
(1.40) 
 
ALP: alkaline phosphatase.  
Table 5.6 Serum clinical chemistry parameters for 13 week old rats treated with vehicle (control) or 
CCl4 at 1.2 mL/kg. Animals were dosed by gavage. At 24 hours post-dosing serum was collected as 
described in Section 5.2.3 and enzyme assays were carried out as described in Section 2.7. Values are 
means and SD of 10 animals per group. Values that differ significantly from controls by Students’ t-test 
are shown: 
*
P<0.05; 
***
P<0.001. 
 
Serum parameters 
CCl4 dose level (mL/kg) 
0 1.2 
ALP 
(U/L) 
207.70 
(43.66) 
322.70
***
 
(50.65) 
Albumin 
(g/L) 
34.60 
(0.52) 
37.00
***
 
(1.49) 
Creatinine 
(µmol/L) 
29.00 
(2.73) 
33.40
*
 
(5.62) 
Glucose 
(mmol/L) 
7.73 
(0.78) 
5.70
***
 
(0.37) 
Urea 
(mmol/L) 
5.69 
(0.66) 
9.66
***
 
(0.79) 
Total protein 
(g/L) 
56.30 
(1.70) 
58.50 
(2.88) 
 
ALP: alkaline phosphatase.  
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5.5.5 Urine clinical chemistry 
Total protein in the urine was significantly decreased in comparison to control animals 
in CCl4-treated animals at both 7 and 13 weeks of age (Table 5.7, Table 5.8). 
Urinary levels for NAG, creatinine and glucose did not show evidence of a CCl4-
treatment related effect in either 7 or 13 weeks old animals (Table 5.7, Table 5.8). 
Table 5.7 Urinary clinical chemistry parameters for 7 week old rats treated with vehicle (control) 
or CCl4 at 1.2 mL/kg. Animals were dosed by gavage and urine collected for 18 hours post-dosing as 
described in Section 5.2.3. Clinical parameters were assayed as described in Section 2.7. Values are 
means and SD of 10 animals per group. Values that differ significantly from controls by Students’ t-test 
are shown: 
***
P<0.001. c.p. = collection period (18 hours). 
 
Urinary parameters 
                 CCl4 dose level (mL/kg) 
0 1.2 
Total protein 
(mg/c.p.) 
4.91 
(0.99) 
1.93
***
 
(0.33) 
NAG 
(mU/c.p.) 
172.00 
(22.86) 
144.70 
(29.65) 
Creatinine 
(µmol/c.p.) 
37.50 
(4.17) 
37.50 
(3.24) 
Glucose 
(µmol/c.p.) 
4.10 
(0.57) 
4.70 
(0.67) 
Volume 
(mL) 
19.40 
(8.26) 
29.10 
(15.91) 
NAG: N-acetyl-D-glucosamine.  
Table 5.8 Urinary clinical chemistry parameters for 13 week old rats treated with vehicle (control) 
or CCl4 at 1.2 mL/kg. Animals were dosed by gavage and urine collected for 24 hours post-dosing as 
described in Section 5.2.3. Clinical parameters were assayed as described in Section 2.7. Values are 
means and SD of 10 animals per group. Values that differ significantly from controls by Students’ t-test 
are shown: 
*
P<0.01; 
***
P<0.001. c.p. = collection period (24 hours). 
 
Urinary parameters 
CCl4 dose level (mL/kg) 
0 1.2 
Total protein 
(mg/c.p.) 
10.29 
(2.16) 
3.78
***
 
(1.53) 
NAG 
(mU/c.p.) 
168.60 
(29.99) 
143.60 
(27.02) 
Creatinine 
(µmol/c.p.) 
74.30 
(4.76) 
66.90 
(13.15) 
Glucose 
(µmol/c.p.) 
5.70 
(0.67) 
6.30 
(1.43) 
Volume 
(mL) 
17.19 
(7.92) 
29.99
*
 
(16.39) 
 
NAG: N-acetyl-D-glucosamine.  
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5.5.6 Histopathology 
At autopsy livers and kidneys were removed for all animals for histopathological 
examination (Figure 5.11).  
For all CCl4-treated animals (7 and 13 week old) hepatic injury was present and 
characterised by centrilobular hepatocellular vacuolation with ballooning of the 
cytoplasm and hepatocyte necrosis. There was also a focal mixed inflammatory 
infiltrate present. Vacuolated cells were seen in midzonal to periportal regions (Figure 
5.11).  
In the kidneys, CCl4 treatment-related findings were present in 2 animals at 13 weeks of 
age and consisted of proximal epithelial vacuolation. For all other CCl4-treated animals 
there was no evidence of CCl4-induced kidney injury. 
 
Figure 5.11 Histology of liver sections from 7 week old male Hanover-Wistar rats treated with 
vehicle (control) or CCl4 at 1.2 mL/kg and autopsied 24 hours post-dosing. Original magnification, 
x 100; H&E. Rats were dosed by gavage. At autopsy, liver samples were collected and processed for 
histopathology as described in Section 2.8. (A) control rat: central vein (c) and a portal vein (p); (B) CCl4-
treated rat at 1.2 mL/kg: central vein (c) with some degenerate hepatocytes; others showing vacuolation 
(arrow indicates area of vacuolation).  
 
c 
p 
A B 
p 
c 
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Figure 5.12 Histology of liver sections from 13 week old male Hanover-Wistar rats treated with 
vehicle (control) or CCl4 at 1.2 mL/kg and autopsied 24 hours post-dosing. Original magnification, 
x 100; H&E. Rats were dosed by gavage. At autopsy, liver samples were collected and processed for 
histopathology as described in Section 2.8. (A) control rat: central vein (c) and a portal vein (p); (B) CCl4-
treated rat at 1.2 mL/kg: centrilobular vacuolation, necrosis (arrow indicates area of vacuolation). 
5.5.7 1D 1H NMR spectrometry 
To investigate the urinary metabolite changes following CCl4-induced hepatic injury in 
7 and 13 week old male Hanover-Wistar rats, urine samples from this study were 
analysed by 1D 
1
H NMR spectrometry.  
Firstly, urine samples from control and CCl4-treated animals at 7 weeks of age were 
compared by OPLS-DA. The scores plot for the OPLS-DA model is shown in Figure 
5.13 A. Control samples were clustered on the left hand side of the score plot whereas 
samples from animals treated at 1.2 mL/kg were located on the right half of the plot and 
there was perfect separation along the discriminating component t[1]. As in the previous 
metabolomic studies there was great intragroup variation (displayed in the orthogonal 
component). The corresponding S-plot is shown in Figure 5.13 B. 
Variables that may discriminate between control and CCl4-treated samples are located 
on the extremes of the S-shaped curve, i.e., on the upper right quadrant or lower left 
quadrant of the plot. Chemical shifts labeled in the S-plot in Figure 5.13 B were selected 
based on the VIP plots for the corresponding models (data not shown). 
A B 
p 
c 
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Figure 5.13 Scores plot (A) and S-plot (B) from an OPLS-DA model derived from 1D 
1
H NMR 
spectral data of urine samples from 7 week old male Hanover-Wistar rats treated with vehicle 
(control) or CCl4 at 1.2 mL/kg. Rats were dosed by gavage and urine collected for 18 hours as described 
in Section 5.2.3. Each spot in the scores plot represents one urine sample. Each spot in the S-plot 
represents a NMR variable labelled as chemical shift in ppm. R
2
X (cum) = 0.757, Q
2
 = 0.956). 
Chemical shifts were identified according to previously published data and Table 5.9 
shows the changes to urinary metabolite concentration following the administration of a 
single dose of 1.2 mL/kg CCl4 to 7 week old rats. Integral regions were compared using 
a Student’s t-test for statistical significant differences between control and 7 week old 
animals treated at 1.2 mL/kg CCl4. Decreases were found in the resonances of 
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hippurate, taurine and creatinine whereas increases were noted for formate, 2-
oxoglutarate, citrate, creatine and succinate.   
Table 5.9 OPLS-DA detected 1D 
1
H NMR chemical shifts responsible for the separation of 1D 
1
H 
NMR derived spectra from the urine of 7 week old male Hanover-Wistar rats treated with vehicle 
(control) or CCl4 at 1.2 mL/kg. Rats were dosed by gavage and urine collected for 18 hours as described 
in Section 5.2.3. Chemical shifts were compared by means of a Students’ t-test. Values that differ 
significantly from controls are shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
 
Chemical shift (δ), 
multiplicity 
Endogenous 
metabolites 
Change in urinary metabolite 
concentration 
(increase (+); decrease (-)) 
8.46-8.50 (s) formate +
* 
7.70-7.74 (d) hippurate -
***
 
7.62-7.66 (t) hippurate -
***
 
7.54-7.58 (t) hippurate -
***
 
4.06-4.10 (s) creatinine - 
3.98-4.02 (d) hippurate -
***
 
3.94-3.98 (s) creatine + 
3.42-3.46 (t) taurine - 
3.26-3.30 (t) taurine - 
3.06-3.10 (s) creatinine - 
2.98-3.02 (t) 2-oxoglutarate + 
2.70-2.74 (d) citrate + 
2.54-2.58 (d) citrate +
**
 
2.42-2.46 (t) 2-oxoglutarate + 
2.38-2.42 (s) succinate + 
 
S, singlet; d, doublet; t, triplet. 
 
Urine samples from 13 week old Hanover-Wistar rats treated with CCl4 at 0 and 1.2 
mL/kg were analysed by 1D 
1
H NMR. Due to technical reasons spectra could only be 
obtained for 5 control and 5 CCl4-treated samples. The corresponding OPLS-DA scores 
plot and S-plot are shown in Figure 5.14. As with the 7 week old animals, urine samples 
from 13 week old rats displayed great cluster separation between control and CCl4-
treated samples.  
Chemical shifts identified from the S-plot that were considered to be mainly responsible 
for cluster separation were labelled and a Students’ t-test was carried out to statistically 
compared these chemical shifts in CCl4-treated urine samples to control. Table 5.10 
shows the major metabolites changes following CCl4-induced hepatic injury to 13 week 
old male Hanover-Wistar rats. These changes include an increase in the resonances of 
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formate, taurine, creatine, 2-oxoglutarate and citrate, and a decrease in the resonances of 
hippurate, creatinine and succinate. 
A 
 
B 
 
Figure 5.14 Scores plot (A) and S-plot (B) from an OPLS-DA model derived from 1D 
1
H NMR 
spectral data of urine samples from 13 week old male Hanover-Wistar rats treated with vehicle 
(control) or CCl4 at 1.2 mL/kg. Rats were dosed by gavage and urine collected for 24 hours as described 
in Section 5.2.3. Each spot in the scores plot represents one urine sample. Each spot in the S-plot 
represents a NMR variable labelled as chemical shift in ppm. R
2
X (cum) = 0.946, Q
2
 = 0.995. 
 
 220 
 
Table 5.10 OPLS-DA detected 1D 
1
H NMR chemical shifts responsible for the separation of 1D 
1
H 
NMR derived spectra from the urine of 13 week old male Hanover-Wistar rats treated with vehicle 
(control) or CCl4 at 1.2 mL/kg. Rats were dosed by gavage and urine collected for 24 hours as described 
in Section 5.2.3. Chemical shifts were compared by means of a Students’ t-test. Values that differ 
significantly from controls are shown: 
*
P<0.05; 
**
P<0.01. 
Chemical shift (δ), 
multiplicity 
Endogenous 
metabolites 
Change in urinary metabolite 
concentration  
(increase (+); decrease (-)) 
8.46-8.50 (s) formate + 
7.70-7.74 (d) hippurate -
*
 
7.62-7.66 (t) hippurate -
*
 
7.54-7.58 (t) hippurate -
**
 
4.06-4.10 (s) creatinine -
**
 
3.98-4.02 (d) hippurate -
*
 
3.94-3.98 (s) creatine + 
3.42-3.46 (t) taurine + 
3.26-3.30 (t) taurine + 
3.06-3.10 (s) creatinine -
**
 
2.98-3.02 (t) 2-oxoglutarate +
*
 
2.70-2.74 (d) citrate +
**
 
2.54-2.58 (d) citrate +
**
 
2.42-2.46 (t) 2-oxoglutarate +
**
 
2.38-2.42 (s) succinate - 
 
S, singlet; d, doublet; t, triplet. 
 
The main objective of this experiment was to compare the effect on urinary metabolites 
of administering 1.2 mL/kg CCl4 to male Hanover-Wistar rats at different ages (7 and 
13 weeks old). A PCA model was constructed for the urine samples from control and 
CCl4-treated animals at both time points (7 and 13 weeks old) (Figure 5.15). It will be 
important to rule out changes to urinary metabolites due to the different ages of the rats. 
However, in Figure 5.15, the 2 groups of control samples were mostly located on the 
same quadrant of the scores plot suggesting the absence of significant differences 
between them. This is in agreement with the scores plot in Figure 5.4 A from the growth 
curve in which samples from both time points appeared to be overlapped.  
To compare changes to urinary metabolites at the 2 different ages (7 and 13 weeks) 
following the induction of hepatic injury a OPLS-DA model was performed for the 
urine 1D 
1
H NMR spectral data collected from animals dosed with 1.2 mL/kg CCl4 at 7 
and at 13 weeks (Figure 5.16). The scores plot for this model is shown in Figure 5.16 A. 
Separation according to age occurred along the discriminating component t[1], with 2 
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clear sample clusters; one for urine from 7 week old animals, and the other from 13 
week old rats.  
The corresponding S-plot is shown in Figure 5.16 B. The upper right quadrant shows 
the chemical shifts that were increased in older animals after the administration of CCl4 
at 1.2 mL/kg; and in the lower left quadrant integral regions that were increased in 
younger animals (7 weeks) following CCl4 treatment. 
Figure 5.15 PCA scores plot from a PCA model derived from 1D 
1
H NMR spectral data of urine 
samples from 7 week old and 13 week old male Hanover-Wistar rats treated with vehicle (control) 
or CCl4 at 1.2 mL/kg. Rats were dosed by gavage and urine collected for 18 and 24 hours for 7 and 13 
week old rats respectively, as described in Section 5.2.3. Each spot in the scores plot represents one urine 
sample. R
2
X (cum) = 0.815, Q
2
 = 0.327. 
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A 
 
B 
Figure 5.16 Scores plot (A) and S-plot (B) from an OPLS-DA model derived from 1D 
1
H NMR 
spectral data of urine samples from 7 week old and 13 week old male Hanover-Wistar rats treated 
with CCl4 at 1.2 mL/kg. Rats were dosed by gavage and urine collected for 18 and 24 hours for 7 and 13 
week old rats respectively, as described in Section 5.2.3. Each spot in the scores plot represents one urine 
sample. Each spot in the loadings plot represents a NMR variable labelled as chemical shift in ppm. R
2
X 
(cum) = 0.677, Q
2
 = 0.958. 
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The chemical shifts labelled on the S-plot were identified and statistical analysis was 
carried out with integral values to determine significant differences between the 7 week 
and 13 week old animals (as described in Section 2.11). At 13 weeks of age, CCl4-
treated animals had greater urinary levels of creatinine, hippurate, creatine, taurine and 
creatinine, and lower levels of citrate, 2-oxoglutarate and succinate, when compared to 
rats at 7 weeks old following administration of CCl4 at the same dose level. 
Table 5.11 OPLS-DA detected 1D 
1
H NMR chemical shifts responsible for the separation of 1D 
1
H 
NMR derived spectra from the urine of 7 and 13 week old male Hanover-Wistar rats treated with 
CCl4 at 1.2 mL/kg. Rats were dosed by gavage and urine samples collected for 18 and 24 hours for 7 and 
13 week old rats respectively, as described in Section 5.2.3. Chemical shifts were compared by means of 
a Students’ t-test. Values that differ significantly from 7week old rats are shown: *P<0.05; **P<0.01; 
***
P<0.001. 
 
Chemical shift (δ), 
multiplicity 
Endogenous 
metabolites 
Change in metabolites concentration 
in 13 week old rats when compared to 
7 week old rats 
(increase (+); decrease (-)) 
4.06-4.10 (s) creatinine +
**
 
3.98-4.02 (d) hippurate + 
3.94-3.98 (s) creatine + 
3.42-3.46 (t) taurine +
**
 
3.26-3.30 (t) taurine +
**
 
3.06-3.10 (s) creatinine +
***
 
2.98-3.02 (t) 2-oxoglutarate -
**
 
2.70-2.74 (d) citrate - 
2.54-2.58 (d) citrate -
*
 
2.42-2.46 (t)  2-oxoglutarate -
*
 
2.38-2.42 (s) succinate -
**
 
 
S, singlet; d, doublet; t, triplet. 
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5.6 Discussion 
In the dose response study described in Chapter 3 we determined the optimal dose level 
of CCl4 that would induce hepatotoxicity but not cause injury to other tissues. In 
Chapter 3, male rats of approximately 7 weeks of age were used. However, we did not 
know if animals at this age were sexually mature or fully fertile, or even if this change is 
an important factor in a CCl4-induced hepatotoxicity model. Therefore, in the present 
Chapter we wished to monitor changes in urinary metabolite levels with age and 
determine the age at which the animals became sexually mature. With this information, 
we then wished to conduct a comparative study of metabolites in the urine following 
CCl4 administration in pre- and post-sexually mature rats. 
Experiment 1 was a growth curve study to characterise changes to the urinary 
metabolite profile as the animals became older and to define baseline levels for some of 
the most commonly measured protein biomarkers at the different ages.  
Some animals in the study (n=10) were placed individually in metabolism cages for 24 
hour urine collection every 2 weeks. While in the metabolism cages a significant drop in 
body weight was observed (Figure 5.1). However, by the end of the study the animals 
that had been metaboled on 6 separate occasions were of a similar weight to the group 
of animals that had not been metaboled. This data suggests that the process of 
metaboling animals for 24 hours during which rats have no access to diet, has no impact 
on the overall growth rate of the animals (Figure 5.1). 
Urine samples collected during the study at days 26, 40, 54, 68, 84 and 91 were 
analysed for urinary biomarkers such as α-GST, GST Yb1, clusterin, KIM-1, RPA1, 
MALB, NAG, osteopontin, lipocalin-2, creatinine, glucose and total protein to establish 
baseline levels for each of the markers as the animals aged (Figure 5.2, Table 5.2). 
Urinary levels of α-GST, GST Yb1 and total protein showed a moderate increase from 
26 to 40 and from 40 to 54 days old, followed by a dramatic increase at 68 days old 
(Figure 5.2, Table 5.2). Mean KIM-1, MALB and osteopontin levels in urine increased 
with age during the first 3 time points and peaked at day 54, after which there was a 
slight decrease in levels. Urinary levels of RPA1 and clusterin increased up to day 84, 
after which a plateau was reached. Urinary levels of NAG, lipocalin-2 and glucose 
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increased from day 26 and were at its highest in 68 days old rats, whereas urinary 
creatinine levels increased consistently with age and were highest at 91 days. 
Age-related differences in urinary protein levels in the rat have been extensively studied 
in the literature (Sellers et al., 1950; Neuhaus and Flory, 1978; Owen and Heywood, 
1986; Williams et al., 2005). Sellers and colleagues (1950) investigated differences in 
urinary protein levels between male, female and castrated rats of the Slonaker-Addis 
strain. The authors demonstrated that after castration the level of urinary protein 
decreased considerably in the males whereas the same did not happen in female 
animals. However, an increase in urinary protein concentration was apparent for both 
male and female rats following the administration of testosterone propionate to castrated 
animals. Therefore, it was suggested that the action site of testosterone is the kidney and 
not the accessory sex glands. The exact mechanism for this interaction is not clear and 
previous authors have demonstrated that testosterone has an effect in the epithelium of 
the proximal and distal tubules, mainly by the induction of hypertrophy (Korenchevsky 
and Ross, 1940). However, it was not clear from the study by Korenchevsky et al., 
(1940) if this effect is enough to affect the glomerular permeability to urine, or to 
decrease the ability of the tubule to reabsorb protein that may be present in the 
glomerular filtrate. Therefore, it is possible that in our study the increased α-GST, GST 
Yb1 and total protein levels in 68 days old rats may be due to increased testosterone 
levels. Subsequently, in the present study, testosterone levels were also measured in the 
urine of rats at 26, 40, 54, 68, 77 and 91 days of age (experiment 2) and it became 
apparent that urinary testosterone followed the same pattern of change as α-GST, GST 
Yb1 and total protein (Figure 5.2, Figure 5.3, Table 5.2).There was a moderate increase 
up to 54 days of age followed by a sharp rise in mean levels at 68 days.  
Fujita and colleagues (1990) studied the correlation of cytochrome P-450 enzyme 
activity and plasma testosterone levels. In their study, male rats were sacrificed at 3, 6, 
12, 25, 28 and 30 months of age. The authors reported a decrease in plasma testosterone 
levels with age which was accompanied by changes in the activity of the drug 
metabolising enzymes. However, the time points in our current study were different and 
consequently only the last collection point of our study overlaps with the first collection 
time point in Fujita’s (1990) study (3 months). In the present study urinary testosterone 
levels reached peak levels at 84 days, and there was a slight decrease at 91 days (3 
months).  
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In the present study, the correlation of urinary protein levels and testosterone adds 
further evidence to the proposed relationship between testosterone levels and 
proteinuria. The observed increase in urinary testosterone levels may be due to the rat 
reaching sexual maturity at these time points.  
Urine samples collected during this study from the same animals at different time points 
were analysed by 1D 
1
H NMR and statistical methods for the detection of age-related 
changes in metabolite concentration. The PCA and OPLS scores plots demonstrated 
evidence of some cluster separation between samples collected from 84 days old rats 
and the urine samples at all other time points (Figure 5.4). The OPLS model showed 
perfect separation of samples along the discriminating component t[1] except for those 
samples from 84 day old rats which appeared in an entirely different quadrant on the 
scores plot. This suggested there was a change in metabolites with increasing age but 
with additional different changes occurring at 84 days old (Figure 5.4 B).  
There was some degree of variability in most of the chemical shifts but there was a 
general trend of increased levels of many metabolites at 84 days followed by a decrease 
at 91 days. Metabolites which followed this pattern included creatinine, creatine, 
taurine, 2-oxoglutarate, citrate and succinate (Table 5.3). 
In this study, regions containing the 2 triplets for taurine had opposite loadings at 40 
and 54 days old, therefore the effect of increasing age was difficult to determine. 
However, at day 68 there was a highly significant increase (
***
P<0.001) followed by a 
decrease at 91 days old when compared to day 84, but levels remained increased 
compared to 84 days. Williams et al., (2005) investigated the effect of age on the profile 
of endogenous metabolites in the male Alderley-Park rat. They found that urinary 
taurine levels varied significantly throughout the study increasing at 4 and 6 weeks of 
age, then dropping at week 8 followed by a sharp increase at week 10 and a decrease at 
week 14. The significant increases observed in urinary taurine levels in the present 
study at day 68 (approximately week 10), compares with the data described by Williams 
et al., (2005), for which the greatest fold increase was also recorded at week 10. 
A study by Bell at al., (1991) reported increases in urinary levels of creatinine and 
taurine in the ageing rat. The authors suggested that the increase in creatinine levels 
reflects the growth of the animals, particularly the growing muscles of bigger and 
heavier rats, and the age-related increase in glomerular filtration rate. Creatinine is 
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spontaneously produced when the phosphate bond in creatine phosphate is hydrolysed 
for the release of energy in the muscle (Ropero-Miller et al., 2000; Waters et al., 2005). 
Therefore, creatinine levels in the body are affected by muscle mass. Changes in taurine 
levels in this study appeared to follow the temporal pattern of creatinine. However, it 
has also been shown that urinary taurine is dependent not only on the age of the animals 
but also on their nutritional status and consequently their diet (Connor et al., 2004). 
More recently, a study was conducted investigating the effect of taurine on male 
reproduction in Wistar rats of different ages (Yang et al., 2010b). The authors reported a 
decrease in the biosynthesis of taurine in the testis in the ageing rat. In the male 
reproductive system, taurine has been reported to be present in Leydig cells, vascular 
endothelial cells, interstitial cells of testis and epithelial cells of the efferent ducts (Yang 
et al., 2010c). Yang et al (2010c) reported that taurine has a positive effect in 
reproduction by stimulating testosterone secretion in Leydig cells, therefore suggesting 
a role for taurine in testicular function. 
The changes to urinary levels described in the present study for citrate and hippurate 
mirror the results reported by Williams et al., (2005). In the study by Williams et al., 
(2005), there was evidence of an age-dependent decrease in urinary levels of citrate and 
in our study, a similar decrease was present. Succinate excretion appeared to follow the 
same changes in urine as citrate. Bell et al., (1991) proposed that the variability in 
urinary levels of some TCA cycle intermediates may be the result of changes to the 
acid-base balance in the kidneys. The excretion of TCA cycle intermediates via the 
urine depends on the rate at which they are reabsorbed into the tubular cells, which in 
turn depends on the pH of the kidney. Therefore, an imbalance in any of these factors 
will be reflected in the urinary metabolites (Nicholson et al., 1985; Bell et al., 1991).  
In the present study levels of the metabolite hippurate demonstrated an age-related 
increase up to 68 days of age; at 84 days the levels were decreased when compared to 
those at 68 days, but greater at 91 days than 84 days. In the study by Williams and 
colleagues (2005) hippurate levels were relatively low at weeks 4 and 6 but increased 
dramatically at 8 weeks of age (56 days) after which there was evidence of an age-
dependent decrease up to 14 weeks followed by a slight increase after this time point. In 
our study we also found a similar trend although the time points were slightly different. 
Williams et al (2005) suggested that the changes in hippurate levels at the earlier time 
point may be due to changes in the gut microflora of the young rat (4 weeks of age) as 
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the animals mature and adapt to the diet. Hippurate results from the conjugation of 
benzoate with glycine. Benzoate in turn, is produced by the microbial degradation of 
aromatic compounds in the intestine (Williams et al., 2010). Therefore, the maturation 
of the gut microflora is likely to be responsible for the age-related changes seen in 
younger animals. 
Overall, the growth curve study revealed that between the age of 68 and 84 days of age, 
there were major changes to the serum and urine clinical chemistry, as well as in the 
urinary metabolite profile of the male Hanover-Wistar rat. Since the urinary testosterone 
levels followed the same general trend these changes are likely to be due to sexual 
maturation of the rat. Consequently, a sexual maturity study was carried out to 
determine the exact age at which the male Hanover-Wistar rat used in our studies 
reaches sexual maturity. 
In a study by Robb and colleagues (1978) it was shown in Wistar rats that the absolute 
testicular weight increased rapidly up to 75 days of age, and then continued to increase 
although at a slower rate. The authors suggested that sexual maturity was reached 
between the age of 75 and 100 days based on sperm production rates and epididymal 
sperm numbers. A more recent study by Campion et al. (2013) reported that in the 
Hanover-Wistar rat the absolute testis weight increased consistently until day 70 after 
which it remained essentially unchanged. The authors considered the male Hanover-
Wistar rat to reach sexual maturity at 70 days of age (10 weeks).  
In this study relative weights for the testes peaked at day 52 and after this time point 
slightly decreased (Figure 5.7 A). The relative weight of the epididymides also 
increased with age and peaked in 77 days old rats. Histological examination of the testes 
and epididymides were carried out. For classification purposes in this study, sexual 
maturity was considered to be the stage at which mature sperm were produced and 
stored in the caudal epididymides. Consequently, at day 63 (9 weeks), animals were 
considered to be both sexually mature and fully fertile. This is in agreement with the 
growth curve study data in which levels of urinary testosterone were found to be 
significantly increased at day 68. We therefore, defined the age at which the male 
Hanover-Wistar reaches sexually maturity as 63 days old.  
Since there was a fluctuation in urinary biomarker levels in control animals as sexual 
maturity occurs, it was considered of interest to determine biomarker levels in our CCl4-
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induced hepatic model in pre- and post-sexually mature animals. For this comparative 
study we chose animals at 7 weeks (49 days) and 13 weeks (91 days). The 7 week old 
animals should reflect low testosterone levels according to Figure 5.2 and those at 91 
days fall just after the peak in urinary testosterone. Hepatic injury was induced in both 
groups of animals as determined by serum enzyme measurements and histopathology of 
the liver. There were great differences in the fold increase over control values for some 
serum parameters in the 2 groups of animals. For example, ALT levels in the serum of 
animals treated with 1.2 mL/kg CCl4 were 7.91- and 33-fold increased above controls, 
in 7 and 13 week old rats respectively. The fold increase for AST was 3.25 and 10 for 
younger and older animals, respectively (Figure 5.9, Figure 5.10). 
In 7 week old rats serum urea revealed a statistical significant difference and values 
were 1.52-fold greater in the CCl4-treated group compared to control animals 
(
***
P<0.001) (Table 5.5). In 13 week old rats, serum levels of albumin, urea and 
creatinine were all significantly increased over controls (1.7- and 1.2-fold, for urea and 
creatinine respectively) (Table 5.6). These results suggest a difference in the effect CCl4 
has on serum biochemistry as the animals reach sexual maturity. It would appear that 
the older animals (13 week old) have a greater degree of injury as shown by the larger 
fold increases in serum ALT and AST; however, this was not evident in the 
histopathology reports.  
In this experiment urine samples were collected for 18 hours for 7 week old rats, and for 
24 hours for 13 week old rats. However, urinary chemistry is expressed per collection 
period, and therefore, it is corrected for the urine volume produced. Even though 
collection periods were different for rats at different ages, they were the same for 
vehicle-treated and CCl4-treated animals at the same age, therefore allowing comparison 
of urinary levels. 
The main purpose of this study was to compare the effect of CCl4-induced 
hepatotoxicity on the urinary metabolite profile at the 2 different ages (pre- and post-
sexually maturity). 
OPLS-DA models were constructed to investigate changes to urinary metabolites at the 
2 different ages. When compared to control samples, treated samples from animals at 7 
weeks of age had increased levels of formate, 2-oxoglutarate, citrate, creatine and 
succinate and decreased concentrations of hippurate, creatinine and taurine (Table 5.9). 
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The integral regions including the 2 triplet peaks for taurine were decreased compared 
to control samples, but did not show evidence of a statistically significant difference. 
These results generally compare to those described in the dose response study in 
Chapter 3 where similar changes were present with the exception of taurine which was 
significantly increased.  
In the 13 week old rats, there was an increase in the resonances corresponding to the 
metabolites formate, taurine, creatine, 2-oxoglutarate and citrate, and a decrease in the 
levels of metabolites hippurate, creatinine and succinate following CCl4-induced hepatic 
injury (Table 5.10). 
Therefore, similar changes (either increase/decrease in level) were observed for most of 
the identified metabolites when the treated samples are compared to controls at their 
respective time points. However, since 7 week old animals, as shown by the previous 
study, have lower testosterone levels than 13 week old animals it is possible that there 
may be a greater degree of change for some metabolites at the 2 different rat ages 
(Bassil et al., 2009). 
The PCA scores plot revealed no significant differences between both groups of control 
samples as they clustered on the same principal component (Figure 5.15). This analysis 
was necessary in order to prove that any difference to metabolite levels in the treated 
animals were mainly due to CCl4 administration and not to increasing age.  
An OPLS-DA model to identify differences between 7 week old and 13 week old rats 
treated with CCl4 at 1.2 mL/kg (Figure 5.16) showed very clear clustering separation 
between the 2 groups. Further statistical analysis of the integral regions revealed that, 
following the administration of the same dose level of CCl4 (1.2 mL/kg), older animals 
(13 weeks) appeared to excrete greater levels of creatinine, hippurate, creatine and 
taurine, whereas a decrease was noted in the urinary excretion of 2-oxoglutarate, citrate 
and succinate compared to 7 week old rats (Table 5.10). Therefore, this suggests that the 
higher testosterone levels in older rat (13 weeks) have an influence in the response to 
CCl4-induced hepatic injury as reflected in changes to the urinary metabolome.  
Previous studies have investigated the influence of age on the toxicological response to 
several model compounds for hepatic injury, and, in particular, changes to the 
metabolising enzymes (cytochrome P-450) with age. However, the results are often 
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contradictory and while some authors report a decrease in cytochrome P-450 levels with 
age (Rikans and Notley, 1982; Rikans, 1989), other authors suggest the absence of an 
age-related effect both in rats (Schmucker and Wang, 1981) and in humans (Hunt et al., 
1990). 
Carbon tetrachloride is metabolised by cytochrome P-450 2E1 forming the free radicals 
responsible for the initiation of damage. Consequently a change in CYP2E1 levels or 
activity with age would change the rate of metabolism of CCl4. Wauthier et al., (2004) 
reported an increase in CYP2E1 activity between 3 to 8 months of age, followed by a 
decrease at 18 months. However, those time points are much later than in the current 
experiment. In another study in Long Evans rats, it was shown that hepatic CYP2E1 
content decreased with age from 3 to 6 weeks and then remained constant up to 12 week 
old animals (Thomas et al., 1987). Najakima et al., (1987) also reported a decrease in 
CYP2E1 levels between 3 week old (21 days) rats and 18 week old (126 days) rats. 
These studies demonstrating a decrease in CYP activity have all been carried out in 
male rats. A similar change is not thought to occur in female rats, thus leading to the 
proposal of the existence of 2 forms of cytochrome P-450: a male P-450 and a female P-
450 (Kamataki et al., 1983). It has also been suggested that it is the decrease in 
testosterone levels that leads to a decrease in the enzyme activity for the male form of 
cytochrome P-450. This in turn, will lead to the feminization of the male rats with 
regards to the cytochrome P-450 composition (Kamataki et al., 1985).  
Overall, the series of investigations in this Chapter has allowed the characterisation of 
the sexual maturation process of the male Hanover-Wistar. An extensive 
1
H NMR-
based metabolomics investigation was carried out to determine levels of urinary 
metabolites with increasing age up to and just beyond sexual maturity in the male 
Hanover-Wistar rat.  
The outcome of the present studies is that we can now confirm that the male Hanover-
Wistar rat reaches sexual maturity at 63 days old. This is characterised by a significant 
increase in urinary testosterone levels which is thought to decrease again with age after 
sexual maturity is reached. Previous reports describing a possible link between 
testosterone and CYP activity should be considered when designing our experiments 
with CCl4. Consequently, we now know that at 7 weeks old (the age of the animals used 
in our previous CCl4 studies in Chapter 3), urinary testosterone levels have not yet 
reached the peak that they do at 9 weeks of age. Therefore, testosterone levels are 
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unlikely to affect our CCl4-induced hepatic model. Hence, we will continue to use 7 
week old animals for our future CCl4 studies in Chapters 6 and 7. In Chapter 7 we will 
present results of a chronic dose study and we should keep in mind that there may be a 
change in urinary metabolites in this study as the animal ages.  
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CHAPTER SIX 
CCl4 time course study 
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Chapter 6  
6.1 Introduction 
In Chapter 3 we developed an acute model of hepatic injury using CCl4 and we are 
confident that at dose levels of 2.0 mL/kg and below CCl4-induced kidney injury is 
avoided. In Chapter 4, we determined the most sensitive biomarkers for nephrotoxicity 
and these will be evaluated in this Chapter to ensure CCl4-induced nephrotoxicity does 
not occur. We also identified many changes to the urinary metabolome following the 
induction of hepatic injury as described in Chapters 3 and 5. In the current Chapter we 
wish to evaluate the sensitivity of these urinary metabolite markers as injury is induced 
and regeneration occurs. We did this by conducting a time course study. 
In our Chapter 3 studies, animals were placed in metabolism cages at 6 hours post-
dosing and urine samples collected for 18 hours. This means our animals had access to 
diet immediately after dosing. Therefore, it would be interesting to analyse the urinary 
metabolites identified in Chapter 3 during the period between 0 and 6 hours following 
CCl4 administration. To incorporate this question into the current time course study it 
was decided that we should collect urine samples every 6 hours for the first 24 hours 
and at regular time intervals post 24 hours. Therefore, in the present study, animals were 
placed in metabolism cages for only 6 hours at a time during the first 24 hours and for 
12 hours at later time points. In the present study animals were fasted for shorter periods 
of time. We should be aware, therefore, that this may affect the urinary metabolite 
profile in this study. 
CCl4 is known to induce a toxic response within 5 minutes of administration 
(Recknagel, 1967; Rao and Recknagel, 1968), and maximal injury has been reported to 
occur at 24-36 hours (Rao et al., 1996). Peak levels of serum enzymes ALT and AST 
have been reported at 36 hours post-CCl4 administration to rats (Giffen et al., 2003; Zira 
et al., 2013). Rao et al., (1997) also reported maximal centrilobular necrosis at 24 to 48 
hours post-dosing. Therefore, we would hope to see maximum change in the urinary 
metabolites at approximately 24 hours post-dosing. The liver has great regenerative 
ability and studies have shown complete restoration of normal liver architecture within 
3 to 6 days following a single dose of 1.0 mL/kg CCl4 (Zira et al., 2013). Urine samples 
in this study were collected for up to 10 days following CCl4 administration to 
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demonstrate further changes to the urinary metabolome as the liver undergoes 
regeneration. 
Thus, the primary purpose of the current Chapter was to determine if the urinary 
metabolites described in Chapter 3 were sensitive indicators of hepatic injury. A good 
biomarker will indicate early changes following a toxic insult, will be sensitive to the 
level of injury induced, and remain in the biofluid long enough to be detected. In 
addition, a return to control values would demonstrate a good response to recovery from 
the injury.  
Urine samples collected in this study were analysed by 1D 
1
H NMR and pattern 
recognition methods such as PCA to determine the response of the previously identified 
metabolites with time following a single dose of CCl4 to the Hanover-Wistar rat. 
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6.2 Animal experimental design 
Eighty male Hanover-Wistar rats (mean body weight 215.3 ± 5.14 g) were divided into 
8 groups of 10 animals each (groups were labelled A to H). At time 0 hours, 5 animals 
in each group were dosed by gavage with corn oil (controls) (rats 1-5) and 5 animals 
were dosed with 2.0 mL/kg CCl4 (rats 6-10). Immediately after dosing (0 hours), 
animals in group A were placed in metabolism cages for 6 hour urine collection prior to 
autopsy at 6 hours post-dosing. At 6-12 hours post-dosing, group B were housed in 
metabolism cages prior to autopsy at 12 hours. This process of urine collection for 6 
hour time slots continued up to 24 hours post-dosing according to the schedule shown in 
Table 6.1. At all time points after 24 hours post-dosing urine was collected for 12 hours. 
To keep the numbers of animals used in this study to a minimum, some groups were 
bled from the tail-vein upon removal from the metabolism cages instead of from the 
abdominal aorta at autopsy.  
The first 24 hours were thought to be the most crucial and therefore, these animals were 
killed in order to obtain tissue samples for histopathological examination. 
At autopsy, blood was taken for the preparation of serum which was stored at -80 ºC 
until analysis. The liver and kidneys were removed and placed in fixative as described 
in Section 2.8.  
Table 6.1 Schedule showing the time points at which animals were placed in metabolism cages for 
urine collection prior to collection of a blood sample. Animals were placed in metabolism cages for 
either 6 or 12 hour urine sample collections. At the end of the metabolism cage session a blood sample 
was obtained from the animal either from the tail vein (TVB) or by killing the animal and sampling from 
the abdominal aorta at autopsy (Terminal) (n=10). 
 
Time point post-
dosing 
Animal group 
Type of sample 
collected 
0-6 hours A Terminal 
6-12 hours B Terminal 
12-18 hours C Terminal 
18-24 hours D Terminal 
24-36 hours E TVB 
36-48 hours F Terminal 
48-60 hours G TVB 
60-72 hours E Terminal 
72-84 hours H TVB 
84-96 hours G Terminal 
Day 6 H TVB 
Day 10 H Terminal 
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6.3 Results 
6.3.1 Body weights 
The mean change in body weight for CCl4-treated animals was compared to the change 
in body weight for the concurrent control animals (Table 6.2). At 6-12, 12-18 and 60-72 
hours post-dosing, CCl4-treated animals lost significantly less weight than the control 
rats (
*
P<0.05). However, CCl4-treated animals at 24-36 hour post-dosing lost more 
weight than the corresponding control group (11.36 and 14.96 g, for control and CCl4-
treated rats respectively; 
*
P<0.05).  
Table 6.2 Body weight change for male Hanover-Wistar rats treated with vehicle (control) or CCl4 
at 2.0 mL/kg and sampled at various time points post-dosing. Animals were dosed by gavage and 
placed individually in metabolism cages for the collection of urine samples at the time points shown 
according to the schedule in Table 6.1. Animals had access to water but not diet while in the metabolism 
cages. Weight changes are shown as mean and SD of 5 animals per group. Changes in weight that are 
statistically different to the changes for control animals by Students’ t-test are shown: *P<0.05. 
 
 
6.3.2 Liver weights 
Relative liver weights for CCl4-treated rats were significantly increased over the 
respective controls up to 96 hours (day 4) post-dosing (Figure 6.1 A). At 24 hours post-
dosing, there was a 1.4-fold increase over concurrent controls (
***
P<0.001) which was 
the maximum fold difference observed. By day 10 post-dosing, liver weights from 
CCl4-treated animals were similar to controls. 
 
Change in mean (SD) body weight (g) 
Time post-dosing 0 mL/kg CCl4 2.0 mL/kg CCl4 
0-6 hours  -8.92 (1.69) -9.76 (1.72) 
6-12 hours -10.18 (2.83) -6.50
*
 (2.07) 
12-18 hours -12.20 (1.92) -8.66
*
 (2.44) 
18-24 hours -10.94 (1.67) -13.12 (1.33) 
24-36 hours -11.36 (1.15) -14.96
*
 (2.24) 
36-48 hours -15.52 (2.87) -13.12 (6.72) 
48-60 hours -13.76 (0.68) -11.26 (4.03) 
60-72 hours -15.04 (1.28) -11.84
*
 (2.08) 
72-84 hours -13.32 (0.79) -12.72 (0.83) 
84-96 hours -15.00 (2.58) -13.72 (1.09) 
Day 6 -16.50 (1.51) -16.50 (2.08) 
Day 10 -13.76 (1.14) -14.40 (2.22) 
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6.3.3 Kidney weights 
The mean relative kidney weights for rats treated with CCl4 were similar to control at all 
time points, except for 18 hours post-dosing when they were significantly decreased 
(5.74 and 5.39 g/kg BW, respectively; 
*
P<0.05) (Figure 6.1 B). 
A
 
B 
Figure 6.1 Relative liver (A) and kidney (B) weights from male Hanover-Wistar rats treated with 
vehicle (control) or CCl4 at 2.0 mL/kg and sampled at various time points post-dosing. Animals were 
dosed by gavage. At the time points shown, animals were killed, livers and kidneys were removed and 
weighed as described in Section 6.2. The kidney weight was expressed as the mean of the left and right 
kidneys. Results are shown as mean organ weight per kg body weight (BW) with SD indicated by vertical 
bars of 5 animals per group. Relative organ weights that differ significantly from controls at the 
respective time point by Students’ t-test are shown:*P<0.05; **P<0.01; ***P<0.001. 
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6.3.4 Serum clinical chemistry 
Clinical chemistry parameters including ALT, AST, GLDH, ALP, TIMP-1, MCP1, 
A2M, AGP, lipocalin-2, urea, creatinine, albumin, glucose and total protein were 
measured in the serum from vehicle-treated (control) and CCl4-treated animals in this 
study.  
Serum ALT was significantly raised over concurrent controls at 12 hours post-dosing, 
reaching a peak between 12-24 hours. At 18 hours post-dosing there was a 72-fold 
increase in ALT levels (
*
P<0.05) (Figure 6.2 A), and serum ALT remained significantly 
increased over control until 48 hours post-dosing. By day 4 (96 hours post-dosing), 
control and CCl4-treated ALT levels were similar.  
AST was statistically increased at the first time point (6 hours post-dosing) (10-fold; 
*
P<0.05) (Figure 6.2 B). Levels of AST increased steadily up to 24 hours post-dosing 
when a maximum serum level was reached (4944.00 U/L for CCl4-treated animals and 
101.80 U/L for control rats; 
*
P<0.05). After 48 hours, the AST values began to fall and 
were back to control levels. 
Mean GLDH was significantly increased at 6 hours post-dosing (10-fold increase; 
***
P<0.001). Levels of GLDH peaked at 48 hours when there was a 243-fold increase 
over concurrent controls; however this was not statistically significant. After 48 hours 
there appeared to be a decrease in GLDH levels with time back to control levels at day 
10 (Figure 6.2 C). 
Serum ALP was significantly increased over controls in CCl4-treated animals at 12 
hours post-dosing reaching peak levels at 18 hours (938.20 U/L compared to a control 
mean value of 440.20 U/L, 
*
P<0.05) (Table 6.3, Table 6.4). After 18 hours, ALP levels 
began to fall and were similar to controls by day 10 post-dosing. 
At 24 to 36 hours post-dosing serum ALP, AST, GLDH and ALP levels for CCl4-
treated animals are the means of 4 rats, since there was not enough serum sample from 1 
animal to measure the levels of these enzymes. 
TIMP-1 serum levels were significantly increased above controls at all time points 
between 6 and 60 hours post-dosing. Peak values of TIMP-1 were reached at 48 hours 
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post-dosing, when an approximate 14-fold increase over controls was observed. TIMP-1 
levels returned to control values by day 6 post-dosing (Table 6.3, Table 6.4).  
Serum A2M mean values were significantly greater than controls at 12, 24, 72 and 84 
hours and at days 6 and 10 post-dosing (Table 6.3, Table 6.4). The greatest fold-
increase was observed at 84 hours post-dosing (33.40 and 79.20 mg/L for controls and 
CCl4-treated animals respectively; 
*
P<0.05). 
MCP1 serum levels were almost 2-fold greater than concurrent controls at 6 hours post-
dosing and levels remained significantly elevated up to 36 hours. The greatest fold 
increase was recorded at 24 hours post-dosing, when an approximate 29-fold increase 
was seen (7.40 and 211.80 µmol/L, respectively; 
**
P<0.01) (Table 6.3, Table 6.4). 
MCP1 levels were similar to controls at 72 hours post-dosing. 
Mean AGP levels were significantly greater than control values between 18 and 96 
hours post-dosing. Serum AGP increased up to 48 hours post-dosing reaching a peak of 
approximate 10-fold increase over control (65.40 and 614.00 mg/L; 
**
P<0.01). By day 
10, AGP levels had returned to control values (Table 6.3, Table 6.4). 
Serum lipocalin-2 was increased over controls from 6 hours post-dosing, however, 
values were only significantly different from control at 12, 24, 48, 60 and 72 hours post-
dosing. Levels peaked at 48 hours with a 27-fold increase over controls (37.80 and 
1021.25 µg/L, respectively 
*
P<0.05). By day 6, lipocalin-2 was similar in control and 
CCl4-treated animals. 
Levels of TIMP-1, MCP and lipocalin-2 at 24 to 36 hours, are the means of 3 control 
and 3 CCl4-treated animals, whereas levels of A2M and AGP are the means of 4 control 
and 3 CCl4-treated animals as there was not enough sample from the missing animals in 
each group to carry out the serum assays. Similarly, at 36 to 48 hours the values for 
serum TIMP-1, A2M, MCP, AGP and lipocalin-2 are the means of 4 CCl4-treated 
animals. 
To assess the possibility of kidney injury, mean urea, creatinine, albumin, glucose and 
total protein were also measured in the serum of all animals in this study (Table 6.3, 
Table 6.4). At 24 to 36 hours post-dosing values for urea, creatinine, albumin, glucose 
and total protein are the means of 4 CCl4-treated animals. 
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Urea levels were significantly raised over concurrent controls as early as 6 hours post-
dosing (1.44-fold increase). Levels reached a maximum at 48 hours and after this time 
point serum levels were similar in control and CCl4-treated animals. Serum creatinine 
was significantly increased in CCl4-treated animals at 18, 24, 36, 48 and 60 hours post-
dosing (Table 6.3, Table 6.4). The greatest fold difference was observed at 48 hours 
post-dosing (1.6-fold increase) (
**
P<0.01).  
Serum albumin was significantly increased in CCl4-treated animals at 12 hours post-
dosing but no other differences were apparent (Table 6.3, Table 6.4). 
Glucose levels, however, were significantly decreased in the serum of CCl4-treated 
animals between 6 and 24 hours post-dosing. At 36 hours, glucose was increased in the 
serum from CCl4-treated animals, before showing a decrease at 48 and 60 hours post-
dosing. By 84 hours post-dosing serum glucose levels in CCl4-treated animals were 
similar to control. 
Total protein levels in the urine were significantly increased over concurrent controls at 
12 hours post-dosing (1.03-fold increase, 
*
P<0.05), but at the following time point (12-
18 hours post-dosing) levels were significantly decreased compared to controls at the 
same time point (
*
P<0.05).  
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Figure 6.2 Serum ALT, AST and GLDH levels for male Hanover-Wistar rats treated with vehicle 
(control) or CCl4 at 2.0 mL/kg and sampled at various time points post-dosing. Animals were dosed 
by gavage and sampled at the time points shown according to the schedule in Table 6.1. Serum was 
collected as described in Section 6.2 and enzymes were assayed as described in Section 2.7. Values are 
means with SD indicated by vertical bars of 5 animals per group, except at 24 to 36 hours post-dosing 
where n=4. Values that differ significantly from controls by Students’ t-test are shown:*P<0.05; **P<0.01; 
***
P<0.001. 
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Table 6.3 Serum clinical chemistry for male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 2.0 mL/kg and sampled at various time points between 6 and 48 
hours post-dosing. Animals were dosed by gavage and sampled at the time points shown according to the schedule in Table 6.1. Serum was collected as described in Section 6.2 and 
enzymes were assayed as described in Section 2.7. Values are the means and SD of 5 animals per group except at 24 to 36 hours post-dosing where TIMP-1, MCP and lipocalin-2 
values are the means of 3 control and 3 CCl4-treated animals, and A2M and AGP values are the means of 4 controls and 3 CCl4-treated animals. At 36 to 48 hours post-dosing, 
TIMP-1, A2M, MCP, AGP and lipocalin-2 are the means of 4 CCl4-treated animals. Values that differ significantly from controls by Students’ t-test are shown:
*
P<0.05; 
**
P<0.01; 
***
P<0.001. C: control; T: CCl4-treated rats. 
Time (hours) 
Serum parameters 
ALP 
(U/L) 
TIMP-1 
(μg/L) 
A2M 
(mg/L) 
MCP1 
(μg/L) 
AGP 
(mg/L) 
Lipocalin-2  
(μg/L) 
          Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
Albumin 
(g/L) 
Glucose 
(mmol/L) 
Total 
protein 
(g/L) 
0-6  
hours 
C 
590.00 
(217.19) 
5.60 
(1.34) 
34.60 
(8.08) 
11.20 
(1.48) 
61.80 
(7.22) 
34.00 
(5.05) 
6.44 
(1.00) 
21.60 
(1.14) 
34.80 
(1.30) 
9.46 
(0.63) 
56.20 
(3.11) 
T 
783.80 
(244.92) 
18.00
*
 
(7.00) 
34.80 
(8.20) 
23.40
*
 
(8.93) 
83.40 
(19.78) 
77.00 
(53.63) 
9.28
**
 
(1.12) 
23.00 
(2.55) 
35.20 
(1.10) 
7.28
**
 
(0.97) 
55.40 
(1.67) 
6-12 
hours 
C 
405.80 
(110.03) 
6.00 
(2.00) 
18.60 
(2.51) 
9.00 
(1.22) 
61.00 
(14.09) 
38.00 
(7.14) 
6.68 
(0.74) 
25.00 
(2.00) 
33.40 
(0.89) 
8.48 
(0.30) 
54.20 
(0.84) 
T 
560.80
*
 
(78.66) 
20.80
***
 
(3.96) 
26.20
*
 
(5.54) 
28.00
*
 
(9.95) 
70.60 
(13.72) 
102.60
*
 
(58.82) 
8.44
**
 
(0.60) 
25.20 
(2.59) 
34.80
*
 
(0.84) 
7.02
**
 
(0.51) 
55.60
*
 
(0.55) 
12-18 
hours 
C 
440.40 
(106.00) 
5.60 
(1.67) 
21.60 
(7.96) 
8.00 
(1.22) 
80.40 
(21.10) 
34.40 
(4.61) 
6.06 
(0.72) 
22.80 
(2.59) 
33.40 
(0.89) 
10.29 
(0.70) 
54.20 
(1.30) 
T 
938.20
*
 
(340.23) 
33.75
*
 
(12.39) 
30.00 
(9.92) 
51.00
*
 
(23.47) 
108.40 
(50.56) 
269.00 
(383.47) 
8.32
**
 
(0.80) 
32.40
*
 
(5.90) 
34.20 
(0.84) 
6.81
***
 
(0.70) 
52.20
*
 
(0.84) 
18-24 
hours 
C 
456.60 
(10.67) 
6.00 
(1.22) 
24.40 
(6.80) 
7.40 
(1.14) 
66.60 
(12.30) 
30.00 
(2.92) 
6.00 
(0.87) 
21.20 
(1.64) 
33.20 
(0.84) 
9.39 
(1.09) 
52.40 
(1.14) 
T 
839.80
*
 
(215.27) 
85.40
***
 
(27.92) 
35.60
*
 
(6.88) 
211.80
**
 
(83.45) 
365.20
**
 
(114.62) 
867.20
*
 
(455.53) 
9.52
***
 
(0.81) 
37.40
**
 
(5.90) 
34.60 
(1.34) 
6.69
**
 
(0.54) 
54.80 
(2.59) 
24-36 
hours 
C 
385.60 
(110.92) 
7.33 
(1.15) 
32.00 
(8.52) 
8.67 
(1.53) 
49.50 
(6.61) 
47.33 
(10.60) 
4.12 
(0.54) 
20.80 
(0.45) 
34.20 
(1.48) 
6.76 
(1.21) 
53.80 
(1.92) 
T 
686.50
*
 
(204.45) 
75.33
*
 
(19.86) 
53.00 
(14.93) 
157.33
**
 
(24.79) 
457.67
**
 
(116.07) 
432.33 
(261.78) 
7.15
**
 
(1.28) 
28.75
*
  
(3.59) 
35.50 
(1.73) 
8.50
*
 
(0.38) 
55.50 
(3.42) 
36-48 
hours 
C 
403.40 
(139.70) 
7.20 
(1.64) 
41.40 
(12.54) 
8.00 
(0.71) 
65.40 
(16.56) 
37.80 
(4.60) 
7.62 
(0.59) 
23.60 
(1.67) 
32.40 
(2.07) 
7.89 
(0.88) 
50.60 
(3.78) 
T 
756.00
*
 
(288.38) 
100.50
*
 
(41.97) 
82.75 
(38.06) 
94.75 
(70.23) 
614.00
**
 
(127.57) 
1021.25
*
 
(560.15) 
11.14
*
 
(2.80) 
37.60
**
 
(8.79) 
33.20 
(3.03) 
5.85
**
 
(0.70) 
52.80 
(4.87) 
ALP: alkaline phosphatase; TMIP-1: tissue inhibitor of matrix metalloproteinase; A2M: alpha-2 macroglobulin; MCP 1: monocyte chemoattractant factor 1; AGP: alpha-1 acid 
glycoprotein.  
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Table 6.4 Serum clinical chemistry for male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 2.0 mL/kg and sampled at various time points between 48 hours 
and day 10 post-dosing. Animals were dosed by gavage and sampled at the time points shown according to the schedule in Table 6.1. Serum was collected as described in Section 
6.2 and enzymes were assayed as described in Section 2.7. Values are the means and SD of 5 animals per group except at 24 to 36 hours post-dosing where values are the means of 4 
CCl4-treated animals. Values that differ significantly from controls by Students’ t-test are shown:
*
P<0.05; 
**
P<0.01; 
***
P<0.001. C: control; T: CCl4-treated rats. 
Time 
(hours/days) 
Serum parameters 
ALP 
(U/L) 
TIMP-1 
(μg/L) 
A2M 
(mg/L) 
MCP1 
(μg/L) 
AGP 
(mg/L) 
Lipocalin-2  
(μg/L) 
         Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
Albumin 
(g/L) 
Glucose 
(mmol/L) 
Total 
protein 
(g/L) 
48-60 
hours 
C 
327.00 
(43.10) 
6.40 
(1.95) 
41.20 
(14.31) 
8.60 
(1.14) 
60.20 
(10.94) 
40.20 
(3.27) 
5.52 
(0.77) 
21.40 
(1.14) 
34.60 
(1.52) 
7.64 
(0.47) 
54.40 
(2.19) 
T 
669.00 
(314.66) 
54.00
**
 
(19.13) 
77.80 
(71.75) 
38.60 
(32.76) 
404.00
**
 
(119.42) 
400.80
*
 
(273.02) 
6.66 
(2.16) 
27.20
**
 
(2.77) 
34.40 
(2.30) 
5.52
**
 
(0.72) 
53.60 
(1.67) 
60-72 
hours 
C 
393.20 
(103.74) 
6.00 
(1.58) 
30.60 
(11.26) 
7.00 
(1.58) 
45.20 
(7.19) 
42.20 
(6.46) 
7.44 
(0.62) 
23.40 
(2.41) 
34.20 
(1.30) 
8.19 
(1.02) 
53.80 
(1.64) 
T 
616.60 
(258.83) 
27.00 
(20.43) 
55.20
*
 
(18.06) 
9.80 
(4.21) 
274.80
**
 
(97.68) 
211.80
*
 
(114.94) 
7.74 
(1.32) 
25.60 
(3.05) 
35.40 
(1.14) 
6.83 
(1.08) 
55.60 
(1.67) 
72-84 
hours 
C 
427.60 
(104.18) 
6.40 
(1.52) 
33.40 
(8.96) 
8.20 
(1.48) 
54.60 
(4.16) 
46.40 
(2.30) 
6.00 
(0.64) 
20.80 
(1.64) 
36.00 
(1.58) 
7.39 
(1.40) 
56.80 
(2.59) 
T 
623.80 
(297.58) 
15.40 
(8.73) 
79.20
*
 
(36.96) 
9.00 
(3.46) 
249.80
*
 
(138.59) 
237.80 
(211.85) 
5.64 
(1.44) 
23.40 
(2.61) 
34.40 
(2.07) 
7.90 
(0.82) 
55.00 
(3.74) 
84-96 
hours 
C 
325.60 
(32.78) 
5.80 
(1.64) 
32.60 
(16.52) 
7.60 
(0.89) 
73.00 
(23.48) 
44.00 
(2.74) 
7.46 
(0.39) 
24.20 
(1.48) 
34.40 
(1.14) 
7.06 
(1.04) 
55.00 
(1.41) 
T 
400.20 
(88.86) 
9.60
*
 
(2.97) 
61.40 
(46.60) 
7.40 
(1.34) 
151.80
*
 
(49.09) 
90.20 
(67.63) 
6.34 
(1.10) 
23.00 
(1.41) 
34.40 
(1.14) 
7.04 
(0.39) 
54.80 
(1.92) 
Day 6 
C 
391.40 
(85.98) 
6.60 
(1.82) 
27.20 
(5.72) 
9.00 
(0.71) 
61.80 
(11.54) 
44.60 
(6.50) 
7.76 
(1.10) 
22.20 
(4.76) 
33.20 
(1.30) 
8.74 
(0.54) 
53.60 
(2.61) 
T 
432.20 
(85.83) 
7.40 
(1.34) 
47.20
*
 
(12.76) 
7.80 
(3.70) 
89.80 
(27.22) 
41.60 
(6.58) 
7.02 
(1.39) 
21.60 
(2.30) 
34.60 
(2.51) 
8.41 
(1.81) 
54.80 
(3.27) 
Day 10 
C 
369.00 
(75.92) 
5.40 
(1.34) 
20.00 
(5.29) 
8.40 
(0.89) 
54.20 
(9.15) 
39.40 
(3.44) 
7.94 
(0.99) 
23.60 
(2.41) 
34.80 
(1.10) 
8.94 
(0.26) 
56.00 
(2.83) 
T 
387.80 
(59.74) 
6.20 
(0.84) 
27.60
*
 
(4.28) 
8.00 
(1.58) 
61.20 
(9.15) 
34.60 
(4.34) 
8.80 
(0.75) 
21.80 
(1.30) 
35.00 
(1.41) 
9.33 
(0.90) 
55.20 
(1.64) 
ALP: alkaline phosphatase; TMIP-1: tissue inhibitor of matrix metalloproteinase; A2M: alpha-2 macroglobulin; MCP 1: monocyte chemoattractant factor 1; AGP: alpha-1 acid 
glycoprotein.  
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6.3.5 Urine clinical chemistry 
Urine samples generated in this study were analysed for markers of kidney toxicity 
(Table 6.5, Table 6.6) as measured in Chapter 4.  
Levels of urinary α-GST in CCl4-treated animals did not show evidence of a statistically 
significant difference compared to controls during the first 24 hours post-dosing but at 
36 hours there was a significant decrease (Table 6.5). At 48 hours after the CCl4 
administration, mean urinary α-GST was approximately 12-fold increased over controls, 
but this was not statistically significant. Urinary GST Yb1 was significantly increased at 
12 hours post-dosing and then showed a non-significant increase in levels at 48 hours 
(Table 6.5, Table 6.6). 
KIM-1 was significantly increased at 12 hours and at 84 hours post-dosing but was 
similar to control at all other time points (Table 6.5, Table 6.6). Clusterin levels in the 
urine were significantly increased in CCl4-treated animals compared to control at 36 and 
48 hours post-dosing. Levels of clusterin were then lower than controls at 84 hours post-
dosing and at day 6 of the study (Table 6.5, Table 6.6). 
Osteopontin showed no evidence of a CCl4-administration related effect at the earlier 
time points but urinary levels were significantly increased at 36 hours post-dosing. At 
48 to 60 hours post-dosing mean urinary values in CCl4-treated animals were 
approximately 5 times greater than control values (58.00 and 12.00 ng/c.p. for CCl4-
treated and control animals respectively; 
*
P<0.05). Urinary lipocalin-2 was increased 
over controls in CCl4-treated animals as early as 12 hours post-dosing (2.4-fold) and by 
48 hours post-dosing the fold increase was 107 for CCl4-treated animals compared to 
concurrent controls (2242.00 and 241574.00 ng/c.p. for control and treated animals 
respectively; 
**
P<0.01) (Table 6.5, Table 6.6). Lipocalin-2 levels were similar to 
controls by day 6 of the study. 
Urinary creatinine was significantly decreased by 1.8-fold when compared to controls at 
6 hours post-dosing (
*
P<0.05). At 72 hours post-dosing mean creatinine levels were also 
significantly decreased in CCl4-treated animals (
**
P<0.01) but at all other time points 
creatinine levels were similar to controls (Table 6.5, Table 6.6).  
Urinary total protein concentration was lower in CCl4-treated animals than in control at 
all time points except at 48 hours post-dosing when a 3-fold increase was observed 
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(Table 6.5, Table 6.6). However, this increase was not statistically significant due to the 
large standard deviation within the group. 
Albumin was significantly increased in CCl4-treated animals when compared to controls 
at intermittent time points (12, 48 and 60 hours post-dosing). Urinary excretion of 
albumin was greatest at 48 hours post-dosing (1246.20 ng/c.p. over 44.00 ng/c.p. for 
CCl4-treated and control rats respectively; 
*
P<0.05). However, at 84 hours, and at day 6, 
urinary albumin levels were significantly decreased compared to controls (
**
P<0.01 and 
*
P<0.05, respectively) (Table 6.5, Table 6.6).  
Urinary glucose did not show evidence of a CCl4 treatment-related effect whereas urine 
volume was significantly increased over controls in CCl4-treated animals at 24 and 48 
hours post-dosing (
*
P<0.05). 
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Table 6.5 Urinary clinical chemistry for male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 2.0 mL/kg and sampled at various time points between 6 and 
48 hours post-dosing. Animals were dosed by gavage and sampled at the time points shown according to the schedule in Table 6.1. Urine was collected as described in Section 6.2 
and clinical parameters were assayed as described in Section 2.7. Values are the means and SD of 5 animals per group. Values that differ significantly from controls by Students’ t-
test are shown:
*
P<0.05; 
**
P<0.01; 
***
P<0.001. C: control; T: CCl4-treated rats. c.p. = collection period, 6 hours (6-24 hours) and 12 hours (24 hours-day 10). 
Time 
(hours/days) 
Urinary parameters 
α-GST 
(ng/c.p.) 
GST Yb1 
(ng/c.p.) 
Clusterin 
(ng/c.p.) 
KIM-1 
(ng/c.p.) 
Osteopontin 
(ng/c.p.) 
Lipocalin-2 
(ng/c.p.) 
Creatinine 
(µmol/c.p.) 
Total 
protein 
(mg/c.p.) 
Albumin 
(mg/c.p.) 
Glucose 
(µmol/c.p.) 
Volume 
(mL) 
0-6  
hours 
C 
72.00 
(90.11) 
10.00 
(0.00) 
10.20 
(6.02) 
4.40 
(1.14) 
28.00 
(29.50) 
1086.00 
(359.35) 
16.40 
(4.04) 
2.64 
(0.69) 
55.00 
(25.90) 
2.60 
(0.89) 
7.40 
(4.28) 
T 
42.00 
(21.68) 
8.00 
(4.47) 
9.60 
(5.90) 
2.60 
(1.82) 
10.00  
(7.07) 
394.00
**
 
(157.00) 
9.00
*
 
(2.83) 
0.90
**
 
(0.32) 
27.60 
(19.31) 
1.60 
(0.55) 
6.80 
(3.56) 
6-12 
hours 
C 
22.00 
(10.95) 
8.00 
(8.37) 
13.80 
(7.89) 
3.60 
(1.52) 
36.67 
(15.28) 
636.00 
(111.94) 
14.80 
(4.66) 
2.30 
(0.90) 
25.00 
(9.75) 
1.80 
(0.84) 
8.20 
(6.02) 
T 
112.00 
(98.08) 
38.00
*
 
(14.83) 
5.40 
(1.67) 
6.20
*
 
(1.30) 
24.00 
(5.48) 
1544.00
***
 
(398.79) 
20.40 
(4.51) 
1.32
*
 
(0.46) 
145.40
*
 
(125.89) 
3.20 
(1.64) 
5.40 
(1.67) 
12-18 
hours 
C 
50.00 
(35.36) 
10.00 
(0.00) 
20.80 
(8.07) 
2.00 
(1.22) 
24.00 
(18.17) 
620.00 
(374.63) 
12.80 
(2.49) 
2.40 
(0.74) 
47.20 
(38.43) 
2.20 
(0.45) 
8.80 
(2.59) 
T 
98.00 
(84.08) 
18.00 
(8.37) 
14.40 
(6.35) 
3.60 
(1.95) 
44.00 
(20.74) 
2118.00 
(1300.68) 
16.80 
(4.76) 
0.78
**
 
(0.31) 
51.60 
(21.82) 
3.00 
(1.22) 
14.40 
(6.35) 
18-24 
hours 
C 
86.00 
(66.18) 
10.00 
(7.07) 
14.80 
(12.91) 
3.80 
(1.48) 
40.00 
(30.00) 
916.00 
(487.83) 
14.40 
(3.91) 
2.98 
(2.08) 
36.06 
(34.98) 
2.40 
(0.89) 
7.46 
(3.27) 
T 
60.00 
(28.28) 
26.00 
(18.17) 
49.60 
(41.13) 
4.20 
(2.28) 
40.00 
(20.00) 
10052.00
**
 
(6747.47) 
17.60 
(2.61) 
1.04
*
 
(0.33) 
82.60 
(82.30) 
2.60 
(0.55) 
24.00* 
(14.98) 
24-36 
hours 
C 
514.00 
(257.45) 
26.00 
(15.17) 
10.40 
(3.85) 
6.80 
(0.84) 
8.00 
(4.47) 
1314.00 
(382.79) 
27.80 
(4.32) 
2.46 
(0.80) 
50.00 
(12.81) 
3.20 
(0.45) 
7.60 
(1.67) 
T 
82.00
*
 
(105.69) 
18.00 
(8.37) 
22.00
*
 
(9.59) 
6.20 
(2.59) 
30.00
*
 
(7.07) 
14098.00
**
 
(13245.64) 
21.40 
(5.41) 
1.14
**
 
(0.29) 
70.80 
(44.53) 
2.60 
(0.55) 
10.80 
(3.03) 
36-48 
hours 
C 
262.00 
(353.37) 
170.00 
(318.98) 
21.40 
(8.35) 
5.40 
(1.52) 
18.00 
(8.37) 
2242.00 
(592.22) 
20.60 
(4.39) 
2.26 
(0.62) 
44.00 
(32.89) 
2.80 
(1.10) 
13.00 
(6.00) 
T 
3106.00 
(4290.29) 
1332.00 
(1739.82) 
75.80
*
 
(64.41) 
4.40 
(2.30) 
54.00
*
 
(31.30) 
241574.00
**
 
(223697.62) 
20.60 
(1.52) 
6.90 
(6.97) 
1246.20
*
 
(1337.29) 
1.80 
(0.45) 
25.80
*
 
(6.26) 
 
α-GST: glutathione S-transferase; GST Yb1: glutathione S-transferase Yb1; KIM-1: kidney injury molecule-1. 
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Table 6.6 Urinary clinical chemistry for male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 2.0 mL/kg and sampled at various time points between 48 
hours and day 10 post-dosing. Animals were dosed by gavage and sampled at the time points shown according to the schedule in Table 6.1. Urine was collected as described in 
Section 6.2 and clinical parameters were assayed as described in Section 2.7. Values are the means and SD of 5 animals per group. Values that differ significantly from controls by 
Students’ t-test are shown:*P<005; **P<0.01; ***P<0.001. C: control; T: CCl4-treated rats. c.p. = collection period, 12 hours (24 hours-day 10). 
Time 
(hours/days) 
Urinary parameters 
α-GST 
(ng/c.p.) 
GST Yb1 
(ng/c.p.) 
Clusterin 
(ng/c.p.) 
KIM-1 
(ng/c.p.) 
Osteopontin 
(ng/c.p.) 
Lipocalin-2 
(ng/c.p.) 
Creatinine 
(µmol/c.p.) 
Total 
protein 
(mg/c.p.) 
Albumin 
(mg/c.p.) 
Glucose 
(µmol/c.p.) 
Volume 
(mL) 
48-60 
hours 
C 
462.00 
(423.52) 
68.00 
(87.01) 
14.80 
(8.44) 
6.80 
(3.70) 
12.00 
(8.37) 
1584.00 
(732.69) 
26.00 
(12.02) 
3.02 
(1.55) 
93.20 
(31.92) 
3.40 
(1.67) 
8.80 
(4.15) 
T 
56.00
*
 
(33.62) 
40.00 
(15.81) 
13.80 
(7.36) 
9.60 
(2.79) 
58.00
*
 
(33.47) 
133698.00
***
 
(150960.30) 
27.80 
(5.81) 
1.70 
(0.23) 
144.40
*
 
(82.43) 
2.40 
(0.55) 
11.60 
(5.77) 
60-72 
hours 
C 
138.00 
(180.47) 
28.00 
(13.04) 
45.20 
(14.25) 
6.20 
(1.48) 
34.00 
(11.40) 
2026.00 
(1136.06) 
24.40 
(3.91) 
2.02 
(0.41) 
46.00 
(23.24) 
2.80 
(0.45) 
17.20 
(4.15) 
T 
134.00 
(104.31) 
22.00 
(10.95) 
40.40 
(10.24) 
5.60 
(1.52) 
26.00 
(8.94) 
11462.00
**
 
(10174.38) 
15.60
**
 
(3.76) 
0.88
**
 
(0.25) 
31.20 
(22.52) 
1.40
**
 
(0.55) 
17.20 
(5.93) 
72-84 
hours 
C 
126.00 
(59.41) 
14.00 
(8.94) 
18.80 
(7.43) 
6.00 
(1.87) 
26.00 
(8.94) 
1786.00 
(441.28) 
22.40 
(4.83) 
3.76 
(1.48) 
74.80 
(27.11) 
3.20 
(1.30) 
9.20 
(2.28) 
T 
50.00
*
 
(23.45) 
28.00 
(29.50) 
16.00
*
 
(15.68) 
9.00
*
 
(1.22) 
44.00 
(18.17) 
46002.00
*
 
(59102.75) 
27.20 
(2.77) 
1.30
**
 
(0.24) 
24.60
**
 
(6.99) 
2.20 
(0.84) 
9.40 
(1.34) 
84-96 
hours 
C 
76.00 
(40.37) 
26.00 
(13.42) 
37.40 
(6.47) 
5.60 
(0.89) 
34.00 
(5.48) 
1476.00 
(441.17) 
22.40 
(5.68) 
2.28 
(0.83) 
34.80 
(23.39) 
2.40 
(0.89) 
16.00 
(6.44) 
T 
194.00
*
 
(70.92) 
88.00 
(124.78) 
42.20 
(39.58) 
8.00 
(6.16) 
18.00
**
 
(4.47) 
6476.00
**
 
(5561.73) 
21.20 
(2.28) 
0.98
**
 
(0.13) 
26.40 
(19.57) 
2.40 
(0.55) 
10.60 
(3.58) 
Day 6 
C 
44.00 
(15.17) 
22.00 
(4.47) 
49.20 
(11.63) 
7.40 
(1.67) 
40.00 
(10.00) 
2170.00 
(617.74) 
30.40 
(7.23) 
3.98 
(1.06) 
86.00 
(45.25) 
4.40 
(1.52) 
17.20 
(4.38) 
T 
66.00 
(61.07) 
116.00
*
 
(138.31) 
29.60
*
 
(7.80) 
6.20 
(1.48) 
32.00 
(21.68) 
2036.00 
(469.61) 
23.80 
(4.87) 
1.42
**
 
(0.53) 
24.80
*
 
(10.73) 
2.80
*
 
(0.84) 
14.00 
(4.90) 
Day 10 
C 
44.00 
(15.17) 
24.00 
(8.94) 
18.20 
(12.58) 
3.20 
(1.10) 
8.00 
(4.47) 
594.00 
(244.81) 
17.20 
(5.54) 
2.64 
(0.54) 
36.20 
(17.78) 
0.40 
(0.89) 
12.20 
(3.35) 
T 
66.00 
(61.07) 
14.00 
(5.48) 
10.20 
(8.11) 
3.40 
(3.21) 
4.00 
(5.48) 
620.00 
(687.86) 
13.40 
(10.04) 
1.42 
(1.06) 
18.00 
(15.18) 
0.40 
(0.55) 
9.60 
(2.41) 
 
α-GST: glutathione S-transferase; GST Yb1: glutathione S-transferase Yb1; KIM-1: kidney injury molecule-1. 
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B A 
6.3.6 Histopathology 
In this study, liver and kidney samples were analysed from 3 randomly chosen CCl4-
treated animals and 1 control animal at each time point due to the large number of 
samples generated (Figure 6.3). 
At the first time point (6 hours post-dosing) there was vacuolation of hepatocytes, 
mainly in the midzonal area. By 12 hours post-dosing, the eosinophilic staining had 
increased in intensity, which indicates early cellular degeneration. At 18 hours post-
dosing there was clear evidence of degeneration or necrosis of these centrilobular cells. 
The degeneration and necrosis had become more widespread by 24 hours post-dosing 
and there was also evidence of early inflammatory cell infiltration in the centrilobular 
zone. By 48 hours, there was a marked increase in centrilobular mixed inflammatory 
cells infiltration and mitotic midzonal hepatocytes were also evident. 
At 72 hours a very small number of necrotic hepatocytes were still present and there 
was less centrilobular inflammatory cell infiltrate. However, an increase in the number 
of fibroblasts was apparent. By day 10 post-dosing the architecture of the liver had 
returned to near-normal. 
In the kidneys of some CCl4-treated animals, changes were similar across all time points 
and consisted of minimal or trace vacuolation of proximal tubular epithelium. 
 
c 
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Figure 6.3 Histology of liver sections from male Hanover-Wistar rats treated with vehicle (control) 
or CCl4 at 2.0 mL/kg and sampled at various time points post-dosing. H&E staining. Rats were 
treated with vehicle or CCl4 and autopsied at 6, 12, 18, 24, 48 hours and at day 10 post-dosing. At 
autopsy, liver samples were collected and processed for histopathological examination as described in 
Section 2.8. (A) control liver: central (c) and portal vein (p) (original magnification, x 40); (B) CCl4-
treated rat at 6 hours post-dosing: midzonal vacuolation (original magnification, x 200); (C) CCl4-treated 
rat at 12 hours post-dosing: degenerative changes in centrilobular hepatocytes (original magnification, x 
200); (D) CCl4-treated rat at 18 hours post-dosing: degeneration and necrosis of centrilobular hepatocytes 
(original magnification, x 200); (E) CCl4-treated rat at 24 hours post-dosing: extensive degeneration and 
necrosis of centrilobular hepatocytes (original magnification, x 200); (F) CCl4-treated rat at 48 hours post-
dosing: necrosis of centrilobular hepatocytes with cellular infiltration and midzonal mitotic hepatocytes 
(original magnification, x 200); (G) CCl4-treated rat at day 10 post-dosing: near normal architecture 
(original magnification, x 200). 
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6.3.7 1D 1H NMR spectrometry 
In this study we wished to investigate the pattern of urinary metabolites as hepatic 
injury occurs and with subsequent recovery from the injury over a period of 10 days 
post-dosing.  
Due to technical problems with the NMR instrument urine samples collected between 
24 and 48 hours post-dosing were not analysed by 1D 
1
H NMR. All other samples were 
analysed for the construction of a temporal map of urinary metabolite changes. A PCA 
scores plot of all these samples did not allow visualisation of a pattern of change since 
the high number of samples did not allow good separation on the scores plot (data not 
shown). 
A PCA model for all urine samples from CCl4-treated animals in this study revealed the 
presence of outliers located outside the Hotelling’s T2 ellipse. Of these outliers, 3 were 
above the 99 % T2 critical value in the Hotelling’s T2 range plot (1 sample at 12-18 
hours, 1 sample at 48-60 hours, and 1 sample at day 10 post-dosing). The spectra for 
these data points were visually inspected and it was considered that spectra acquisition 
was compromised either due to poor water suppression or problems with the NMR 
instrument. The remaining samples were not excluded from the model. The PCA scores 
plot for this model is shown in Figure 6.4.  
The great number of samples included in this PCA model did not allow the 
identification of a trajectory pattern since many points overlapped and did not cluster 
well. Therefore, a new PCA model was constructed using only the average spectrum for 
each group of control and CCl4-treated samples in the study (Figure 6.5). 
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Figure 6.4 PCA scores plot from a PCA model derived from 1D 
1
H NMR spectral data of urine 
samples from male Hanover-Wistar rats treated with CCl4 at 2.0 mL/kg and sampled at various 
time points post-dosing. Rats were dosed by gavage and sampled at the time points shown and urine 
collected as described in Section 6.2. Each spot in the scores plot represents one urine sample. R
2
X (cum) 
= 0.683, Q
2
 (cum) = 0.476. 
  
Figure 6.5 PCA trajectory plot from a PCA model derived from 1D 
1
H NMR spectral data of urine 
samples from male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 2.0 mL/kg and 
sampled at various time points post-dosing. Rats were dosed by gavage and sampled at the time points 
shown and urine collected as described in Section 6.2. Points in the trajectory plot represent the spectra 
created from the average of integral regions for each group of samples. R
2
X (cum) = 0.695, Q
2
 (cum) = 
0.445. Arrows represent direction of movement. 
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The trajectory plot shown in Figure 6.5 demonstrated the change in location on the PCA 
scores plot with time which corresponded to a change in metabolites with time. The 
numbers (1-9) labelled on the scores plot represent the order of sample collection with 
time. Inspection of this PCA plot revealed that the average urine sample collected 
between 0 to 6 hours post-dosing positioned closely to the control samples, shown in 
grey colour and located on the left hand-side of the scores plot. Urine samples collected 
between 6 and 24 hours following a single dose of CCl4 had shifted towards the right 
side of the scores plot, away from controls and the 0 to 6 hours time point. However, at 
the 48 to 60 hours post-dosing time point it was observed that sample points had moved 
back towards the left side of the plot closer to control samples, indicating a possible 
return to an almost control-like urinary metabolite composition. At later time points, 
samples from CCl4-treated animals were located in the same quadrant as the respective 
controls and no separation was clearly visible.  
The 2 different trends in this PCA model of acute liver injury were in opposite 
directions and correspond to the injury occurring in the first 24 hours followed by a 
period of hepatic regeneration, during which the liver tissue recovers from the injury 
and restores its normal appearance. 
To identify the specific changes to urinary metabolites which were responsible for 
sample clustering and trajectory trends, individual OPLS-DA models were constructed. 
For the first plot CCl4-treated samples at 6 hours post-dosing were compared to controls 
and thereafter CCl4-treated samples from consecutive time points were compared 
(Figure 6.6). The discriminating component on the scores plots t[1] showed the variance 
between the samples, whereas t[0] corresponded to intragroup variation. Individual 
OPLS-DA scores plot revealed evidence of very good degrees of separation between 
CCl4-treated samples at the different time points.  
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Figure 6.6 Scores plots from OPLS-DA models derived from 1D 
1
H NMR spectral data of urine 
samples from male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 2.0 mL/kg and 
sampled at various time points post-dosing. Rats were treated dosed by gavage and urine collected as 
described in Section 6.2. (A) Control and CCl4-treated animals at 0 to 6 hours post-dosing; (B) CCl4-
treated animals at 0 to 6 hours and 6 to 12 hours post-dosing; (C) CCl4-treated animals at 6 to 12 hours 
and 12 to 18 hours post-dosing; (D) CCl4-treated animals at 12 to 18 hours and 18 to 24 hours post-
dosing; (E) CCl4-treated animals at 18 to 24 hours and 48 to 60 hours post-dosing; (F) CCl4-treated 
animals at 48 to 60 hours and 60 to 72 hours post-dosing; (G) CCl4-treated animals at 60 to 72 hours and 
72 to 84 hours post-dosing; (H) CCl4-treated animals at 72 to 84 hours and 84 to 96 hours post-dosing; (I) 
CCl4-treated animals at 84 to 96 hours and 132 to 144 hours post-dosing and (J) CCl4-treated animals at 
132 to 144 hours and 212 to 224 hours post-dosing. 
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Potential biomarkers were selected based on the S-plots and VIP plots (data not shown) 
and were statistically compared using a Students’s t-test. The changes in metabolites 
with time following a single dose of CCl4 are summarized in Table 6.7. However, we 
also wished to characterise changes in the urine of CCl4-treated animals compared to 
controls at 24 hours and at day 10 post-dosing respectively (Figure 6.7, Table 6.8). 
 
 
 
 
 
 
 
 
Figure 6.7 Scores plots from OPLS-DA models derived from 1D 
1
H NMR spectral data of urine 
samples from male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 2.0 mL/kg and 
sampled at 24 hours and 224 hours (day 10) post-dosing. Rats were dosed by gavage and urine 
collected as described in Section 6.2. (A) Control and CCl4-treated animals at 18 to 24 hours post-dosing; 
(B) Control and CCl4-treated animals at 212 to 224 hours (day 10) post-dosing. 
 
Formate was increased in CCl4-treated samples at 6 hours when compared to control 
(Table 6.7). This level decreased at 12 hours compared to CCl4-treated animals at the 
previous time point. There was an increase in urinary formate in CCl4-treated animals at 
18 and 24 hours post-dosing. At 24 hours post-dosing urinary formate was increased in 
CCl4-treated animals compared to controls at the same time point (Table 6.8). After this 
time point there appeared to be a decreasing trend in urinary formate excretion and by 
day 10, formate levels in the urine of CCl4-treated animals were decreased compared to 
concurrent control rats (Table 6.8). 
Taurine was decreased at the first time point (6 hours) when compared to control, 
however, CCl4-treated samples at 12 and 18 hours had increased amounts of taurine 
A B 
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(212-224 hr) 
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compared to treated samples at 6 and 12 hours respectively (Table 6.7). From 18 hours 
post-dosing, taurine levels decreased with time in the CCl4-treated samples, but were 
still increased over concurrent controls in CCl4-treated animals at 24 hours post-dosing 
(Table 6.8). From 48 hours to day 10 post-dosing urinary taurine levels decreased 
consistently compared to previous time points and there appeared to be a return to 
control levels at day 10 (Table 6.8). Creatinine levels showed an increasing trend during 
the first 24 hours and at this time point they were significantly increased in CCl4-treated 
rats over vehicle-treated animals (Table 6.7). By day 10 post-dosing, urinary creatinine 
levels were decreased in CCl4-treated rats compared to concurrent controls (Table 6.8). 
Urinary 2-oxoglutarate appeared to decrease in CCl4-treated animals during the first 18 
hours post-dosing up to 24 hours post-dosing at which time levels were significantly 
decreased compared to the concurrent controls (Table 6.7, Table 6.8). At the later time 
points levels increased indicating a possible correlation with regeneration of the liver 
but by day 10 levels had still not reached control values (Table 6.8). Citrate followed a 
similar pattern of change with time post-dosing; at 24 hours levels were significantly 
decreased compared to control rats, after which they appeared to increase with time and 
by day 10 they were increased over control animals (Table 6.7, Table 6.8). Hippurate 
levels in the urine were decreased at the earlier time points and at 24 hours they were 
significantly decreased compared to concurrent controls. Levels increased at the later 
recovery time points from 60 hours post-dosing; again indicating a correlation with 
injury and regeneration in this model (Table 6.7, Table 6.8). 
Metabolites that appeared to show an increasing trend during the first 18 hours 
following CCl4-administration include formate, creatinine, creatine, taurine and 
succinate whereas hippurate, 2-oxoglutarate and citrate demonstrated a decrease in 
urinary excretion during the first 24 hours of treatment. After this time point there 
appeared to be a general decrease in the levels of creatine and taurine excretion in the 
rat urine, and an increase in the resonances corresponding to the metabolites 2-
oxoglutarate and citrate. 
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Table 6.7 OPLS-DA detected 1D 
1
H NMR chemical shift regions responsible for the separation of NMR derived spectra from the urine of male Hanover-Wistar rats 
treated with vehicle (control) or CCl4 at 2.0 mL/kg and sampled at various time points between 6 hours and day 10 post-dosing. Rats were treated dosed by gavage and 
sampled at the time points shown as described in Section 6.2. Chemical shifts were statistically compared by means of a Students’ t-test. Control animals at 6 hours were compared 
to CCl4-treated animals at 6 hours; after this, CCl4-treated animals were compared to CCl4-treated rats at the previous time point. Values that differ significantly from controls, or 
CCl4-treated animals at the previous time point are shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
 
Chemical 
shift (δ), 
multiplicity 
Endogenous 
metabolite 
Control (0-6 hours) vs CCl4-
treated  
(0 – 6 hours) 
6 – 12 
 hours 
12 – 18  
hours 
18 – 24  
hours 
48 – 60  
hours 
60 – 72  
hours 
86 – 96  
hours 
Day 10 
8.46-8.50 (s) formate +
***
 - + + - + - - 
7.70-7.74 (d) hippurate + - + + - - -
*
 +
**
 
7.62-7.66 (t) hippurate -
***
 -
***
 - + + + + - 
7.54-7.58 (t) hippurate  -
***
 -
***
 - + + + + - 
4.06-4.10 (s) creatinine + + - + - + + + 
3.98-4.02 (d) hippurate -
***
 -
***
 - +
*
 + + + - 
3.94-3.98 (s) creatine - + + - - - + - 
3.42-3.46 (t) taurine - +
**
 + - - - - - 
3.26-3.30 (t) taurine - + + - - - - - 
3.06-3.10 (s) creatinine + +
*
 -
*
 + -
*
 - - - 
2.98-3.02 (t) 2-oxoglutarate - - - + + +
**
 -
*
 +
**
 
2.70-2.74 (d) citrate - - -
**
 - +
***
 + + - 
2.54-2.58 (d) citrate - - - - +
**
 + + - 
2.42-2.46 (t) 2-oxoglutarate + -
*
 -
*
 - +
**
 + + +
*
 
2.38-2.42 (s) succinate + + - + - + - + 
 
S, singlet; d, doublet; t, triplet. 
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Table 6.8 OPLS-DA detected 1D 
1
H NMR chemical shift regions responsible for the separation of NMR derived spectra from the urine of male Hanover-Wistar rats 
treated with vehicle (control) or CCl4 at 2.0 mL/kg at 24 hours and at day 10 post-dosing. Rats were dosed by gavage and sampled at the time points shown as described in 
Section 6.2. Chemical shifts were statistically compared by means of a Students’ t-test. CCl4-treated animals at 24 hours and at day 10 post-dosing were compared to concurrent 
controls. Values that differ significantly from controls are shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
  
Chemical shift (δ), multiplicity Endogenous metabolite 
Control (18-24 hours) vs 
CCl4-treated (18-24 hours) 
Controls (day 10) vs  
CCl4-treated (day 10) 
8.46-8.50 (s) formate + - 
7.70-7.74 (d) hippurate +
*
 +
**
 
7.62-7.66 (t) hippurate -
***
 - 
7.54-7.58 (t) hippurate  -
***
 - 
4.06-4.10 (s) creatinine + - 
3.98-4.02 (d) hippurate -
**
 - 
3.94-3.98 (s) creatine + - 
3.42-3.46 (t) taurine +
*
 -
*
 
3.26-3.30 (t) taurine +
*
 + 
3.06-3.10 (s) creatinine +
***
 - 
2.98-3.02 (t) 2-oxoglutarate -
**
 - 
2.70-2.74 (d) citrate -
***
 + 
2.54-2.58 (d) citrate -
***
 + 
2.42-2.46 (t) 2-oxoglutarate -
***
 -
*
 
2.38-2.42 (s) succinate +
**
 + 
 
S, singlet; d, doublet; t, triplet. 
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6.4 Discussion 
An acute model of CCl4-induced hepatic injury was developed in Chapter 3 and in this 
study we investigated the change in urinary metabolites as hepatic injury developed and 
subsequent regeneration occurred. An ideal marker will be sensitive to early signs of 
hepatic injury, will remain in the biofluid long enough to be detected and will return to 
normal levels upon recovery of the injury. Therefore, the purpose of this time course 
study was to investigate such characteristics in the urinary metabolites that were 
previously identified in Chapter 3. 
The dose level used in the present study was 2.0 mL/kg CCl4 since this was previously 
identified in Chapter 3 as below the threshold level for CCl4-related nephrotoxicity (2.8 
mL/kg). The first sample time point was 0-6 hours post-dosing since we thought it 
would be interesting to determine if injury could be detected in the urinary metabolites 
as early as 6 hours post-dosing. It is known that CCl4-induced lipid peroxidation can be 
detected within 5 minutes of dosing (Recknagel, 1967; Rao and Recknagel, 1968). 
Sampling was carried out according to the schedule in Table 6.1. Relative liver weights 
for CCl4-treated animals were significantly increased over controls at all terminal time 
points with the exception of day 10. This suggests injury at 6 hours post-dosing; the 
maximum fold-increase over controls was observed at 18-24 hours. After 48 hours post-
dosing the liver weights began to return to control values. 
The trend suggesting hepatic injury as early as 6 hours after a single CCl4 dose and 
increasing up to 24-48 hours post-dosing followed by an apparent recovery by day 10 
was reflected in the serum ALT, AST, GLDH and ALP measurements (Figure 6.2, 
Table 6.3, Table 6.4).  
At 6 hours post-dosing, the increase in ALT levels, unlike AST and GLDH was not 
statistically significant due to the large interanimal variability (Figure 6.2). By 96 hours 
post-dosing it appeared that ALT, AST and GLDH levels had returned to control values. 
In a previous time course study by Zira and colleagues (2013) male Wistar rats were 
dosed with 1 mL/kg CCl4 and autopsied at 12, 24, 36, 48, 60 and 72 hours post-dosing. 
The authors discovered that ALT and AST levels reached peak plasma concentrations at 
36 hours post-treatment. Similar results were described by Giffen and co-workers 
(2003). Rats were administered with CCl4 at 0.8 mL/kg and autopsied at 12, 24, 36, 48, 
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60, 72 hours post-dosing and at 4, 7, 11 and 17 days post-dosing. In this study, levels of 
serum enzymes ALT, AST and GLDH were also found to have reached peak 
concentrations at 36 hours post-treatment. By 72 hours after CCl4 administration, mean 
enzyme levels had returned to control values (Figure 6.2).  
TIMP-1 and A2M levels were also measured in the serum of rats in this study and 
appeared to follow the same general trend (Table 6.3, Table 6.4). Mean values generally 
increased with time and reached maximum concentrations at 48 hours post-CCl4 
treatment. TIMP-1 was shown to be a more sensitive serum marker than A2M since 
mean levels for TIMP-1 were significantly increased 3.26-fold over concurrent controls 
at the earliest time point (6 hours post-dosing), whereas the first significant difference 
for A2M was not observed until 12 hours post-dosing (1.41-fold increase; 
*
P<0.05). At 
48 hours post-dosing there was a 14-fold increase over controls for TIMP-1 compared 
to a 2-fold increase for A2M. In Chapter 3, TIMP-1 was significantly increased in 
animals treated with CCl4 at 1.2 mL/kg whereas for A2M an increase was observed at 
2.4 mL/kg and higher. Herbst and colleagues (1997) carried out a time course study 
investigating the levels of TIMP-1 expression following a single i.p. injection of CCl4 at 
1.25 mL/kg to female Sprague-Dawley rats. This group reported that TIMP-1 
expression in the rat liver was increased as early as 1 hour after treatment, and highest 
serum TIMP-1 levels were present at 72 hours following a single CCl4 administration 
(Herbst et al., 1997). TIMP-1 is strongly associated with hepatic inflammation as well 
as the development of fibrosis therefore the increase in serum levels immediately after a 
single dose of CCl4 would be due to the inflammatory response (Roderfeld et al., 2006). 
A2M has been shown to be involved in the inhibition of collagenase activity and 
therefore, changes to serum A2M are more often seen during the development of 
hepatic fibrosis and chronic injury (Barrett and Starkey, 1973; Montfort and Perez-
Tamayo, 1978; Truden and Boros, 1988).  
In the present study, levels of serum MCP1 were significantly increased over concurrent 
controls at 6 hours post-dosing and reached maximum concentration at 24 hours before 
returning to control levels by 72 hours after a single CCl4 administration (Table 6.3, 
Table 6.4). MCP1 is a chemotactic factor secreted by HSCs, which are responsible for 
ECM accumulation during chronic liver injury/disease (Marra et al., 1993). In a study 
by Czaja et al., (1994), male Sprague-Dawley rats were administered with a single oral 
dose of CCl4 at 0.5 mL/100 g of BW and sampled at various times after treatment. The 
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authors reported increased MCP1 mRNA levels at 2 hours after CCl4 administration 
with maximum levels observed between 12 and 48 hours. However, by 60 to 72 hours 
after CCl4 treatment MCP mRNA levels had returned to control values (Czaja et al., 
1994).  
Serum AGP and lipocalin-2 levels were also greatest at 48 hours following a single 
CCl4 administration (9.39- and 27.02-fold increase over concurrent controls for AGP 
and lipocalin-2 serum levels, respectively) (Table 6.3, Table 6.4). Lipocalin-2 was 
significantly increased over concurrent controls at 12 hours post-dosing whereas AGP 
did not show evidence of a significant difference until 24 hours post-dosing. Lipocalin-2 
is released by the liver in response to inflammation. Previous studies have reported 
increases in AGP plasma levels following CCl4-administration which is thought to be in 
response to the presence of reactive oxygen species following metabolism of CCl4 
(Sugihara et al., 1992).  
In this study, histopathological examination confirmed the presence of hepatic injury at 
6 hours post-dosing (Figure 6.3). CCl4-treated livers showed vacuolation of hepatocytes. 
At 12 and 18 hours post-dosing there was clear evidence of degeneration and necrosis of 
hepatocytes, and by 24-48 hours pathological changes had progressed. From 72 hours 
post-dosing regenerative changes were apparent and by 224 hours post-dosing (day 10), 
the architecture of the liver had returned to near normal. This mirrors what we would 
have expected from the liver weight and serum enzyme data obtained in this study. 
In the study by Giffen and colleagues (2003), histopathological examination of the 
livers sampled at several time points after administration of CCl4 at 0.8 mL/kg revealed 
that the most marked pathological changes occurred at 36 and 48 hours post-dosing, 
corresponding to the period of maximal injury. By day 4 following CCl4 treatment there 
was complete resolution of necrosis and inflammation but hepatocellular vacuolation 
remained evident in a small proportion of animals until day 17 in the study. A similar 
pattern of microscopic changes was reported by Zira and co-workers (2013) following 
the administration of CCl4 at 1 mL/kg. Maximum injury as determined by the degree of 
centrilobular inflammation and necrosis occurred between 24 and 36 hours post-dosing. 
After this time point the livers from CCl4-treated animals showed evidence of 
regeneration in the form of an increase in mitotic activity in the hepatocytes. By 72 
hours post-dosing livers from treated animals were histopathologically similar to livers 
from control animals (Zira et al., 2013). 
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Therefore, the results in our study confirm injury as early as 6 hours post-dosing and 
reaching a maximum level at 24-48 hours post-dosing. Following this, there is a period 
of regeneration and return to normal liver by day 10 post-dosing.  
Since the purpose of this study was to evaluate potential urinary biomarkers of hepatic 
injury, the absence of nephrotoxicity was important. In Chapter 4 we evaluated a wide 
range of biomarkers for nephrotoxicity and our results suggest the most sensitive 
biomarkers for kidney injury are urinary levels of α-GST, albumin, KIM-1, glucose, 
clusterin and osteopontin. In the current study these markers were used to determine if 
CCl4-induced nephrotoxicity was present (Table 6.5, Table 6.6). 
Urinary α-GST was increased over concurrent control levels at 48 hours post-dosing, 
but this increase was not statistically significant due to the large intragroup variation, 2 
animals in this group had very large increases in urinary α-GST compared to the rest of 
the group. At the other time points in the study α-GST showed some significant 
decreases and increases compared to concurrent controls, however, the changes were 
not consistent (Table 6.5, Table 6.6). 
Urinary osteopontin was significantly increased in CCl4-treated animals at 36, 48 and 60 
hours post-dosing. It is worth noticing, however, that at these time points, values for 
control animals were considerably less than at the earlier time points. Urinary lipocalin-
2 levels were significantly decreased compared to control animals at 6 hours post-
dosing, but at 12 hours after CCl4 administration a 2.43-fold increase was recorded 
(
***
P<0.001) and there appeared to be a time-related relationship, with peak urinary 
concentrations being recorded at 48 hours post-dosing. However, lipocalin-2 is not 
considered to be a reliable kidney injury biomarker since levels are also known to 
increase following hepatic damage.  
Urinary clusterin levels were also significantly increased above concurrent controls at 
36 and 48 hours post-dosing but the highest concentration was recorded at 48 hours 
following CCl4-treatment (3.54-fold increase; 
*
P<0.05). In the HCBD studies (Chapter 
4) clusterin was shown to be a marker of regeneration and peak levels were found at 
days 4 and 5 after a single nephrotoxicant insult. At these time points in the current 
study clusterin was significantly decreased compared to controls. 
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KIM-1 was significantly increased above concurrent controls at 12 and 84 hours post-
dosing but did not show evidence of a dose-related effect. Indeed KIM-1 has been 
previously described as a marker of both kidney injury and regeneration (Chapter 4) 
(Swain et al., 2012; Maguire et al., 2013). In the present study the increases at 12 hours 
and 84 hours were 1.72- and 1.50-fold, respectively. In the HCBD-time course study in 
Chapter 4, KIM-1 urinary levels peaked at day 4 and an 83-fold increased over controls 
was observed following a single administration of 45 mg/kg HCBD. 
Urinary levels of albumin were approximately 28-fold increased over concurrent 
controls at 48 hours post-dosing (
*
P<0.05) but there was no consistent evidence of an 
effect at the other time points, and the same was the case for urinary glucose which was 
significantly decreased at 72 hours and at day 6 post-dosing (Table 6.5, Table 6.6).  
It is important to mention however, that at 36 to 60 hours post-dosing there was a great 
deal of intragroup variation, which is seen in the standard deviations, and potentially 
reflects the differences in the degree of CCl4-induced injury, particularly at the time 
points when the effect was maximal. 
These results suggested that perhaps mild kidney injury may have occurred in this 
study; however, histopathological examination of the kidneys revealed the presence of 
vacuolation of the proximal tubule which was present to a similar degree in CCl4-treated 
animals at all time points. We have seen similar vacuolation of the proximal tubule in 
control animals in the dose response study in Chapter 3. Therefore, we are confident 
that renal function was not compromised in the current study. 
In the dose response study carried out in Chapter 3 the main urinary metabolite changes 
following a single dose of CCl4 were formate, hippurate, creatine, taurine, 2-
oxoglutarate and succinate. These metabolites were found to be either increased or 
decreased 24 hours after CCl4 administration. In Chapter 3, however, urine samples 
were collected from 6-24 hours post-dosing; therefore, urinary changes reflect this 
entire time point. 
In the present study we evaluated the change in urinary levels of these metabolites at a 
series of time points over 10 days following a single dose of CCl4. At the first time 
point (0-6 hours) taurine urinary levels decreased in comparison to control samples, but 
this was followed by increases at the next 2 consecutive time points (6-12 hours and 12-
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18 hours). From 18 hours there was a gradual decrease in urinary taurine with time. 
However, at 24 hours post-dosing taurine levels were still significantly increased over 
concurrent controls. By day 10, the signals for taurine excretion showed a statistically 
significant decrease compared to the previous time point, which we suggest is an 
indication that taurine levels are returning to control levels (Table 6.7, Table 6.8). 
In our previous study in Chapter 3, we reported increases in taurine excretion at 24 
hours post-CCl4 administration. Similar results have been described by other groups 
(Waterfield et al., 1991; Waterfield et al., 1993) and also in a model of acute hydrazine-
induced toxicity (Beckwith-Hall et al., 1998; Holmes et al., 2000; Nicholls et al., 2001). 
In a study by Lin and co-workers (2009), male Wistar rats were given a single 
administration of CCl4 at 1 mL/kg and urine samples collected in intervals of 24 hours 
starting immediately after dosing. Increased taurine levels in the urine, as detected by 
LC-MS analysis, were observed during the first collection period. The fact that taurine 
levels in urine increased during the first 18 hours after CCl4 dosing suggests that it is a 
reliable marker for the initial pathological changes that occur following a single dose of 
CCl4. However, it is interesting that from 18-24 hours when maximum injury is 
occurring the levels fall compared to at 18 hours but still remain significantly increased 
over control levels (Table 6.7, Table 6.8). 
Formate levels in the urine were significantly increased at 6 hours post-dosing 
compared to concurrent controls and showed a general trend of increasing with time up 
to 24 hours post-CCl4 treatment. In our previous dose-response investigation in Chapter 
3, formate levels were also found to be significantly increased over control animals at 
24 hours following the administration of 2.0 mL/kg CCl4. In our current study, urinary 
formate levels decreased with time after the first 24 hours of treatment, apart from 
between 60-72 hours post-dosing. By day 10 post-dosing, urinary formate values were 
decreased compared to control animals (Table 6.7, Table 6.8). Dow and co-workers 
(2000) carried out a time course study in male Fischer 344 rats following a single oral 
dose of CCl4 at 100 mg/kg in corn oil, 5 mL/kg. Urine samples were collected at 24 
hour intervals and analysed by 
1
H NMR for the detection of formate levels. Excretion of 
this metabolite was increased at 24 hours post-dosing but levels were greatest on day 2 
of the study. The authors also reported evidence of increased formate excretion in the 
rat urine following administration of chloroform and dichloroacetic acid. These 
compounds are also known to generate free radicals upon metabolism, similar to CCl4. 
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Dow and green (2000) suggested that CCl4, chloroform and dichloroacetic acid induce 
vitamin B12 deficiency resulting in decreased levels of tetrahydrofolate which is 
necessary for the metabolism of formate. Decreased levels of tetrahydrofolate will result 
in increased urinary formate excretion as formate metabolism is impaired (Dow and 
Green, 2000). 
Of the 4 chemicals shifts identified as hippurate, 3 demonstrated a significant decrease 
with time during the first 6 hours post-dosing, and at 12 and 18 hours, levels further 
decreased compared to previous time points (Table 6.7). However, at 18 to 24 hours 
following CCl4 treatment, levels in the urine were increased compared to the previous 
time point but still remained less than controls at 24 hours (Table 6.8). In Chapter 3, 
levels of hippurate were found to be decreased at 24 hours post-dosing. The results from 
the present study add further proof that urinary hippurate levels decrease during the first 
24 hours after dosing with CCl4. It also suggests that hippurate is a sensitive marker 
since the decrease compared to control at 6 hours post-dosing is consistent with the 
decrease seen at 24 hours. Lin and colleagues (2009) described a decrease in the 
excretion of hippuric acid in the urine of rats immediately after dosing with 1 mL/kg 
CCl4. Decreased hippurate levels in the urine occur as a result of ATP depletion which 
occurs during the process of hepatic necrosis (Gatley and Sherratt, 1977; Kim et al., 
2008a). This explains the early decreases in hippurate levels following CCl4-induced 
hepatic toxicity. From 48 hours, there appeared to be a trend for hippurate levels to 
increase with time. However, our results also demonstrate that by day 10 post-dosing, 
hippurate excretion in the urine was still decreased in CCl4-treated compared to control 
animals at the same time point (Table 6.8). This suggests hippurate is a good marker for 
the early stages of hepatic injury and levels also reflects the liver regeneration phase.  
In the current study, levels of TCA cycle intermediates, such as citrate and 2-
oxoglutarate were decreased compared to controls during the first 24 hours after CCl4 
treatment and at 24 hours this decrease was statistically significant (Table 6.8), whereas 
succinate appeared to show a general increasing trend and was increased over controls 
at 24 hours post-dosing (Table 6.8). In an investigation by Robertson et al., (2000) male 
albino Wistar rats were given a single i.p. injection of CCl4 at 10 mL/kg. The authors 
reported decreased resonances for 2-oxoglutarate, succinate and citrate in the 24 hour 
period after dosing. In experiments carried out by Holmes et al., (2000), and by Nicholls 
and colleagues (2001), using a hydrazine-induced hepatotoxicity model in the rat, levels 
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of TCA cycle intermediates such as citrate, succinate, 2-oxoglutarate and of the 
metabolite hippurate were reported to be decreased in the urine following hydrazine 
administration. In both studies, animals were kept in individual metabolism cages with 
access to food throughout the duration of the study.  
In our previous dose response study described in Chapter 3, the level of TCA 
intermediates in the urine was increased at 24 hours post-dosing following a single dose 
of CCl4. However, in Chapter 3, rats were fed for a period of 6 hours immediately after 
CCl4-treatment, before being placed in metabolism cages without access to diet for the 
collection of 18 hour urine samples. In the present time course study, animals were only 
starved for 6 hour periods during the first 24 hours and for 12 hour periods at all later 
time points. It is possible that this discrepancy between the studies accounts for the 
different metabolite levels for TCA intermediates. A study by Connor et al., (2004) 
investigated the effect of feeding and body weight loss on the 
1
H NMR urine spectra of 
male Hanover-Wistar rats treated with CCl4 at either 1.58 or 3.16 g/kg. The study used 
several groups of animals: 2 CCl4-treated groups, 1 ‘pair-fed’ group for each CCl4-
treatment group where animals were dosed with vehicle and were given the same 
quantity of food as that actually consumed by animals in the treatment group, and 1 
‘true control’ group that were dosed with vehicle and that had access to food ad libitum. 
In a PCA model of the urine samples, the authors observed the presence of 3 different 
clusters for each CCl4 dose level, due mainly to the effect of feeding and weight loss 
rather than CCl4 administration. The Connor group reported that citrate and glucose 
were the metabolites responsible for the separation between control and ‘pair-fed’ 
animals, whereas levels of taurine and creatine changed following CCl4 administration. 
The authors demonstrated the importance of establishing a correlation between the toxic 
effect induced by the toxicological compounds used, and possible body weight loss due 
to a starved state. In our study we assume that the difference observed for some TCA 
intermediates between the present study and the previous dose-response investigation 
(Chapter 3) may be related to the different feeding and starved time periods used in 
these 2 studies. However, this effect of diet and starvation requires further investigation.  
In the current study creatine levels in the urine of CCl4-treated animals appeared to 
follow the same trend as taurine during the first 24 hours of the toxic insult. Levels were 
decreased compared to control animals at 6 hours post-dosing, but at the following 2 
time points urinary creatine excretion was increased. At 24 hours following CCl4 
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administration urinary excretion of creatine was decreased compared to the previous 
collection period (12-18 hours). However, the levels remained elevated in CCl4-treated 
animals compared to vehicle-treated rats at 24 hours post-dosing (Table 6.8). These 
results reflect the increase in creatine excretion in the urine of male rats dosed at 2.0 
mL/kg CCl4 as reported in Chapter 3. Since creatine is metabolised in the liver, 
increased urinary excretion is often a result of hepatocyte leakage (Waterfield et al., 
1993). In the present study, after 24 hours of CCl4 administration, there appeared to be a 
trend for the decrease in creatine excretion in the urine and by day 10 creatine levels 
were decreased in CCl4-treated animals compared to concurrent control rats but this was 
not statistically significant (Table 6.8). We suggest this may be related to the process of 
hepatic regeneration as reported in the histopathological examination of the livers 
collected at autopsy, which revealed a decrease in the number of necrotic hepatocytes, 
which may result in reduced urinary creatine levels. 
Throughout the present time course study creatinine levels appeared to increase and 
decrease intermittently with the 2 chemical shifts for the metabolite showing opposite 
changes and therefore making interpretation of results difficult. However, the same 
degree of variability was reported in the urine clinical chemistry data. In the clinical 
chemistry data in Table 6.6 creatinine was significantly decreased in CCl4-treated 
animals compared to controls at 6 hours post-dosing. OPLS-DA analysis of the 1D 
1
H 
NMR data shows the opposite effect at 6 hours. However, other changes with time were 
generally similar between both methods. At 24 hours post-dosing, urinary creatinine 
was significantly increased in CCl4-treated animals compared to control animals at the 
same time point and by day 10 they appeared to be decreased compared to concurrent 
controls (Table 6.8).  
Similar to the metabolomics study in Chapter 3, this current time course study revealed 
many other chemical shift changes, however, we were not able to identify these based 
on previous publications. Future work would attempt to use mass-spectrometry to 
identify these metabolites.  
In the present studies urinary metabolites which were identified in Chapter 3 as being 
potential markers for CCl4-induced hepatic injury were further characterised to 
determine the relationship of injury and metabolite levels with time post dosing. 
Histopathological examination revealed injury at 6 hours post-dosing; maximal injury at 
24-48 hours and a gradual return to almost normal at day 10. Of the metabolites 
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previously identified taurine, citrate, 2-oxoglutarate and hippurate were the most 
sensitive to time following a single dose of CCl4. All showed a similar change in 
direction in the first 18-24 hours followed by an opposing change in urinary levels 
during the liver regeneration phase. Citrate appears to be the most sensitive marker 
showing the progression of injury and then resolution of injury of the injury after 60 
hours post-dosing.  
These metabolites are sensitive to a single dose of CCl4 and therefore may have 
potential to be urinary biomarkers of acute hepatic injury. It will be very interesting to 
determine if the same urinary metabolites will change in a model of chronic injury. We 
will therefore, investigate this in Chapter 7 in a CCl4-induced hepatic fibrosis rat model.  
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CHAPTER SEVEN 
Development of a model of CCl4-induced liver fibrosis in the male Hanover-Wistar 
rat and investigation of urine metabolite profile changes using a 
1
H NMR-based 
metabolomics approach 
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Chapter 7  
7.1 Introduction 
In Chapters 3, 5 and 6, CCl4 was used as the hepatotoxicant to induce acute injury to the 
liver. In Chapter 3, we investigated urinary metabolites associated with the hepatic 
degeneration and necrosis induced by a single administration of CCl4. Chapter 6 
followed the pattern of change in these metabolites with time from 24 hours to day 10 
after a single dose. 
In this Chapter we were interested in developing a model of hepatic fibrosis using CCl4, 
and in investigating urinary metabolite changes in this model. CCl4 is known to induce 
fibrosis of the hepatic tissue which may further progress to cirrhosis if the stimuli 
persists (Post et al., 1942; Constandinou et al., 2005; Smyth et al., 2007; Smyth et al., 
2009a; Fujii et al., 2010). A single dose of CCl4 initiates lipid peroxidation (Hafeman 
and Hoekstra, 1977; Lee et al., 1982; Burk et al., 1984; Recknagel et al., 1989) which 
results in the disruption of cellular and organelle membrane integrity and subsequent 
leakage of cellular contents into the blood (Recknagel, 1983; Brattin et al., 1985). With 
continued CCl4 administration HSCs are activated, become myofibroblast-like cells, and 
secrete ECM components including collagen as the liver undergoes regenerative 
processes to repair the damage induced (Friedman et al., 1985; Olaso and Friedman, 
1998). Fibrosis develops because of an imbalance between the increased synthesis and 
the decreased degradation of ECM components, resulting in the formation of bridging 
fibrosis.  
In humans, the gold standard method for the detection of fibrosis has long been liver 
biopsy (Rossi et al., 2007; Martinez et al., 2011). However, due to the small sample size 
obtained, liver biopsy may result in erroneous results. Additionally, biopsy cannot be 
used as a routine clinical tool (Bedossa et al., 2003; Standish et al., 2006; Carey and 
Carey, 2010) because it is a highly invasive technique causing discomfort to, and even 
mortality in a patient (Thampanitchawong and Piratvisuth, 1999; Dufour, 2005).  
Traditional serum biomarkers of liver injury include enzymes such as ALT, AST and 
GLDH (Giffen et al., 2002). Increased levels of these enzymes occur following 
breakdown of the hepatocellular membrane with subsequent leakage of the enzymes 
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into the blood (Schmidt and Schmidt, 1988; Gores et al., 1990; Van Hoof et al., 1997). 
However, these serum enzymes lack specificity and sensitivity (Friedman, 1999). 
Serum biomarkers for liver fibrosis normally fall into 1 of 2 categories: direct or 
indirect markers. Direct markers are degradation products of extracellular matrix 
produced by the HSCs (MMPs, TIMPs, hyaluronic acid (HA), collagens IV and VI). 
Indirect markers tend to be released into the blood as a result of inflammation (ALT and 
AST). This category also includes molecules synthesised or excreted by the liver 
(clotting factors, cholesterol) and markers of processes that can be disrupted as a 
consequence of impairment of liver function (such as insulin resistance) (Adams, 2011; 
Castera, 2011).  
MMPs are a family of enzymes that are responsible for the degradation of the 
components of the extracellular matrix (Iredale et al., 1996) and TIMPs act as inhibitors 
of MMPs (Brew et al., 2000). TIMPs are known to increase in expression as fibrosis 
progresses and thus this will have an impact on MMP activity, resulting in lower levels 
of MMPs in serum. Therefore, decreased levels of MMPs in the serum are associated 
with injury progression, whereas TIMP levels, on the contrary, are increased with the 
increase in injury severity (Iredale et al., 1996). HA is also classified as a direct marker 
of liver fibrosis. It is a high molecular weight polymer (>1x10
6
 Da) (Maharjan et al., 
2011) which is synthesised by HSCs (Rostami and Parsian, 2013). Consequently, 
increased serum levels of HA can be used to measure the progression of liver fibrosis 
(Rossi et al., 2007; Rostami and Parsian, 2013).  
The ideal marker for liver fibrosis should be specific for the liver, able to detect the 
early stages of liver fibrosis and assess the progression of disease and response to 
therapy (Marrero and Lok, 2004; Mayeux, 2004). 
However, currently, no single serum biomarker can be measured for the reliable 
detection of liver fibrosis. Many of the biomarkers measured together form a reliable 
panel of biomarkers for hepatic fibrosis, but are not useful for routine monitoring. 
Additionally, the measurement of biomarkers in the serum involves the collection of a 
blood sample, which is an invasive procedure. The use of urinary biomarkers, as the 
main focus of this thesis, would represent a more ideal situation for the early prediction 
of fibrosis in the general population. The ability to develop a quick, non-invasive test 
for early signs of chronic liver injury would have a huge advantage in diagnosis. 
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In this Chapter we also wish to address the potential for reversibility of a fibrotic injury. 
Although traditionally liver fibrosis and cirrhosis have been considered to be 
irreversible, evidence has suggested that this may not be the case, and that fibrosis may 
reverse to an almost normal histological appearance (Benyon and Iredale, 2000). Our 
main interest will be focused on the change of urinary metabolites in the male rat during 
a recovery phase following the induction of fibrosis. 
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7.2 Animal experimental design 
The first experiment was a repeat dose response study to determine the dose level of 
CCl4 that upon repeated administration would induce hepatic fibrosis in the rat, without 
causing injury to other organs or death. The progression of fibrotic injury was 
monitored during the study by evaluating a panel of serum biomarkers and confirmed 
by histopathological examination of tissue samples collected during the dosing period. 
The CCl4 dose level determined in the first experiment was then used in a second repeat 
dose study. In this experiment, serum enzymes, urinary metabolites, biomarkers, gene 
expression and histopathology were investigated as fibrosis progressed (during the 
dosing period) and as injury recovered (during a no treatment, recovery period). 
7.2.1 Experiment 1: A repeat dose study to determine the dose level of 
CCl4 for the development of hepatic fibrosis 
Eighty male Hanover-Wistar rats (mean body weight 193.23 ± 4.37 g) were divided into 
4 groups (n=20). In each group, n=5 rats were dosed by gavage with CCl4 at 0 
(controls), 0.4, 0.8 and 1.2 mL/kg. Control animals were dosed with equivalent volumes 
of corn oil by gavage. Animals were dosed 3 times a week on Mondays, Wednesdays 
and Fridays and volumes were adjusted according to the body weights recorded prior to 
dosing.  
Twenty four hours after the first dose, blood was collected from the tail vein from 5 rats 
in each CCl4 dose level group (0, 0.4, 0.8 and 1.2 mL/kg CCl4). In Chapter 3, serum 
samples were analysed at 24 hours post-dosing. Therefore, we wished to compare the 
results from this study with the previously generated data in Chapter 3. In order to avoid 
having to sacrifice the animals, blood was taken from the tail vein for serum analysis.  
Five animals from each group were scheduled to be killed after 3, 6, 9, 12 weeks of 
dosing. Animals to be dosed for 12 weeks would receive a total of 36 CCl4 doses. Prior 
to autopsy animals were placed in metabolism cages for 18 hour urine collection (16:00 
hr to 10:00 hr). When not in metabolism cages animals were kept in communal cages 
with access to water and diet ad libitum. All urine samples were collected over ice and 
stored at -80 ºC until further analysis. However, the health of the animals deteriorated 
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during the study and CCl4 dosing had to be stopped at different time points for each 
dose level before the scheduled autopsies as described in Section 7.3.1. 
At each autopsy blood was taken for the preparation of serum and stored at -80 ºC until 
analysis, except during the autopsies carried out during the recovery period. At these 
autopsies only organs were removed for histopathological examination. The liver, 
kidneys, spleen, pancreas, adrenals, thymus, thyroid, testes, heart with lungs inflated and 
head were removed and placed in the fixative as described in Section 2.8. 
7.2.2 Experiment 2: Investigation of protein, gene and metabolite changes 
during the development of hepatic fibrosis and subsequent recovery 
Eighty male Hanover-Wistar rats (mean body weight 185.67 ± 2.56 g) were divided into 
8 groups of 10 animals each. The dose level used (0.4 mL/kg) in experiment 2 was 
chosen based on the data from experiment 1 since this dose level had the lowest 
mortality rate. Similarly, we decided that the dosing period in experiment 2 should not 
last for more than 6 weeks since after this time point it was felt that there could have 
been an increase in mortality.  
In each group, 5 animals were dosed by gavage with CCl4 at 0 (controls) and 5 animals 
were dosed at 0.4 mL/kg CCl4. Control animals were dosed with equivalent volumes of 
corn oil by gavage. Animals were dosed 3 times a week on Mondays, Wednesdays and 
Fridays and volumes were corrected for changes in body weight as recorded prior to 
dosing. Ten animals were killed at each of weeks 1, 2, 3, 4, 5 and 6 during the dosing 
period and weeks 9 and 12 (i.e. weeks 3 and 6 during the recovery period). During the 
recovery period, blood samples were collected from the tail vein at the weeks when no 
autopsies were scheduled, that is, at weeks 7, 8, 10 and 11. At week 7, the group of 
animals to be autopsied at week 9 was bled from the tail vein, whereas at weeks 8, 10 
and 11 animals to be autopsied at week 12 were bled from the tail vein. 
Each week during the dosing period of the study and at weeks 9 and 12 of the recovery 
period, 5 control and 5 CCl4-treated animals were selected for ultrasonographic 
examination of the abdominal area and images were stored for future analysis. After 
each session animals were returned to their communal cages. 
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Throughout the experiment animals were kept in communal cages in groups of 5 with 
water and diet ad libitum. However, before each post-mortem, 5 control rats and 5 CCl4-
treated rats were placed in metabolism cages for the collection of 18 hour urine samples. 
They were placed in individual metabolism cages at 16:00 hr and removed at 10:00 hr 
the following day. During this time animals had access to water but not diet. All urine 
samples were collected over ice and stored at -80 ºC for further analysis. Animals were 
autopsied at 10:00 hr following removal from the metabolism cages. At each autopsy 
blood was taken for the preparation of serum and stored at -80 ºC until analysis. The 
liver, kidneys, spleen, pancreas, adrenals, thymus, thyroid, testes, heart with lungs 
inflated and head were removed and placed in the fixative as described in Section 2.8. 
For gene expression analysis a section was cut from the left lobe of the liver, placed in 
RNALater tubes and stored at 4 ºC until analysis.  
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7.3 Experiment 1 
7.3.1 Observations during the study 
Throughout the study animals were observed for signs of ill-health and clinical 
observations recorded during the post-mortem procedure. 
After 3 weeks of dosing at 0, 0.4, 0.8 and 1.2 mL/kg all animals appeared normal. 
However, at autopsy, livers from CCl4-treated animals were paler in colour and enlarged 
compared to control animals, and showed pitting of the surface. Four animals treated 
with 0.8 mL/kg, and 2 animals treated with 1.2 mL/kg CCl4 had clear fluid in the 
abdominal cavity. 
Groups were terminated when 3 animals per group were either found dead or killed in 
extremis. The autopsies schedule is shown in Table 7.1. 
At week 4, 2 animals in the 1.2 mL/kg CCl4-treated group were found dead and it was 
necessary to kill 1 animal in extremis (K.I.E.). At the beginning of week 5 it was 
decided that the group should not receive any further doses of CCl4. At this time point 
there were 12 animals left in the group that had received a total of 13 CCl4 
administrations. Of these, 9 animals were selected for autopsy and the remaining 3 were 
left to recover (treatment free) for the rest of the study (8 weeks). However, 1 of the 3 
rats in the recovery period had to be killed (K.I.E.) during the second week of the 
recovery period.  
At week 5, 2 animals in the 0.8 mL/kg CCl4 group were found dead and 1 animal had to 
be killed. The animals in the group had received a total of 15 CCl4 doses. Of the 
remaining 12 animals, 9 were autopsied and 3 rats were left to recover for 4 weeks 
without CCl4 treatment. 
At week 6, after receiving 18 doses, 2 animals in the 0.4 mL/kg CCl4 group had to be 
killed. This was a scheduled autopsy time point, therefore, 5 controls and 5 CCl4-treated 
animals were autopsied as planned. However, due to the 2 animals which needed to be 
killed in extremis, it was decided that this group would not be dosed further. Of the 8 
animals remaining 4 were kept for a further 4 weeks without treatment and 4 were were 
kept for 8 weeks in total without treatment.  
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At autopsy, livers from treated animals at 0.4, 0.8 and 1.2 mL/kg CCl4 and collected at 
the end of the study, were generally paler in colour and showed diffuse pitting of the 
surface. In some animals, small cysts (1 mm) were reported on the liver surface. These 
cysts were present in 2 animals treated with 0.4 and 0.8 mL/kg and in 3 animals dosed 
with 1.2 mL/kg CCl4. After 3 weeks of treatment the spleens from 2 animals treated at 
0.8 and 1.2 mL/kg CCl4 were enlarged in size but normal in colour. At the group 
termination autopsies the proportion of animals showing increased size spleens 
increased to 5 and 6 out of 9 animals in the 0.8 and 1.2 mL/kg CCl4 respectively, and in 
the highest dose level group one of these rats showed a reduction in the size of the testes 
compared to the other animals in the group. There was also the presence of fluid in the 
abdominal cavity with prominent and enlarged veins in the abdominal wall. After 6 
weeks of treatment at 0.4 mL/kg CCl4 all animals had accumulation of fluid in the 
abdominal cavity and 3 animals also showed enlarged veins in the abdominal wall. At 
termination of the 0.8 and 1.2 mL/kg CCl4 treatment groups all animals showed 
presence of fluid in the abdominal cavity and 4 and 5 animals also had enlarged veins, 
respectively.  
Animals autopsied during the recovery period showed signs of improved health. In 
some animals the livers were still slightly paler in colour compared to control rats and 
showed evidence of diffuse pitting of the surface, but in general, the livers from CCl4-
treated animals had a normal appearance, both in terms of size and colour. Some of the 
spleens remained enlarged compared to control animals, and both the number of 
animals with fluid accumulation and the volume of fluid found in the abdominal cavity 
had significantly reduced compared to the findings during the dosing period. 
Table 7.1 Autopsy time points during the dosing period and number of animals autopsied/found 
dead/killed in extremis during the dosing period, per CCl4 dose level group and per week. 
 
CCl4 dose 
level 
(mL/kg) 
Day 1 
Week 3 
(9 doses) 
Week 4/5 
(13 doses) 
Week 5 
(15 doses) 
Week 6 
(18 doses) 
Number of 
animals dosed 
Number of autopsies and unscheduled deaths 
0 20 5 - - 5 
0.4 20 5 - - 2
 a
 + 5  
0.8 20 5 - 2
 a
 + 1
 b
  - 
1.2 20 5 2 
a
 + 1
b
  - - 
 
a 
number of animals that were found dead; 
b 
number of animals that were K.I.E (killed in extremis).
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B
W
 (
g)
Number of doses
Control
0.4 ml/kg
0.8 ml/kg
1.2 ml/kg
7.3.2 Body weight changes 
Throughout the study animals were weighed 3 times a week. After day 29 (week 4), 
some groups had to be terminated which meant that while some animals had begun the 
recovery phase, others were still in the dosing period. Therefore, time points after day 
29 are not shown in Figure 7.1. At day 29 all animals had received 13 doses of CCl4. 
In Figure 7.1 it is clear that animals followed the same pattern in body weight change 
during the study. Control animals gained weight at a faster rate than CCl4-treated 
animals. Rats in the highest dose level group (1.2 mL/kg) remained consistently lighter 
throughout the study and at the end of the study it appeared that the body weights were 
dependent on the dose level of CCl4.  
At the last time point (day 29/week 4), control animals had increased in weight by 50 % 
compared to day 1, whereas the increase recorded for CCl4-treated animals was smaller 
(27, 21 and 15 % for 0.4, 0.8 and 1.2 mL/kg treated animals, respectively). 
Figure 7.1 Increase in body weight for male Hanover-Wistar rats treated with increasing doses of 
CCl4, with increasing number of CCl4 administrations. Animals were dosed with vehicle (control, 0 
mL/kg) or CCl4 at the doses shown by gavage. Animals were weighed 3 times a week before each 
administration as described in Section 7.2.1. Results are shown as mean body weight with SD indicated 
by vertical bars of 20 animals per group (week 1 to week 9) and 15 animals per group (week 10 to 13). 
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7.3.3 Liver weights 
At the week 3 autopsies, livers from CCl4-treated rats at 0.4, 0.8 and 1.2 mL/kg were 
significantly heavier than controls (
***
P<0.001). Animals treated with CCl4 at 0.8 mL/kg 
had the heavier liver weights which corresponded to a 2.23-fold increase over controls 
(data not shown).  
Relative liver weights for control animals at week 6 were compared to the relative liver 
weights for CCl4-treated animals with 0.4, 0.8 and 1.2 mL/kg at the group termination 
autopsies, that is, at week 6, 5 and 4 respectively. There were no significant differences 
between control and CCl4-treated animals. However, at this time point, livers for CCl4-
treated animals were smaller in size compared to livers for treated animals at week 3 
(data not shown). 
7.3.4 Kidney weights 
At week 3, relative kidney weights were significantly increased over controls at 0.8 and 
1.2 mL/kg CCl4 (1.32-fold; 
**
P<0.01). The increase in size appeared to be dose-
dependent (data not shown). 
At the end of the study, relative weights were significantly increased above controls at 
week 6 at all dose levels (
***
P<0.001), and there appeared to be a dose-related increase 
in relative kidney weights (data not shown). 
7.3.5 Serum clinical chemistry 
Clinical chemistry parameters including ALT, AST, GLDH, ALP, albumin, total 
protein, urea, creatinine and glucose were measured in the serum from control (vehicle-
treated animals) and CCl4-treated rats at day 1 post-dosing, at week 3 and at termination 
of the study groups (Figure 7.2, Table 7.2). No blood samples were collected from 
animals that were found dead, killed in extremis or left to recover, and therefore, no 
serum data is presented for those animals.  
At 24 hours after the first dose of CCl4, levels of serum ALT, AST and GLDH were 
increased over controls and there appeared to be a dose related trend, reaching maximal 
levels at 1.2 mL/kg CCl4 (Figure 7.2 A). At 0.4 mL/kg CCl4 only serum GLDH was 
significantly increased over controls (
*
P<0.05). At 0.8 mL/kg CCl4 both ALT and 
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GLDH were significantly increased over controls, whereas at the highest dose group 
(1.2 mL/kg) all enzyme levels were significantly increase over control animals 
(
***
P<0.001). 
Figure 7.2 B and C show the mean levels for ALT, AST and GLDH after 3 weeks of 
CCl4 dosing (i.e. 9 doses) and at group termination autopsies, respectively. Levels of 
these enzymes were significantly increased at all CCl4 dose levels (0.4, 0.8 and 1.2 
mL/kg) over the respective control animals at the same time point. However, mean 
serum ALT, AST and GLDH were highest in the 0.4 mL/kg CCl4-treated animals and 
appeared to decrease with increasing dose level of CCl4 (Figure 7.2 B and C). 
Levels of ALP were slightly increased over controls at 24 hours after a single dose of 
CCl4, and at the highest dose level (1.2 mL/kg) this increase was statistically significant 
(
***
P>0.001) (Table 7.2). 
All other parameters that were measured 24 hours after a single CCl4 dose were similar 
in CCl4 treated animals compared to controls.  
ALP levels were also significantly increased over controls after 3 weeks (9 doses) of 
treatment at all CCl4 dose levels. The mean value was greatest in the 0.8 mL/kg CC4-
treated group (1301.40 compared to 234.00 U/L, for CCl4-treated and control animals 
respectively, 
***
P<0.001) (Table 7.2). At termination of the groups, mean ALP values 
were also increased over controls but appeared to decrease with increasing CCl4 dose 
level (1465.00, 1290.44 and 1057.67 U/L for animals in the 0.4, 0.8 and 1.2 mL/kg 
CCl4-treated groups respectively). 
Albumin values were significantly decreased in CCl4-treated animals at 0.8 mL/kg at 
week 3 compared to control, and in 0.4, 0.8 and 1.2 mL/kg CCl4-treated animals at the 
group termination autopsies (Table 7.2). 
At week 3, total protein levels in the serum of 0.8 and 1.2 mL/kg CCl4-treated rats were 
significantly decreased compared to controls (
***
P<0.001 and 
*
P<0.05, respectively). At 
termination of the groups, however, mean levels were significantly decreased in all 3 
CCl4-treated groups compared to controls at week 6 (T6) (Table 7.2).  
Serum levels of urea were approximately 1.5-fold increased over control in CCl4-treated 
animals at 0.4 mL/kg at week 3 (7.56 and 11.08 mmol/L for control and CCl4-treated 
animals respectively) (
***
P<0.001) (Table 7.2). However, at the other dose levels there 
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were no statistical differences between controls and CCl4-treated animals. At 
termination, animals in the highest dose level group (1.2 mL/kg) had significantly lower 
urea levels than control animals at the same time point (
*
P<0.05) but there was no 
evidence of a dose-related trend. 
Creatinine levels in the serum showed no evidence of a CCl4-treatment related effect, 
except for animals in the 1.2 mL/kg CCl4 group at the final autopsy. Animals in this 
group had significantly lower levels compared to the time-matched control (
**
P<0.01).  
Serum glucose levels were slightly decreased in animals treated with CCl4 at 1.2 mL/kg 
at the week 3 autopsies but this decrease was not statistically significant. At the final 
autopsy of the group, serum glucose was significantly decreased in the 0.8 mL/kg when 
compared to controls (
**
P<0.01) (Table 7.2). 
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B (Week 3: 9 doses) 
 
C (Week 4-6: 13-18 doses)  
 
Figure 7.2 Serum ALT, AST and GLDH levels for male Hanover-Wistar rats treated with 
increasing doses of CCl4 and sampled at different time points. Animals were dosed with vehicle 
(control, 0 mL/kg) or CCl4 by gavage at the doses shown. Blood was collected from the tail at day 2 (24 
hours post-dosing) (A), and at autopsy at the following time points (B, C) as described in Section 7.2.1. 
Enzymes were assayed according to Section 2.7. At day 2 and week 3 values are the means of 5 animals 
per group. At weeks 4, 5 and 6, values are the means of 5 controls and 5 CCl4-treated animals at 0.4 
mL/kg, and of 9 animals at 0.8 and 1.2 mL/kg CCl4. SD is represented by vertical bars. Values that differ 
significantly from controls by one-way ANOVA test are shown:
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
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Table 7.2 Serum clinical chemistry parameters for male Hanover-Wistar rats treated with 
increasing doses of CCl4 and sampled at different time points. Animals were dosed with vehicle 
(control, 0 mL/kg) or CCl4 by gavage at the doses shown. Blood was collected from the tail at day 2, and 
at autopsy at the following time points as described in Section 7.2.1. Enzymes were assayed according to 
Section 2.7. At day 2 and week 3 values are the means and SD of 5 animals per group. At weeks 4, 5 and 
6 values are the means of 5 controls and 5 CCl4-treated animals at 0.4 mL/kg, and of 9 animals at 0.8 and 
1.2 mL/kg CCl4. Values that differ significantly from controls by one-way ANOVA test are 
shown:
*
P<0.05; 
**
P<0.01; 
***
P<0.001. 
 
CCl4 dose          
level (mL/kg) 
Serum parameters 
ALP 
(U/L) 
Albumin 
(g/L) 
Total 
protein 
(g/L) 
Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
Glucose 
(mmol/L) 
1 dose 
(day 2) 
0 
569.40 
(67.40) 
38.02 
(1.88) 
59.34 
(3.19) 
7.54 
 (1.46) 
31.67 
(11.24) 
6.76 
(1.07) 
0.4 
648.00 
(170.00) 
37.40 
(0.98) 
57.77 
(1.34) 
8.11 
(0.70) 
24.10 
(0.87) 
6.63 
(1.67) 
0.8 
676.60 
(122.88) 
38.24 
(1.27) 
58.86 
(1.68) 
8.98 
(1.17) 
21.27 
(4.27) 
5.75 
(0.69) 
1.2 
754.60
***
 
(35.19) 
36.66 
(0.85) 
56.68 
(1.26) 
7.38 
(1.05) 
22.99 
(2.33) 
6.95 
(0.90) 
9 doses 
(week 3) 
 
0 
234.00 
(54.09) 
36.80  
(1.30) 
58.80 
(2.86) 
7.56  
(0.67) 
32.80  
(5.07) 
5.33 
(1.95) 
0.4 
824.40
***
 
(237.63) 
36.00  
(1.41) 
53.80 
(1.79) 
11.08
***
 
(1.01) 
30.80 
(10.21) 
4.58 
(1.07) 
0.8 
1301.40
***
 
(593.88) 
31.80
*
  
(2.77) 
48.80
***
 
(3.27) 
8.82  
(1.26) 
28.00 
 (4.90) 
4.09 
(0.53) 
1.2 
1076.80
***
 
(392.60) 
33.80 
(3.35) 
52.40
*
 
(4.04) 
9.18  
(1.22) 
32.20  
(4.09) 
3.97 
(0.31) 
18 
(week 6) 
0 
256.80 
(90.02) 
35.80 
(0.84) 
59.60 
(1.67) 
8.22 
(0.55) 
32.00 
(1.41) 
5.71 
(0.90) 
18 
(week 6) 
0.4 
1465.00
***
 
(369.28) 
28.80
**
 
(3.63) 
52.20
*
 
(4.09) 
7.28 
(1.39) 
26.80 
(3.96) 
3.78 
(1.28) 
15 
(week 5) 
0.8 
1290.44
***
 
(213.48) 
27.11
***
 
(2.09) 
47.33
***
 
(2.35) 
6.48 
(1.30) 
32.89 
(6.45) 
2.95
**
 
(0.96) 
13 
(week 4/5) 
1.2 
1057.67 
(244.81) 
28.33
**
 
(4.00) 
47.78
***
 
(4.74) 
6.16
*
 
(1.42) 
24.67
**
 
(2.50) 
5.77 
(1.32) 
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7.3.6 Urine clinical chemistry 
No urine samples were collected from animals that were found dead, killed in extremis 
or left to recover, and therefore, no urine data is presented for those animals.  
Total protein, creatinine and glucose were measured in the urine samples from rats at 
week 3 and at termination of the groups (Table 7.3). 
There appeared to be no CCl4-treatment-related effect on the levels of total urinary 
protein except for animals in the highest dose group (1.2 mL/kg) following the 
administration of 13 doses of CCl4. These animals had lower levels of urinary protein 
compared to the time-matched control animals (2.13 mg/c.p. compared to 6.72 mg/c.p.; 
**
P<0.01) (Table 7.3). 
After 3 weeks of treatment (9 doses) with 1.2 mL/kg CCl4, the mean urinary creatinine 
level was 37.00 µmol/c.p., compared to a control value of 51.00 µmol/c.p and this 
decrease was statistically significant (
*
P<0.05). At the termination autopsies, urinary 
creatinine was significantly decreased compared to control animals at all CCl4 dose 
levels and there appeared to be a dose-related relationship (Table 7.3). 
There was no change in urinary glucose levels at week 3 at any of the CCl4-dose levels. 
However, at termination (week 4 and 5), glucose levels in the urine were significantly 
decreased in the 2 highest dose level groups (0.8 and 1.2 mL/kg CCl4) compared to 
control rats. Mean values were 4.00, 3.22 and 5.40 µmol/c.p. for 0.8 and 1.2 mL/kg 
CCl4-treated rats and control animals, respectively (Table 7.3). There was no effect on 
the urine volume at any dose level and at any of the time points. 
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Table 7.3 Urinary biomarkers for male Hanover-Wistar rats treated with increasing doses of CCl4 
and sampled at different time points. Animals were dosed with vehicle (control, 0 mL/kg) or CCl4 by 
gavage at the doses shown. Urine was collected for 18 hours before each autopsy as described in Section 
7.2.1. Biomarkers were assayed according to Section 2.7. At day 2 and week 3 values are the means and 
SD of 5 animals per group. At weeks 4, 5 and 6 values are the means of 5 controls and 5 CCl4-treated 
animals at 0.4 mL/kg, and of 9 animals at 0.8 and 1.2 mL/kg CCl4. Values that differ significantly from 
controls by one-way ANOVA test are shown:
*
P<0.05; 
***
P<0.001.  
 
 
CCl4 dose level 
(mL/kg) 
Urinary paramters 
Total protein 
(mg/c.p.) 
Creatinine 
(µmol/c.p.) 
Glucose 
(µmol/c.p.) 
Volume 
(mL) 
 
9 doses 
(week 3) 
 
0 5.20 (2.05) 51.00 (7.31) 4.20 (0.84) 31.40 (5.98) 
0.4 2.68 (0.97) 44.40 (5.03) 4.60 (1.34) 16.00 (7.31) 
0.8 5.14 (5.46) 40.40 (8.17) 5.00 (1.22) 17.20 (4.76) 
1.2 3.54 (1.42) 37.00
*
 (8.22) 4.00 (0.71) 32.40 (22.51) 
18 
(week 6) 
0 6.72 (2.03) 77.60 (2.70) 5.40 (1.14) 24.40 (7.27) 
18 
(week 6) 
0.4 3.30 (1.76) 47.20
***
 (3.56) 4.60 (0.89) 22.80 (6.76) 
15 
(week 5) 
0.8 6.69 (5.02) 47.44
***
 (8.56) 4.00
*
 (1.00) 32.78 (8.94) 
13 
(week 4/5) 
1.2 2.13
**
 (1.12) 37.33
***
 (4.87) 3.22
**
 (0.67) 23.78 (11.69) 
7.3.7 Histopathology 
Animals in this study were autopsied after 3 weeks of dosing and at termination of the 
study as described in Table 7.1. Animals in the recovery groups were sacrificed as 
described in Table 7.1. 
At autopsy, livers and kidneys were removed and placed in formalin for 
histopathological examination (Figure 7.3). 
After 3 weeks of dosing (9 doses), the histopathological effects in the liver were similar 
at all dose levels (0.4, 0.8 and 1.2 mL/kg CCl4). There was hepatocellular vacuolation 
with some necrosis of individual cells and the presence of mitotic cells. There was also 
evidence of thickening of the perivascular connective tissue with minimal inflammatory 
cell infiltrate and fibrotic septae penetrating the liver parenchyma. 
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At termination of the study (weeks 4, 5 and 6), there was hepatocellular vacuolation in 
all animals, however, there did not appear be a dose-related trend. Necrotic and mitotic 
cells were still apparent and the development of fibrotic septae as present at 3 weeks 
(bridging fibrosis) had progressed. 
In the kidneys, at 3 weeks of treatment (i.e. after 9 doses of CCl4) there were no CCl4-
related findings, apart from vacuolation of the proximal tubules in 2 animals at 1.2 
mL/kg CCl4. At termination of the study groups, vacuolation of the proximal tubules 
was evident in the majority of the animals receiving the CCl4 treatment but there were 
no other renal changes consistent with CCl4-induced damage. 
Histopathological findings in the livers of recovery animals included hepatocellular 
vacuolation, however, this was much reduced compared to the degree of vacuolation 
observed during the dosing period. Fibrotic septae were still present but were much 
narrower during this recovery period and in some cases were reduced to fine collagen 
strands. In particular individuals there were areas of normal parenchyma indicating 
almost complete recovery of hepatic injury. The degree of resolution observed, 
however, did not correlate with the length of time the animal was allowed to recover, 
therefore, this may reflect the individual variability in the severity of the initial CCl4-
induced injury. 
There were no histopathological changes consistent with CCl4 administration in any of 
the other organs examined during the dosing period, and there were no abnormalities in 
the liver or kidneys collected from control animals at any time point. 
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Figure 7.3 Histology of liver sections from male Hanover-Wistar rats treated with increasing doses 
of CCl4 and sampled at various time points. Original magnification of all images, x 100; H&E. Rats 
were treated with vehicle (control, 0 mL/kg) or CCl4 at 0.4, 0.8 and 1.2 mL/kg as described in Section 
7.2.1. At autopsy, liver samples were collected and processed for histopathological examination as 
described in Section 2.8. (A) Control animal at week 3; (B) 0.4 mL/kg CCl4-treated rat at week 3 (9 
doses): thickening of the perivascular connective tissue around central veins, vacuolated hepatocytes, 
early development of fibrotic septae; (C) 0.4 mL/kg CCl4-treated rat at week 6 (18 doses): bridging 
fibrosis, vacuolated hepatocytes and presence of single cell hepatocyte necrosis; (D) 0.8 mL/kg CCl4-
treated rat for 5 weeks (15 doses) and allowed to recover for 4 weeks without treatment: fibrotic septae 
are very fine, very few vacuolated hepatocytes. 
 
C D 
A B   B 
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7.4 Results for experiment 2 
7.4.1 Observations during the study 
In the present study, animals were administered with CCl4 at 0.4 mL/kg and dosed 3 
times a week for a period of 6 weeks. This dose level was chosen since from the 
previous experiment it was clear that higher dose levels (0.8 and 1.2 mL/kg) resulted in 
a greater degree of mortality, and at the same time there was no histopathological 
difference as to the level of fibrosis induced. Some animals were left to recover for 3 
and 6 weeks without treatment (week 9 and 12). 
Throughout the study animals were observed for signs of ill-health and clinical 
observations recorded during the post-mortem procedure.  
At week 1, all animals appeared normal. At the week 2 autopsies however, livers from 
CCl4-treated animals were paler in colour and enlarged in size compared to control 
animals. There was also diffuse pitting of the liver surface (further discussed in Section 
7.4.9). Veins in the abdominal cavity appeared enlarged and prominent and there was 
slight accumulation of fluid in the abdominal cavity in some of the CCl4-treated 
animals. Similar observations were recorded during autopsies at week 3, 4 and 5 of the 
dosing-period. Additionally, at weeks 4 and 5, some animals had larger spleens. 
After 6 weeks of CCl4 administration 3 times a week, livers from treated animals were 
reduced in size compared to CCl4-treated livers at the previous time point; they were 
paler in colour compared to control animals, showed diffuse pitting of the surface and a 
nodular appearance (Section 7.4.9). There was also fluid accumulation in the abdominal 
cavity, and the abdominal veins and the spleen appeared to be enlarged.  
After 3 weeks of recovery (week 9 of the study) the livers of treated animals had a 
pitted surface and remained slightly paler in colour compared to the control rats. Similar 
findings were present at the 12 week autopsies (following 6 weeks of recovery). 
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7.4.2 Liver weights 
Figure 7.4 A shows the mean relative liver weights for animals autopsied during this 
study. Animals were treated 3 times a week with CCl4 at 0.4 mL/kg and autopsied at 
weeks 1, 2, 3, 4, 5 and 6 during the dosing period and at weeks 9 and 12 (that is, after 3 
and 6 weeks without treatment, respectively). 
Relative liver weights for CCl4-treated rats were compared to control animals at each 
time point for statistical analysis. During the dosing period relative liver weights were 
significantly increased over controls between 1 and 5. At week 6, 2 animals had much 
lower liver weights than the rest of the group. Therefore, the standard deviation of the 
group is large and may have contributed to the lack of statistical significance.  
At week 1 (T1), the relative liver weight for CCl4-treated animals was 1.52-fold 
increased over concurrent controls (
**
P<0.01). The heaviest liver weights for CCl4-
treated rats were seen at week 2 (58.51 and 30.86 g/kg BW for CCl4-treated and control 
animals respectively). From week 3 of the study, there appeared to be a decrease in 
relative liver weights in CCl4-treated animals with time (i.e. number of CCl4 doses 
received). By week 9 and 12, (3 and 6 weeks after stopping dosing), liver weights for 
CCl4-treated animals were only 1.16- (
*
P<0.05) and 1.21-fold (
**
P<0.01) increased over 
concurrent controls (Figure 7.4 A). 
7.4.3 Kidney weights 
Relative kidney weights for CCl4-treated and control animals are shown in Figure 7.4 B. 
Kidney weights were significantly increased over controls at week 4, 5 and 6 during the 
dosing period and at week 12 in the recovery period. At the week 4 autopsies, kidney 
weights were 3.46 and 4.40 g/kg BW for control and CCl4-treated animals, respectively; 
this corresponded to an approximate 1.27-fold increase (
**
P<0.01). It would appear that 
after 4 weeks of dosing there was a CCl4-treatment related effect on kidney weight. At 
week 12 (6 weeks after the end of the dosing period) kidneys were 1.14-fold increased 
over controls (3.40 and 2.99 g/kg BW for CCl4-treated and control animals, 
respectively). However, it is interesting to note that the mean control kidney weights at 
this time point were lower than at all other time points. 
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A  
 
B 
 
Figure 7.4 Relative liver (A) and kidney (B) weights from male Hanover-Wistar rats treated with 
vehicle (control) or CCl4 at 0.4 mL/kg and autopsied at different time points. Animals were dosed by 
gavage and autopsied at the time points shown as described in Section 7.2.2. At autopsy, animals were 
killed, livers and kidneys were removed and weighed. The kidney weight was expressed as a mean of the 
left and right kidneys. Results are shown as mean organ weight per kg body weight with SD indicated by 
vertical bars of 5 animals per group. Relative organ weights that differ significantly from controls at the 
same time point by Students’ t-test are shown:*P<0.05; **P<0.01; ***P<0.001. 
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7.4.4 Weights of other organs 
At post-mortem, the spleen, adrenals, thymus and testes were removed from all animals 
and the relative organ weights calculated (Table 7.4). Relative weights for each CCl4-
treated group were compared to the concurrent control for statistical significance.  
The relative spleen weight was significantly increased above control at week 3 and 
increased with time up to week 6. At week 6, the spleen weights were 2.03 and 4.52 
g/kg BW for control and CCl4-treated animals respectively (2.23-fold increase; 
**
P<0.01). The relative spleen weight was slightly lower than treated animals at week 6 
in the recovery animals, but was still significantly increased over concurrent controls at 
week 9 and 12 (i.e. 3 and 6 weeks of no treatment). The mean relative adrenal weight 
was significantly increased above concurrent controls at week 4, however, there was no 
evidence of an effect on relative weights with increasing number of CCl4 doses. At T4 
and T6, the relative thymus weight was significantly decreased compared to concurrent 
controls (
*
P<0.05) (Table 7.4). There were no statistical differences in the relative testes 
for CCl4-treated when compared to control animals at any time point in the study. 
Table 7.4 Relative organ weights from male Hanover-Wistar rats treated with vehicle (control) or 
CCl4 at 0.4 mL/kg and autopsied at different time points. Animals were dosed by gavage and 
autopsied at the time points shown as described in Section 7.2.2. At autopsy, animals were killed, organs 
were removed and weighed. The testes and adrenals weight was expressed as a mean of the left and right 
organs. Results are shown as mean organ weight per kg body weight (BW) and SD of 5 animals per 
group. Relative organ weights that differ significantly from controls at the same time point by Students’ t-
test are shown: 
*
P<0.05; 
**
P<0.01. C: control; T: CCl4-treated rat. 
Time point (weeks) 
Relative organ weight (g/kg BW) (SD) 
Spleen Adrenal  Thymus Mean testes  
C1 2.58 (0.20) 0.27 (0.04) 2.50 (0.24) 7.69 (0.81) 
T1 2.38 (0.23) 0.32 (0.09) 2.15 (0.29) 7.45 (0.42) 
C2 2.39 (0.26) 0.27 (0.03) 2.20 (0.37) 7.10 (0.43) 
T2 2.26 (0.30) 0.29 (0.04) 1.80 (0.17) 7.25 (0.26) 
C3 2.09 (0.43) 0.27 (0.06) 1.72 (0.24) 6.29 (0.22) 
T3 2.68
*
 (0.30) 0.26 (0.02) 1.69 (0.22) 6.38 (1.25) 
C4 2.10 (0.18) 0.25 (0.03) 1.88 (0.38) 5.89 (0.74) 
T4 3.18
*
 (0.93) 0.32
**
 (0.04) 1.19
*
 (0.45) 6.67 (1.15) 
C5 1.99 (0.12) 0.24 (0.04) 1.85 (0.85) 5.72 (0.55) 
T5 3.76
*
 (1.25) 0.25 (0.07) 1.15 (0.19) 6.13 (0.54) 
C6 2.03 (0.13) 0.24 (0.07) 1.42 (0.18) 5.03 (1.44) 
T6 4.52
**
 (1.12) 0.27 (0.08) 1.08
*
 (0.23) 5.70 (1.53) 
C9 2.02 (0.20) 0.40 (0.34) 1.30 (0.48) 4.75 (1.19) 
T9 3.33
**
 (0.62) 0.20 (0.07) 1.18 (0.20) 4.92 (0.29) 
C12 1.77 (0.20) 0.18 (0.34) 1.06 (0.48) 5.43 (1.19) 
T12 3.18
**
 (0.67) 0.19 (0.03) 1.31 (0.16) 4.65 (0.76) 
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7.4.5 Serum clinical chemistry 
Figure 7.5 shows the levels of the enzymes ALT, AST and GLDH in serum prepared 
from blood collected from animals every week during this study (weeks 1 to 12).   
Serum ALT and AST levels were significantly increased over concurrent controls at all 
time points during the dosing period (T1-T6) (Figure 7.5 A and B). Both enzymes 
increased as the number of CCl4 doses increased up to week 3. At this time point, the 
mean values for CCl4-treated animals and control animals were 8413.00 and 60.80 U/L 
for ALT, and 7676.00 and 135.00 U/L for AST, respectively. This corresponded to a 
139- and a 57-fold increase for ALT and AST. After week 3, the mean level of these 
enzymes gradually decreased but remained increased above concurrent control levels. 
At week 6, ALT and AST levels were approximately 41 and 32 times greater than 
concurrent controls (
***
P<0.001). 
During the recovery period, blood samples were collected at T7, T8, T10 and T11 by 
tail vein bleed, and at autopsy at time points T9 and T12. Mean ALT and AST levels in 
the serum of CCl4-treated animals were much lower than levels in CCl4-treated animals 
at previous time points (during the dosing period) but were still greater than concurrent 
controls. At the 12 week autopsies, mean values for CCl4-treated and control animals 
were 155.20 and 100.20 U/L, respectively (for ALT); and 238.00 and 180.40 U/L, 
respectively (for AST) (Figure 7.5 A and B). 
Serum GLDH levels were significantly increased over concurrent controls at all time 
points (dosing and recovery periods) (Figure 7.5 C). The greatest fold increase over 
controls was seen at week 4 of the study; at this time point GLDH levels were 
approximately 147-fold greater in CCl4-treated animals compared to concurrent controls 
(5.20 and 766.60 U/L for control and CCl4-treated animals respectively; 
***
P<0.001). 
After week 4, GLDH levels still remained significantly increased over control but the 
fold increase declined with time. At week 7 (first time point during the recovery period) 
values for serum GLDH in CCl4-treated animals had fallen from 367.50 U/L at week 6, 
to 57.20 U/L at week 7. By week 12, values for CCl4-treated animals were still 3 times 
greater than controls (
**
P<0.01).  
Serum lipocalin-2 levels were increased over controls at all weeks during the dosing 
period, but this increase was only statistically significant at weeks 4, 5 and 6 (Table 
7.5). Serum levels reached a peak at week 4 (464.40 µg/L and 40.40 µg/L for CCl4-
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treated and control animals, respectively) when they were 11.5-fold increased over 
control (
**
P<0.01). At all other time points (week 7 to 12, period without treatment), 
lipocalin-2 levels were similar to controls in CCl4-treated animals (Table 7.6). 
TIMP-1 levels were significantly increased over controls at all time points during the 
dosing period (Table 7.5). After 4 weeks of treatment, serum TIMP-1 levels were 
approximately 30-fold increased above control in CCl4-treated animals (
**
P<0.01). 
Mean serum levels were still significantly increased over controls at weeks 7, 9, 11 and 
12, but at these time points the fold increases were smaller (Table 7.6).  
MCP1 levels were significantly increased over control animals at weeks 1 to 4, and 
were maximal at week 4 (50.00 µg/L and 7.20 µg/L for CCl4-treated and control 
animals respectively). At this time point there was a 6.9-fold increase (
**
P<0.01). From 
this time point onwards there were no other significant differences between control and 
treated animals (Table 7.5, Table 7.6). 
Serum AGP levels were increased over controls at all time points during the dosing 
period (Table 7.5). At weeks 3 to 6 this increase was statistically significant. At week 6, 
levels were 1.8-fold increased over controls (
**
P<0.01). Between weeks 7 and 12, AGP 
levels in CCl4-treated animals returned to control levels (Table 7.6). 
A2M levels in the serum were significantly decreased in CCl4-treated animals compared 
to controls at week 1 (45.20 mg/L compared to 30.80 mg/L for control and CCl4-treated 
animals respectively; 
*
P<0.05) (Table 7.5). After this time point however, serum A2M 
levels appeared to increase with the number of CCl4 administrations and reached a peak 
at week 6 (12.40-fold increase over controls; 
**
P<0.01). At weeks 7, 9, 11 and 12 (Table 
7.6), A2M levels were still significantly increased over controls in CCl4-treated animals. 
However, at the last time point (week 12), the fold increase recorded was only 2.6-fold 
(
**
P<0.01). 
Levels of glucose, albumin, total protein, urea and creatinine were also measured in 
serum samples from control and CCl4-treated samples at each time point (Table 7.5, 
Table 7.6). Serum glucose levels were significantly decreased in CCl4-treated rats 
compared to concurrent controls at week 2 and 5 during the dosing period (
*
P<0.05 and 
**
P<0.01, respectively). However, at all other time points during the study, glucose 
levels were similar to controls. 
 295 
 
Serum albumin levels were significantly decreased compared to concurrent controls at 
weeks 5 and 6 of the dosing period (Table 7.5) and at weeks 7 to 10 in the recovery 
period (Table 7.6). The lowest albumin levels were found at week 6 autopsies (36.40 
and 27.40 g/L for control and CCl4-treated animals respectively; 
**
P<0.01) (Table 7.5, 
Table 7.6). Serum total protein levels were significantly decreased compared to 
concurrent controls at weeks 5 to 9. At week 6 (the last dosing period time point) the 
mean level for control animals was 65.40 g/L whereas in CCl4 treated animals serum 
total protein was 51.40 g/L (
***
P<0.001). 
Urea levels in the serum of CCl4-treated animals were significantly increased compared 
to control rats at weeks 1, 2 and 3. At week 2 there was a 1.51-fold increase over control 
values (9.04 and 13.66 mmol/L for control and treated animals respectively; 
**
P<0.01) 
(Table 7.5). There were no other significant differences during the dosing period. 
However, at week 8 (recovery period) serum levels for animals receiving CCl4 were 
lower than control animals (7.00 and 8.06 mmol/L respectively; 
*
P<0.05) (Table 7.6). 
Serum creatinine was 1.28- and 1.32-fold increased over concurrent controls at weeks 2 
and 3 (
*
P<0.05 and 
**
P<0.01, respectively) (Table 7.5). However, at T7, T8, T10, T11 
and T12 during the recovery period of the study, serum creatinine levels were 
significantly decreased in CCl4-treated animals compared to the respective control rats 
(Table 7.6). 
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Figure 7.5 Serum ALT, AST and GLDH activities for male Hanover-Wistar rats treated with 
vehicle (control) or CCl4 at 0.4 mL/kg and sampled at different time points. Animals were dosed by 
gavage and sampled at the time points shown. Blood was collected at autopsy at weeks 1-6, 9 and 12; and 
from the tail vein at weeks 7, 8, 10 and 11, as described in Section 7.2.2. Enzymes were assayed 
according to Section 2.7. Values are the means with SD indicated by vertical bars of 5 animals per group. 
Values that differ significantly from controls at the same time point by Students’ t-test are shown: 
P<0.05; 
**
P<0.01; 
***
P<0.001. 
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Table 7.5 Serum clinical chemistry parameters for male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 0.4 mL/kg and sampled at different time points 
during the dosing period. Animals were dosed by gavage and sampled at the time points shown. Blood was collected at autopsy as described in Section 7.2.2. Enzymes were 
assayed according to Section 2.7. Values are the means and SD of 5 animals per group. Values that differ significantly from controls at the same time point by Students’ t-test are 
shown: P<0.05; 
**
P<0.01; 
***
P<0.001. C: control; T: CCl4-treated rat. 
 
 
Time point 
(weeks) 
Serum parameters 
Lipocalin-2 
(µg/L) 
TIMP-1 
(µg/L) 
MCP1 
(µg/L) 
AGP 
(mg/L) 
A2M 
(mg/L) 
Glucose 
(mmol/L) 
Albumin 
(g/L) 
Total protein 
(g/L) 
Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
1 
C 
46.40 
(15.74) 
6.80 
(1.64) 
8.40 
(1.14) 
68.80 
(11.73) 
45.20 
(11.32) 
6.40 
(0.90) 
35.00 
(1.00) 
58.80 
(1.10) 
7.40 
(1.40) 
24.00 
(1.60) 
T 
52.20 
(23.69) 
23.40
***
  
(6.19) 
17.60
***
  
(3.85) 
91.40 
(24.43) 
30.80
*
 
(4.76) 
6.67 
(0.77) 
34.40 
(0.55) 
55.40
** 
(1.82) 
10.42
* 
(0.76) 
25.40 
(3.29) 
2 
C 
41.60 
(5.55) 
5.40 
(0.89) 
8.00 
(1.00) 
57.80 
(4.97) 
28.20 
(5.36) 
6.77 
(0.73) 
34.00 
(1.22) 
58.00 
(1.58) 
9.04 
(1.00) 
27.40 
(1.52) 
T 
111.20 
(60.86) 
49.40
***
 
(22.48) 
28.60
**
 
(10.24) 
76.60 
(16.92) 
29.40 
(8.62) 
4.13
*
 
(1.56) 
34.20 
(0.84) 
55.00
* 
(1.87) 
13.66
** 
(1.99) 
35.20
* 
(5.22) 
3 
C 
49.80 
(8.17) 
6.20 
(1.30) 
8.40 
(1.82) 
63.20 
(5.93) 
24.80 
(2.77) 
3.10 
(0.89) 
34.40 
(1.95) 
59.80 
(3.70) 
7.64 
(0.67) 
27.40 
(2.30) 
T 
291.60 
(237.42) 
69.40
**
 
(51.31) 
36.40
**
 
(29.62) 
106.60
*
 
(40.15) 
61.60
**
 
(19.69) 
3.85 
(1.44) 
34.20 
(1.30) 
57.00 
(5.15) 
12.30
*** 
(1.73) 
36.20
** 
(3.56) 
4 
C 
40.40 
(4.83) 
5.60 
(1.14) 
7.20 
(0.45) 
66.60 
(16.91) 
16.80 
(1.30) 
3.89 
(1.53) 
35.40 
(0.55) 
61.00 
(1.22) 
8.00 
(1.28) 
28.80 
(4.21) 
T 
464.40
**
 
(482.17) 
167.40
**
 
(186.33) 
50.00
**
 
(46.15) 
102.80
*
 
(24.93) 
121.60
**
 
(66.25) 
2.92 
(1.38) 
26.80 
(8.41) 
45.80 
(13.94) 
10.36 
(2.70) 
31.40 
(6.10) 
5 
C 
47.20 
(6.53) 
5.40 
(1.34) 
2.40 
(0.55) 
70.80 
(8.79) 
16.20 
(5.45) 
6.50 
(0.91) 
35.00 
(1.41) 
60.60 
(3.36) 
7.60 
(0.98) 
28.40 
(0.89) 
T 
179.60
***
 
(57.24) 
58.20
***
 
(11.39) 
9.00 
(8.31) 
113.00
**
 
(21.12) 
161.60
***
 
(80.75) 
4.34
**
 
(0.75) 
30.40
*
 
(2.70) 
51.20
** 
(3.96) 
8.74 
(1.34) 
29.00 
(3.32) 
6 
C 
40.80 
(6.91) 
5.40 
(1.34) 
6.00 
(2.83) 
74.40 
(12.18) 
15.20 
(3.35) 
6.56 
(2.23) 
36.40 
(0.89) 
65.40 
(0.89) 
9.54 
(1.15) 
26.80 
(2.39) 
T 
253.40
**
 
(146.12) 
39.00
**
 
(32.80) 
9.00 
(9.90) 
133.20
**
 
(30.87) 
188.60
***
 
(107.09) 
4.95 
(1.35) 
27.40
**
 
(4.39) 
51.40
*** 
(4.22) 
8.00 
(0.96) 
26.40 
(2.97) 
 
TIMP-1: tissue inhibitor of matrix metalloproteinase; MCP 1: monocyte chemoattractant factor 1; AGP: alpha-1 acid glycoprotein; A2M: alpha-2 macroglobulin. 
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Table 7.6 Serum clinical parameters for male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 0.4 mL/kg and sampled at different time points during the 
period without treatment (recovery period). Animals were dosed by gavage and sampled at the time points shown. Blood was collected at autopsy at weeks 9 and 12; and from the 
tail vein at weeks 7, 8, 10 and 11, as described in Section 7.2.2. Enzymes were assayed according to Section 2.7. Values are the means and SD of 5 animals per group. Values that 
differ significantly from controls at the same time point by Students’ t-test are shown: P<0.05; **P<0.01; ***P<0.001. C: control; T: CCl4-treated rat. 
 
 
TIMP-1: tissue inhibitor of matrix metalloproteinase; MCP 1: monocyte chemoattractant factor 1; AGP: alpha-1 acid glycoprotein; A2M: alpha-2 macroglobulin.  
Time point 
(weeks) 
Serum parameters 
Lipocalin-2 
(µg/L) 
TIMP-1 
(µg/L) 
MCP1 
(µg/L) 
AGP 
(mg/L) 
A2M 
(mg/L) 
Glucose 
(mmol/L) 
Albumin 
(g/L) 
Total protein 
(g/L) 
Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
7 
C 
41.20 
(8.41) 
5.00 
(1.58) 
8.80  
(1.30) 
83.40 
(16.10) 
12.80 
(1.79) 
8.42  
(0.41) 
35.80  
(0.84) 
60.60  
(2.07) 
8.40 
(0.97) 
27.60 
(1.52) 
T 
49.80 
(17.89) 
9.80
**
 
(2.39) 
8.80  
(1.64) 
98.20 
(22.48) 
51.40
***
 
(17.50) 
8.61  
(1.20) 
31.80
* 
(2.39) 
53.40
**
  
(3.21) 
7.54 
(1.02) 
20.00
*** 
(1.58) 
8 
C 
43.80 
(9.86) 
9.20  
(4.09) 
8.80 
(1.79) 
92.80 
(7.60) 
53.60 
(61.04) 
8.50  
(0.62) 
36.00  
(1.22) 
59.80  
(1.92) 
8.06 
(0.43) 
30.00  
(1.87) 
T 
43.00 
(11.77) 
6.60  
(2.41) 
8.60 
(1.34) 
90.00 
(24.16) 
26.40 
(22.60) 
8.72  
(0.51) 
30.80
**
  
(2.49) 
55.00
* 
(2.55) 
7.00
* 
(0.57) 
22.20
*** 
(2.17) 
9 
C 
33.40 
(4.83) 
5.00 
(1.22) 
9.00 
(1.22) 
82.80 
(10.18) 
10.00 
(0.71) 
6.32  
(1.46) 
34.60 
(0.55) 
58.20  
(1.30) 
8.60  
(0.72) 
33.60 
(4.16) 
T 
37.80 
(5.63) 
7.20
*
  
(1.30) 
8.40  
(1.34) 
97.60 
(14.10) 
24.00
***
 
(7.11) 
6.98 
(1.15) 
32.40
*
  
(1.34) 
55.40
* 
(1.67) 
8.52 
(0.74) 
28.60 
(2.88) 
10 
C 
32.20 
(4.87) 
5.20 
(1.10) 
8.40  
(0.55) 
87.40 
(18.77) 
12.20 
(0.84) 
7.97  
(0.79) 
35.80  
(0.84) 
60.20 
 (1.64) 
7.86  
(0.47) 
27.80 
(1.64) 
T 
34.33 
(11.02) 
7.33  
(1.53) 
8.33 
(2.08) 
82.25 
(6.70) 
44.75 
(53.67) 
7.59  
(1.38) 
30.60
* 
(3.97) 
54.80  
(7.26) 
6.94 
(0.91) 
23.60
* 
(2.07) 
11 
C 
35.75 
(8.81) 
5.25  
(0.96) 
8.00 
(0.82) 
90.50 
(27.53) 
11.50 
(1.29) 
7.08 
(1.23) 
36.20 
(0.45) 
60.80 
(1.30) 
9.34 
(0.72) 
25.40 
(0.89) 
T 
57.20 
(15.80) 
9.40
*
  
(1.52) 
7.60  
(1.95) 
95.20 
(15.17) 
31.20
*
 
(21.81) 
8.32  
(0.62) 
33.60 
(2.70) 
58.80 
(3.90) 
8.88  
(0.57) 
22.20
* 
(1.79) 
12 
C 
30.20 
(11.65) 
5.00 
(1.41) 
6.40  
(1.67) 
70.40 
(22.73) 
9.00  
(2.55) 
6.10  
(1.20) 
33.40  
(1.30) 
56.80  
(1.60) 
8.90  
(0.90) 
36.00 
(2.90) 
T 
46.80 
(9.12) 
9.00
**
  
(2.00) 
6.60 
 (0.55) 
92.00 
(14.92) 
23.60
**
 
(14.35) 
7.03  
(0.61) 
32.20  
(1.48) 
55.80 
(2.17) 
7.84  
(1.02) 
26.60
***
  
(1.14) 
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7.4.6 Urine clinical chemistry 
Urinary biomarkers and clinical chemistry parameters were measured in urine samples 
collected from rats every week during this study (week 1 to 12) to investigate the 
possibility of CCl4-induced nephrotoxicity with repeated administration. 
Urinary α-GST was decreased in CCl4-treated animals compared to controls at weeks 1 
to 5 during the dosing period, and at weeks 1 and 2 this decrease was statistically 
significant (
*
P<0.05 and 
**
P<0.01, respectively) (Table 7.7). At week 6, urinary α-GST 
was 1.56-fold increased over control levels in CCl4-treated animals; however, due to the 
large standard deviation this increase was not statistically significant. There were no 
significant differences between CCl4-treated animals and control animals at any other 
time point in the study (Table 7.8). GST Yb1 levels in the urine were significantly 
increased above controls after 6 weeks of CCl4 treatment. At this time point, mean 
urinary levels reached a peak and were 196.00 ng/c.p. and 98.00 ng/c.p. for CCl4-treated 
animals and control rats, respectively (
*
P<0.05) (Table 7.7). Between weeks 7 and 12 no 
statistically significant differences were observed (Table 7.8). 
Urinary KIM-1 was significantly increased over controls at week 6 (last week during 
the dosing period), when values were maximal, and a 1.35-fold increase over controls 
was recorded (
*
P<0.05) (Table 7.7). During the period without treatment, KIM-1 levels 
in the urine were still significantly increased over controls at all time points (Table 7.8). 
Lipocalin-2 levels in the urine were significantly increased over controls at weeks 2 to 6 
during the dosing period (Table 7.7). After 6 weeks of CCl4-treatment there was an 
approximate 23-fold increase over controls (
***
P<0.001). Between weeks 7 and 10, and 
at week 12, urinary lipocalin-2 levels were still significantly increased over control; the 
fold increase was 1.9-fold at week 12 (
*
P<0.05) (Table 7.8). 
Osteopontin levels reached a peak in the urine of CCl4-treated animals at week 4 
(102.00 ng/c.p. and 39.00 ng/c.p. for CCl4-treated and control animals, respectively) 
(
*
P<0.05). Osteopontin remained significantly increased over controls at week 5 and 6, 
but by week 7 (first week without treatment) values had returned to control levels and 
no other significant differences were observed (Table 7.8). 
Clusterin values were significantly decreased over controls at week 3 during the dosing 
period (44.20 ng/c.p. and 14.00 ng/c.p. for CCl4-treated animals and control rats, 
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respectively; 
**
P<0.01) (Table 7.7); and at weeks 8 and 12 during the period without 
CCl4-treatment (Table 7.8). 
Mean urinary creatinine was significantly decreased in the urine from CCl4-treated 
animals at weeks 5, 6 and 7. However, there was a return to control values after week 7.  
Glucose levels in the urine were significantly decreased at week 6, but at all other time 
points urinary glucose was similar to control (Table 7.7, Table 7.8). Urinary total 
protein levels were significantly decreased compared to concurrent controls at week 1, 
2, 3 and 5 during the dosing period. At T1 the mean value for CCl4-treated rats was 1.48 
mg/c.p., compared to 4.58 mg/c.p. in control animals (
***
P<0.001). This was the lowest 
total protein value in this study. After week 5, total protein levels appeared to be greater 
in CCl4-treated animals than controls. This increase was significant at week 8 
(approximately 3-fold greater).  
There was no evidence of CCl4-induced effect in urine volume at any time points (Table 
7.7, Table 7.8). 
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Table 7.7 Urinary biomarkers in male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 0.4 mL/kg and sampled at different time points during the dosing 
period. Rats were dosed by gavage and urine collected for 18 hours at the time points shown, as described in Section 7.2.2. Biomarkers were assayed as described in Section 2.7. 
Values are the means and SD of 5 animals per group and are expressed per c.p. (collection period, 18 hours). Values that differ significantly from controls at the same time point by 
Students’ t-test are shown: *P<0.05; **P<0.01; ***P<0.001. C: control; T: CCl4-treated rat. 
 
Time point 
(weeks) 
Urinary parameters 
α-GST 
(ng/c.p.) 
GST Yb1 
(ng/c.p.) 
KIM-1 
(ng/c.p.) 
Lipocalin-2 
(ng/c.p.) 
Osteopontin 
(ng/c.p.) 
Clusterin 
(ng/c.p.) 
Albumin 
(mg/c.p.) 
Creatinine 
(µmol/c.p.) 
Glucose 
(µmol/c.p.) 
Total 
protein 
(mg/c.p.) 
Volume 
(mL) 
1 
C 
298.00 
(238.37) 
56.00 
(41.59) 
9.00 
(1.00) 
2906.00 
(714.97) 
20.00 
(10.00) 
34.80 
(17.87) 
0.04 
(0.05) 
38.40  
(2.07) 
3.60 
(0.55) 
4.58 
 (0.66) 
24.20  
(5.40) 
T 
120.00
*
 
(41.23) 
26.00 
(5.48) 
10.67 
(1.67) 
3442.00 
(352.66) 
66.00
**
 
(33.62) 
19.80 
(6.34) 
0.00 
(0.00) 
35.80  
(2.17) 
3.80 
(0.45) 
1.48
***
 
(0.23) 
19.80  
(6.34) 
2 
C 
392.00 
(194.47) 
34.00 
(8.94) 
10.40 
(2.30) 
2848.00 
(699.41) 
28.00  
(8.37) 
25.60 
(11.26) 
0.06 
(0.09) 
54.40  
(6.62) 
5.60 
(1.14) 
6.40 
 (1.12) 
15.60  
(2.70) 
T 
126.00
**
 
(76.35) 
46.00 
(18.17) 
10.80 
(0.84) 
6758.00
*
 
(3401.02) 
98.00
***
 
(26.83) 
16.20 
(7.29) 
0.18 
(0.22) 
48.20  
(4.21) 
4.20 
(0.84) 
2.14
***
 
(0.68) 
14.00 
 (6.75) 
3 
C 
270.00 
(85.73) 
56.00 
(11.40) 
10.60 
(2.30) 
2828.00 
(532.89) 
34.00 
(15.17) 
44.20 
(23.79) 
0.10 
(0.10) 
65.00  
(7.18) 
5.00 
(1.41) 
6.40 
 (2.65) 
23.40 
(11.82) 
T 
174.00 
(164.71) 
52.00 
(39.62) 
10.40 
(3.21) 
22480.00
*
 
(22075.48) 
58.00
*
 
(20.49) 
14.00
**
 
(2.92) 
0.60 
(0.61) 
53.80  
(8.50) 
4.60 
(0.89) 
3.12
* 
(1.32) 
12.40  
(3.65) 
4 
C 
452.00 
(225.65) 
62.00 
(32.71) 
10.00 
(3.24) 
2052.00 
(592.34) 
38.00 
(30.33) 
68.00 
(44.43) 
0.04 
(0.05) 
57.40 
(11.04) 
4.40 
(1.67) 
4.48 
(1.72) 
30.20 
(17.24) 
T 
412.00 
(437.86) 
120.00 
(88.03) 
10.80 
(3.42) 
53090.00
***
 
(34198.02) 
102.00
*
 
(37.68) 
48.40 
(60.40) 
1.34 
(1.11) 
47.00 
(14.51) 
6.40 
(3.21) 
4.00 
(1.25) 
12.40  
(2.07) 
5 
C 
400.00 
(123.90) 
68.00 
(31.14) 
10.00 
(2.24) 
2900.00 
(614.90) 
24.00 
(5.48) 
62.00 
(21.82) 
0.08 
(0.13) 
68.20 
 (7.33) 
5.20 
(0.84) 
6.50 
(1.37) 
26.80 
(11.88) 
T 
286.00 
(77.01) 
102.00 
(60.99) 
13.40 
(1.82) 
29004.00
***
 
(6305.44) 
62.00
***
 
(10.95) 
50.80 
(20.38) 
1.16 
(0.87) 
48.60
**
 
(4.83) 
4.80 
(0.45) 
3.48
*
  
(1.45) 
24.20 
(5.02) 
6 
C 
480.00 
(226.83) 
98.00 
(41.47) 
11.40 
(2.70) 
2786.00 
(614.68) 
32.00 
(13.04) 
51.00 
(10.39) 
0.14 
(0.17) 
80.40  
(6.35) 
6.80 
(0.84) 
7.32 
(2.01) 
19.20  
(5.07) 
T 
752.00 
(473.47) 
196.00
*
 
(55.05) 
15.40
*
 
(2.41) 
64516.00
***
 
(30151.16) 
76.00
*
 
(27.02) 
51.60 
(35.84) 
9.60 
(6.64) 
54.20
**
 
(10.01) 
4.60
* 
(1.14) 
13.90  
(8.20) 
16.00 
(6.67) 
 
α-GST: glutathione S-transferase; GST Yb1: glutathione S-transferase Yb1; KIM-1: kidney injury molecule-1.  
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Table 7.8 Urinary biomarkers in male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 0.4 mL/kg and sampled at different time points during the period 
without treatment (recovery period). Rats were dosed by gavage and urine collected for 18 hours at the time points shown, as described in Section 7.2.2. Biomarkers were assayed 
as described in Section 2.7. Values are the means and SD of 5 animals per group and are expressed per c.p. (collection period, 18 hours). Values that differ significantly from 
controls at the same time point by Students’ t-test are shown: *P<0.05; **P<0.01; ***P<0.001. C: control; T: CCl4-treated rat. 
 
Time point 
(weeks) 
Urinary parameters 
α-GST 
(ng/c.p.) 
GST Yb1 
(ng/c.p.) 
Kim-1 
(ng/c.p.) 
Lipocalin-2 
(ng/c.p.) 
Osteopontin 
(ng/c.p.) 
Clusterin 
(ng/c.p.) 
Albumin 
(mg/c.p.) 
Creatinine 
(µmol/c.p.) 
Glucose 
(µmol/c.p.) 
Total 
protein 
(mg/c.p.) 
Volume 
(mL) 
7 
C 
624.00 
(403.03) 
70.00 
(35.36) 
9.40 
(0.55) 
2098.00 
(437.12) 
40.00 
(12.25) 
64.00 
(45.19) 
0.04 
(0.05) 
70.40 
(4.34) 
5.20 
(0.45) 
6.02 
(1.52) 
18.20 
(9.86) 
T 
466.00 
(302.37) 
44.00 
(18.17) 
13.60
*
 
(2.61) 
5466.00
**
 
(2936.67) 
44.00 
(23.02) 
55.80 
(18.23) 
8.20 
(6.89) 
49.40
***
 
(4.83) 
4.60 
(0.89) 
10.74 
(7.06) 
19.40 
(6.84) 
8 
C 
462.00 
(174.56) 
62.00 
(43.24) 
9.20 
(1.30) 
2544.00 
(536.78) 
44.00 
(11.40) 
76.40 
(28.47) 
0.02 
(0.04) 
78.00 
(8.80) 
5.40 
(1.14) 
5.76 
(1.17) 
21.80 
(6.94) 
T 
406.00 
(265.25) 
76.00 
(59.83) 
14.20
**
 
(1.30) 
5828.00
*
 
(2788.61) 
50.00 
(17.32) 
39.20
*
 
(13.08) 
13.18 
(11.85) 
67.40 
(7.48) 
5.40 
(1.14) 
17.80
* 
(8.05) 
19.60 
(6.54) 
9 
C 
228.00 
(125.58) 
40.00 
(25.50) 
8.20 
(1.48) 
2332.00 
(880.89) 
48.00 
(19.24) 
68.20 
(55.08) 
0.04 
(0.09) 
64.60 
(10.06) 
5.00 
(1.58) 
4.92 
(1.75) 
18.60 
(13.09) 
T 
208.00 
(98.84) 
38.00 
(13.04) 
14.20
*
 
(4.76) 
4596.00
**
 
(1135.97) 
36.00 
(15.17) 
79.00 
(20.40) 
1.18 
(0.99) 
58.96 
(22.40) 
5.06 
(2.07) 
6.58 
(2.46) 
19.15 
(4.82) 
10 
C 
328.00 
(160.37) 
38.00 
(30.33) 
7.40 
(1.14) 
2406.00 
(436.27) 
26.00 
 (5.48) 
61.60 
(32.32) 
0.00 
(0.00) 
70.80 
(13.85) 
4.80 
(0.84) 
5.00 
(1.19) 
16.60 
(5.08) 
T 
626.00 
(650.02) 
82.00 
(50.70) 
12.40
**
 
(2.30) 
5042.00
*
 
(3173.96) 
28.00 
(13.04) 
63.20 
(62.62) 
8.82 
(12.86) 
67.60 
(10.92) 
4.80 
(1.30) 
14.30 
(12.11) 
18.40 
(7.40) 
11 
C 
530.00 
(271.29) 
80.00 
(65.95) 
6.00 
(1.22) 
1928.00 
(395.06) 
30.00 
(12.25) 
94.60 
(35.49) 
0.02 
(0.04) 
57.40 
(13.24) 
4.60 
(1.14) 
4.20 
(1.07) 
16.00 
(3.94) 
T 
504.00 
(301.71) 
76.00 
(61.07) 
9.60
*
 
(3.21) 
3376.00 
(1513.63) 
32.00 
(13.04) 
62.60 
(25.04) 
5.50 
(7.40) 
52.60 
(8.32) 
4.60 
(0.55) 
9.26 
(7.31) 
16.00 
(3.24) 
12 
C 
516.00 
(224.12) 
54.00 
(16.73) 
7.00 
(0.71) 
1782.00 
(519.63) 
34.00  
(8.94) 
96.20 
(36.24) 
0.00 
(0.00) 
75.60 
(9.86) 
4.40 
(0.89) 
5.20 
(0.69) 
16.80 
(3.70) 
T 
400.00 
(285.83) 
70.00 
(48.99) 
11.20
***
 
(1.48) 
3384.00
*
 
(1178.17) 
38.00 
(13.04) 
53.00
*
 
(15.52) 
3.50 
(4.10) 
67.40 
(11.84) 
5.80 
(1.30) 
8.18 
(3.36) 
14.60 
(4.34) 
 
α-GST: glutathione S-transferase; GST Yb1: glutathione S-transferase Yb1; KIM-1: kidney injury molecule-1.  
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7.4.7 Gene expression 
Gene expression analysis was performed to follow changes in hepatic gene expression 
levels during the period of injury progression (week 1 to week 6) and injury recovery 
and repair (week 9 and 12), and to correlate this information with the metabolism and 
toxic effects of CCl4 in the liver (Table 7.9). 
Due to the large number of samples generated in the study, liver gene expression data 
was collected from 6 control animals at week 1, 4, 5, 9 and 12 and from 6 CCl4-treated 
animals at all time points. Statistical analysis was performed whereby CCl4-treated 
animals at weeks 1 and 2 were compared to control animals at week 1; CCl4-treated 
animals at week 3 and 4 were compared to control animals at week 4 and CCl4-treated 
animals at week 5 and 6 were compared to control animals at week 6. During the 
recovery period CCl4-treated rats were statistically compared against the concurrent 
controls.  
CYP1A2 and CYP2C mRNA expression were downregulated in CCl4-treated animals 
compared to the respective controls at all time points. By week 9 (3 weeks without 
treatment) CYP1A2 and CYP2C levels were increased compared to those at week 6 and 
by week 12 a return to basal mRNA levels was evident (Table 7.9). NQO1 mRNA 
expression was increased compared to control animals at week 1, and at all time points 
during the study (week 1 to 12). 
Gene expression of HMOX1 increased from week 1 to week 4 and decreased after this 
time point; by week 12 it was significantly decreased compared to control animals. 
LCN2 and TIMP1 mRNA expression was also upregulated at all time points during the 
study but the fold increases over controls decreased considerably during the recovery 
period (Table 7.9). 
COL1A1 and COL5A2 appeared to follow the same trend; mRNA expression increased 
consistently during the dosing period and was maximal at week 5 after which it 
decreased. MMP12, TGF-β and ACTA2 mRNA expression levels were found to be 
significantly upregulated at week 1, that is, after 3 CCl4 administrations. There was a 
general trend for increase in mRNA expression during the dosing period up to week 5, 
followed by a decrease at weeks 9 and 12 indicating a tendency for return to control 
levels. 
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Table 7.9 Liver gene expression in male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 0.4 mL/kg and sampled at different time points during the study. 
Rats were dosed by gavage as described in Section 7.2.2. At autopsy, liver expression was measured as described in Section 2.9. Results are represented as copy number [x10
3
/2 ng 
cDNA]. Values are the means and SD of 5 animals per group. Values that differ significantly from controls as described in Section 7.4.7, by Students’ t-test are shown: *P<0.05; 
**
P<0.01; 
***
P<0.001. 
 
Category/gene name symbol 
Control 
(week 1) 
Time point (weeks) 
1 2 3 4 5 6 9 12 
Xenobiotic metabolism           
Cytochrome P450 1A2 CYP1A2 
2112.90  
(409.46) 
545.04
***
 
(199.03) 
219.93
***
 
(173.61) 
208.20
***
 
(168.03) 
175.86
***
 
(104.87) 
413.01
**
 
(91.69) 
422.45
**
 
(325.99) 
2155.56
*
 
(910.74) 
1856.72  
(790.89) 
Cytochrome P450 2C CYP2C 
1762.56 
(1069.15) 
122.63
**
 
(122.63) 
38.33
**
 
(41.07) 
127.56
***
 
(203.79) 
7.30
***
 
(8.02) 
6.08
*** 
(2.89) 
9.90
***
 
(7.48) 
1038.35 
(1061.67) 
1166.78 
(1539.87) 
NAD (P)H dehydrogenase, 
quinone 1 
 
NQO1 
36.22 
 (21.79) 
78.99
*
  
(24.36) 
42.67 
 (34.35) 
85.40
** 
 (35.63) 
69.87
* 
 (38.04) 
87.00
*
  
(32.78) 
85.51  
(56.53) 
76.12
*
  
(22.94) 
65.19 
 (23.27) 
Oxidative stress           
Heme oxygenase (decycling) 1 HMOX1 
94.05 
(19.53) 
335.28
* 
 (173.82) 
392.10
***
 
(115.23) 
473.69
**
 
(242.24) 
594.9 
5 (521.23) 
368.29
***
 
(108.43) 
207.29
*
  
(119.60) 
90.33  
(25.36) 
64.13
**
  
(13.95) 
Inflammation           
Lipocalin-2 LCN2 
8.16 
 (1.45) 
68.70
*
  
(50.46) 
291.39
* 
 (240.76) 
655.11
* 
 (567.17) 
3335.77 
(5511.26) 
705.07
***
 
(234.01) 
1185.50
**
 
(754.47) 
74.42
*** 
 (27.87) 
56.67
*
  
(45.17) 
Tissue inhibitor of 
metalloproteinase 1 
 
TIMP1 
12.69 
 (3.43) 
54.63
*** 
 (16.31) 
109.40
** 
 (46.56) 
151.12
* 
 (103.51) 
314.86
* 
 (250.95) 
190.00
***
 
(29.10) 
116.33
* 
 (95.77) 
27.50
** 
*
 (2.90) 
26.74
*
  
(16.57) 
Markers hepatic fibrosis           
Collagen, type 1, alpha 1 COL1A1 
20.95 
 (9.36) 
123.21 
 (121.40) 
282.01 
 (286.61) 
564.46
**
 
(345.86) 
1142.42
*
 
(844.33) 
1456.83
***
 
(152.73) 
822.57
** 
 (520.48) 
171.39 
 (40.86) 
89.53 
 (89.55) 
Collagen, type 5, alpha 2 COL5A2 
12.27 
 (4.01) 
29.70 
 (18.09) 
50.51
* 
 (27.90) 
75.30
** 
 (34.34) 
121.84
** 
 (56.01) 
139.68
***
 
(16.11) 
86.41
** 
 (42.54) 
24.48
*** 
 (0.87) 
17.18
* 
 (8.23) 
Matrix metallopeptidase 12 MMP12 
0.49 
 (0.50) 
28.18
*** 
 (7.19) 
125.60
** 
 (80.41) 
121.37
** 
 (70.74) 
113.93
** 
 (65.44) 
136.51
***
 
(29.78) 
83.16
**
  
(49.54) 
23.38
***
  
(3.95) 
14.83
*
  
(10.37) 
Transforming growth factor- β1 TGF-β1 
27.36 
 (4.62) 
68.38
** 
 (23.49) 
69.12
** 
 (24.14) 
94.91
** 
 (31.91) 
134.07
***
 
(27.00) 
142.94
***
 
(26.74) 
123.13
** 
 (40.25) 
47.85
***
  
(7.89) 
45.22
* 
 (15.02) 
Smooth muscle α-actin ACTA2 
4.19  
(1.50) 
15.47 
 (10.96) 
57.07 
 (58.86) 
89.04
* 
 (78.01) 
159.89
* 
 (119.47) 
101.92
** 
 (44.73) 
38.35 
 (45.03) 
5.64
**
  
(1.18) 
6.32
* 
 (2.71) 
 
Results for control animals at week 1 are given, results for weeks 2 to 6, and 9 and 12 are not presented. 
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7.4.8 Ultrasonography  
US was performed to carry out a time course evaluation of the liver changes associated 
with CCl4 treatment and to develop a potential correlation between the imaging 
endpoints and the histopathology data. US sessions were scheduled to be conducted 
every week during the dosing period and at the recovery time points (week 9 and 12) 
(Figure 7.6). 
At each session images of the kidneys were recorded to compare the echographic 
texture with that of the liver. When examined with ultrasound, body tissues are 
visualised in various shades of grey. When the sound waves are transmitted into the 
body they interact with tissues and, consequently, are attenuated, either by absorption, 
scattering and beam divergence. Some sound waves are reflected (echoes) to the 
transducer and are converted into an image. Echogenecity refers to the variety of 
characteristics that define the appearance of tissues. 
Due to technical problems it was not possible to carry out an ultrasonographic 
examination of the animals during the first 2 weeks of the study. At all other time 
points, a qualitative assessment of the liver was performed by comparing the 
echogenicity of the liver parenchyma against other organs and between vehicle-treated 
(controls) and CCl4-treated animals at each week.  
Between weeks 3 and 6 during the dosing period, livers from CCl4-treated animals 
appeared to be increased in size in the longitudinal projection, and all treated animals 
showed increased echogenecity of the liver compared to the kidneys. At week 6, 2 of 
the CCl4-treated animals showed the presence of fluid in the abdominal cavity. For the 
remaining 3 animals in the treated group there were no observable differences from 
animals at week 5 (Figure 7.6 A, B and C). 
After 3 weeks without treatment, which corresponded to week 9 (Figure 7.6 D) in the 
study, it was observed that livers from CCl4-treated animals were still hyperechoic 
(increased echogenicity) and appeared slightly enlarged compared to control animals, 
but decreased in size compared to the previous US session at week 6. There was no 
evidence of fluid in the abdominal cavity. After 6 weeks without treatment (week 12), 
livers showed signs of recovery, although they still remained hyperechoic and slightly 
enlarged compared to control animals. There was no evidence of the presence of fluid at 
either of the recovery time points. 
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Figure 7.6 Ultrasonography images of male Hanover-Wistar rats treated with vehicle (control) or 
CCl4 at 0.4 mL/kg and sampled at various time points. Animals were dosed by gavage and 
ultrasonography images collected as described in Section 2.5. (A) control animal at week 4: normal 
echogenecity of the liver with intraparenchymal vasculature texture, and comparison against the kidney; 
(B) CCl4-treated animal at week 3: increased echogenecity of the liver compared to the apical pole of the 
kidney; (C) CCl4-treated animal at week 6: hyperechoic liver surrounded by fluid in the abdominal cavity 
(F), transverse sections of the intestine and well defined kidney; (D) CCl4-treated animal at week 9: 
slightly hyperechoic liver, intravasculature more evident. 
 
7.4.9 Images collected at autopsy 
At each autopsy, photographic images were taken of the macroscopic appearance of the 
livers from all rats. Figure 7.7 A shows a control liver at week 1, (after 3 
administrations of corn oil). The liver surface appeared smooth and shiny and the liver 
was dark red in colour as would be expected for a control liver. However, after 9 doses 
of CCl4 at 0.4 mL/kg (3 weeks), livers appeared paler in colour compared to control 
A. B 
C D 
Liver Kidney Liver Kidney 
F 
F 
Intestine Liver Kidney Liver Kidney 
Liver 
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animals (Figure 1.7 B). The surface had diffuse pitting and there was the presence of red 
blotches in some liver lobes (indicated by arrows).  
At the 6 week autopsy (after 18 doses), livers from CCl4-treated animals were decreased 
in size and paler in colour compared to control animals at the same time point. There 
was evidence of more severe pitting of the surface and also the presence of small cysts 
of approximately 1 mm in diameter (indicated by arrow) (Figure 1.7 C).  
Figure 1.7 D shows an image of a liver from an animal that had been treated with CCl4 
for 6 weeks and then allowed to recover for a further 3 weeks without treatment (T9). At 
this time point livers from CCl4-treated animals were slightly darker in colour compared 
to animals at T6, although they remained paler than the controls at the same time point. 
There was also pitting of the surface but to a lesser extent than at T6. At week 12 livers 
from animals that had been allowed to recover for 6 weeks (T12) were similar to those 
at T9. 
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Figure 7.7 Photographic images of livers from male Hanover-Wistar rats treated with vehicle 
(control) or CCl4 at 0.4 mL/kg and autopsied at various time points. Rats were dosed by gavage and 
autopsied as described in Section 7.2.2. (A) control animal autopsied at week 1; (B) 0.4 mL/kg CCl4-
treated animal at week 3: red blotches and pitted surface (indicated by arrows); (C) 0.4 mL/kg CCl4-
treated animal at week 6: cyst in liver surface (indicated by arrow), and (D) 0.4 mL/kg CCl4-treated 
animal at week 9 (3 weeks without treatment).  
7.4.10  Histopathology 
At autopsy, liver and kidneys from control and CCl4-treated animals were removed for 
histopathological examination. Additional tissues such as the spleen, pancreas, adrenal 
glands, lungs and heart, thymus, thyroid, nasal cavity and testes were also removed for 
histopathological examination. Due to the large number of samples generated during the 
study, liver and kidneys from only 2 animals from each group (control and CCl4-
A B 
C D 
Cyst 
Pitting 
Red blotches 
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treated) were examined at each time point during the dosing period (T1-T6). This is 
because we expect fibrosis to develop in this study in the same way that it did in the 
previous repeat study (experiment 1). During the recovery period, livers from all 
animals autopsied at week 9 and 12, were examined histopathologically, but only 
kidneys from 2 control and 2 CCl4-treated animals at T9 and T12 were examined.  
At week 1 (T1), there was evidence of centrilobular necrosis, ballooning and 
vacuolation mainly in midzonal areas with minimal presence of centrilobular 
inflammatory cell infiltration. There were also a few cases of periportal hepatocytes in 
mitosis. 
Livers from week 2 animals had centrilobular necrosis, marked ballooning and 
vacuolation in midzonal areas and there was also mild centrilobular inflammatory cell 
infiltration with evidence of fibroblasts. The number of periportal hepatocytes in mitosis 
had also increased compared to T1. At the following time point (week 3) all the injury 
described above had become more widespread and the centrilobular inflammatory cell 
infiltrate was associated with thickening of the perivascular structure and there was the 
presence of small fibrous tissue structures indicating the early formation of septae. 
At week 4 (T4), there was minimal hepatocellular necrosis with diffuse ballooning and 
vacuolation. When compared to animals at week 3 the perivascular thickening had 
become more pronounced and the fibrous septae were well established. At weeks 5 and 
6 the pathological findings described above became more pronounced. 
At weeks 9 and 12 (recovery period), livers from treated animals showed no evidence of 
hepatocellular vacuolation. The fibrous septae as reported during the dosing period 
remained well established but were narrower than those observed at week 6 of the 
dosing period. 
In the kidneys of animals treated with CCl4 at all time points there was minimal 
vacuolation of the proximal tubular epithelium, however, vacuolation was also present 
in a control animal and therefore, it is less likely that this microscopic finding in the 
kidney was related to CCl4 treatment. 
With regards to the additional tissues removed at autopsy, there was no 
histopathological evidence of CCl4 induced toxicity to the spleen, pancreas, adrenals, 
lungs and heart, thyroid, thymus, nasal cavity and testes. 
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Figure 7.8 Histology of liver sections from male Hanover-Wistar rats treated with vehicle (control) 
or CCl4 at 0.4 mL/kg and autopsied at various time points. Original magnification x100; H&E. Rats 
were dosed by gavage as described in Section 7.2.2. At autopsy, liver samples were collected and 
processed for histopathological examination as described in Section 2.8. (A) control rat at week 1; (B) 
CCl4-treated rat at week 1: centrilobular necrosis and vacuolation (indicated by arrow); (C) CCl4-treated 
rat at week 3: early development of fibrous septae; (D) CCl4-treated rat at week 6: increased fibrous 
thickening and well establish septae; (E) CCl4-treated rat for 6 weeks and left to recover for 6 weeks: 
thinner septae. 
7.4.11 1D 1H NMR spectrometry 
In this study, we wished to conduct an extensive 
1
H NMR-based metabolomics 
investigation into the change in urinary metabolites as CCl4-induced liver fibrosis 
developed and with a subsequent recovery period. Urine samples collected from rats 
weekly during the dosing period (week 1 to 6), and after 3 and 6 weeks of no treatment 
in the recovery period (T9 and T12) were analysed by 1D 
1
H NMR. 
PCA was used to identify differences and similarities between urine from control and 
CCl4-treated animals. Figure 7.9 shows a scores plot from a PCA model derived from 
the 1D 
1
H NMR spectral data from urine samples collected at all time points. At first 
examination of the scores plot it appeared that some points were located outside of the 
Hotelling’s T2 ellipse. To determine whether these samples points should be excluded 
before further analysis, an investigation was carried out of the individual samples. 
Serum and urine clinical data, and histopathology data for these animals was analysed 
to determine if these animals had a greater degree of injury.  
E 
Fibrotic 
septae 
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Visual analysis of the Hotelling’s T2 range plot indicated the presence of significant 
differences between the 1D 
1
H NMR spectral data from 2 animals sampled at week 4 
(circled in red in the scores plot in Figure 7.9) and the remaining samples in the study. 
Analysis of the contribution plot of these samples showed integral regions 
corresponding to the taurine peaks to be increased over the PCA model average, 
whereas regions matching the creatinine peaks appeared to be decreased compared to 
the average (Figure 7.10). This was further confirmed by visual inspection of the 1D 
1
H 
NMR spectra. Furthermore, analysis of the serum clinical markers such as ALT, AST 
and GLDH for these individual animals revealed particularly elevated values for these 
parameters compared to the group average; this could indicate that these animals have a 
greater degree of CCl4-induced liver injury. Indeed, histopathological examination of 
liver tissue collected at autopsy revealed a significant degree of variability in the 
response of animals within the same group to the CCl4 treatment. We, therefore, did not 
consider these samples to be true outliers, and instead it is thought that these samples 
were from animals with more severe hepatic injury than the group average. The other 
points, not encircled in the scores plot in Figure 7.9 that appeared outside the 
Hotelling’s T2 ellipse, fell below the 99 % T2 critical value in the Hotelling’s T2 range 
plot, and therefore, were not excluded from analysis. 
 
Figure 7.9 PCA scores plot from a PCA model derived from 1D 
1
H NMR spectral data of urine 
samples from male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 0.4 mL/kg and 
sampled at different time points during the study. Rats were dosed by gavage and urine collected for 
18 hours at the time points shown, as described in Section 7.2.2. Each spot in the scores plot represents 
one urine sample. R
2
X (cum) = 0.880, Q
2
 (cum) = 0.583. Control samples are circled in black. Samples 
from animals treated with 0.4 mL/kg CCl4 for 4 weeks are circled in red.
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Figure 7.10 Contribution plot of 2 samples treated with CCl4 for 4 weeks compared to the model 
average. Rats were treated with vehicle (control, 0 mL/kg) or CCl4 by gavage and urine collected for 18 
hours at various time points as described in Section 7.2.2. 
 
Once the model was verified, it was possible to observe from the PCA scores plot 
(Figure 7.9) that although there was a considerable degree of overlap between spots, 
there appeared to be some degree of separation between control samples (grey spots, 
circled in black), and urine samples collected from CCl4-treated animals (coloured 
spots). However, there were too many samples included in this model, coupled with 
great overlap, to visualise any potential metabolite patterns occurring with the 
progression of the study from week 1 to 12.  
Therefore, a PCA trajectory scores plot was constructed and is shown in Figure 7.11. 
Each spot in the figure represents the average spectrum for each sample group (control 
and CCl4-treated samples). The trajectory from week 1 to week 6, during which animals 
received 3 weekly administrations of CCl4, and from week 6 to 12, which represented 
the recovery period is shown by the arrows. Control samples are circled in black. 
 314 
 
 
Figure 7.11 PCA trajectory plot from a PCA model derived from 1D 
1
H NMR spectral data of 
urine samples from male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 0.4 ml/kg 
and sampled at different time points during the study. Rats were dosed by gavage and urine collected 
for 18 hours at the time points shown, as described in Section 7.2.2. Points in the trajectory plot represent 
the spectra created from the average of integral regions for each group of samples. R
2
X (cum) = 0.878, Q
2
 
(cum) = 0.494. Arrows represent direction of movement. 
 
This trajectory plot revealed that as fibrosis developed there was a general movement 
away from control samples (located on the left side of the plot), to the right side of the 
scores plot. During the recovery period, there was a move back to the left side of the 
scores plot (T9 and T12). Also, examination of the trajectory plot in Figure 7.11 
revealed that, from week 5 to 6, there was a move in CCl4-treated samples from the 
lower right quadrant, to the upper right quadrant. This shift was also present in control 
samples (in grey). Urine samples collected up to week 3 were located in the lower left 
quadrant, and samples collected at weeks 4, 5, 6, 9 and 12 were located on the upper left 
quadrant. We suggest that this might be a reflection of an age-related effect. 
A PCA model created with 
1
H NMR spectral data from control samples (data not 
shown) did not reveal significant differences between the groups of control samples at 
any time point. Therefore, control samples at week 1 were chosen to be representative 
of all controls in the study. Figure 7.12 A shows an OPLS scores plot for urine samples 
from animals treated repeatedly with 0.4 mL/kg CCl4 and sampled weekly between 
weeks 1 and 6, and at week 9 and 12, and controls at week 1. By reducing the number 
week 1 
week 2 
week 3 
week 4 
week 5 
week 6 
week 9 
week 12 
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of samples used to construct the model, and by introducing a Y variable corresponding 
to the number of CCl4 doses received by the animals it was possible to increase the 
degree of sample separation for further metabolite profile comparison. However, in this 
model, samples at 6, 9 and 12 all received the same number of doses, and therefore, the 
Y variable for these samples was the same.  
Figure 7.12 B and C show the corresponding loadings and S-plot for the OPLS model in 
Figure 7.12 A, and provide information on the chemical shifts most relevant for sample 
separation. According to both plots, the following chemical shifts were increased in the 
samples from animals that had received the CCl4-treatment, compared to controls at 
week 1: δ 3.42 and δ 3.26 (identified in previous studies as the triplets for taurine), δ 
2.70 and δ 2.54 (corresponding to the citrate doublets), δ 2.98 and δ 2.42 (2-
oxoglutarate), δ 4.06 and δ 3.06 (creatinine) and δ 3.02 (creatine). 
 
A
 
 316 
 
B
 
C
 
Figure 7.12 OPLS score plot (A), loadings (B) and S-plot (C) from an OPLS model derived from 1D 
1
H NMR spectral data of urine samples from male Hanover-Wistar rats treated with vehicle 
(control) or CCl4 0.4 mL/kg and sampled at different time points during the study. Rats were dosed 
by gavage and urine collected for 18 hours at the time points shown, as described in Section 7.2.2. Each 
spot in the scores plot represents one urine sample. Each spot in the loadings and S-plot represents a 
NMR variable labelled as chemical shift in ppm. R
2
X (cum) = 0.626, Q
2
 = 0.863. Arrows represent 
direction of movement.
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One limitation of the previously described OPLS model was that samples collected at 
week 6, 9 and 12 had all received the same number of CCl4 administrations. Therefore, 
2 new OPLS models were created to further confirm the existence of differences at 
these time points; the first one including urine samples collected during the dosing 
period (week 1 to 6), which differ in regards to the number of CCl4 administrations 
(Figure 7.13 A); and the second with samples collected at week 6 (0 weeks without 
treatment), 9 and 12 (3 and 6 weeks without treatment respectively) (Figure 7.13 B), 
and which differ in regards to the number of weeks without treatment. Arrows in Figure 
7.13, represent the direction of movement of samples. 
 
A
 
 
 318 
 
B
 
Figure 7.13 OPLS scores plots from OPLS models derived from 1D 
1
H NMR spectral data of urine 
samples from male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 0.4 mL/kg and 
sampled at different time points during the study. Rats were dosed by gavage and urine collected for 
18 hours at the time points shown, as described in Section 7.2.2. (A) samples collected from control 
animals at week 1 and CCl4-treated animals at weeks 1 to 6, R
2
X (cum) = 0.683, Q
2
 = 0.853; (B) samples 
collected from CCl4-treated animals at week 6 (dosing period) and at weeks 9 and 12 (recovery period, 3 
and 6 weeks without treatment), R
2
X (cum) = 0.750, Q
2
 = 0.862. Arrows represent direction of 
movement. 
 
In this experiment 2, a statistical analysis was performed to investigate changes to 
urinary metabolite levels with increasing number of CCl4 administrations and thus 
development of hepatic fibrosis, and also during the recovery/no treatment period. To 
achieve this, individual OPLS-DA models were constructed using 1D 
1
H NMR spectral 
data from the study. The following data paired samples were compared in OPLS-DA 
models: control and CCl4-treated samples at week 1; and CCl4-treated samples at week 
1 and 2; 2 and 3; 3 and 4; 4 and 5; 5 and 6; 6 and 9 and 9 and 12 (Figure 7.14).  
The scores plot for each OPLS-DA model displayed perfect group separation along the 
discriminating component 1 (t[1]) whereas the orthogonal component represented the 
degree of intragroup variability. The S-plot and VIP plot were further analysed for each 
OLPS-DA model in order to determine the most relevant chemical shifts responsible for 
the sample separation (data not shown). The statistical significance of chemical shift 
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differences was determined by performing a Student’s t-test comparing consecutive 
time points, such as chemical shifts from CCl4-treated animals at week 1 and 2. This 
data is summarized in Table 1.8.  
It appeared that after 1 week of CCl4-treatment there was an increase in the resonances 
of formate, taurine, 2-oxoglutarate, citrate and succinate when compared to control 
animals, and a decrease in the resonances of hippurate, creatinine and creatine. 
Excretion of hippurate in the urine was further decreased at the next 2 time points (T2 
and T3) and formate levels appeared to be increased over control at week 1, but were 
decreased at week 2 compared to week 1, and at week 3 compared to the previous time 
point (week 2). Similar findings were reported for 2-oxoglutarate and citrate, both 
increased in week 1 treated animals but were lower week 2 and again at week 3. 
However, taurine appeared to increase in concentration as the number of CCl4 
administrations increased up to week 3. Creatinine was also increased at week 2 and 3, 
but was decreased compared to control animals at week 1. At week 4 most of the 
metabolites were increased compared to week 3. However, the 2 triplet peaks 
corresponding to the metabolites taurine, 2-oxoglutarate and hippurate showed opposite 
signals. At week 5 and 6, taurine was decreased compared to the week 4 and 5 
autopsies, respectively, whereas metabolites belonging to the TCA cycle, such as 2-
oxoglutarate and citrate, were reported to be increased. At this time point CCl4-dosing 
was stopped. 
At week 9, 3 weeks after the last CCl4 administration, urinary excretion of hippurate, 
creatinine, creatine and taurine were increased compared to controls at week 6. Levels 
of 2-oxoglutarate, citrate and succinate, however, appeared to have decreased in the 
recovery period. At the last time point, following 6 weeks of no treatment, taurine, 
creatinine, creatine and succinate were decreased in the urine, whereas formate, 
hippurate and citrate were increased compared to the previous time point. 
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Figure 7.14 Scores plots from OPLS-DA models derived from 1D 
1
H NMR spectral data of urine 
samples from male Hanover-Wistar rats treated with vehicle (control) or CCl4 at 0.4 mL/kg and 
sampled at different time points during the study. Rats were dosed by gavage and urine collected for 
18 hours at the time points shown, as described in Section 7.2.2. (A) control and CCl4-treated rats at week 
1; (B) CCl4-treated rats at week 1 and 2; (C) CCl4-treated rats at week 2 and 3; (D) CCl4-treated rats at 
week 3 and 4; (E) CCl4-treated rats at week 4 and 5; (F) CCl4-treated rats at week 5 and 6; (G) CCl4-
treated rats at week 6 and 9 (0 and 3 weeks recovery without treatment) and (H) CCl4-treated rats at week 
9 and 12 (3 and 6 weeks recovery without treatment). 
In addition to investigating the differences between 2 consecutive time points, we were 
also interested in studying the potential for reversibility. Two OPLS-DA models were 
created using the 
1
H NMR spectral data from CCl4-treated animals at week 1 (3 doses) 
and week 6 (18 doses) (Figure 7.15), and with the 
1
H NMR of treated animals at week 6 
(last week of dosing period) and week 12 (6 weeks of recovery period without 
treatment) (Figure 7.15 B). 
 
Figure 7.15 Scores plots from OPLS-DA models derived from 1D 
1
H NMR spectral data of urine 
samples from male Hanover-Wistar rats treated with CCl4 at 0.4 mL/kg and sampled at different 
time points during the study. Rats were dosed by gavage and urine collected for 18 hours at the time 
points shown, as described in Section 7.2.2. (A) CCl4-treated rats at week 1 and 6; (B) CCl4-treated rats at 
week 6 and 12 (0 and 6 weeks recovery without treatment, respectively). 
G H 
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week 9 
CCl4-treated 
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A B 
CCl4-treated 
week 1 
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CCl4-treated 
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Figure 7.15 revealed good separation between CCl4-treated samples collected at 
different time points during the dosing period (week 1 and 6) and between the dosing 
and recovery periods (week 6 and 12, respectively). 
A statistical analysis of the integral regions corresponding to the chemical shifts 
identified from the S-plot (data not shown) was performed between treated animals at 
week 1 and 6, and between week 6 and 12 and is shown in Table 7.11.  
It appears from the table that after 6 weeks of CCl4 treatment, the urinary excretion of 
formate, hippurate, creatine and succinate was decreased in treated animals compared to 
animals that had received 3 doses of CCl4 (week 1), whereas resonances corresponding 
to the metabolites creatinine, taurine, citrate and 2-oxoglutarate were increased 
compared to animals at week 1.  
At week 12 (6 weeks without treatment) there was a decrease in the urinary levels of 
formate, taurine, 2-oxoglutarate and succinate compared to animals at the end of the 
dosing period. On the other hand, hippurate, creatinine, creatine and citrate were 
increased after 6 weeks of recovery (week 12). 
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Table 7.10 OPLS-DA detected 1D 
1
H NMR chemical shift regions responsible for the separation of NMR derived spectra from the urine of male Hanover-Wistar rats 
treated with vehicle (control) or CCl4 at 0.4 mL/kg and sampled at different time points. Rats were dosed by gavage and urine collected for 18 hours at the time points shown, 
as described in Section 7.2.2. Chemical shifts were statistically compared by means of a Students’ t-test. Values that differ significantly from controls, or CCl4-treated animals at the 
previous time point are shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001.  
 
Chemical 
shift (δ), 
multiplicity 
Endogenous 
metabolite 
C1 vs T1 T1 vs T2 T2 vs T3 T3 vs T4 T4 vs T5 T5 vs T6 T6 vs T9 T9 vs T12 
8.46-8.50 (s) formate + - - + + - -
*
 +
*
 
7.70-7.74 (d) hippurate -
***
 - - + - - +
**
 -
*
 
7.62-7.66 (t) hippurate - - - + - - +
*
 + 
7.54-7.58 (t) hippurate  - - - + + - +
**
 + 
4.06-4.10 (s) creatinine -
**
 +
*
 + - - + +
**
 - 
3.98-4.02 (d) hippurate - - - - - - +
**
 + 
3.94-3.98 (s) creatine - - + + - - +
*
 - 
3.42-3.46 (t) taurine +
*
 + +
**
 - - - + - 
3.26-3.30 (t) taurine + + + + - -
*
 + - 
3.06-3.10 (s) creatinine -
**
 +
*
 + - - + +
**
 - 
2.98-3.02 (t) 2-oxoglutarate + -
*
 - - +
**
 - - - 
2.70-2.74 (d) citrate +
*
 - - + + + - + 
2.54-2.58 (d) citrate +
**
 - - + +
*
 + - + 
2.42-2.46 (t) 2-oxoglutarate + - - + +
*
 + - + 
2.38-2.42 (s) succinate +
*
 - + - - - - -
*
 
 
S, singlet; d, doublet; t, triplet.  
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Table 7.11 OPLS-DA detected 1D 
1
H NMR chemical shift regions responsible for the separation of 
NMR derived spectra from the urine of male Hanover-Wistar rats treated with CCl4 at 0.4 mL/kg 
and sampled at different time points. Rats were dosed by gavage and urine collected for 18 hours at the 
time points shown, as described in Section 7.2.2. Chemical shifts were statistically compared by means of 
a Students’ t-test. Values that differ significantly from CCl4-treated animals at previous time points are 
shown: 
*
P<0.05; 
**
P<0.01; 
***
P<0.001.  
 
Chemical shift (δ), 
multiplicity 
Endogenous 
metabolite 
T1 vs T6 T6 vs T12 
8.46-8.50 (s) formate -
*
 -
*
 
7.70-7.74 (d) hippurate -
***
 + 
7.62-7.66 (t) hippurate -
**
 +
**
 
7.54-7.58 (t) hippurate  -
***
 +
**
 
4.06-4.10 (s) creatinine +
*
 +
*
 
3.98-4.02 (d) hippurate -
***
 +
**
 
3.94-3.98 (s) creatine -
**
 + 
3.42-3.46 (t) taurine +
**
 - 
3.26-3.30 (t) taurine + - 
3.06-3.10 (s) creatinine + +
*
 
2.98-3.02 (t) 2-oxoglutarate - - 
2.70-2.74 (d) citrate +
**
 + 
2.54-2.58 (d) citrate +
**
 + 
2.42-2.46 (t) 2-oxoglutarate +
**
 - 
2.38-2.42 (s) succinate - -
*
 
 
S, singlet; d, doublet; t, triplet.  
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7.5 Discussion 
In Chapter 3, we identified a dose level range of CCl4 that following a single 
administration would induce hepatic injury but that would not induce toxicity in other 
tissues. It was decided in Chapter 3 that dose levels above 2.0 mL/kg are likely to 
induce nephrotoxicity.  
In the current Chapter, we wished to develop a model of chronic liver injury and since 
this would be a repeat dose study the dose range of CCl4 chosen was between 0.4 and 
1.2 mL/kg, i.e., much lower than 2.0 mL/kg. However, it was still unknown whether 
lower dose levels administered chronically would induce toxicity in other organs. 
Therefore, the purpose of experiment 1 in this Chapter was to determine the ideal dose 
level for our hepatic fibrosis model and investigate the potential for other toxicities.  
The dosing regimen used in experiment 1 for the development of fibrosis included 3 
weekly administrations of CCl4 by gavage on alternate days (Monday, Wednesday and 
Friday). CCl4 has been shown to be readily absorbed by the GI tract in rats (Kim et al., 
1990). In the present studies we wished to induce fibrosis in the rat by administering 
CCl4 in the shortest period of time possible and with minimal mortality. One of the 
aspects that needs to be taken into account when devising a schedule for CCl4 
administration is the fact that free radicals produced as a result of the metabolism of 
CCl4 by cytochrome P-450 have the ability to irreversibly inactivate the cytochrome P-
450 (Manno et al., 1992). CCl4, therefore, inhibits its own metabolism; this process is 
called “suicidal inactivation” and appears to confer some protection against CCl4-
induced toxicity (Ugazio et al., 1972). Therefore, most of the dosing regimens described 
in the literature consist of 2 or 3 administrations. In the present study, we opted for a 
model of 3 administrations per week on alternate days using a low dose of CCl4. This 
would allow us to increase exposure to CCl4 at the same time as avoiding a greater 
degree of cytochrome P-450 inactivation. 
In this study, the experimental design involved dosing 80 animals 3 times a week at 0 
(controls), 0.4, 0.8 and 1.2 mL/kg CCl4, and killing 5 animals per group every 3 weeks 
up to 12 weeks of dosing. However, after week 3, the general bodily condition of some 
animals in the 0.8 and 1.2 mL/kg CCl4 began to deteriorate with each CCl4 
administration. Consequently, after 3 unscheduled deaths it was decided that the dosing 
period would be stopped and the study terminated. However, since we wished to gain as 
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much information as possible from this preliminary study which would help the 
development of our fibrosis model, we decided to allow 3 animals in the 0.8 and 1.2 
mL/kg CCl4 groups to recover untreated for a further 6 and 8 weeks respectively. After 
2 animals in the 0.4 mL/kg CCl4 group had to be killed, it was also decided that 4 of the 
8 remaining animals would be allowed to recover for 4 weeks, and 4 animals would be 
allowed to recover for 8 weeks. This would provide us with information regarding the 
feasibility of recovery from our potential model and the possible period required. 
Animals that had received the higher dose level (i.e. 1.2 mL/kg) would be allowed to 
recover for longer.  
Clinical observations were recorded at autopsy and it was seen that after 3 weeks of 
dosing, livers from CCl4-treated animals with 0.4, 0.8 and 1.2 mL/kg were paler in 
colour and enlarged compared to control animals, and showed pitting of the surface. 
Animals in the highest dose level groups (0.8 and 1.2 mL/kg) also showed evidence of 
fluid in the abdominal cavity. At the end of the study, the livers of CCl4-treated animals 
at all CCl4 dose levels were generally paler in colour. There was also evidence of pitting 
of the surface and the presence of small cysts (1 mm) on the liver surface which were 
seen in animals treated with 0.4, 0.8 and 1.2 mL/kg CCl4. The spleens from some 
animals were enlarged but normal in colour whereas the testes appeared reduced in size. 
There was also the presence of fluid in the abdominal cavity with prominent and 
enlarged veins.  
During the study, at all autopsies, livers were removed and weighed and relative 
weights were calculated. After 3 weeks of CCl4 dosing, relative liver weights were 
significantly increased above controls at all CCl4-dose levels. At later time points, there 
were no significant differences between relative liver weights from control animals 
autopsied at week 6, and 0.4, 0.8 and 1.2 mL/kg CCl4-treated animals at termination. An 
increase in relative liver weight has been previously documented in Chapter 3 following 
a single administration of CCl4 and has also been previously described in chronic dose 
studies. In a study by Khan and colleagues (2012), male Sprague-Dawley rats were 
administered with CCl4 at 3 mL/kg (intraperitoneally) twice a week for a total of 4 
weeks and autopsied 24 hours after the last treatment. At post-mortem, relative liver 
weights were significantly increased compared to control animals. Other studies have 
reported similar findings following the repeat administration of CCl4. In one study, male 
Hanover-Wistar rats were dosed orally, twice a week, with 2 mL/kg CCl4 for a period of 
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8 weeks after which a 185 % increase in liver weights over control animals was reported 
(Fang and Lin, 2008). An increase in liver weight was also reported in female Sprague-
Dawley rats following i.p. injections of CCl4 over an 8 week period (Hauso et al., 
2008). Stowell and Lee (1950) attributed this increase in relative weight to a greater 
fluid accumulation and an increased lipid content of the damaged liver.  
Serum biochemistry analysis was performed to further investigate the development of 
liver toxicity following CCl4 administration. In the present study, blood samples were 
collected from the tail vein at 24 hours following the first administration of CCl4, at 
week 3 and at group termination autopsies. Blood samples were not collected from 
animals at the recovery period autopsies. 
Serum biochemistry results revealed that after a single dose of CCl4 (24 hours after the 
first dose) at 0.4, 0.8 and 1.2 mL/kg, mean serum levels of ALT, AST and GLDH were 
increased over control to a similar degree as the increases described in Chapter 3 
(Figure 7.2 A). This measurement after the first dose was carried out in serum prepared 
from blood collected via the tail vein whereas in the previous Chapter 3 study the blood 
was collected from the abdominal aorta at autopsy. During the course of the repeat dose 
study it was going to be necessary to collect blood from the tail vein at some time 
points. Therefore, these results confirm the method of blood collection should not affect 
the serum enzyme levels. 
Levels of ALP were slightly increased over controls at 24 hours after a single dose of 
CCl4, and at the highest dose level (1.2 mL/kg) this increase was statistically significant 
(
***
P>0.001) (Table 7.2). No statistically significant changes were recorded for the other 
parameters measured at 24 hours after a single dose of CCl4. 
After 3 weeks of CCl4 administration (9 doses in total), mean levels of ALT, AST and 
GLDH were significantly increased over controls at all CCl4 dose levels, with a much 
greater fold increase than at 24 hours after a single dose. However, the fold increase 
over control for ALT and AST decreased with increasing CCl4 concentrations, i.e., the 
levels were greater at 0.4 mL/kg (lowest concentration) (Figure 7.2 B). Levels of ALP 
were also significantly raised above control at 0.4, 0.8 and 1.2 mL/kg CCl4, but were 
maximal at 0.8 mL/kg (5.6-fold increase; 
***
P<0.001) (Table 7.2). 
At the final autopsies, enzyme levels of ALT, AST, GLDH and ALP followed the same 
trend as above and the greatest serum enzyme levels were found at the lowest dose level 
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(0.4 mL/kg) (Figure 7.2 C). However, they were still considerably greater than control 
values.  
It is interesting to note that at the later time points there was a reduction in fold increase 
over control when compared to the 3 week samples. This trend, and the lower fold 
increases at the later time point may reflect the severity of the hepatic injury, thus 
compromising the synthesis of these enzymes. Increased levels of these enzymes are 
routinely associated with liver injury and have been previously described following 
repeat CCl4 administration. In a study by Fu et al. (2008), male Sprague-Dawley rats 
were injected intraperitoneally at 0.1 mL/100g BW every day for a period of 8 weeks 
and autopsied at 48 hours after the last administration. Biochemical analysis of serum 
samples revealed significant increases in ALT, AST and ALP levels in the CCl4-treated 
animals compared to control rats. Domitrovic and colleagues (2009) found similar 
results in a mouse model of CCl4-induced fibrosis. Mice were injected intraperitoneally 
with CCl4 at 0.4 mL/kg, twice a week for 6 weeks. Seventy two hours after the last 
administration animals were sacrificed and levels of ALT, AST and ALP were 
significantly elevated above control levels. Smyth et al. (2007) also reported significant 
increases in ALT, AST and GLDH serum levels after 6 weeks of twice weekly 
administration of CCl4 at a range of concentrations varying from 0.06 to 0.36 mL/kg.  
Since albumin is synthesised in the liver, decreased serum levels of albumin can often 
be indicators of chronic liver injury (Carey and Carey, 2010). In this study, after 9 doses 
(T3), albumin was decreased in the serum of CCl4-treated animals, but this decrease was 
only significant at 0.8 mL/kg (Table 7.2). However, at the final time point autopsies, all 
CCl4-treated animals showed significantly lower albumin levels compared to control 
rats. A study by Gou et al. (2013), revealed a significant decrease in serum albumin 
levels in a model of hepatic fibrosis in rats that had been dosed twice weekly with CCl4 
at 1.0 mL/kg for 9 weeks by i.p. injection.  
Levels of total protein in the serum also reflect the synthesis turnover of the liver, and 
therefore, are often used to assess liver function. In the present experiment 1, serum 
protein levels were significantly decreased after 9 administrations of CCl4 at 0.8 and 1.2 
mL/kg, and at the final time points in all CCl4-treated animals (Table 7.2). Similar 
decreases in serum protein levels have been previously reported in rodent models of 
CCl4-induced fibrosis (Castilla-Cortazar et al., 1997; Yang et al., 2010a). 
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In the present study, serum creatinine levels were significantly decreased in the serum 
of animals that had received 13 administrations of CCl4 at 1.2 mL/kg, whereas serum 
urea levels were significantly increased in animals that received 9 doses of 0.8 mL/kg 
CCl4, and at termination urea levels were significantly decreased in animals treated at 
the highest dose level (1.2 mL/kg CCl4) (Table 7.2). In fact, decreased urea synthesis 
(Rudman et al., 1973) and decreased creatinine production (Cocchetto et al., 1983) have 
been previously reported in cirrhotic patients. One of the mechanisms responsible for 
decreased creatinine production in cirrhotic patients is the compromise in creatine 
production as well as decreased muscle mass (Cocchetto et al., 1983). Creatine is 
synthesised via 2 enzyme-catalysed reactions. The first reaction occurs between 
arginine and glycine. This process occurs mainly in the kidneys and pancreas and to a 
lesser extent in the liver. The product of this reaction, guanidinoacetic acid is converted 
to creatine via a methylation reaction that occurs mainly in the liver and to a lesser 
extent in other tissues, as the kidneys, pancreas, spleen, brain and testes. The synthesis 
of creatine does not occur in the muscle tissue, but due to the existence of a specific 
membrane transport system, creatine accumulates within the skeletal muscle (Cocchetto 
et al., 1983) where it exists as creatine phosphate (Waters et al., 2005). Therefore, the 
creatine pool is related primarily to the muscle mass, which is affected by gender and 
age. Consequently, considerable changes in muscular mass will affect the excretion of 
urinary creatinine making it a useful and accurate index of body muscle mass.  
In advanced stages of liver cirrhosis, the liver function in carbohydrate metabolism is 
compromised and therefore, both hyperglycaemia and hypoglycaemia may be observed 
in cirrhotic patients. On the one hand, impaired insulin sensitivity and consequent 
impaired glucose tolerance, are often seen in states of chronic liver disease such as 
cirrhosis due to a reduction of liver function (Petrides et al., 1998; Hickman and 
Macdonald, 2007). Insulin resistance may arise from decreased clearance of insulin by 
the liver due to reduced hepatic function (Garcia-Compean et al., 2009; Ishikawa et al., 
2013). In fact, the liver is the primary site of insulin clearance (Duckworth et al., 1998). 
Serum glucose levels may thus reflect a change in insulin resistance. On the other hand, 
hypoglycaemia may be associated with cirrhotic livers due to a reduced rate of 
glycogenolysis as a result of extensive liver parenchymal destruction (Petersen et al., 
1999). In the current study, serum glucose levels were decreased in all CCl4-treated 
animals compared to control rats after 9 CCl4 administrations, and at the final time 
points of the study the decrease in glucose levels was statistically significant in the 0.8 
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mL/kg CCl4-treated group. Similar findings have been previously reported in a study by 
Cortazar and colleagues (1997) in which cirrhotic rats showed significantly lower levels 
of serum albumin, total protein and glucose, compared to control animals. 
In this study, the presence of fibrotic septae were reported following histopathological 
examination of the livers after 3 weeks of repeat dosing. By the end of the study this 
fibrotic process had progressed and bridging fibrosis was apparent. Thus, initial signs of 
fibrosis were present in experiment 1 after 3 weeks of repeat CCl4 dosing (Figure 7.3). 
Parsons et al. (2004), used a model of CCl4-induced fibrosis in the male Wistar rat and 
reported the presence of septal fibrosis and extensive bridging and inflammation at day 
24 (week 3.5) into the study. In their study animals were dosed with CCl4 by gavage at 
412 mg CCl4/kg olive oil. Similar results were reported by Chobert and colleagues 
(2012) following the administration of CCl4 at 1.0 mL/kg twice a week, following an 
initial single dose of CCl4 at 2.0 mL/kg. After 2 weeks, fibrosis was characterised by the 
deposition of thin collagen fibres in necrotic areas. Four weeks into the treatment there 
was evidence of fibrotic septae connecting centrilobular areas and at week 6 there were 
multiple fibrotic septae interconnected and dividing the hepatic lobules. Smyth et al., 
(2007) administered CCl4 at dose levels between 0.4 and 1.0 mL/kg, twice a week for a 
period of 6 weeks. At 6 weeks there was evidence of fibrosis with bridging between 
centrilobular, periportal and capsular areas. 
In the livers of animals that were allowed to recover, fibrotic septae were still detected 
by histopathological examination (Figure 7.3). However, the collagen fibres present 
were considerably narrower than those found in animals during the dosing period. Some 
individual rats demonstrated almost complete recovery. However, there was no 
correlation between the degree of resolution and the time allowed for recovery, which 
reflects the great intragroup variability observed in CCl4-induced injury. Nevertheless, 
these preliminary results suggest that our model of hepatic fibrosis has potential to be 
reversible upon cessation of treatment. 
Measurement of urinary levels of total protein, creatinine and glucose in experiment 1 
revealed that all 3 were decreased when compared to controls at week 6 in animals 
treated at the highest dose level (1.2 mL/kg) (Table 7.3). As described earlier, in 
cirrhosis, due to reduced hepatic synthesis of creatine, serum levels of creatinine are 
often decreased. Therefore, in conditions of cirrhosis, the level of creatinine does not 
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provide an accurate reflection of the glomerular filtration rate (Betrosian et al., 2007) 
and is not reliable for assessing renal function (Mackelaite et al., 2009). 
In this experiment it was very important to ensure that repeated CCl4 administration did 
not induce nephrotoxicity since we would be using this model to investigate urinary 
biomarkers. Relative kidney weights were significantly increased over controls at 0.8 
and 1.2 mL/kg after 3 weeks, and in all CCl4-treated animals at the group termination 
autopsies.  
However, the absence of CCl4-induced nephrotoxicity at all of the dose levels was 
confirmed by histopathological examination of the kidneys. In addition, no evidence 
was found of CCl4-induced changes to any of the other organs examined at any dose 
level, or any time point. Therefore, we can be confident that the model we chose for the 
induction of hepatic fibrosis based on the results from this experiment 1 will not induce 
injury to any other target organs. 
From the results obtained in experiment 1 it was clear that our original plan of dosing 
the animals for 12 weeks was too long and would result in a high mortality rate. 
Additionally, there was no difference between the CCl4 dose levels as to the level of 
fibrosis induced as determined histopathologically. There were no deaths in the 0.4 
mL/kg group, until week 6 at which time point 2 animals had to be killed, compared to 
3 at each of the higher dose levels that occurred before 6 weeks of treatment. It was 
therefore decided, that the dose level for our hepatic fibrosis model should be 0.4 mL/kg 
CCl4. With regards to the length of time/number of CCl4 administrations, 6 weeks was 
chosen as the ideal since it was felt that longer than this could result in 
morbidity/mortality of the animals. Therefore, our model for hepatic fibrosis was to 
administer CCl4 at 0.4 mL/kg by gavage 3 times a week for 6 weeks. 
In experiment 2 we used this model to investigate changes to serum enzymes, liver gene 
expression and urinary metabolites as fibrosis developed. We also included a period of 
6 weeks of no treatment at the end of the dosing period to further investigate the 
potential of reversibility of the lesion.  
In general, the organ weight data from experiment 2 compare to the results described in 
experiment 1. However, relative spleen weights were increased above controls in all 
CCl4-treated animals, although in the recovery period the fold increase over control was 
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less than during the dosing period (Table 7.4). Splenomegaly is frequently observed in 
humans with cirrhosis-related portal hypertension, known as congestive splenomegaly. 
In portal hypertension there is an increase in the portal vascular resistance which 
compromises the blood flow through the splenic vein as it empties into the portal vein 
(Gusberg et al., 1994). 
As with experiment 1, at autopsy, many CCl4-treated animals had the presence of fluid 
in the abdominal cavity and showed enlarged veins in the abdominal wall. 
Accumulation of fluid in the abdominal cavity is known as ascites and is the most 
common complication of cirrhosis. In cirrhosis there is the development of intrahepatic 
hypertension and consequently there is retention of sodium and water which eventually 
move from the capillaries into the peritoneal space (Kashani et al., 2008). 
Simultaneously, when the pressure in the portal vein increases, there is venous 
enlargement and development of varices which can bleed (Mahl and Groszmann, 1990). 
Relative liver weights were greater in CCl4-treated animals when compared to controls, 
and at weeks 1 to 5 this increase was statistically significant (Figure 7.4). However, 
after week 2, the fold increases declined. At week 6 there was large intragroup 
variability with regards to liver weight but this is a common finding in CCl4-induced 
hepatic injury. By week 9 and 12 (3 and 6 weeks into the recovery period, respectively), 
relative liver weights were still significantly enlarged compared to concurrent controls 
but had considerably decreased when compared to livers from treated animals during 
the dosing period. The results from experiment 2 compare with the results previously 
described in experiment 1. In advanced stages of cirrhosis it is known that the liver is 
often decreased in size and nodular due to replacement of healthy tissue by the scar 
tissue (Carey and Carey, 2010). 
As in experiment 1, serum levels of ALT, AST and GLDH were significantly increased 
over concurrent controls at all time points during the dosing period (Figure 7.5). A 
similar trend of a reduction in fold increase over control with increasing CCl4 
administrations was also observed. By week 12, the last week of the study, values were 
still increased over concurrent controls indicating that the liver function was not fully 
restored following the 6 week recovery period.  
In experiment 2, serum lipocalin-2, TIMP-1 and MCP1 levels were increased over 
concurrent controls at all time points but maximum increases were present at week 4 
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with 11.5-, 29.9- and 6.9-fold increases over control levels, respectively (
**
P<0.01) 
(Table 7.5). By week 7 (week 1 of recovery period), mean serum levels of lipocalin-2 
and MCP1 had returned to control values, whereas TIMP-1 remained significantly 
increased over controls, even though the fold increase was significantly smaller 
(approximately 2-fold increase) (
**
P<0.01). At week 12 (6 weeks without treatment) 
serum TIMP-1 was still significantly increased over controls (Table 7.6). AGP levels 
increased as the number of CCl4 doses increased and were highest after 6 weeks of CCl4 
administration (Table 7.5). During the recovery period AGP levels remained similar to 
controls. Serum A2M levels also peaked at week 6 (12.4-fold increase over controls; 
***
P<0.001) and remained significantly increased over controls during the recovery 
period apart from weeks 7 and 10 (Table 7.5, Table 7.6). In the acute study carried out 
in Chapter 3, levels of these biomarkers were also measured in the serum following the 
single administration of CCl4. Apart from A2M serum levels, which did not show 
evidence of a dose-related effect, mean values for all other markers appeared to increase 
significantly with the CCl4 dose level. 
Increases in serum lipocalin-2 levels have been previously described in models of CCl4-
induced hepatic fibrosis. Kamphorst et al. (2011) used a protocol of twice weekly 
administrations of CCl4 at 1.0 mL/kg for a period of 12 weeks to induce fibrosis in the 
male Sprague-Dawley rat. The authors found increased lipocalin-2 expression in liver 
tissue and immunohistochemistry revealed strong staining in the hepatocytes. 
Throughout the experiment, increased serum levels of lipocalin-2 were reported 
although they did not necessarily correlate with the degree of injury. The authors 
suggested that damaged hepatocytes were the main source of lipocalin-2 production. In 
our current study, lipocalin-2 levels were also measured in the urine, as an indicator of 
CCl4-induced lesion. Urinary excretion of lipocalin-2 was increased in CCl4-treated 
animals at weeks 3 to 6 during the dosing period and levels were maximal at week 6 
when there was a 23-fold increase (
***
P<0.001). Levels remained significantly increased 
over controls at most time points during the recovery period but the fold increases were 
much smaller. Increases in urinary lipocalin-2 were also reported by Smyth et al., 
(2009a) following CCl4-induced fibrosis in a rat model. However, lipocalin-2 is more 
commonly used to assess kidney injury as discussed in Chapter 3 and 4. 
TIMP-1 is produced by activated HSCs and Kupffer cells and has been suggested to be 
a serum marker of liver fibrosis (Herbst et al., 1997; Roderfeld et al., 2006; Wang et al., 
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2011), whereas MCP1 is one of the most important chemotactic factors secreted by 
HSCs and has also been found to be up-regulated in experimental models of CCl4-
induced hepatotoxicity (Karlmark et al., 2009). In a study by Marsillach et al. (2009) 
liver fibrosis was induced in male Wistar rats using a model of twice weekly i.p. 
injections of 0.5 mL CCl4 diluted 1:1 in olive oil for a period of 12 weeks. Animals 
were autopsied at 6, 8, 12, 13 and 14 weeks of the study (13 and 14 reflected 1 and 2 
weeks of recovery). The authors reported a moderate increase in plasma MCP1 
concentrations during the dosing period and a return to normal values during the 
recovery period.  
AGP is an acute phase protein and is mainly secreted by hepatocytes and has been 
shown to increase following hepatic injury (Fournier et al., 2000). It has been proposed 
that following necrosis of the hepatic parenchymal cells, pro-inflammatory cytokines, 
such as IL-6 and TNF-α are released which could trigger the production of acute-phase 
proteins like AGP (Sugihara et al., 1992). AGP is responsible for regulating the 
inflammatory response, mainly by inhibiting platelet aggregation so as to reduce tissue 
damage caused by inflammatory cells (Costello et al., 1979; Janciauskiene, 2001). 
A2M has been shown to bind and inactivate proteases from the metalloproteinase class 
including collagenases; collagenases are responsible for the degradation of collagen 
(Barrett and Starkey, 1973). Previous studies have shown a decrease in collagenase 
activity as liver fibrosis progresses (Montfort and Perez-Tamayo, 1978) and A2M is 
thought to play a major role in mediating this decreased activity and thus allowing the 
progression of fibrosis (Truden and Boros, 1988). Kawser et al. (1998) studied the role 
of A2M in fibrosis in male Sprague-Dawley rats dosed by i.p. injection with 0.2 mL/100 
g body weight CCl4 twice a week for 1 week (early fibrosis) and 4 weeks (established 
fibrosis). The group found an increase in A2M plasma levels in treated animals in both 
models of fibrosis, providing further evidence that A2M plays a role in the inhibition of 
collagenases during fibrogenesis (Kawser et al., 1998).  
Having been able to characterise changes occurring to serum markers of hepatic 
fibrosis, we also aimed to investigate the changes in hepatic gene expression with the 
induction of injury, and with injury recovery. One of the mechanisms for CCl4-induced 
toxicity is the generation of reactive oxygen species and free radicals which may cause 
oxidative stress to the cell. As discussed in Chapter 4, HMOX1, which encodes for 
heme oxygenase 1, plays a critical role in protecting against oxidative and inflammatory 
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stress (Gu et al., 2012). Therefore, it is not surprising that a statistically significant 
increase was seen in the hepatic expression of HMOX1 after 1 week of CCl4 treatment, 
as a protective mechanism against CCl4-induced oxidative stress (Table 7.9). In the 
present study, hepatic HMOX1 was upregulated compared to control animals at all time 
points during the dosing period, but by week 9 and 12 a downregulation was seen and at 
12 weeks this was statistically significant. In a study by Chung et al., (2005b), Sprague-
Dawley rats were injected with 0.5 mL/kg CCl4, 3 times a week and killed at day 0, 30, 
60 and 90. The authors reported an increase in HMOX1 expression compared to 
controls up to day 60, after which there was a decrease in hepatic expression, which 
may be a reflection of the severe degree of injury induced to the liver. In the present 
study, hepatic expression of HMOX1 was maximal at week 4, and decreased after this 
time point. Similarly, hepatic expression of NQO1 was also significantly upregulated 
compared to control animals after 3 administrations of CCl4. The expression of NQO1 
is induced by oxidative stress (Nioi and Hayes, 2004) and it encodes an enzyme which 
prevents the formation of reactive oxygen species (Ross, 2004; Vasiliou et al., 2006). 
The enzyme NAD(P)H dehydrogenase, quinone 1, has been found to be present in high 
concentrations in the rat liver (Sharkis and Swenson, 1989) and is considered a 
detoxification enzyme due to its ability to convert reactive quinones to less reactive 
hydroquinones which have antioxidant properties. The ability to scavenge O2
-.
 has also 
been proposed for NQO1 and may account for the induction of this enzyme following 
oxidative stress (Siegel et al., 2004). In the study by Chung and co-workers (2005b) 
NQO1 expression was also upregulated up to day 60 and downregulated at day 90 in a 
model of rat hepatic fibrosis. Previous studies have also reported increases in NQO1 
expression as detected after 8 weeks of CCl4 subcutaneous injections twice a week at 
0.3 mL/100 g of BW to male Sprague-Dawley rats (Wang et al., 2010b). In the present 
study, the expression of NQO1 mRNA was found to be upregulated to approximately 
2.8-fold in CCl4-treated animals over concurrent controls at week 5 during the dosing 
period (maximal gene expression) and after this time point NQO1 mRNA levels 
decreased. These results compare with the liver gene expression data from the dose-
response study in Chapter 4, where a 1.7-fold upregulation was recorded for NQO1 in 
the liver after administration of HCBD at 5 mg/kg.  
Hepatic expression of CYP1A2 and CYP2C was also determined at all time points in 
the study. CYP1A2 and CYP2C mRNA expression was significantly downregulated at 
week 1 and levels remained significantly downregulated during the dosing period, that 
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is, up to week 6. However, after this time point, CYP1A2 and CYP2C mRNA levels 
started to increase and appeared to return to control values. Several studies have focused 
on the effects of liver function in the levels of cytochromes, particularly of cytochrome 
P-450. This is because inhibition or induction of these enzymes is often seen in cases of 
drug interactions. CYP1A2 is predominantly a hepatic enzyme (Floreani et al., 2013). 
Floreani and colleagues (2013) reported a decrease in CYP1A2 mRNA following the 
induction of cirrhosis, and this decrease appeared to correlate with the severity of injury. 
Similar decreases in the levels of CYP1A2 were described by Bastien and co-workers in 
a rat model of CCl4-induced cirrhosis. Decreases in the hepatic expression of CYP2C 
have also been reported in rat models of CCl4-induced injury (Young et al., 2003). 
CYP1A2 has a protective role against the production of ROS and therefore, decreased 
expression of CYP1A2 might be deleterious (Nakai et al., 2008). Levels of CYP1A2 
have also been found to be decreased in human samples of cirrhotic livers (Guengerich 
and Turvy, 1991). 
In the category of inflammation, hepatic LCN2 expression was upregulated at all time 
points. Previous studies have shown that lipocalin-2 is expressed and released by the 
liver in response to inflammation (Liu and Nilsen-Hamilton, 1995; Flo et al., 2004). 
Kamphorst et al. (2011) reported increased hepatic expression of lipocalin-2 in the rat 
liver in a model of CCl4-induced hepatic fibrosis and suggested the main source of 
lipocalin-2 production to be the damaged hepatocytes. In the present study, LCN2 
mRNA expression was greatest at week 4 which coincided with peak levels of lipocalin-
2 observed in the serum. 
In the present study, it was observed that TIMP-1 mRNA was increased compared to 
control at all time points. It appeared to increase up to week 4, after which a decrease in 
hepatic expression was seen. Increases in TIMP-1 mRNA expression have been 
previously reported in chronic liver injury studies. Herbst and colleagues (1997) 
investigated TIMP expression in a chronic model of CCl4-induced hepatic injury. 
Herbst injected rats with 1.0 mL/kg every 4 days for 3 weeks and sacrificed at 12, 24 or 
48 hours after the last injection. This group found TIMP-1 expression to be upregulated 
in the fibrotic rat liver. Another study also demonstrated increased levels of TIMP 
mRNA in a rat model of CCl4-induced hepatic fibrosis (Iredale et al., 1996). TIMPs are 
responsible for regulating the activity of MMPs which in turn are responsible for the 
degradation of extracellular matrix (Iredale et al., 1996). In hepatic fibrosis/cirrhosis 
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there is an accumulation of extracellular matrix which is caused by decreased MMP 
activity and increased TIMP activity. In the work carried out by Chung and co-workers 
(2005b) TIMP-1 was also reported to be upregulated in a rat model of CCl4-induced 
fibrosis. The present study has been able to show a good degree of correlation between 
hepatic expression of TIMP-1 and serum levels. In fact, serum clinical chemistry also 
reported maximum levels of TIMP-1 after 4 weeks of CCl4 treatment and similar fold 
increases were recorded for serum TIMP-1 and TIMP-1 expression at week 1 (3.4-fold 
and 4.3-fold respectively). The significant decrease seen in TIMP-1 levels at week 9 and 
12 is consistent with the process of regeneration and repair of the liver. Significant 
decreases in TIMP-1 mRNA have been reported as early as 1 week following 
interruption of CCl4 administration in models of CCl4-induced fibrosis (Benyon and 
Iredale, 2000). The authors reported this decrease in TIMP-1 expression to coincide 
with a period of rapid collagen degradation and consequent liver regeneration. TIMP-1 
appears to be particularly relevant to the inhibition of MMP-13 in the rat (Arthur et al., 
1999). In the present study MMP-12 mRNA was significantly increased at all time 
points but at week 9 and 12 the fold increase was smaller. Similar results to those 
described in the present study were previously reported by Chung et al (2005b) and by 
Pellicoro and co-workers (2012a). MMP-12 is expressed by hepatic macrophages in the 
fibrotic liver and is responsible for the degradation of elastin. Pellicoro et al., (2012a) 
reported that elastin is expressed from the onset of injury, but unlike collagen I, elastin 
only accumulates in the late stages of fibrosis. The authors suggested, therefore, that 
during the initial phases of injury there is degradation of elastin by MMP-12. The 
authors reported an increase in MMP-12 expression with increasing duration of injury, 
however, the results also show that there was a concomitant increase in TIMP-1 
expression and immunoprecipitation assays showed increased levels of TIMP-1 bound 
to MMP-12 in severe fibrosis. 
COL1A1 and COL5A2 mRNA levels were found to be increased at all time points in 
the study, however fold increases during the recovery period were much smaller than 
those recorded during the dosing period. Collagens I and III are 2 of the main 
components of the extracellular matrix and the major components of these proteins are 
produced by COL1A1 and COL3A1 (Kanemoto et al., 2011). In a mouse model of 
CCl4-induced liver fibrosis, COL1A1 expression was found to be increased after 4 
weeks of treatment (Jiang et al., 2004). Another study has suggested that lipid 
peroxidation stimulates collagen gene transcription; lipid peroxidation is one of the 
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main features of CCl4-induced hepatic injury. The authors were able to show the 
existence of a temporal relationship and co-localisation of lipid peroxidation and 
increased expression of COL1A1, following a single administration of CCl4 but not with 
allyl alcohol. Administration of allyl alcohol induced extensive necrosis but there was 
no increase in COL1A1 (Bedossa et al., 1994). TGF-β1 hepatic expression levels were 
also measured throughout the study and were shown be upregulated at all time points, 
but similarly to COL1A1 and COL5A2, the fold increase decreased considerably during 
the recovery period. Increased expression of TGF-β1 has been previously reported 
following the administration of CCl4 for 4 weeks to mice (Jiang et al., 2004). An 
investigation into the different cellular sources of TGF-β1 in the liver revealed that, in 
the normal liver, TGF-β1 was predominantly found in the Kupffer cells (De Bleser et 
al., 1997). However, in the fibrotic liver, it appears that TGF-β1 mRNA is increased 
selectively in HSCs, which are the main cells involved in the process of hepatic fibrosis. 
Indeed, it has been reported that TGF-β1 is particularly important to the response of 
HSCs to CCl4. In addition, TGF-β1 has been shown to increase the expression of 
collagen and fibronectin which are components of the ECM at the same time as 
enhancing the production of TIMPs (Nakatsukasa et al., 1990). The upregulation of 
TGF-β1 expression observed during the dosing period in this study is consistent with 
the development of liver fibrosis as confirmed by histopathology, and appears to follow 
the same general trend of increased COL1A1, COL5A2 and TIMP-1 mRNA levels 
between week 1 and 6, with a decrease in expression during the recovery period. 
In the present study, ACTA2 mRNA expression was upregulated at all time points, 
upregulation was maximal at week 5 and by week 9 and 12 there appeared to be a return 
to control levels. ACTA2 is found mainly in the smooth muscle but has also been 
reported to be expressed by myofibroblasts (Rockey et al., 2013). Repeated 
administration of CCl4 to male Sprague Dawley rats has been shown to cause activation 
of HSCs into myofibroblast-like cells, with consequent upregulation of ACTA2 mRNA 
expression and development of fibrosis. Upregulation of ACTA2 in HSCs appears to be 
involved in the process of cell motility and contractility during the process of cellular 
activation into myofibroblasts (Rockey et al., 2013). Yang and co-workers also reported 
increases in ACTA2 mRNA levels in a mice model of CCl4-induced fibrosis as detected 
by immunohistochemical analysis. The upregulation in ACTA2 expression reported in 
the present study constitutes further evidence of the role of ACTA2 in the process of 
myofibroblast activation associated with the development of hepatic fibrosis/cirrhosis. 
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Similarly, we suggest that the decrease in mRNA expression at weeks 9 and 12 is 
associated with the process of liver regeneration. 
With this experiment we also wished to assess the potential to use US in a time course 
evaluation of CCl4-induced liver changes, and to correlate this information with the data 
collected from histopathological examination of the livers collected at autopsy. 
Although histological assessment of the liver remains the gold-standard for the 
diagnosis of fibrosis, the limitations associated with the procedure compromise its use 
in clinical practice. US has the ability to detect alterations to the hepatic parenchyma 
due to moderate to severe liver fibrosis/cirrhosis (Hirata et al., 2001) and it is often the 
first imaging procedure in cases of suspected liver disease (Tchelepi et al., 2002). US is 
a non-invasive technique, inexpensive and has been proven to be an important tool in 
detecting hepatocellular carcinoma (Nishiura et al., 2005). Normally, the hepatic 
parenchyma is homogeneous with medium level echogenecity and equal or slightly 
more echogenic than the kidneys and its echogenic texture is interrupted by the portal 
and hepatic veins. A fibrotic/cirrhotic liver is characterised by heterogeneous patchy or 
diffuse echogenecity and this is related to the development of fatty liver and scar tissue 
(Tchelepi et al., 2002). Changes to the liver include changes in the size and shape of the 
liver, parenchymal nodularity and inhomogeneity, and changes to parenchymal 
echogenecity which may be increased compared to adjacent organs such as the kidneys 
(Tchelepi et al., 2002).  
In the present study, scanning sessions were performed between weeks 3 and 6 during 
the dosing period, to assess the progression of injury, and at weeks 9 and 12 to evaluate 
the potential for recovery. To allow correlation of US images and histopathological 
data, the same animals were scanned 2 days before their scheduled autopsy. 
At weeks 3, 4 and 5, i.e., after receiving 9, 12 and 15 doses of CCl4, the livers from 
treated animals were hyperechoic compared to the kidneys and appeared to be enlarged 
in the longitudinal projection compared to livers from control rats. At week 6 there was 
evidence of fluid in the abdominal cavity (Figure 7.6 C) which was confirmed during 
the autopsies. By week 9 and 12 (3 and 6 weeks without treatment) US revealed the 
presence of some degree of recovery with the absence of fluid in the abdominal cavity, 
although livers were still hyperechoic and enlarged compared to control livers. 
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US has been used to evaluate the progression of CCl4-induced injury in rat models. In a 
study by Lessa and colleagues (2010), CCl4-induced cirrhosis was induced in female 
Wistar rats (0.05 mL/kg CCl4 by i.p. injection 3 times a week on alternate days for 15 
weeks). In this study, animals were examined at the beginning of the experiment and at 
weeks 4, 8 and 15. The authors reported an increase in liver echogenecity compared to 
the renal cortex and the presence of ascites in CCl4-treated animals, there was also 
development of heterogeneous hepatic parenchyma associated with nodular liver 
surface which revealed good correlation with the diagnosis of cirrhosis by 
histopathological examination (Lessa et al., 2010). Dias et al., (2008) used a model of 
CCl4-induced cirrhosis to evaluate the potential for reversibility. Female rats were dosed 
with 0.05 mL/kg CCl4 3 times a week for a period of 15 weeks. At the end of the dosing 
period 6 animals were left to recover for 8 weeks. US analysis revealed increased liver 
echogenecity with heterogeneous hepatic parenchyma at week 15; however, after 8 
weeks of recovery the same observations were reported. The presently described study 
provides further evidence of the potential for liver regeneration and repair in a model of 
CCl4-induced injury. Also, we have been able to establish a good degree of correlation 
between US examination and the morphologic appearance of the livers collected at 
autopsy.  
In this experiment, histopathological examination of the livers confirmed the 
development of hepatic fibrosis and thus further validated our model. Pathological 
findings were similar to those described in experiment 1. During the recovery period 
there was an improvement in the microscopic and gross appearance of the liver, similar 
to that described in experiment 1. Therefore, while full resolution of the injury did not 
occur, these results further confirm the reversibility of hepatic fibrosis in this particular 
model.  
In 1991, Fischer and co-workers (1991) described the rat model of CCl4-induced 
cirrhosis as irreversible. In the past, fibrosis was also considered to be an irreversible 
process which resulted from complete destruction of the hepatic parenchyma (Popper 
and Uenfriend, 1970). More recently, studies have focused on the possibility of 
reversibility of fibrosis (Benyon and Iredale, 2000; Bataller and Brenner, 2005; 
Pellicoro et al., 2012b). The discussion of the mechanisms associated with reversibility 
is ongoing, with some authors suggesting that either removal of HSCs or the reversal or 
HSCs activation may be necessary for recovery from fibrosis (Benyon and Iredale, 
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2000). Therefore, the present studies are particularly important to the current debate 
regarding the development of fibrotic lesion and in the understanding of the potential 
mechanisms involved in reversibility.  
In all of our CCl4 liver studies we are concerned about the potential for CCl4 induced 
nephrotoxicity since the ultimate aim is to identify urinary markers of hepatotoxicity. 
In Chapter 4, an investigation was carried out to compare the sensitivity of several 
urinary markers of kidney injury showed GST Yb1 and α-GST to be the most sensitive 
markers. These are enzymes which are present in the proximal and distal tubules and are 
involved in the detoxification process of many compounds (Lock and Reed, 1998; van 
Lieshout et al., 1998). In the present study, α-GST was significantly decrease compared 
to control animals at week 1 and 2, but by week 6 it was approximately 1.6-fold 
increased over controls (Table 7.7, Table 7.8). GST Yb1 was significantly increased 
over concurrent controls after 6 weeks of CCl4 treatment (approximately 2-fold 
increase), and this increase was statistically significant (
*
P<0.05). However, by the end 
of the first week of recovery (week 7) levels of both enzymes had returned to 
approximate control values. The fold-increases recorded in the present experiment 2 
were, however, much smaller than the ones seen in the time course study in Chapter 4 
using a model of HCBD-induced renal toxicity. At 24 hours post-dosing with HCBD, α-
GST and GST Yb1 reached peak levels; α-GST was 356.9-fold increased over controls, 
whereas the fold increase for GST Yb1 was approximately 17-fold. It is important to 
note that α-GST is located in the hepatocytes and it has also been shown to be released 
into the blood following marked hepatocellular damage (van Wagensveld et al., 1997; 
Giffen et al., 2002). Therefore, the increase reported in the current study may be a 
consequence of the severe degree of injury induced by chronic administration of CCl4 
(Clarke et al., 1997).  
Our previous study (Chapter 4) also showed evidence that supported the classification 
of KIM-1 and osteopontin as markers of both kidney injury and repair. In the currently 
described fibrotic model the first significant difference in urinary KIM-1 was seen at 
week 6 at which time point levels reached a peak (
*
P<0.05). During the recovery period 
mean values slightly decreased compared to that at week 6, but were still increased 
compared to concurrent controls. Urinary osteopontin was significantly increased in 
CCl4-treated animals at all time points during the dosing period and levels were 
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maximal at week 4. However, by week 7 (first week of recovery period) they were 
similar to controls.  
Urinary levels of clusterin were measured in the urine of rats during the dosing and 
recovery period. In the present study, clusterin values were significantly decreased over 
controls at week 3 during the dosing period, and at weeks 8 and 12 during the period 
without CCl4-treatment. In 1996 Hogasen and co-workers investigated the relationship 
between serum clusterin (apolipoprotein J) and decreased hepatic function in cirrhotic 
patients (Hogasen et al., 1996). The authors reported significantly decreased serum 
levels in hepatic cirrhosis, suggesting the liver is the main site for clusterin production. 
We therefore suggest, that the decreased urinary clusterin levels seen in the present 
study, may be a reflection of decreased clusterin production by the liver. 
It should be noted that while some of these kidney biomarkers were increased during 
the course of this study, the fold difference over control was small and thus 
confirmation of absence of nephrotoxicity would be made by histopathological 
examination of the kidneys.  
In this study, we found no evidence of an effect in the kidneys that could be attributed 
to CCl4 administration. There was minimal vacuolation of the proximal tubular 
epithelium but this was also recorded in one control animal and therefore no clear 
association between CCl4-treatment and the microscopic findings in the kidneys could 
be established. Therefore, we now had confidence in our hepatic fibrosis model and we 
could reliably investigate changes to the urinary metabolome during the development of 
fibrosis and subsequent recovery from the injury induced. 
Initial investigation of the PCA scores plot in Figure 7.9 indicated the presence of 
differences between control animals and animals that received the CCl4-treatment. 
However, the degree of cluster separation was compromised by the great number of 
samples included in the model. A trajectory plot representing the mean 
1
H NMR urine 
spectra for control samples and for CCl4-treated samples at all time points showed a 
move towards the right side of the plot with CCl4 treatment with time up to week 5 
(Figure 7.11). At week 6 there was a continuation of the trend towards the upper right 
quadrant, but it is not known why week 6 is located to the left of week 5. This 
movement to the upper quadrant is similar to what happens in the control samples with 
time, so it may be a reflection of age-related changes. The greatest change during the 
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dosing period occurs between week 2 and 3. Between week 6 and 9 there is a distinctive 
shift back to the left side of the scores plot, this is reflecting changes due to the recovery 
period. Further investigation of these metabolite changes using OPLS-DA models 
revealed that after receiving 3 doses of 0.4 mL/kg CCl4 there was an increase in the 
resonances of taurine, 2-oxoglutarate, citrate, succinate and formate. Similar findings 
had been previously reported in the dose response study described in Chapter 3 after a 
single administration of CCl4 at 2.0 mL/kg and in other single dose studies (Waterfield 
et al., 1993; Li et al., 2013; Zira et al., 2013).  
Formate levels in the urine were increased at week 1 compared to control animals 
(Table 7.10). In our previous dose-response investigation (Chapter 3) and time course 
study (Chapter 6), formate levels were also found to be significantly increased over 
control animals at 24 hours following the administration of 2.0 mL/kg CCl4. In the 
present study formate levels increased at week 4 and 5, but by the time the dosing 
period finished (week 6), levels were decreased compared to week 1 (Table 7.10). 
Formate urinary excretion further decreased at week 9 but by week 12 (6 weeks into the 
recovery period) levels increased again. Decreased urinary levels of formate have been 
described in the literature as consequence of CCl4-induced decreased tetrahydrofolate 
which will result in decreased formate metabolism and subsequent increase in formate 
urinary excretion (Dow and Green, 2000).  
Fatty liver is one of the most commonly seen features of liver cirrhosis. It may develop 
if there is a decrease in choline, an essential nutrient for phospholipids, which are 
needed for the elimination of triglycerides from the liver in the form of VLDLs. Choline 
synthesis requires a carbon from formate that has to be bound to tetrahydrofolate before 
it can be used (Corbin and Zeisel, 2012). The decrease in formate levels in the present 
study is further evidence that this may be one of the contributing causes for fatty liver.  
Urinary hippurate excretion appeared to decrease with the induction of injury. At week 
6, last week of the dosing period, hippurate levels were decreased compared to week 1, 
but after removal of the toxic agent levels appeared to increase; at week 9 urinary 
hippurate was increased compared to week 6, and at week 12 (6 weeks without 
treatment), levels were increased compared to week 9 (3 weeks without treatment) and 
week 6 (Table 7.10, Table 7.11). Similar results were described for hippurate levels in 
Chapter 3 and 6 with reported decreases in urinary excretion following a single 
administration of CCl4. As described in Chapter 6, decreased hippurate happens as a 
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consequence of ATP depletion that occurs during the process of hepatic necrosis 
(Gatley and Sherratt, 1977; Kim et al., 2008a) and which is more severe during the 
process of liver fibrosis/cirrhosis. During the recovery period, there was an increase in 
hippurate levels and this suggests the existence of some degree of liver regeneration. 
As previously discussed, taurine is synthesised in the liver and increased urinary 
excretion may result from hepatocyte leakage (Waterfield et al., 1993; Waterfield et al., 
1998). Up to week 3, taurine levels appeared to increase consistently but this was 
followed by a reduction in urinary excretion in weeks 5 and 6 (Table 7.10). The 
decrease in urinary taurine has been previously described in mice with severe liver 
damage or cirrhosis (Warskulat et al., 2006). A reduction in the hepatic taurine 
concentration was also previously reported following the chronic administration of CCl4 
for 5 and 10 weeks in a rat model of fibrosis (Miyazaki et al., 2004; Miyazaki et al., 
2005). This is the result of impaired liver function with reduced taurine synthesis in the 
liver and therefore a decrease in the levels of hepatic taurine, which is reflected by 
lower levels of urinary excretion.  
Our study revealed that even though taurine levels appeared to have been decreasing in 
the urine of CCl4-treared rats at weeks 5 and 6, at week 6 they were still increased over 
week 1 (Table 7.11). At week 9 (3 weeks without treatment), urinary taurine had 
increased compared to week 6 and this could reflect the initial stage of liver 
regeneration.  
Therefore, this metabolomic study in experiment 2 has added further evidence that the 
urinary excretion of taurine correlates well with liver injury. Initial increases in urinary 
taurine levels appear to be a result of hepatocyte necrosis and release of cellular content 
(Waterfield et al., 1991). However, as the injury progresses less taurine is synthesised 
and taurine levels in urine appear to decrease as a result of impaired hepatic function. 
We have also been able to demonstrate, that during the recovery phase, when no further 
exposure to the toxic stimulus was present, taurine levels increased again. This suggests 
that hepatic function was returning to normal during the recovery phase but full 
resolution had not occurred. 
Urinary excretion of TCA cycle intermediates such as 2-oxoglutarate, citrate and 
succinate were increased over controls after 1 week of CCl4 treatment. Levels of 2-
oxoglutarate and citrate were decreased at weeks 2 and 3 when compared to the 
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previous time point, but at week 4 a rise in urinary excretion was observed compared to 
at week 3. Urinary succinate on the other hand, was decreased from week 4 onwards. At 
week 6 levels were decreased compared to week 1 and after 6 weeks of recovery (week 
12), urinary succinate excretion remained decreased compared to week 6. In a model of 
thioacetamide-induced liver fibrosis/cirrhosis in the rat, succinate was found to be 
increased in the aqueous liver extract as detected using 
1
H NMR after 1 and 2 months of 
treatment; at later time points succinate levels decreased (Constantinou et al., 2007). 
In a study by Gou et al. (2013) hepatic fibrosis was induced in rats by twice weekly i.p. 
injection of CCl4 at 1.0 mL/kg 50% CCl4 for 9 weeks. This study showed increased 
urinary levels of citrate. In our study, citrate levels were increased from previous time 
points from week 4 onwards. At week 9 (3 weeks without treatment) citrate was 
decreased compared to week 6, but levels appeared to increase with time without 
treatment, at week 12 (6 weeks recovery), citrate urinary excretion was increased 
compared to week 9 and week 6 (Table 7.11). 
Several enzymes in the TCA cycle, such as α-ketoglutarate dehydrogenase and pyruvate 
dehydrogenase, have been shown to be inhibited by oxidative stress (Humphries and 
Szweda, 1998); oxidative stress is one of the major molecular mechanisms involved in 
CCl4-induced injury (Humphries and Szweda, 1998). It has also been demonstrated that 
α-ketoglutarate dehydrogenase is able to produce H2O2 and could therefore be a source 
of ROS in the mitochondria (Tretter and Adam-Vizi, 2004). Inhibition of enzymes is 
due to modifications of lipoic acid residues bound to one of the subunits of the 
enzymes, and results in the slowing down of the TCA cycle as a feedback mechanism to 
reduce the production of free radicals (Humphries and Szweda, 1998). This, in turn, 
may result in increased levels of TCA cycle intermediates as they are not being used up 
in the cycle and consequently could be excreted in the urine. Other studies have also 
reported inhibition of the TCA cycle in a model of D-galactosamine-induced fulminant 
hepatic failure (Yokoyama et al., 2005). We suggest that this mechanism can be the 
reason for increased 2-oxoglutarate and citrate levels at week 6 compared to weeks 1 
(Table 7.11).  
The metabolite creatinine was also identified as a metabolite responsible for sample 
separation as determined by analysis of the S-plot and VIP plots (data not shown). After 
6 weeks of CCl4 treatment creatinine was increased compared to week 1, and it further 
increased at week 9. However, at the following time point (week 12; 6 weeks without 
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treatment), it appeared that creatinine levels decreased slightly but were still increased 
compared to urinary excretion at the end of the dosing period (week 6) (Table 7.10, 
Table 7.11). The NMR data for creatinine peaks and the creatinine assay data obtained 
from the clinical chemistry analysis (Table 7.7, Table 7.8) showed the same pattern of 
change. This is further evidence of the sensitivity of the NMR spectrometry in our 
experiments. 
As previously discussed, creatinine is produced from creatine which in turn is 
synthesised in the liver. Therefore, a decreased liver functional capacity as a result of 
fibrosis/cirrhosis could be reflected by decreased levels of creatine and consequently of 
creatinine (Cocchetto et al., 1983; Ropero-Miller et al., 2000; Waters et al., 2005). In 
our study, creatine was found to be decreased in the urine at week 1 and 2 and at weeks 
5 and 6, compared to earlier time points, and at week 6, creatine levels in the urine, as 
measured by 
1
H NMR were decreased from week 1 (Table 7.10, Table 7.11). Levels of 
creatine appeared to be increased in the urine after 3 weeks without treatment (week 9 
compared to week 6) and were decreased at week 12 compared to week 9 and 6.  
Creatine is a by-product of cysteine synthesis in the liver. Cysteine is an amino acid that 
is necessary for the competitive synthesis of protein and taurine, therefore, changes in 
the amount of protein synthesis will affect the availability of hepatic cysteine for taurine 
synthesis. Increased hepatic cysteine availability would result in increased taurine 
synthesis and consequently, in increased urinary taurine levels, whereas decreased 
cysteine availability would result in decreased taurine synthesis (Clayton et al., 2003). 
When protein synthesis is inhibited, as in the case of hepatic impairment, cysteine is 
diverted and is used in the synthesis of taurine, resulting in hypertaurinuria. However, 
because there is excess hepatic cysteine there is no need for increased cysteine synthesis 
and therefore, there is no increased creatine production (Clayton et al., 2003). This may 
explain the hypertaurinuria without hypercreatinuria that is observed in the first 2 weeks 
of the study. In fact, both serum and urine clinical chemistry revealed a statistically 
significant decrease in total protein levels at both week 1 and 2 (Table 7.5, Table 7.7).  
With the completion of the 2 experiments described in this study, we have successfully 
been able to develop an animal model of hepatic fibrosis in the male Hanover-Wistar 
rat. We have shown that following administration of CCl4, 3 times a week, for a period 
of 6 weeks our rat model displays most of the main characteristics of fibrosis seen in 
humans. After 3 and 6 weeks without treatment, there was evidence of histopathological 
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regeneration and the histological features of fibrosis showed some degree of recovery 
even if complete reversibility to a morphologically normal liver was not observed. 
There is very limited data regarding changes to urinary metabolites in rat models of 
CCl4-induced fibrosis during the period of injury progression and regeneration using 
1
H 
NMR-based metabolomics approach. We suggest that metabolites such as creatinine, 
citrate and succinate are likely to be better markers of the initial stages of injury, as they 
significantly changed in the urine at week 1. Citrate and succinate, however, did not 
show a statistically significant difference at week 9 compared to week 6, further 
confirming the potential to be early injury markers.  
We have shown that after 3 weeks without treatment there was a significant change in 
the general metabolite profile of urine samples. Hippurate levels showed a decreasing 
trend during the dosing period, but at week 9, urinary excretion significantly increased 
and was further increased at week 12, and this appeared to correlate well with both 
clinical chemistry and histopathology data showing signs of injury recovery. Similarly, 
we have further established taurine as a marker of liver toxicity and have contributed to 
the knowledge of the role of urinary taurine in liver fibrosis/cirrhosis. By the end of the 
dosing period taurine levels were increased over controls, but after CCl4 administration 
was stopped, urinary taurine levels decreased. We therefore suggest that urinary levels 
of hippurate and taurine may also serve as good indicators of regeneration.  
Furthermore, this study provides an extensive characterisation of serum and urinary 
markers, as well as a detailed investigation into the gene expression changes occurring 
in the liver as a result of repeated CCl4-administration to the male Hanover-Wistar rat. 
We were able to assess the progression and regeneration of injury as revealed by 
biomarkers levels, and to correlate this information with data from US and 
histopathological examination. 
It is relevant to mention that although metabolomic-based investigations are mostly 
applied to rodent models of liver disease, there are reports in the literature of 
metabolomics investigations, that appear to parallel the findings described for the rat, in 
particular the elevation in taurine and 2-oxoglutarate levels seen in models of liver 
fibrosis/cirrhosis (Gao et al., 2009). Indeed, the metabolites described here are involved 
in metabolic pathways that are not exclusive to the rat and can also be found in humans. 
This adds further importance to the results described in the present study in which we 
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have demonstrated the potential for taurine as a marker of progression of fibrosis and 
for regeneration from injury. 
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CHAPTER EIGHT 
Conclusion 
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This project was concerned with the development of models of CCl4-induced acute 
injury and hepatic fibrosis in the male Hanover-Wistar rat. CCl4 was the chosen 
hepatotoxicant since it has been widely used in rat models for liver injury (Brattin et al., 
1984). Extensive 1D 
1
H NMR-based metabolomics investigations were carried out to 
determine changes in urinary levels of metabolites with acute and chronic hepatic 
injury. Urine was chosen as the preferred biofluid since it can be obtained using non-
invasive methods. 
We began this series of investigations by performing a dose response study examining 
for possible extra-hepatic sites of CCl4-induced damage. CCl4 may cause injury to other 
organs, particularly the kidneys at high dose levels (Ozturk et al., 2003; Makni et al., 
2012). In Chapter 3 we defined the ideal dose level of CCl4 for the induction of 
hepatotoxicity to be 2.0 mL/kg. Above this dose level results from serum and urine 
clinical chemistry as well as histopathological examination of kidney tissue samples 
revealed evidence of nephrotoxicity consistent with CCl4 administration. Therefore, in 
subsequent CCl4 studies, we kept the dose level administered to the rat below this 
threshold value. 
Since we were interested in urinary biomarkers of hepatic toxicity kidney function was 
of great concern. Any CCl4-induced nephrotoxicity could make interpretation of urinary 
biomarker levels difficult. Therefore, the possibility of renal damage was consistently 
evaluated in all our CCl4 liver studies. In Chapter 4 we used a rat model of HCBD-
induced nephrotoxicity to evaluate a group of biomarkers recently approved by the FDA 
for voluntary inclusion in investigational and regulatory studies, which included KIM-1, 
albumin, clusterin and total protein. These markers were compared for sensitivity in a 
dose response study and also to determine their response to injury with time from an 
initial insult in a time course study. It was determined that, of the markers studies, α-
GST, KIM-1 and albumin were the most sensitive biomarkers of proximal tubular injury 
showing significant differences compared to control animals at the lowest dose levels 
and with greater fold changes. Therefore, we decided that these sensitive markers would 
be useful to measure in our CCl4 liver studies alongside histopathological evaluation of 
kidney tissue samples to rule out CCl4-induced nephrotoxicity. 
One of our concerns for the chronic hepatic fibrosis study was that as the animals age 
and reach sexual maturity this may have an effect on the degree of CCl4-induced injury 
as well as on the levels of urinary metabolites. For this reason, a series of animal 
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experiments were devised in Chapter 5, in which samples were collected between 3 and 
13 weeks of age. The results from these experiments revealed a dramatic increase in 
urinary testosterone levels between 54 and 68 days of age. This time point corresponded 
to the histological findings that suggested animals were both sexually mature and fully 
fertile at 63 days old. Interestingly, our experiment also revealed that urinary levels of 
α-GST, GST Yb1 and total protein followed the same pattern as testosterone. Age-
related differences in urinary protein levels in the rat have been extensively studied in 
the literature (Sellers et al., 1950; Neuhaus and Flory, 1978; Owen and Heywood, 1986; 
Williams et al., 2005) and there is undergoing investigation regarding the relationship 
between the urinary protein profile and the levels of testosterone in the urine of the male 
rat (Vettorazzi et al., 2013). The results from our investigations add further evidence to 
the proposed existence of a relationship between testosterone levels and proteinuria and 
greatly contribute to the ongoing debate. However, the mechanism behind sexual 
maturity and increased urinary protein is yet to be fully explained.  
1D 
1
H NMR combined with PCA/OPLS analysis of the urine samples collected at 
different ages, also revealed significant differences to the concentration of urinary 
metabolites. There was a general trend of a dramatic increase in urinary levels of many 
metabolites at 84 days followed by a decrease at 91 days. Metabolites which followed 
this pattern included creatinine, creatine, taurine, 2-oxoglutarate, citrate and succinate. 
This proved that the urinary metabolites were affected by the male sexual maturation 
process.  
Our comparative study of CCl4-induced toxicity in pre- and post-sexually mature 
animals (7 and 13 weeks old respectively) revealed no significant differences in the 
severity of liver damage as confirmed by histopathological examination. However, it 
appeared from 
1
H NMR analysis of urine samples that older animals excreted greater 
levels of creatinine, hippurate, creatine and taurine in the urine, and lower quantities of 
2-oxoglutarate, citrate and succinate compared to 7 week old rats. We hypothesise that 
the change observed in urinary testosterone may be related to the changes in urinary 
metabolites; however, confirmation of this observation requires further investigation. 
Since the peak in testosterone levels appears to decline after the animals reach sexual 
maturity it is thought that any changes to the metabolites may be temporary.  
In Chapter 6 we investigated the time course at which injury and subsequent recovery 
occurs following a single dose of CCl4. As early as 6 hours post-dosing there were 
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significant increases in serum markers including AST, GLDH, TIMP-1 and MCP1. In 
general, there was an increasing trend in serum levels with time reflecting the 
progression of injury and reaching maximum levels at 24 to 48 hours post-dosing. By 
96 hours (i.e. day 4 post-dosing) it appeared that serum levels had returned to baseline 
values. The pattern observed in the serum chemistry analysis was confirmed by 
histopathological examination revealing maximal severity at 24-48 hours, and a return 
to normal by day 10.  
1
H NMR analysis of urine samples in this study contributed further to our knowledge of 
the metabolite changes seen at 24 hours post-dosing as described in Chapter 3. Taurine, 
citrate, 2-oxoglutarate and hippurate were considered the most sensitive urinary markers 
and all showed a general change in the first 18-24 hours followed by an opposing 
change in urinary levels during the liver regeneration phase.  
Using the information collected from our acute liver injury model generated in Chapter 
3 we developed a model of CCl4-induced fibrosis in the rat in Chapter 7. Our model 
involved the administration of 0.4 ml/kg CCl4, 3 times a week for 6 weeks. We included 
a 6 week period without treatment at the end of the dosing period to evaluate the 
potential of reversibility of the lesion. 
The pathological changes observed in this model reflect many of the most frequently 
seen complications of fibrosis and cirrhosis in humans, such as ascites and 
splenomegaly (Gusberg et al., 1994; Kashani et al., 2008). 
Using this hepatic fibrosis model we conducted a detailed investigation into serum 
markers and gene expression changes during both the dosing period and subsequent 
recovery. Serum ALT, AST and GLDH showed a similar profile, with increasing levels 
up to week 3-4 followed by a decrease and a tendency to return to control levels by 
week 12 (i.e. after 6 weeks without treatment). The same pattern was evident in the 
serum concentrations of other markers including lipocalin-2, TIMP-1 and MCP1. 
Histopathological examination showed progression of injury from week 1 to week 6 
with the presence of fibrous tissue structures reflecting the formation of septae. During 
the recovery period, it was observed that the fibrous septae were narrower than at week 
6, thus possibly indicating some degree of reversibility.  
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Urinary metabolites were analysed in the urine samples collected at relevant time points 
during the study by 
1
H NMR. Taurine levels were increased following chronic injury 
therefore suggesting this metabolite could be a useful marker of both acute and chronic 
liver damage. Interestingly, the urinary excretion of taurine appeared to correlate with 
histopathological evidence of regeneration at weeks 9 and 12, with an increase in 
urinary levels compared to previous time points. However, urinary metabolites 
including creatinine, citrate and succinate appeared to be more sensitive to the initial 
stages of injury. The urinary excretion of these metabolites changed in comparison to 
control animals as early as 1 week of CCl4 treatment but a reverse change occurred at 
week 6 of the dosing period. On the other hand, hippurate levels showed a decreasing 
trend during the dosing period, which was followed by an increase during the 
reversibility period, therefore appearing to correlate with the process of hepatic 
regeneration. This also suggests hippurate could be a sensitive marker for injury and 
subsequent recovery. 
In these studies, we developed and characterised models of both acute and chronic 
CCl4-induced hepatotoxicity in the male Hanover-Wistar rat. We were able to determine 
changes to urinary metabolite levels at 24 hours following a single dose of CCl4, and to 
investigate the profile of urinary metabolites in a time course study up to day 10 post-
dosing. Similar metabolites were changed in the hepatic fibrosis model and thus we 
were able to correlate changes to the urinary concentration during induction of fibrosis 
and subsequent recovery. 
During our 1D 
1
H NMR investigations many chemical shifts were revealed to be 
relevant for cluster separation, however, it was not possible to identify or quantify all of 
the metabolites in the time frame of this project. We suggest that future work may 
involve the use of two-dimensional (2D) NMR methods such as 2D 
1
H NMR J-resolved 
(JRES) NMR spectroscopy which has the ability to increase peak dispersion compared 
to a 1D NMR spectrum, and therefore facilitates spectral assignments and 
quantification. Alternatively, we propose the use of LC-MS for urinary metabolite 
identification. Some of these metabolites may prove to be very sensitive and specific 
markers for hepatic injury.  
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